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Abstract 
African trypanosomiasis is a disease caused by the Kinetoplastida parasites 
Trypanosoma brucei rhodesiense and T. b. gambiense. The distribution of the 
disease is split geographically with T. b. rhodesiense found in eastern sub-
Saharan Africa and T. b. gambiense in the west of the continent. Current 
treatment for this fatal disease is wholly unsatisfactory with problems such as 
extreme toxicity, affordability and the emergence of resistance. The case for 
the generation of new potential chemotherapies is compelling and urgent. 
Phosphodiesterase (PDE) enzymes degrade the secondary signalling molecule 
cyclic adenosine monophosphate (cAMP) to AMP by hydrolysis, thereby 
modulating and regulating the signal transduction to the effector proteins. The 
phosphodiesterase enzymes in the PDEB family in T. brucei were shown to be 
essential to the host-infective bloodstream forms and validated as good drug 
targets using RNA-interference (Zoraghi, R. and Seebeck, T., 2002; Oberholzer, 
M., 2007). Prompted by these findings, two series of putative trypanosomal PDE 
inhibitors, from different sources, were thoroughly assessed in this project for 
their anti-trypanosomal activity and their intracellular effects on the 
trypanosome. 
The whole-cell in vitro efficacy for each compound, against T. brucei wildtype 
and the drug-resistant strain TbAT1 knockout, was established by the standard 
resazurin reduction assay. 25 compounds from Series 1 had EC50 values below 0.5 
µM, with 7 under 100 nM and the most active having an EC50 value of 5.8   ± 3.4 
nM. For the much smaller Series 2 (GJS Compounds), the most active compound 
was GJS-128 with an EC50 value of 79.4 ± 10.3 nM. This demonstrates that a 
number of compounds from both series have potent in vitro activity against 
trypanosomes that is better than or equal to the current chemotherapeutic 
compound diminazene, and some Series 1 compounds are on a par with 
pentamidine and melarsoprol. No major cross-resistance was displayed by the 
TbAT1 knockout strain to either Series 1 or the GJS series. Similarly, a panel of 
Series 1 compounds tested against the B48 strain (resistant to pentamidine and 
melaminophenyl arsenical drugs), and also against Trypanosoma equiperdum 
wildtype and diminazene resistant (PBR) strains, showed no major cross-
resistance displayed by the other resistant strains. This suggests that there 3 
would also be little or no cross-resistance from refractory strains in the field, 
and also that the compounds are active against multiple Trypanosoma species. A 
small panel of Series 1 compounds were also tested for efficacy against 
trypanosomes in infected mice. 4 daily doses of 20 mg/kg bodyweight of 
Compound 48 significantly reduced parasitaemia by approximately 60% compared 
to untreated controls, however higher concentrations were not tolerated by the 
mice so a cure could not be demonstrated. 
A high-throughput method for monitoring the speed of action of test compounds 
on trypanosomes in real time was developed, based on the fluorescence of 
propidium iodide when bound with DNA. Optimisation of the protocol to 96-well 
plates and low cell densities provided higher resolution and accurate traces of 
the lysis of trypanosomes in a cell suspension compared to previously used 
methods, as well as a greatly increased capacity. The propidium iodide assay 
could also be converted to provide end-point EC50 values that were directly 
comparable to those established by the standard resazurin reduction assay. 
The majority of Series 1 compounds did not increase the intracellular 
concentration of cAMP on incubation with bloodstream form trypanosomes; 
those that did only induced a minor elevation of the intracellular concentration 
of the signalling molecule. Since genetic disruption to phosphodiesterase 
enzymes resulted in large increases in cAMP levels (Oberholzer, M. et al, 2007; 
Zoraghi, R. and Seebeck, T., 2002), the lack of increase in cAMP by the Series 1 
compounds strongly suggest that they do not sufficiently inhibit the PDEs in live 
trypanosomes and kill the cells via an alternative pathway. 
In contrast, incubation with the GJS compounds did result in significant 
increases in intracellular cAMP concentration with the most active being GJS-128 
recording an approximately 3-fold increase in cAMP over 3 hours at just 30 nM. 
The concentrations that begin to increase cAMP level are consistent with the 
EC50 values for trypanosomes cultured in vitro (this study), and is also in line 
with inhibition data of recombinant TbrPDEB enzymes (work conducted by Dr. 
Herrmann Tenor, ALTANA Pharma, and Prof. Thomas Seebeck, University of 
Bern). This gives a clear and consistent link between the cause of cAMP rise 
(inhibition of PDEB by GJS compounds) and the effect of that concentration 
increase on bloodstream form trypanosomes (cell death), demonstrating that the 4 
GJS series are inhibitors of trypanosomal PDEs and chemically validate PDEs as 
drug targets for potential new chemotherapies against African trypanosomiasis. 
The effect of PDE inhibition on the physiology of the bloodstream form 
trypanosomes was also investigated. Flow cytometry analysis and the assessment 
of DNA configuration by fluorescence microscopy after DAPI staining determined 
that PDE inhibition by GJS-128 resulted in a precise block of the cell cycle in 
cytokinesis. The replicating trypanosome synthesized and segregated its DNA 
into two nuclei and kinetoplasts as normal and proceeded to initiate the physical 
separation of mother and daughter cells. The cleavage furrow between the old 
and new flagella progressed normally until the point of abscission, at which 
point division was halted with only a small section of plasma membrane 
connecting the two almost separated cells. Both cells appeared viable and 
underwent subsequent rounds of DNA replication, segregation and attempted 
physical separation that was always blocked near completion. This indicates 
cAMP signalling plays an important role in the correct physical separation of the 
replicating bloodstream form trypanosomes. 
A trypanosome cell line resistant to GJS-128 was developed by chemical 
mutagenesis and continuous culture with gradually increasing, but sub-lethal 
concentrations of the PDE inhibitor. This cell line, termed R0.8, was >15-fold 
less sensitive to GJS-128 and displayed significant cross-resistance to the other 
GJS compounds, as well as to stable, membrane permeable cAMP analogues. The 
mode of resistance was investigated by comparing the cAMP profile of the R0.8 
and parental wildtype strains on incubation with GJS-128. No major differences 
were observed suggesting that both the adenylyl cyclase and phosphodiesterase 
activities remained unchanged in the PDE inhibitor-resistant strain. In support of 
this, the sequencing of TbrPDEB1 and TbrPDEB2 in both strains, while uncovering 
the loss of heterozygosity in the R0.8 line, revealed no mutations that would 
impact on enzyme function or inhibitor binding in the resistant cell line. These 
data strongly suggest that the adaptation resulting in resistance to PDE inhibitors 
is located in the effector proteins downstream of the PDEs and adenylyl cyclases 
in the cAMP signalling pathway. 
Identifying a compound that inhibits phosphodiesterases in trypanosomes and 
elevates cAMP concentrations, along with the generation of a PDE inhibitor-5 
resistant cell line will allow more detailed examination of all aspects of the 
cAMP signalling pathway in T. brucei and across the Kinetoplastida. 
Phosphodiesterases have also been demonstrated to be chemically inhibitable in 
trypanosomes and could prove to be the target of a new generation of 
chemotherapies against African trypanosomiasis. 6 
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1  General Introduction Matthew K Gould, 2009     Chapter 1, 22 
1.1 African trypanosomes and human African 
trypanosomiasis (HAT) 
1.1.1 Classification and epidemiology 
African trypanosomes are flagellated protozoans that belong to the genus 
Trypanosoma and are part of the subphylum Kinetoplasta. All members of this 
subphylum share a distinguishing organelle called the kinetoplast, which can be 
found close to the flagella. This organelle contains DNA that is ordered into 
linked circles of differing sizes. The small circles (minicircles) can number up to 
20,000 while there are usually between 20 and 50 larger circles 
(maxicircles)(Roberts, L. S. and Janovy, J., 2000). The position of the 
kinetoplast in relation to other organelles forms the basis for identification of 
different stages of the life cycle.  
Trypanosomes are part of the family termed the Trypanosomatidae and share 
many morphological and biochemical features with other important pathogenic 
members, like the American trypanosomes and the leishmanias. For example 
they all are either elongated with a single flagellum or are more spherical with a 
flagellum that does not extend past the end of its body. Many of the members of 
the family, including African trypanosomes, have more than one host in their life 
cycle and as such are termed heterozenous; they usually require blood or blood 
components when cultured in the laboratory and are, therefore, also called 
hemoflagellates (Roberts, L. S. and Janovy, J., 2000).  
Human African Trypanosomiasis (HAT), or ‘sleeping sickness’ is caused by the 
trypanosome species Trypanosoma brucei which is generally accepted as having 
three subspecies: Trypanosoma brucei gambiense, T. b. rhodesiense and the 
animal infective T. b. brucei (Gilles, H. M., 1999). The parasite is spread to 
humans by the bloodsucking tsetse fly that lives in areas ideal for agricultural 
cultivation and habitation, that is: close to rivers and lakes, and in the vast 
savannahs (WHO, 2001). 
T. b. brucei, while infectious to a large number of mammalian hosts, cannot 
infect humans as it is killed by a haptoglobin-like molecule in human serum 
(Smith, A. B. et al, 1995); T. b. gambiense and rhodesiense, on the other hand, Matthew K Gould, 2009     Chapter 1, 23 
are both resistant to this lysing action of human serum and so can be 
transmitted to man. Not only can they infect man but they both have animal 
reservoir hosts as well: T. b. gambiense can live in domestic pigs and cattle 
while T. b. rhodesiense can also infect game and savannah cattle, amongst 
others (Pépin, J. and Méda, H. A, 2001). 
 
Figure 1.1: The epidemiological status and distribution of the causative species of human 
African trypanosomiasis. The black line denotes the approximate geographical separation 
of species endemicity. Reproduced from Simarro, P. P. et al, 2008. 
 
As their names suggest T. b. rhodesiense and gambiense have different 
geographical distributions. T. b. gambiense is generally found in the tropical 
areas of West and Central Africa while T. b. rhodesiense is usually located in the 
wooded areas of East Africa (WHO, 2000; Simarro, P. P. et al, 2008)(Figure 1.1).  
Human African trypanosomiasis cases were greatly reduced and well under 
control by the 1960s (Kennedy, P. G. E., 2004), however factors such as the 
withdrawal of the old colonial powers leading to social, political and economic 
instability led to a disruption of the surveillance and disease control strategies 
previously adopted (Abel, P. M. et al, 2004). As a result an epidemic began in Matthew K Gould, 2009     Chapter 1, 24 
the 1970s and continues, over 30 years later, to the turn of the millennium 
(WHO, 2000). In 1999 there were nearly 45,000 reported cases of HAT but 
according to the World Health Organization the real number could be between 
300,000 and 500,000 due to a severe lack of screening in the countries affected 
(WHO, 2001). HAT cases have been recorded in over 35 countries in sub-Saharan 
Africa leaving over 60 million people at risk of infection (Barrett, 1999). In 
Sudan, the Democratic Republic of Congo, Angola, and Uganda the prevalence 
has risen to over 20% in the worst afflicted areas (Bouteille et al, 2003). In 2006, 
the actual prevalence of infected cases was estimated at between 50,000 and 
70,000 (WHO, 2006), with recent control strategies having reduced the 
prevalence greatly from its peak (Simarro, P. P. et al, 2008). 
1.1.2 Life cycle and morphology 
T. brucei is obliged to infect a mammalian host and an insect vector in order for 
it to complete its life cycle (Neva, F. A. and Brown, H. W., 1994). Multiplying 
stages alternate with differentiating stages where the cell changes its structure 
and the orientation and location of some of the organelles within (Figure 1.2). 
As the tsetse fly feeds, it infects the host with metacyclic form trypanosomes via 
the insect’s saliva, which are pre-adapted, metabolically, for life inside a 
mammalian host. Once inside the mammalian host the metacyclics differentiate 
to form trypomastigotes, or ‘slender bloodstream forms,’ and proliferate rapidly 
in the blood and lymph (Roberts, L. S. and Janovy, J., 2000).  
When the number of parasites begins to reach the maximum density, the long 
slender form trypomastigotes begin to transform into non-dividing, short ‘stumpy 
forms’ giving a population of trypanosomes with two differing morphologies, 
which is termed pleiomorphic. The stumpy forms appear like their name 
suggests: shorter and fatter than the slender bloodstream forms, with their 
flagellum greatly shortened so that it barely protrudes past the main body of the 
cell. It appears that the trypomastigotes secrete a molecule called Stumpy 
Induction Factor (SIF), which, when accumulated, triggers cell cycle arrest via 
the cyclic AMP (cAMP) signalling pathway in the cell and may instigate 
differentiation (Vassella, E. et al, 1997). This density sensing mechanism allows 
the parasites to transform into a pre-adapted stage ready for ingestion in a Matthew K Gould, 2009     Chapter 1, 25 
blood meal by the tsetse fly. It may also help control the parasitaemia in order 
to prevent the host dying from the infection before transmission to the insect 
vector. 
   
Figure 1.2: Life cycle of Trypanosoma brucei in the mammalian and insect host. 
Reproduced from Vickerman, K., 1985.  
 
The stumpy forms are ideally prepared for the abrupt change in environment 
found in the midgut of the tsetse fly, and differentiate into the procyclic 
trypomastigotes forms between 48 –72 hours after ingestion. The procyclics cross Matthew K Gould, 2009     Chapter 1, 26 
the peritrophic matrix, a bag like structure that surrounds the blood bolus, 
where they grow and multiply over the period of about a week, then transform 
again to become proventricular mesocyclic forms that do not divide. After this 
they begin a migration through the body of the tsetse fly to the salivary glands, 
probably via the oesophagus and mouthparts, which can take between 3 and 5 
weeks from the initial blood meal. Once in the salivary glands the trypanosomes 
undergo four further differentiations. The stage that does most of the 
proliferating is the epimastigote form, which has attached itself, by its 
flagellum, to the microvilli of the gland. The final stage in the tsetse fly occurs 
when the trypanosome disengages from the microvillus as a mature metacyclic, 
the only form in the fly that is infective to mammals, and is ready for 
inoculation of the host via saliva secreted by the fly during feeding. 
The bloodstream form trypomastigotes of T. b. gambiense and T. b. rhodesiense 
are difficult to tell apart morphologically. The flagellum and main body of the 
cell are coated in a plasma membrane with the flagellum being anchored along 
the length of the cell so that, when thrashing, it forms an ‘undulating 
membrane’ (Figure 1.3). The part of the flagellum extending past the anterior of 
the cell rotates in a flailing, corkscrew fashion and pulls the body of the cell 
through the medium, however, the origin of the flagellum is to be found near 
the posterior of the trypanosome in close proximity to the kinetoplast. 
Surrounding the basal body of the flagellum is the flagellar pocket through which 
receptor-mediated endocytosis can take place (Vickerman, K. et al 1993; Gilles, 
H. M., 1999; Roberts, L. S. and Janovy, J., 2000; Garcia, L. S., 2001).  
Variant surface glycoproteins (VSGs) are extruded from the flagellar pocket after 
synthesis in the Golgi apparatus and transportation through the cytosol on 
vesicles (Vickerman, K. et al, 1993). VSGs form a dense coat covering the entire 
plasma membrane and flagellum of the metacyclic and bloodstream forms, and 
are thought to protect the trypanosome from the innate and acquired immune 
response of the mammalian host (Sternberg, J. M., 1998). The coat may act as a 
shield by preventing antibodies from recognizing some of the invariant molecules 
necessary for survival which are attached to the surface of the cell; molecules 
like receptors and essential nutrient transporters.  Matthew K Gould, 2009     Chapter 1, 27 
Figure 1.3: Diagram showing the principle structures of the Trypanosoma brucei 
bloodstream form. Reproduced from Vickerman, K. et al, 1993. 
 
The VSG molecule is made up of two domains: the more conserved carboxyl 
terminal domain and the highly variable amino terminal domain. Although there 
are up to 1000 differing genes, each coding for a different VSG in the 
trypanosome’s repertoire, only one variant is expressed at a time coating the 
entire surface membrane (Barry, J. D. and McCulloch, R., 2001). A population of 
trypanosomes with the same VSG being expressed will continue to proliferate 
until an antibody is raised to recognize that particular protein coat. Once Matthew K Gould, 2009     Chapter 1, 28 
recognized by the host’s immune system the parasite numbers will ‘crash’ until a 
mutant arises with a different VSG coat that is not recognized by the host; then 
the parasite population will proliferate again. This system of controlled 
switching is called antigenic variation and gives rise to the characteristic 
fluctuating parasitaemia seen in cases of HAT. 
1.1.3 Clinical manifestations and pathology of HAT 
The two causative species of HAT give rise to slightly differing symptoms. T. b. 
gambiense generally produces a chronic illness that gradually increases in 
severity from the almost asymptomatic incubation period of the first couple of 
months, to the severe neurological problems and terminal coma after, 
sometimes, several years. T. b. rhodesiense, on the other hand, is more acute 
and the onset of noticeable symptoms can occur within one to four weeks from 
the initial inoculation by the tsetse fly. The span of the rhodesiense infection 
ends fatally, usually within a year (Garcia, L. S., 2001). 
After an infective bite from a feeding fly a swelling, called a chancre, may 
develop a few days later at the location of the bite. This sore usually resolves 
itself within one or two weeks. The metacyclic stage makes its way from the 
bite site into the bloodstream and lymph and starts differentiating and 
proliferating, marking the onset of stage one of the infection sometimes know as 
hemolymphatic trypanosomiasis. During stage one, many patients display non-
specific symptoms such as an irregular or intermittent fever, tiredness, myalgia, 
aching joints and a general malaise. The periodicity of these symptoms correlate 
to the fluctuating parasitaemia levels brought on by the antigenic variation of 
the VSG protective coat. Some of the afflicted show swelling of the posterior 
cervical lymph nodes, termed Winterbottom’s sign, and is noticeable in up to 
85% of patients hospitalized. 10 to 20% have enlarged spleens or livers and 
others have areas of edema and facial puffiness (Pépin, J., 2000).  
The crossing of the blood-brain barrier by the trypanosomes and entry into the 
cerebro-spinal fluid (CSF) and central nervous system (CNS) denotes the onset of 
stage two, or meningoencephalitic trypanosomiasis. This can occur as quickly as 
within a few weeks with T. b. rhodesiense and as much as years later with T. b. 
gambiense. Headaches increase and become prolonged and more severe; Matthew K Gould, 2009     Chapter 1, 29 
patients become more apathetic and show changes in their personalities 
presenting paranoid and antisocial behavior. Characteristic disruption of the 
circadian rhythms and other sleep problems give the disease its colloquial name 
of ‘sleeping sickness’. Muscle tremors and muscle rigidity and tone increase, 
with changes in gait and speech also apparent. Eventually the deterioration of 
neurological function leaves the patient in an ever-deepening coma until death 
(Lalloo, D. G., 2004). 
1.1.4 Diagnosis of HAT 
The diagnosis of HAT caused by T. b. gambiense has three main steps: suspicion 
aroused by symptom history or screening, trypanosome detection, and 
determination of stage of infection. The clinical presentations of early stage HAT 
are easily confused with a variety of ailments. The chancre, visible at the bite 
site of the tsetse fly, not only can be mistaken for the bites of other insects but, 
as it spontaneously resolves itself after a few weeks, is sometimes not present 
when the patient seeks medical help. The relapsing fever, caused by the 
fluctuating parasitaemia, can often be mistaken for malaria, typhoid and other 
febrile diseases (Gilles, H. M., 1999). Even the neurological impairment caused 
by late stage HAT can be confused with other psychiatric illnesses. Nevertheless, 
these symptoms, combined with local knowledge of endemic diseases and their 
epidemiology, may help to point in the right direction and prompt serological 
screening or inspection of body fluids by microscopy for trypanosomes. 
The definitive diagnosis of stage one trypanosomiasis is ideally done by the 
identification of trypanosomes in samples from blood, lymph nodes and, rarely, 
bone marrow. However due to the irregular parasitaemia of T. b. gambiense, 
there are usually relatively few parasites in the peripheral blood circulation and 
a false negative diagnosis results in 20 to 30% of patients using this technique 
(Chappuis, F. et al, 2005). For that reason multiple samples over a long period of 
time, especially at times of fever which are indicative of high parasitaemia, are 
required to give a reliable diagnosis. This is time consuming and requires skilled 
workers with laboratory facilities. Consequently, simple and easy to perform 
tests are of vital importance in determining HAT when screening large 
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The Card Agglutination Test for Trypanosomiasis (CATT) is now the diagnostic 
tool of choice in the field as it is simple to use, reliable and quick. It was 
developed in the late 1970s by the Institute of Tropical Medicine in Antwerp, 
Belgium, and works by inducing antibodies from a sample from an infected 
patient to agglutinate to a stained antigen derived from in vivo cultured 
trypanosomes of variant antigen type LiTat 1.3 (Figure 1.4).  The reported 
sensitivity is between 87 and 98% with a specificity of around 95% when whole 
blood is assayed, however this can be improved further by using the blood serum 
only and diluting 1:4 (Chappuis, F. et al, 2005). Although the CATT technique 
does not give a definitive diagnosis it saves valuable resources by narrowing 
down those that need further investigation from a large population, given that 
the incidence of HAT is usually less than 5%. 
   
Figure 1.4: An example of a CATT conducted on 10 serum samples. Samples 1 – 3 are 
strongly positive, sample 4 is weakly positive and samples 5 – 10 are negative. Reproduced 
from Chappuis, F. et al, 2005. 
 
Determining whether the patient is in stage one of the infection or if the 
trypanosomes have crossed into the cerebro spinal fluid to give stage two is of 
critical importance in deciding on a course of treatment. The only way to do this 
reliably is to examine the CSF by lumbar puncture after a single dose of suramin 
or pentamidine, which clears the parasites from the blood and prevents 
contamination of the CSF by the sampling procedure. The World Health 
Organization defines late stage HAT as a patient having at least one from three 
observations: (1) having live trypanosomes in the CSF sample, (2) a white blood 
cell count greater than 5 cells/µl, and (3) a protein content greater than 370 
mg/litre, measured by the dye-binding protein assay. Apart from (1), these Matthew K Gould, 2009     Chapter 1, 31 
defining thresholds are controversial and hotly debated as they could be 
achieved by other CSF infections and some countries have set their own limits in 
the light of recent findings (Chappuis, F. et al, 2005). For T. b. rhodesiense field 
screening, before parasitological confirmation, is based solely on case history 
and symptoms. This is because there is no comparable CATT serological assay 
available. Conversely definitive diagnosis is more straightforward with T. b. 
rhodesiense than with gambiense as the trypanosomes are more readily detected 
in the blood samples due to the generally higher parasitaemia of a rhodesiense 
infection. Stage determination is carried out in the same way as for T. b. 
gambiense. 
At present the two species causing human trypanosomiasis do not coexist in the 
same geographical areas. Detecting trypanosomes in the blood and knowledge of 
the endemicity of an area has been enough to differentiate between the acute 
and chronic forms of infection, allowing determination of specific treatment 
schedules tailored to the species infecting the patient. This natural separation of 
the two species cannot be relied upon in the future. Evidence from molecular 
identification of human infective parasites in domestic herds of cattle indicates 
that T. b. rhodesiense is spreading north in Uganda towards an area already 
endemic for T. b. gambiense (Welburn, S. C. and Odiit, M., 2002). Should the 
two forms mix then confusion over diagnosis is bound to arise since the species 
are indistinguishable morphologically, resulting in incorrect treatment decisions 
and treatment failures. CATT screening could no longer be relied upon, as it 
cannot detect T. b. rhodesiense, forcing control programs to resort to the time 
consuming and expensive diagnosis by microscopy placing an added burden on 
the overstretched and under funded health services in sub-Saharan Africa. 
1.1.5 Treatment of HAT 
The treatment strategies and chemotherapies used against HAT are dependant 
on the stage of the infection presented to the clinician. Some of the drugs 
cannot cross the blood-brain barrier so cannot kill the trypanosomes in the CSF, 
whereas the main drug used against stage two infections can be extremely toxic, 
occasionally resulting in death from the side-effects, and so is only used once 
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Stage one or hemolymphatic trypanosomiasis is treated with pentamidine if the 
patient is infected with T. b. gambiense and with suramin if infected with T. b. 
rhodesiense (Table 1.1). Pentamidine is given intramuscularly at a recommended 
dosage of 4 mg/kg either daily or on alternating days for a total of seven to ten 
administrations (Bouteille, B. et al, 2003). Suramin’s treatment protocol is 
usually a 5 mg/kg test dose on day one to check for allergic reactions, followed 
by 10 mg/kg on day 3 of treatment. 20 mg/kg is given on days 5, 11, 23, and 30 
(Legros, D. et al, 2002). Each dispensation of drug is given by a slow intravenous 
infusion to reduce the risk of anaphylactic shock and other side-effects.  
 
Table 1.1: Table showing chemotherapies for Human African Trypanosomiasis and their 
dosing protocols and side-effects. Compiled from Legros, D. et al, 2002; Bouteille, B. et al, 
2003 and Fairlamb, A. H., 2003. 
 
Melarsoprol is the drug of choice for treating late stage HAT, however there is no 
standard protocol for dosage or length of treatment. The most commonly used 
strategy is made up of three series, between seven and ten days apart, of three 
or four-day courses at a dosage of 3.6 mg/kg per day by single intravenous 
injection. Melarsoprol is active against both stage one and stage two infections 
however, since 5-10% of cases suffer from a serious reactive encephalopathy, 
half of which die as a result, it is only used for late stage trypanosomiasis as 
other less toxic drugs are available for stage one (Fairlamb, A. H., 2003). Matthew K Gould, 2009     Chapter 1, 33 
Eflornithine can be used against late stage T. b. gambiense infections as it is less 
toxic than melarsoprol, but it is very expensive and difficult to administer so is 
generally only used in cases resistant to melarsoprol. The regimen for this drug 
is 400 mg/kg per day, which is spread over four 2 hour infusions, for seven to 
fourteen days. 
Nifurtimox is a drug used against the American trypanosome T. cruzi, which 
causes Chagas disease, but has not been approved for use against African 
trypanosomes. Nevertheless it has been used when patients have not been cured 
by melarsoprol or eflornithine and is under going clinical trials with conflicting 
results (Bouteille, B. et al, 2003). 
Due to the recrudescent abilities of human African trypanosomes it is 
recommended that patients should be reviewed periodically for 2 years after 
treatment to detect those that relapse. Those relapsing after treatment with 
suramin or pentamidine, having been infected with T. b. gambiense, can be 
treated with melarsoprol or eflornithine, while those infected with T. b. 
rhodesiense can be given a course of melarsoprol. Nifurtimox can be used as a 
last resort if all previous treatments fail (Lalloo, D. G., 2004). 
1.1.6 Modes of action and limitations of current chemotherapies 
1.1.6.1  Pentamidine 
Pentamidine is a water-soluble aromatic diamidine (Figure 1.5), which has been 
used as a chemotherapy since 1937. Not only is it effective against T. b. 
gambiense, but it is also used as a drug against antimony-resistant leishmaniasis 
and also Pneumocystis carinii pneumonia (Docampo, R. and Moreno, S. N., 
2003). An analogue of insulin, it was hoped that pentamidine would be active 
against trypanosomes after a related compound, synthalin, was shown to induce 
hypoglycaemia in humans. The idea was to deprive the parasites of their source 
of glucose in the blood and essentially starve them to death, however 
pentamidine’s mode of action is independent of its effects on the physiology of 
the patient (Denise, H. and Barrett, M. P., 2003). Matthew K Gould, 2009     Chapter 1, 34 
 
 
Figure 1.5: Structures of the drugs used to treat Human African Trypanosomiasis. Dates 
first synthesized in brackets. Reproduced from Fairlamb, A. H., 2003. 
 
Pentamidine is actively taken up by the parasite to millimolar levels inside the 
cell, however there is more than one transporter involved in the accumulation of 
the drug to such high concentrations. Uptake inhibition experiments have shown 
that the P2 aminopurine transporter mediates between 50 – 70% of pentamidine 
uptake by T. b. brucei, with a high-affinity (HAPT1) and a low-affinity 
pentamidine transporter (LAPT1) also implicated (De Koning, H. P., 2001). These 
transporters are essential for the survival of the parasite under normal 
conditions as they import purines scavenged from the host. Trypanosomes 
cannot synthesize purines de novo so have to rely completely on efficient uptake 
of the molecules by their transporters. The transporters recognize specific 
regions of the purine structure, which are also present on pentamidine and some 
other trypanocides, and so take up the drug along with the natural substrate. 
The specific target of pentamidine, once inside the cell, has not been 
definitively determined. It binds tightly to the circular DNA of the kinetoplast, 
however the parasite can still survive when the kinetoplast has been removed 
(Denise, H. and Barrett, M. P., 2003). Pentamidine can also affect the 
mitochondrion by acting as an uncoupler of oxidative phosphorylation, inhibit 
the S-adenosyl methionine decarboxylase (Ado-MetDC) enzyme perhaps 
preventing polyamine synthesis, and interfere with trypanothione metabolism 
(Docampo, R. and Moreno, S. N., 2003; Nok, A. J., 2003). The high intra-cellular Matthew K Gould, 2009     Chapter 1, 35 
concentrations reached by the drug means it may be acting on more than one, or 
all of the above processes or targets. The unpleasant side effects of pentamidine 
can result in poor completion of treatment schedules giving rise to relapse. The 
drug can cause nausea, rash, tachycardia, pruritus and extreme tenderness at 
the site of injection. More seriously kidney failure, diabetes mellitus caused by 
the hypoglycaemic effects to the host, not to mention death from hypotension, 
mean that a course of treatment can leave serious, long-term damage to the 
patient.  
Resistance to pentamidine does not appear to be a major problem, even after 
massive prophylaxis use in the 1950s and ’60s (Fairlamb, A. H., 2003). This is 
because of the multiple transporters used to accumulate the drug; a mutation or 
loss of one would not lower the intra-cellular concentration to a sub-therapeutic 
level; disruption of the TbAT1 purine transporter only results in a minor 
resistance to the drug (Matovu, E. et al, 2003). However a TbAT1 knockout cell 
line that was made further resistant to pentamidine by gradually increasing the 
maximum tolerated concentration in in vitro culturing was also shown to have 
lost the transport activity associated with HAPT1 (Bridges, D. J. et al, 2007). 
 In spite of this resistance has been induced in the laboratory that does not 
involve the loss of uptake, signifying that other mechanisms of resistance can 
arise (Berger, B. J., et al, 1995). 
1.1.6.2  Suramin 
Suramin is the drug of choice for stage one T. b. rhodesiense infections as 
pentamidine was found not to be as reliable. It was first used as a trypanocide in 
the early 1920s when German scientists developed it after similar dyes were 
shown to have remarkable activity against trypanosomes. Suramin is a water 
soluble, polysulfonated naphthylamine (Figure 1.5) and is highly ionic, having six 
positive charges at a physiological pH. Its ionic character means it cannot cross 
the blood-brain barrier (BBB) and so is not used to target trypanosomes in the 
CNS during the late stage of infection. 
The charged nature of the drug may explain how it is taken into the cell; its 
positive charge makes it bind to many plasma proteins including low-density 
lipoproteins (LDLs) allowing it to be accumulated by receptor-mediated Matthew K Gould, 2009     Chapter 1, 36 
endocytosis at the flagellar pocket of the trypanosome. Recent evidence (Pal, A. 
et al, 2002) casts doubt on this hypothesis, however, inferring accumulation may 
occur by a totally different process. 
Excretion of the drug is extremely slow; it has a half-life of 44-54 days and can 
still be detected in the blood between five and eight months after the final 
injection. Again this is probably due to its high charge with 99.7% of the drug 
found bound to plasma proteins after pharmacokinetic analysis (Pépin, J. and 
Milord, F., 1994).  
The mode of action of suramin has not been fully elucidated. The compound 
binds electrostatically to numerous enzymes, such as dihydrofolate reductase 
and thymidine kinase, consequently inhibiting them; nevertheless, this does not 
prove it is the process responsible for the death of the parasite. The reduced 
growth rate suggests interference in glycolysis by the inhibition of glycolytic 
enzymes, which might explain the slow death of the parasite over several days 
(Fairlamb, A. H., 2003; Docampo, R. and Moreno, S. N., 2003); however, any 
evidence is only inferential. More research is required before any firm 
conclusions can be drawn on a definitive mode of action for the drug. 
Anaphylactic shock is a risk with treatment with suramin although rare, having 
an incidence of less than 1 in 2000 patients (Pépin, J. and Milord, F., 1994). 
More common is renal toxicity, however it is usually mild. Other side effects are 
fever, perhaps due to the lysing of the trypanosomes, nausea, vomiting and 
mucocutaneous eruptions. Despite being in use for over eighty years resistance 
to suramin is not a serious problem (Delespaux, V. and De Koning, H. P., 2007). 
1.1.6.3  Melarsoprol 
Also known as Mel B, melarsoprol was first used as a trypanocide in 1949. It is 
one of a class of compounds called the trivalent melaminophenyl arsenicals and 
was synthesized by the addition of British antilewisite (BAL) to the arsenic of 
melarsen oxide (Figure 1.5). It is insoluble in water, and so is administered 
dissolved in propylene glycol. Melarsoprol itself, while active against 
trypanosomes in its own right, may not be the actual compound killing the 
trypanosomes. Mel B is rapidly metabolised to melarsen oxide in the patient, Matthew K Gould, 2009     Chapter 1, 37 
reaching a maximum plasma concentration in 15 minutes after injection, with a 
half-life of nearly four hours (Nok, A. J., 2003). 
Evidence points to the adenosine P2 transporter being responsible for the uptake 
of the arsenicals into the trypanosome. Melarsen oxide and melarsoprol have 
been shown to inhibit the uptake of adenosine by the P2 transporter (Carter, N. 
S. and Fairlamb, A. H., 1993; De Koning, H. P. and Jarvis, S. M., 1999; De 
Koning, H. P., 2001), and only compounds that specifically inhibit P2 reduced 
the lysing affect of melarsen oxide on the trypanosome. More information came 
to light when an arsenical resistant T. brucei clone was investigated and a 
mutant TbAT1 gene, which is normally an adenosine P2 type transporter, was 
found; it had point mutations leading to six amino acid changes and an inability 
to transport adenosine (Mäser, P. et al, 1999). Furthermore, in northwestern 
Uganda 38 isolates out of 65 T. b. gambiense infected patients who had relapsed 
after treatment with melarsoprol had mutated TbAT1 genes, all of which had 
the same nine mutations in the gene (Matovu, E. et al, 2001). Not only does this 
data add weight to the importance of the P2 transporter in the accumulation of 
arsenicals to lethal concentrations inside the cell, but also its loss of function 
may be responsible for increasing resistance to melarsoprol. The high-affinity 
pentamidine transporter (HAPT1) appears to provide a secondary mode of 
uptake into the trypanosome. A TbAT1 knockout cell line made further resistant 
to pentamidine was also cross resistant with arsenical class compounds and was 
demonstrated to have lost HAPT1 activity (Bridges, D. J., et al, 2007). 
The incidence of melarsoprol treatment failure has risen from a standard 5-8% to 
an alarming 30% in Uganda in 1999, with a reported 40% treatment failure in the 
late 1970s. A detailed investigation of the drug sensitivities of isolates from 
these outbreaks produced a confused picture (Brun, R. et al, 2001): the 1970s 
isolates showed a sensitivity one-tenth of that of non-relapse inducing isolates, 
with mouse infections also not being cured by previously therapeutic 
concentrations of drug; the recent Ugandan isolates, however, showed no 
change in sensitivity between isolates from relapsed and curable patients, with 
no difference in plasma concentrations of melarsoprol between the patients. 
This suggests that treatment failure is not just down to the sensitivity of the 
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The exact mode of action of melarsoprol or its metabolite melarsen oxide has 
not been determined yet. The trypanosomes rapidly lose motility and lyse in the 
bloodstream. This has been put down to inhibition of the pyruvate kinase 
enzyme and, consequently, interference with the glycolytic pathway that 
produces the energy, in the form of ATP, that is required for movement; 
however it appears that the cells lyse well before the ATP levels are critically 
depleted (Denise, H. and Barrett, M. P., 2001). Another potential target is the 
trypanothione reductase enzyme, which is essential for maintaining a redox 
balance intracellularly. Melarsen oxide can react with trypanothione to form Mel 
T that can inhibit the trypanothione reductase (Fairlamb, A. H., 2003). 
The most important side effect of treatment with melarsoprol is reactive 
encephalopathy. It occurs in between 5-10% of patients and is defined as a rapid 
decline in the level of consciousness and/or seizures; followed by pulmonary 
edema and death in over half of those affected within 24-48 hours (Pépin, J. and 
Milord, F., 1994). Suspending the treatment and giving high doses of 
corticosteroids and anticonvulsants can help to reduce the severity of the 
reaction. Once the encephalopathy has been resolved it is possible to continue 
treatment with melarsoprol without recurrence (Bouteille, B. et al, 2003). Other 
side effects are abdominal and chest pain, skin rashes, headaches, fever, 
tremors, and cardiac, renal and liver toxicity. 
1.1.6.4  Eflornithine 
An analogue of ornithine, eflornithine, sometimes known as DFMO from its 
chemical structure and name DL-alpha-difluoromethylornithine (Figure 1.5), is 
the first and only new drug to be approved for use in humans against Human 
African Trypanosomiasis since 1949.  
It is thought to accumulate intracellularly in the trypanosome by passive 
diffusion although evidence for mediated uptake has been shown (De Koning, H. 
P., 2001). The pharmacokinetics shows that after intravenous infusion the serum 
concentration of eflornithine in patients was 49.2 nmol/ml for children and 87.5 
nmol/ml for adults. The ratio of eflornithine in the cerebro spinal fluid to that in 
the blood plasma was 0.91 for adults and 0.58 for children (Milord, F., et al, 
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It acts as a suicide inhibitor of ornithine decarboxylase (ODC), a key enzyme in 
the synthesis of the polyamines spermidine, spermine, and putrescine that are 
essential for cell proliferation (Burri, C. and Brun, R., 2003). DFMO inhibits both 
the trypanosomal and mammalian ODC enzymes, however its selectivity of effect 
is brought about by the fact that humans degrade and replace their ODC enzyme 
much more rapidly than the trypanosome. DFMO is only efficacious against T. b. 
gambiense because T. b. rhodesiense has a much shorter half-life for its ODC 
meaning it replaces its enzyme faster than T. b. gambiense, and also fast enough 
to avoid the chemotherapeutic affects of eflornithine. It has been noted that 
DFMO is not trypanocidal; rather it merely prevents the growth and proliferation 
of the trypanosomes in the bloodstream and cerebrospinal fluid long enough for 
the patient’s immune system to kill the parasites. This is backed up by the fact 
that eflornithine does not cure patients that are also HIV-positive, indicating 
that a competent immune system is vital for treatment success. 
Resistance to DFMO can be relatively easily induced, at least in the procyclic 
forms, in in vitro culture by gradually increasing the sub-lethal concentration of 
the drug. However, the mode of resistance has not definitively been identified. 
There are conflicting reports about whether transport of the drug into the cell is 
responsible (Iten, M. et al, 1997; Phillips, M. A. and Wang, C. C., 1987), with 
others suggesting an increased level of ornithine, which competes with DFMO for 
the binding site of ODC, gives rise to the resistance (Bellofatto, V. et al, 1987). 
Adverse reactions to eflornithine are similar to those of cancer treatments, for 
which DFMO has also undergone trials, and are reversible after treatment is 
completed. Nausea, vomiting and diarrhea are often reported with hair loss in 5-
10% (Burri, C. and Brun, R., 2003). Convulsions can occur but are of a different 
type to those caused by the melarsoprol-induced encephalopathy. 
1.1.6.5  Nifurtimox 
Nifurtimox is a 5-nitrofuran derivative (Figure 1.5) that was developed in the 
1960s for use against Chagas disease, which is caused by the American 
trypanosome Trypanosoma cruzi. It has not yet been registered for use against 
African trypanosomiasis but permission has been given on compassionate grounds 
to treat those where melarsoprol and eflornithine have both failed in late-stage 
infections (Bouteille, B. et al, 2003). Matthew K Gould, 2009     Chapter 1, 40 
In T. cruzi nifurtimox enters the cell by passive diffusion and it seems likely that 
this would be the mode of uptake by African trypanosomes although no work has 
been carried out on T. brucei in this respect (Denise, H. and Barrett, M. P., 
2001). Nifurtimox is a prodrug and its toxicity is thought to be derived from the 
production of free radicals after metabolism of the compound by nitroreductases 
(NTRs) (Wilkinson, S. R. et al, 2008). Free radicals are extremely reactive and 
could cause damage to multiple processes and pathways in the cell (Fairlamb, A. 
H., 2003).  
Recently nifurtimox resistance was induced in T. cruzi parasites in vitro by 
culturing the parasites in 10 µM of the drug. This concentration inhibits the 
growth of more than 99% of the trypanosome population. The surviving parasites 
were shown to have a reduction in nifurtimox reducing activity and were 4-fold 
less sensitive to the drug (Wilkinson, S. R. et al, 2008). A type I NTR from T. 
cruzi, recombinantly expressed, was demonstrated to be able to metabolize 
nitrofuran compounds including nifurtimox, and null TcNTR mutants were 
approximately 4-fold resistant to the drug. In the same study one allele of the 
homologous gene in T. brucei was disrupted, with the heterozygous TbNTR
+/- 
parasites also showing resistance to nifurtimox; overexpression of the same gene 
in bloodstream form T. brucei resulted in a marked increase in sensitivity to all 
nitroaromatic compounds tested. These data strongly implicate the type I 
nitroreductase in metabolising the prodrug to its toxic, free radical producing 
metabolite and that mutation or differential regulation of the NTR can result in 
resistance to the drug (Wilkinson, S. R. et al, 2008). 
Side effects to nifurtimox in patients treated for Chagas disease are very 
common with 50% not able to complete a full course of treatment. Since 
treatment in patients with HAT is limited to those in late stage and also 
refractory to melarsoprol and eflornithine it is difficult to differentiate between 
side effects and natural symptoms to the terminal stages of the infection 
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1.2 Cyclic-nucleotide signalling in protozoa: adenylyl 
cyclases (AC) 
1.2.1 Kinetoplastids 
Adenylyl cyclase activity was first reported in trypanosomes in 1974 in T. 
gambiense (Walter, R. D., 1974), followed quickly by the first measurement of 
cyclic-AMP in trypanosomes in different life cycle stages, where it was observed 
that in T. lewisi the cAMP concentration in the non-reproducing adult form was 
approximately twice that of the reproducing form (Strickler, J. E. and Patton, C. 
L., 1975). Further changes in intracellular cAMP concentration were measured in 
T. brucei: as the parasitaemia in rats increased, the cAMP concentration rose 
with it. In strains that caused a relapsing parasitaemia, the same initial change 
in cAMP was observed, however, as the proportion of trypanosomes in the long 
slender form decreased to give way to the short stumpy forms, so the 
intracellular cAMP concentration fell too, until a basal level was reached when 
short stumpy forms were predominant. When the next parasitaemic wave of long 
slender forms grew, cAMP concentration in the trypanosomes rose also, 
suggesting a link between morphological form of bloodstream trypanosome and 
cAMP response to changing cell density (Mancini, P. E. and Patton, C. L., 1981). 
1.2.1.1  Calcium mediated adenylyl cyclase regulation 
Adenylyl cyclase (AC) activity was found to be predominantly localised to the 
membrane portion of sub-cellular fractions of T. cruzi (Pereira, N. M. et al, 
1978) and T. brucei (Martin, B. R. et al, 1978). Further characterisation of the 
AC activity in T. brucei membrane fractions revealed that it is constitutively 
active in the presence of Mg
2+ and completely unaffected by the usual 
mammalian AC effectors glucagon, guanyl-5'-yl imidodiphosphate (p[NH]ppG), 
adrenaline or adenosine; and is inhibited by pyrophosphate (PPi), the secondary 
product of adenylyl cyclase (Martin, B. R., et al, 1978). The AC activity in the 
membrane fraction was also inhibited by Ca
2+; however, measuring its effect in 
whole, intact cells showed that calcium actually stimulated AC activity, reaching 
a maximum effect at a concentration of 300 µM before gradual attenuation of 
activation at concentrations up to 2 mM (Voorheis, H. P. and Martin, B. R., 
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To investigate the effects of calcium in situ, Voorheis and Martin developed a 
technique, termed ‘swell dialysis’, whereby membrane permeability was 
achieved by carefully lowering the osmotic strength of the cell suspension 
medium, disrupting the membrane enough to allow small molecular weight 
compounds or molecules to cross the lipid bi-layer and enter the cytoplasm. 
Using this technique it was observed that calcium crossed the plasma membrane 
and equilibrated with the external concentration within just 30 seconds, 
however, there was a time-lag of several minutes (depending on Ca
2+ 
concentration) before the adenylyl cyclase activity was stimulated (Voorheis, H. 
P. & Martin, B. R., 1981). The addition of the ionophore A-23187 hastened the 
Ca
2+ stimulation in osmotically swollen cells. This seems somewhat strange since 
the accumulation of calcium intracellularly in swollen cells is so rapid: the 
authors hypothesized that the ionophore allows Ca
2+ to access the lipid bi-layer 
plasma membrane faster than just swelling alone and that the calcium receptor 
is located in the membrane, possibly located in the part of the membrane-
embedded region of the adenylyl cyclase. More circumstantial evidence of the 
AC-stimulating calcium receptor being located in the plasma membrane comes 
from the fact that the local anaesthetic benzyl alcohol can activate adenylyl 
cyclase in the presence of Ca
2+ (Voorheis, H. P. & Martin, B. R., 1982). Benzyl 
alcohol is a membrane perturbating agent in mammals and it may act by 
disrupting the plasma membrane of trypanosomes allowing faster access to the 
putative membrane embedded receptor for calcium. 
The addition of calcium and the ionophore A-23187 also result in the shedding of 
the variant surface glycoprotein (VSG) coat by the bloodstream form 
trypanosomes (Bowles, D. J. & Voorheis, H. P., 1982; Voorheis, H. P., et al 
1982). Indeed VSG shedding and adenylyl cyclase stimulation appear to share 
numerous characteristics in common: the activation by calcium and ionophore; 
stimulation by the rupturing or perturbation of the plasma membrane; and 
blocking of stimulation by the addition of Zn
2+ (Voorheis, H. P. et al, 1982), all 
suggesting a link between AC activation and VSG shedding. The investigation of 
the calcium-mediated activation of adenylyl cyclase in the differentiation of 
bloodstream form trypanosomes to procyclics appeared to substantiate this 
connection. Swell dialysis of both forms showed that Ca
2+ stimulated the AC of 
bloodstream forms only, having no apparent effect on procyclic AC which have a 
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(Rolin, S. et al, 1990). AC activity and VSG shedding were monitored after 
triggering differentiation of bloodstream to procyclic forms by lowering the 
incubation temperature form 37 ºC to 27 ºC and adding citrate/cis-aconitate to 
pleomorphic trypanosomes harvested from the rodent host after 8 days post-
infection (where more than 90% of the trypanosomes are non-proliferative 
intermediate and stumpy forms). After 4 hours post differentiation induction 
transforming cells began to appear with 100% of the trypanosomes transforming 
after 9 hours; procyclic forms began to appear at 12 hours with virtually all 
having fully differentiated by 22 hours (Rolin, S. et al, 1993). VSG was rapidly 
shed with around 50% released after 5 hours post induction and only a residual 
level remaining after 10 hours; AC activity began to rise sharply 4-6 hours after 
triggering differentiation and peaking around 7-8 hours before falling to a basal 
level after 10 hours, a further transient peak spanned the 20-40 hour time period 
where the procyclics were reproducing. These data suggest that AC stimulation 
does not appear to be responsible for the release of VSG, as the first peak in 
activity only appears after VSG shedding is well under way, but may be 
modulating the subsequent stages of differentiation since this peak coincides 
with the appearance of transforming trypanosomes. Interestingly, it was 
observed that for cultures that did not appear to be differentiating together, the 
addition of 1 mM cAMP to the triggering conditions synchronised the 
transformation of the whole cell population (Rolin, S. et al, 1993), lending 
weight to the above hypothesis. 
It was also speculated that it may be the release of VSG itself that might 
stimulate the adenylyl cyclase enzymes. Bloodstream form trypanosomes were 
treated with trypsin, which cleaves VSG from the plasma membrane by 
proteolysis, and VSG shedding and AC activity were monitored over time. The 
result was a lag of 15 minutes between the detection of the N-terminal domain 
of cleaved VSG in the medium by anti-VSG antibody and the stimulation of 
adenylyl cyclase (Rolin, S. et al, 1996). Treating the trypanosomes with trypsin 
for 15 minutes then adding soybean trypsin inhibitor resulted in a slightly 
different picture: the N-terminal domain of VSG was detected as before, with a 
lag phase until the activation of AC, however, detection of the C-terminal 
domain of VSG in the medium by anti-CRD antibodies was paralleled by the 
stimulation of adenylyl cyclase. The C-terminal domain of VSG is released only 
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phospholipase C (GPI-PLC). Incubating the trypanosomes at pH 5.5 also resulted 
in VSG release and AC activation; again the AC stimulation paralleled the release 
of the C-terminal domain of VSG by GPI-PLC (Rolin, S. et al, 1996). 
Similar experiments conducted on a pleomorphic line of T. brucei highlighted 
the different responses to the same type of stress conditions by long slender and 
stumpy bloodstream forms. Trypanosomes harvested on differing days post 
infection from infected rodents were subjected to pH 5.5 medium: only the 
trypanosomes taken early in the infection, when the majority are long slender 
forms, activated their adenylyl cyclase and triggered GPI-PLC mediated VSG 
release (Nolan, D. P. et al, 2000). Likewise, incubation with trypsin resulted in 
only the predominantly long slender form cultures activating AC and releasing C-
terminal VSG. This suggests that only the long slender forms are sensitive to 
stress-activated AC stimulation and GPI-PLC mediated VSG release. Exposure to 
Ca
2+ under swell dialysis conditions however, showed an equal activation of AC 
by both long slender and stumpy forms. 
The data above suggest that the release of the C-terminal domain of VSG by GPI-
PLC directly stimulates adenylyl cyclase activity. However, further investigation 
with GPI-PLC null mutants and PKC inhibitors showed both effects were 
simultaneous but independent. Incubation of the mutant trypanosomes at pH 5.5 
resulted in AC stimulation but no release of VSG. Also, it had been observed that 
PKC inhibitors also induced GPI-PLC mediated VSG release and AC stimulation. 
Total inhibition of adenylyl cyclase with p-chloromercuriphenylsulfonic acid 
(pCMPS) and incubation with the PKC inhibitor Myr-ψ-PKC-α resulted in the 
release of C-terminal domain VSG but no activation of AC (Rolin, S. et al, 1996). 
While it is now apparent that VSG release and AC activation are independent 
processes, they may be triggered by the same stimuli and resulting signalling 
cascade. 
1.2.1.2  Isolation and biochemical characterisation of adenylyl cyclase genes 
and their proteins 
The first identification of a putative kinetoplastid adenylyl cyclase gene 
occurred when the gene expression site of an active VSG was sequenced in T. 
brucei (Pays, E. et al, 1989). The sequencing revealed that there were multiple 
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termed expression-site associated genes (ESAGs), and one of them, ESAG4, 
showed homology with an adenylyl cyclase from yeast. The sequence homology 
was mostly restricted to two regions in the C-terminal end of the gene which, in 
the yeast AC, is responsible for enzyme activity. ESAG4 is expressed in the 
bloodstream form only by an α-amanitin resistant polymerase; however, 
sequences similar to that of ESAG4 can be detected in the procyclic form as well 
as the bloodstream form, having been transcribed by an α-amanitin sensitive 
polymerase (Pays, E. et al, 1989; Alexandre, S. et al, 1990). Hybridization with 
an ESAG4 probe of a procyclic cDNA library could not pick out a single clone 
identical to ESAG4, but detected several related sequences. Restriction mapping 
of the clones separated them into two categories, with the largest from each 
further characterised and named GRESAG4.1 and GRESAG4.2 (for genes related 
to ESAG4). Southern blots using 5' and 3' regions of ESAG4 showed that related 
genes were also found in Trypanosoma gambiense, T. congolense, T. mega and 
T. vivax (Alexandre, S. et al, 1990). Specific antibodies against ESAG4 and 
GRESAG4.1 showed differential expression in transforming bloodstream forms, 
with most of the ESAG4 AC lost around 9 hours after differentiation was 
triggered, paralleling the decline in the proportion of stumpy forms; while the 
level of GRESAG4.1 remained constant from stumpy form through to reproducing 
procyclics (Rolin, S. et al, 1993). A further GRESAG4 was found by using the 
cDNA of GRESAG4.1 and GRESAG4.2 as probes against bloodstream form cDNA. 
The GRESAG4.1 probe identified an identical clone from the bloodstream cDNA 
library while the GRESAG4.2 probe picked up a slightly different clone and the 
gene contained within was termed GRESAG4.3. The sequences of the GRESAG4 
genes were aligned with that of ESAG4: this revealed a highly homologous region 
in the C-terminal, located immediately after a hydrophobic stretch big enough 
to be membrane spanning. This strongly conserved region also shares a high 
degree of homology to the catalytic domains of adenylyl cyclase in 
Saccharomyces cerevisiae and also the guanylyl cyclase found in the rat brain 
(Alexandre, S. et al, 1990).  
Proof that the putative AC genes actually coded for adenylyl cyclase enzymes 
came when ESAG4 and GRESAG4.1 were transfected into a temperature sensitive 
cyr1 yeast mutant, which lacks adenylyl cyclase activity at 34 ºC (Paindavoine, 
P. et al, 1992). Both ACs complemented the yeast mutant and were detected by 
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activated by Mg
2+, but more so by Mn
2+; however, ESAG4 is stimulated by Ca
2+, 
whereas GRESAG4.1 is not, indicating that ESAG4 may be responsible for the 
calcium mediated activation of AC activity observed by Voorheis and Martin in 
intact bloodstream form T. brucei (Voorheis, H. P. and Martin, B. R., 1980; 1981; 
1982). Similar work using the related parasite Trypanosoma equiperdum also 
uncovered a homologous AC gene in the VSG expression site (Ross, D. T. et al, 
1991). This gene shared 92% homology with ESAG4 and, when transfected into a 
yeast mutant with its cyr-1 AC gene almost completely deleted, also displayed 
constitutive adenylyl cyclase activity.  
In Leishmania donovani a tightly clustered family of at least five adenylyl 
cyclase genes were identified, and two sequenced and characterised (Sanchez, 
M. A. et al, 1995). Sequence alignment showed the putative ACs, termed rac-A 
and rac-B, shared a high degree of homology with GRESAG4.3 from T. brucei, 
being over 50% identical in the C-terminal catalytic domain and also sharing the 
transmembrane domain immediately before the catalytic region. Attempts to 
transform and complement yeast AC mutants were unsuccessful, however, but 
functional expression in Xenopus laevis oocytes showed that rac-A could produce 
cAMP whereas rac-B could not, or at least not in this expression system. 
A GRESAG 4.3 fragment from T. brucei was used to screen a T. cruzi cosmid 
library: again a multi-gene family of putative adenylyl cyclases was identified 
and two were sequenced and characterised and termed TcADC 1 and TcADC 4 
(Taylor, M. C. et al, 1999). The catalytic domain of TcADC 1 was expressed in, 
and complemented, an E. coli cya AC mutant; AC activity was measured in the 
presence of Mg
2+ and Mn
2+ with a preference shown for the latter by a 6-fold 
increase in activity at 10mM. No guanylyl cyclase activity was detected 
indicating that TcADC 1, at least, is specific for ATP over GTP. Sequence analysis 
determined that they shared the same predicted protein architecture as in T. 
brucei and L. donovani having a transmembrane domain followed by a highly 
conserved cytosolic catalytic domain. The regions responsible for the binding of 
the Gsα and Gβγ subunits of the heterotrimeric G-proteins that regulate 
mammalian adenylyl cyclases were not conserved in TcADC 1 or TcADC 4 or any 
of the other kinetoplastid AC genes, suggesting that trypanosomal ACs are not 
regulated or activated by G-proteins homologous to those of mammals. Indeed, 
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cruzi (Eisenschlos, C. et al, 1986; Coso, O. A. et al, 1992), no homologous 
sequences homologous to the G-protein subunits have been identified in the 
genomes of any of the kinetoplastids sequenced to date.  
Interestingly, the change of one residue, from serine in the mammalian 
adenylate cyclases to aspartic acid in TcADC 1 or TcADC 4, at the position 
corresponding to amino acid 942 of the C2 domain of rat type II AC, predicts that 
the binding of forskolin to kinetoplastid ACs would be impeded. Forskolin is a 
stimulator of mammalian ACs and has been used uncritically in investigations of 
protozoal AC activity, including kinetoplastids, on the unproven assumption that 
its effects in mammalian cells would be replicated in other systems. Functional 
characterisation of the two T. cruzi AC genes in E. coli back up the sequence 
observation, as forskolin had no effect on T. cruzi AC activity (Taylor, M. C. et 
al, 1999), in agreement with an early report on activity in T. cruzi AC purified 
with the aid of monoclonal antibodies which also failed to see an effect from 
forskolin (Torruella, M. et al, 1986). Similarly, another T. cruzi AC gene (TczAC) 
was identified and characterised and was also shown to be insensitive to 
forskolin and mammalian G-protein regulators (D’Angelo, M. A. et al, 2002). 
Work published previously with the effects of forskolin on trypanosomes as a 
component, while probably genuinely observed and diligently reported, will 
need to be reappraised in the light that forskolin-mediated effects may be due 
to non-adenylyl cyclase or non-cAMP signalling effects. 
1.2.1.3  Adenylyl cyclase protein structure 
As became apparent from the sequencing of numerous ACs from several species, 
the adenylyl cyclase enzymes from kinetoplastids all share a similar over-arching 
protein structure. They all have a large extracellular N-terminal domain with low 
homology between individual genes and/or species, and a single membrane 
spanning region that connects to the catalytic domain. This is in stark contrast 
to mammalian ACs that generally have 12 transmembrane domains, with the 
exception of the soluble AC. Until recently it was thought that the N-terminal 
extracellular domain of trypanosomal adenylyl cyclases had no similarity with 
any other protein domains, although it had been suggested that since there were 
no G-protein coupled receptors in the kinetoplastid genomes this region may act 
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Laxman, S. and Beavo, J. A., 2007). A Blast search and hidden Markov modelling 
revealed a relationship with an E. coli L-leucine-binding protein with the N-
terminal of a representative AC from T. brucei (Emes, R. D. and Yang, Z., 2008). 
In Pseudomonas aeruginosa a leucine-binding protein (LBP) acts as an amide 
receptor (O’Hara, B. P. et al, 2000).  
The C-terminal region of the ACs is highly conserved between kinetoplastids and 
is also highly related to that of the mammalian Class I adenylyl cyclase catalytic 
domain and to the receptor guanylyl cyclase. A C-terminal extension, found 
after the catalytic domain, appears to be unique to kinetoplasts and has a large 
amount of sequence variation. The cytosolic domains of T. brucei AC genes 
GRESAG4.1 and GRESAG4.3, with 110 residues of the C-terminal extension 
removed, were crystallized and their structures solved by high resolution X-ray 
analysis of the crystals formed (Bieger, B. and Essen, L.-O., 2000; 2001). As 
expected from the sequence analysis, the structures of the crystallized 
trypanosomal ACs are very similar to that of the C1A domain of dogs and the C2A 
domain found in rats, with overall structural differences equal between the T. 
brucei ACs and the mammalian and those between the mammalian ACs 
themselves.  
The crystals of the catalytic domain of GRESAG4.1 and GRESAG4.3 were formed 
exclusively in a monomeric state. However, there is evidence to suggest that the 
active forms of the trypanosomal ACs are dimers. In L. donovani RAC-A was 
expressed in Xenopus laevis oocytes and was shown to produce cAMP; co-
expression with RAC-A∆ (RAC-A with part of its catalytic domain removed) 
resulted in a dramatic reduction in cAMP production (Sanchez, M. A. et al, 
1995). Also, co-expression of RAC-A with RAC-B – an apparently non-functional 
pseudogene – also resulted in the inhibition of cAMP production. This suggests 
that RAC-A can interact with the other non-active gene products, possibly 
oligomerizing. Gel filtration analysis of a new family of T. brucei AC, GRESAG4.4 
confirmed that trypanosomal adenylyl cyclase catalytic domains could 
spontaneously and stably dimerise. The addition of a leucine zipper to the N-
terminal of the catalytic domain increased the Vmax of the enzyme 20-fold, while 
the Km remained constant (Naula, C. et al, 2001). This implies that dimerisation 
is linked to increased cyclase activity, or that by slightly altering the 
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increased. The authors suggest that this could act as a form of AC regulation, 
speculating that a small ligand molecule could alter the conformation of the 
dimer by binding and thereby stimulate the AC. The predicted substrate binding 
and active sites indicated that two molecules of ATP would be bound per 
catalytically active homodimer (Liu, Y. et al, 1997), in contrast to the one active 
site in mammalian Class I ACs. This was confirmed by heterodimerization with 
differential active site mutants of GRESAG4.1: a single site mutant in a dimer 
with the wildtype resulted in a loss of 60% of the activity, consistent with the 
loss of one active site; whereas a differential double mutant dimer results in the 
activity falling below 10%. Dimers made from complementary mutants could 
restore the activity of one active site (Bieger, B. and Essen, L.-O., 2001). Super 
imposition of the active site of GRESAG4.1, GRESAG4.3 and the mammalian C1A, 
as well as a common key-residue active site mutagenesis profile all suggest that 
the actual mechanism of catalysis of ATP to cAMP in trypanosomal ACs is very 
similar to that of mammalian Class I ACs. 
The major structural difference between the T. brucei adenylyl cyclases and 
Class I ACs is the insertion of a 36 amino acid region in the loop between the α3 
helix and the β4 sheet (Figure 1.6). This insertion forms two extra helices called 
α3A and α3B and together have been called the ∆-subdomain. In Class I ACs the 
α3 – β4 loop is involved in the interaction of G-protein subunits; that 
trypanosomal ACs have such a variation at that particular point suggests the ∆-
subdomain may have a regulatory role and gives a structural reason for the 
inability of G-protein subunits to affect kinetoplastid ACs. Further analysis of the 
crystal structure of GRESAG4.1 and GRESAG4.3 show that together with the α4 – 
β7 loop and parts of β4 and β8, the ∆-subdomain forms a cavity of 95 Ǻ
3, large 
enough to be a binding pocket for a small molecule or protein co-factor that may 
exert an allosteric or regulatory effect on the enzyme (Bieger, B. and Essen, L.-
O., 2001). Interestingly, a recent analysis of the kinetoplastid genomes published 
to date, investigating adaptive evolution in a number of large multigene 
families, identified 29 trypanosomal adenylyl cyclases as having sites of 
predicted positive selection (Emes, R. D. and Yang, Z., 2008). The majority were 
located in the N-terminal extracellular region, whereas only 4 codons were 
predicted to have been subject to positive selection in the catalytic domain. 
These 4 amino acid changes are all apparently located on the α4 helix, possibly 
capable of interacting with the cavity enclosed by the ∆-subdomain. Matthew K Gould, 2009     Chapter 1, 50 
 
Figure 1.6: Reproduced from Bieger, B. and Essen, L., 2003. Overall structure of 
GRESAG4.1. The ∆-subdomain between α3 and β4 that is absent in other adenylyl cyclases 
is highlighted in orange. 
 
1.2.1.4  Why such diversity of adenylyl cyclase? 
With the genomes of a number of kinetoplastids recently published, the number 
of predicted adenylyl cyclases identified is surprisingly large: T. brucei has over 
50 putative ACs and (Laxman, S. and Beavo, J. A, 2007), at the last count, T. 
cruzi has at least 18 AC genes distributed over a minimum of 6 chromosomes 
(Cerquiera, G. C. et al, 2008). The question that immediately springs to mind is 
‘Why might a trypanosome need to have such a large panel of adenylyl cyclase 
enzymes?’ In reviews by Seebeck, et al (2001; 2004) the paradox of a relatively 
small cell size combined with an apparently overwhelming array of expressed 
ACs at any one time, has highlighted the necessity for strict regulation and 
modulation of the cAMP signal produced by the ACs. 
One explanation, already outlined above, is that the extracellular N-terminal 
domain acts as a receptor for small molecules or protein ligands; and that the 
diversity in this non-conserved region allows for substrate specificity and thereby 
specificity of response to the ligand. Probable positively selected sites of 
adaptive evolution have been identified in regions of the putative LBP 
homologous fragment that come into close proximity to the ligand after binding 
(Emes, R. D. and Yang, Z., 2008). No ligand has been positively identified as yet. Matthew K Gould, 2009     Chapter 1, 51 
However, a number of candidates have been uncovered. It was observed that 
preparations from the hindguts of the insect host of T. cruzi, that had been fed 
chicken blood, activated the epimastigotes form’s adenylyl cyclase as well as 
stimulate differentiation to the metacyclic form (Fraidenraich, D. et al, 1993). 
After HPLC and reverse-phase chromatography singled out a 10 kDa molecule 
which, when the first 20 amino acids were sequenced, was identified as part of 
chicken α
D-globin and the peptide was designated Globin-Derived Factor (GDF). 
A synthetic peptide made from amino acids 1 – 40 of chicken α
D-globin also 
stimulated AC activity, as did peptides 30 – 49 and 35 – 73 (Garcia, E. S. et al, 
1995). Similarly, for T. brucei, the crude membrane fraction of the 
proventriculus/esophagus of tsetse flies apparently activates the adenylyl 
cyclase enzymes of both bloodstream forms and procyclics (Van Den Abbeele, J. 
et al, 1995). However these observations do not appear to have been followed 
up. 
The cellular localization of the adenylyl cyclases of kinetoplastids may also 
impact on their diversity. In characterizing ESAG4 and GRESAG4.1, antibodies 
raised against recombinant ESAG4 were used in conjunction with immunogold 
staining to identify the localization of the AC families (Paindavoine, P. et al, 
1992). The antibodies used were not specific for ESAG4 over GRESAG4 related 
peptides, however they did show a specific cellular region with which they 
react: the cell surface and only along the flagellum. Interestingly the 
localization of ACs in bloodstream forms was apparently identical to that of 
procyclics. Similarly, in T. cruzi epimastigotes, the calcium-stimulatable TcAC 
was also found to be associated with the flagellum (D’Angelo, M. A. et al, 2002). 
In the TcAC characterization a yeast 2-hybrid system was developed to 
demonstrate dimerisation of the catalytic domain: if the TcAC domains, 
transfected into yeast in two different plasmids, closely interacted with each 
other the two reporter genes, also on the plasmids, would be expressed and 
would rescue the mutant yeast. Dimerisation of the catalytic domains was 
inferred in this manner. In addition, the yeast 2-hybrid approach was also used 
to identify putative regulators of the ACs by screening a cDNA library generated 
from epimastigotes. One of eight that rescued the mutant yeast phenotype 
encoded a portion of the protein paraflagellar rod, an integral component of the 
flagellum. A full length copy of the identified gene was transformed into the 2-
hybrid system and confirmed the interaction with TcAC by complementation of Matthew K Gould, 2009     Chapter 1, 52 
the yeast mutant, implying that the flagellar protein may have a role in 
regulation of the adenylyl cyclase activity (D’Angelo, M. A. et al, 2002).  
The localization of kinetoplastid ACs on the cell surface is the logical expected 
home for these proteins if they are the sensory receptors they are hypothesised 
to be, and the exposure to panoply of small host molecules and immunologically 
active components may have driven the sequence diversity of the N-terminal 
domain and helped generate the multiple gene families of ACs found in the 
respective genomes. As mentioned above, a study investigating adaptive 
evolution in T. brucei identified 29 ACs of having regions of positive selection 
(Emes, R. D. and Yang, Z., 2008). The majority of these regions can be found in 
the N-terminal domain homologous to the leucine-binding protein, specifically 
on the regions predicted to come into close contact with a putative ligand. The 
sequence diversity may give rise to the specificity of ligand recognition requiring 
a multitude of ACs to allow specific activation and cellular response due to a 
specific ligand found in the very different host environments. 
1.2.2 Apicomplexans 
1.2.2.1  Identification of non-mammalian AC in infected erythrocytes 
Early observations of adenylyl cyclase activity in Plasmodium-infected red blood 
cells (RBCs) attributed the changes in cAMP concentration to the host cell 
cyclases. It was noted that erythrocytes infected with strains of P. berghei had 
approximately 2-fold the concentration of cAMP compared to uninfected cells 
(Hertelendy, F. et al, 1979). Also, an investigation of the membrane-bound 
adenylyl cyclase activity of infected and uninfected RBCs suggested that the 
parasitised erythrocyte membranes displayed a 130% increase in AC activity 
compared to those of RBCs from an uninfected host; the AC activity of 
uninfected erythrocytes from an infected host was also raised, but only by 33% 
(Khare, S. et al, 1984).  
However, a more detailed study of the membranes of infected erythrocytes and 
of the isolated parasites identified an adenylate cyclase with characteristics 
different from those displayed by the ACs of the host RBC (Read, L. K. and 
Mikkelsen, R. B., 1991a). Parasites were separated from the host erythrocytes by 
N2 cavitation and Percoll gradient centrifugation and the AC activity profile of Matthew K Gould, 2009     Chapter 1, 53 
the parasite was compared with that of uninfected RBC membranes, as well as 
the AC activity from infected RBCs. The erythrocyte membrane ACs showed a 
marked stimulation of activity on incubation with G protein activators whereas 
the parasites did not show any effect; forskolin also greatly stimulated 
erythrocyte ACs but did not significantly increase the activity of the parasite’s 
cyclase. The two adenylyl cyclase profiles also displayed a differential 
preference for cation co-factor and optimal pH with the parasite ACs working 
better with Mn
2+ and maximally at pH 8.0 and the erythrocytes preferring Mg
2+ 
and pH 9.0. When the AC profile of the isolated parasite was compared to that 
of the erythrocyte still infected with Plasmodium it was found that the two 
profiles were highly similar suggesting that it is the parasite adenylyl cyclase 
that predominantly contributes to the intracellular cAMP of infected RBCs and 
not the host cell’s. This apparent contradiction of earlier work was explained by 
the authors as a function of the techniques used to separate the erythrocyte 
membranes from that of the parasites, with the methods used previously not 
being as discriminatory as thought at the time.  
1.2.2.2  Affect of AC on gametocytogenesis 
Reports as to the effect of cAMP and its signalling cascade on the differentiation 
of blood-stage malaria to gametocytes are also somewhat contradictory. 1 mM 
cAMP added to 4 day old cultures of Plasmodium falciparum in human 
erythrocytes resulted in 5 – 10 times more parasites transforming into 
gametocytes, with similar results for the cAMP analogue dibutyryl cAMP 
(Kaushal, D. C. et al, 1980). The effect of cAMP was narrowed down to the 
stationary phase of growth in culture when nearly 100% of parasites were 
stimulated to differentiate to gametocytes with cAMP, whereas the proportion 
induced to transform was much lower when cAMP was added to cultures in rapid 
growth. In stark contrast to the results above, cAMP was shown to have an 
inhibitory effect on gametocytogenesis in a different strain of Plasmodium 
falciparum, as well as inhibiting asexual growth in the ring-stage but not 
maturation in subsequent stages (Inselburg, J., 1983).  
Comparisons between two more strains of P. falciparum with differing abilities 
to produce gametocytes also implicated cAMP signalling. The parasites were 
isolated from their erythrocyte host cells and their adenylyl cyclase and cAMP-Matthew K Gould, 2009     Chapter 1, 54 
dependent protein kinase activities assessed. Both strains had a similar AC 
activity; however the protein kinase activities differed, with the strain that 
could produce gametocytes in vitro (LE5) being 3-fold higher than the strain that 
could not (T9/96) (Read, L. K. and Mikkelsen, R. B., 1991b). The data suggest 
that it is the inability of the cAMP-dependent protein kinase of strain T9/96 to 
respond to cAMP fluctuations caused by activation of the adenylyl cyclase that 
results in the inhibition of gametocytogenesis. 
1.2.2.3  cAMP and calcium cross-talk 
cAMP signalling has also been linked with the regulation of the synchronisation of 
the Plasmodium cell cycle in the mammalian host, in conjunction with the Ca
2+ 
signalling cascade. The symptomatic periodic fever of sufferers infected with 
malaria is caused by the synchronised rupturing of parasitized erythrocytes and 
the release of merozoites into the bloodstream. The mammalian hormone 
melatonin, which is synthesised in the pineal gland when the host is in darkness, 
has been implicated in the synchronisation of the maturation of parasites in the 
erythrocyte (Hotta, C. T. et al, 2000). Melatonin was shown to increase the 
cytosolic concentration of Ca
2+ in saponin-isolated Plasmodium trophozoites, 
probably via the activation of phospholipase C (PLC) and its production of 
inositol triphosphate (InsP3) resulting in the mobilisation of Ca
2+ from the 
endoplasmic reticulum (Hotta, C. T. et al, 2000). However, melatonin also 
stimulates an increase in the intracellular cAMP concentration in saponin-
isolated trophozoites, which can be blocked by the PLC inhibitor U73122, the 
calmodulin inhibitor calmidazolium and also by the calcium chelator BAPTA 
(Beraldo, F. H. et al, 2005). The hormone affects the maturation rate of blood 
stage malaria by speeding up transformation to the schizont stage (Hotta, C. T. 
et al, 2000). This stimulation can be mimicked by the cAMP analogue and PKA 
activator N6-benzoyl cAMP (6-Bz-cAMP), as well as the phosphodiesterase 
inhibitor IBMX. Furthermore, the melatonin stimulation can be completely 
abolished by the addition of PKA inhibitors providing strong evidence of cAMP 
signalling regulating cell cycle synchrony and sharing a common pathway with 
the calcium cascade (Beraldo, F. H. et al, 2005). While the cell cycle 
experiments were necessarily conducted with P. falciparum-infected 
erythrocytes, creating potential difficulties in the interpretation of signalling, 
the fact that melatonin was shown to act directly on the parasites (Hotta, C. T. Matthew K Gould, 2009     Chapter 1, 55 
et al, 2000; Beraldo, F. H. et al, 2005) is consistent with the PKA modulators 
also acting on the Plasmodium enzyme. 
Continued exploration of the effects of cAMP and melatonin on the cytosolic Ca
2+ 
concentration of Plasmodium unveiled a complex mechanism of cross-talk 
between the two signalling systems via PKA. The rise in cytosolic Ca
2+ due to 
exposure to melatonin is independent of the extracellular Ca
2+ concentration 
and of PKA, as the same level of calcium stimulation is achieved when melatonin 
is assayed against the parasite in Ca
2+ free medium and also in the presence of 
the PKA inhibitor PKI. The cAMP analogue and PKA activator 6-Bz-cAMP also 
increases cytosolic Ca
2+; however, unlike melatonin treatment, this rise is 
transient in calcium free medium, and is blocked by PKI, suggesting that the 
cAMP-induced Ca
2+ increase is mediated by PKA but different from the melatonin 
response. The PLC inhibitor U73122 had no effect on the Ca
2+ increase induced 
by 6-Bz-cAMP, again opposite to what happened with melatonin, but the 
addition of 6-Bz-cAMP after melatonin did not result in a further increase in Ca
2+ 
in the cytosol, suggesting that while the mobilisation of cytosolic Ca
2+ by 
melatonin and cAMP is triggered independently of each other, the two pathways 
utilise the same intracellular source of the calcium (Beraldo, F. H. et al, 2005). 
Further evidence of the identity of the intracellular calcium store utilized by 
both melatonin and cAMP pathways came with the use of thapsigargin (THG). 
THG inhibits the sarco-endoplasmic reticulum Ca
2+ ATPase (Pozzan, T, et al, 
1994) and caused a depletion of cytosolic Ca
2+ stores in Plasmodium. Pre-
treatment with THG thus prevented the cytosolic Ca
2+ increase caused by 
melatonin (Hotta, C. T. et al, 2000). 6-Bz-cAMP also could not increase cytosolic 
calcium after the THG-induced transient increase and vice versa when assayed in 
Ca
2+ free medium. However, 6-Bz-cAMP did induce a second rise in cytosolic 
calcium after that induced by thapsigargin (THG) when calcium was present in 
the assay medium (Beraldo, F. H. et al, 2005). The data suggest that cAMP and 
melatonin utilize the same intracellular store of calcium, but also that cAMP can 
mobilise calcium from the external environment of the parasite while melatonin 
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1.2.2.4  Isolation and characterisation of Plasmodium ACs 
Preliminary release of the Plasmodium falciparum genome database facilitated 
the identification of putative genes coding for the adenylyl cyclase activity. The 
conserved motifs of the catalytic domains from many diverse species were used 
to BLAST search the P. falciparum genome yielding two potential AC genes; one 
on chromosome 14 (PfACα) and the other on chromosome 8 (PfACβ). RT-PCR on 
total RNA from blood stage parasites and examination of upstream and 
downstream sequence data revealed PfACα to have 22 exons, with at least 3 
splice variations at the N-terminal end. Variant 1 was predicted to code for an 
81.2 kDa protein with 2 transmembrane (TM) domains, variant 2 coded for a 98.2 
kDa protein with 5 TM domains and variant 3, made up of all 22 contiguous 
exons, gave a full length 108 kDa protein with 6 TM domains (Muhia, D. K. et al, 
2003). 
PfACβ appears to be quite different from PfACα, having a double catalytic 
domain (C1 and C2) in comparison to the single catalytic domain of PfACα. Both 
the soluble and membrane-bound mammalian adenylate cyclases also have a 
pair of catalytic domains (Sunahara R. K. et al, 1996). Phylogenetic analysis of 
PfACβ puts it into a group containing all known soluble ACs including the 
mammalian bicarbonate sensor and a hypothetical protein from the mosquito 
Anopheles gambiae; PfACα clusters with putative adenylyl cyclases from other 
apicomplexans as well as prokaryotic organisms. Sequence alignments with a 
range of AC catalytic domains show the majority of conserved residues essential 
for catalytic function are present in both genes with the substrate specificity 
residue being lysine for the two Plasmodium genes and in all other known ACs 
(Muhia, D. K. et al, 2003). Interestingly both PfACα and PfACβ have amino acid 
inserts in the catalytic domain in the same position as the ∆-subdomain insert 
found in all kinetoplastid ACs, which has been hypothesized to have a regulatory 
ligand binding role (Bieger, B. and Essen, L.-O., 2001). 
Northern blot analysis of total RNA extracted from asexual and sexual blood 
stage parasites, at various time points after synchronisation with sorbitol or N-
acetylglucosamine (GlcNAc), respectively, showed that PfACα blood stage 
expression is confined to the gametocyte forms, maximally at stages II and III of 
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gametogenesis, indicating that AC activity may be necessary in the mosquito 
forms as well as mammalian forms (Muhia, D. K. et al, 2003).  
In order to express PfACα in a heterologous organism the entire gene was 
resynthesized with the codon bias of Xenopus laevis. This was due to the 
extremely high A/T base-pair percentage, in common with all other Plasmodium 
genes, which can interfere with correct expression in other systems. The full 
length splice variant 3 of PfACα was expressed in Xenopus oocytes resulting in a 
2.5 – 3-fold increase in intracellular cAMP in comparison to the control, 
demonstrating that PfACα is a functional adenylyl cyclase. Variants 1 and 3 
(fused with Yellow Fluorescent Protein) were similarly expressed in 
Dictyostelium discoideum, also resulting in an increase in intracellular cAMP. 
Cell lysates of the transformed D. discoideum showed that the highest AC 
activity was displayed in the presence of Mn
2+ for both variants rather than Mg
2+ 
as usual for mammalian ACs (Muhia, D. K. et al, 2003). 
Further characterisation of a resynthesized PfACα catalytic domain, using 
mammalian codon bias and expression in Sf9 insect cells, confirmed the 
preference for Mn
2+ over Mg
2+ and determined the Km at 115 µM ATP. 
Furthermore GTP was not a substrate and forskolin could not stimulate the AC 
activity (Weber, J. H. et al, 2004). The data from the heterologous expression of 
studies with PfACα are thus strikingly in agreement with the observations of 
Read and Mikkelsen (1991a) on increased AC activity in P. falciparum-infected 
erythrocytes (see section 1.2.2.1).  
Evidence that the N-terminal region of PfACα, which contains the 
transmembrane domains, acts as a putative ion channel emerged from work 
carried out on the homologous adenylyl cyclase genes in ciliates (Weber, J. H. et 
al, 2004). Primers designed from the PfACα genome sequence were used to 
produce a DNA fragment from Paramecium genomic DNA; this was then used to 
probe a Paramecium cDNA library and two clones were identified. Sequence 
analysis combined with membrane topology predictions unveiled a potential 
voltage gated ion channel in Paramecium and also in Tetrahymena, both 
organisms grouped into the Alveolata with the apicomplexans. The N-terminal 
region was made up of two blocks of transmembrane helices: block one 
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voltage gating; block two contained the remaining two TM helices (S5 and S6) 
which are predicted to form the ion pore. The putative ion pore is connected to 
the AC catalytic domain by a short 18 amino acid linker region suggesting the 
regulation of the cyclase activity by the ion channel. The ion pore region also 
contains the signature motif found in potassium channels, indicating the possible 
ion specificity reminiscent of the bifunctional AC/ion-channel activity reported 
earlier in Paramecium tetraurelia, which was blocked by potassium channel 
inhibitors (Schultz, J. E. et al, 1992).  
The domain structure of PfACα is predicted to be topologically identical to the 
ciliate AC with a high degree of conservation in the ion pore region and AC 
catalytic domain; some differences in the S4 transmembrane domain may 
indicate a difference in the range of voltage sensitivity, however. Homologous 
genes were identified in a range of Plasmodium species genome databases as 
well as in that of Toxoplasma gondii and Cryptosporidium parvum, however no 
such bifunctional ACs were spotted in other protozoa such as kinetoplastids, or 
in metazoan, eubacteria archea or plants – suggesting this protein arrangement 
may be unique to the Alveolata (Weber, J. H. et al, 2004). Attempts to express a 
resynthesized version of the Paramecium AC/ion-channel in heterologous 
systems did not result in any detectable cyclase or ion conductance activity, as 
did similar attempts to express the full length resynthesized PfACα. Expression 
of a PfACα catalytic domain fused to an N-terminal hexahistidine tag was 
successful and the results were described above (Weber, J. H. et al, 2004).  
Knock-out of the PfACα homologous gene in P. berghei revealed an essential role 
for this protein in exocytosis and hepatocyte infection by sporozoites, although 
the PbACα mutants were identical to wildtype in blood stages in mice and were 
unimpeded in the generation of gametocytes; similarly in the mosquito, oocysts 
and salivary gland sporozoite numbers were the same as wildtype. (Ono, T. et 
al, 2008). The active invasion of a host hepatocyte is brought about by apically 
regulated and expressed TRAP/SSP2 proteins. The expression of the exocytosis 
proteins is stimulated by migration through the cytoplasm of other host cells on 
the way to the hepatocytes and can also be stimulated by uracil and its derived 
nucleotides UMP, UDP and UTP. The membrane permeable cAMP analogue 8-
bromo-cAMP also induced exocytosis to a similar extent as the uracil derived 
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sporozoites. 8-bromo-cAMP and UD compounds incubated together with 
sporozoites did not result in an increased stimulation suggesting they use the 
same pathway to activate the expression of proteins involved in exocytosis. 
Interestingly, the uracil derivative induced stimulation of exocytosis protein 
expression was inhibited when the assays were carried out in potassium-free 
medium, as well as by incubation with K
+ channel inhibitors; however, 8-bromo-
cAMP could stimulate exocytosis protein expression in potassium-free medium 
suggesting that K
+ is required upstream of cAMP activated effectors, and is 
consistent with the hypothesis that the AC activity of PfACα can be regulated by 
an N-terminal potassium specific ion channel. Re-introduction of PbACα into the 
knockout clone fully restored the phenotype to that of the wildtype with respect 
to infectivity and exocytosis protein expression stimulated by uracil derivatives 
(Ono, T. et al, 2008).  Matthew K Gould, 2009     Chapter 1, 60 
1.3 Cyclic-nucleotide signalling in protozoa: guanylyl 
cyclases (GC) 
1.3.1 Apicomplexans 
1.3.1.1  Role of cGMP in exflagellation 
Early reports of cyclic nucleotide signalling involvement in exflagellation by the 
male gametocytes were somewhat equivocal. In Plasmodium gallinaceum the 
phosphodiesterase inhibitors 8-bromo-cAMP, Squibb 20009 and caffeine initiated 
exflagellation at pH 8.0; however, cyclic AMP analogues dibutyryl cAMP and 8-
OH-cAMP did not (Martin, S. K. et al, 1978). Caffeine also stimulated 
exflagellation at pH 7.4, unlike the other two inhibitors (Martin, S. K. et al, 
1978). In marked contrast, caffeine resulted in strongly inhibited exflagellation 
in P. berghei at both pHs (Kawamoto, F. et al, 1990). Cyclic GMP signalling was 
implicated when IBMX, cGMP, 8-bromo-cGMP and the guanylyl cyclase (GC) 
activator nitroprusside increased exflagellation in P. berghei and P. falciparum 
at pH 7.3 – a pH that is not normally permissive of exflagellation. Also, the GC 
inhibitor N-methylhydroxylamine inhibited exflagellation at the permissive pH of 
8.0 (Kawamoto, F. et al, 1990). 
Further evidence of a role for cGMP signalling in exflagellation came with the 
identification of xanthurenic acid as the gametocyte activating factor that 
triggered exflagellation in vivo. Purification of homogenates by HPLC followed 
by analysis of exflagellation-inducing fractions using mass spectrometry 
identified a molecule with a molecular weight of approximately 204, suggesting 
a molecular composition of C10H7NO4 (Billker, O. et al, 1998; Garcia, G. E. et al, 
1998). This formula is consistent with Xanthurenic acid, which displayed an 
identical mass spectrometry profile and induced exflagellation at concentrations 
in the same range as purified gametocyte activating factor. Purified membranes 
from gametocytes showed a markedly increased guanylyl cyclase activity 
compared to asexual blood stage membranes with a preference for Mg
2+ over 
Mn
2+ and that was inhibited by Ca
2+. Xanthurenic acid also stimulated GC activity 
in gametocyte membranes in a dose dependent manner, reaching a plateau of 
stimulation at 500 µM suggesting that the signal to exflagellate may be 
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1.3.1.2  Isolation and characterisation of ciliate and Plasmodium GCs 
A guanylyl cyclase gene was identified in ciliates with sequence and topology 
homology to a GC found in the then unfinished Plasmodium genome database. 
Originally an attempt to identify the ciliate adenylyl cyclase gene described 
above, a 328 base-pair PCR product presumed to partly code for a mammalian-
type AC was used to clone a guanylyl cyclase from a Paramecium cDNA library 
(Linder, J. U. et al, 1999). The gene coded for a large protein of 2412 amino 
acids with a calculated molecular mass of 282.6 kDa. Hydrophobicity analysis 
predicted five regions containing a total of 22 transmembrane domains; topology 
modelling predicted the protein consisted of two units: an N-terminal P-type 
ATPase-like region and a C-terminal with topology similar to mammalian 
membrane-bound adenylyl cyclases. Further analysis identified a double 
catalytic domain (C1a and C2a), similar to metazoan ACs, but the units appear 
to have switched position. Conserved motifs found in the C1a unit in mammals 
were found in the C2a unit in Paramecium and vice versa. All residues essential 
for catalytic function were conserved, with the substrate specificity residues 
suggesting guanylyl cyclase activity. The N-terminal P-type ATPase segment had 
several deviations from conserved regions in mammalian homologues, suggesting 
the function of the region has changed in Paramecium (Linder, J. U. et al, 1999). 
The Paramecium GC was resynthesized according to mammalian codon bias and 
expressed in HEK293 cells, showing GC activity in the membrane fraction of cell 
lysates. Expression in Sf9 cells gave similar results with a Km for MgGTP of 32 µM 
and specificity for GTP over ATP; however, some AC activity was observed in the 
presence of Mn
2+. Expression in the Sf9 cells resulted in proteolytic cleavage of 
the protein in the region linking the cyclase to the ATPase unit, suggesting that 
GC activity is not dependent on the presence of the ATPase-like section. 
Interestingly, expression of catalytic domain chimeras of Paramecium C1a and 
C2a subunits with bovine type VII AC showed that GC activity is preserved 
irrespective of the order of the catalytic subunits (Linder, J. U. et al, 1999). 
Two guanylyl cyclase genes were identified, isolated and analysed from 
Plasmodium falciparum and termed PfGCα and PfGCβ (Carucci, D. J. et al, 
2000). They both coded for large, apparently bifunctional proteins homologous 
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PfGCα was had one contiguous, intron-free open reading frame. PfGCβ, however 
had 12 introns – all confined to the N-terminal region, which has homology with 
P-type ATPase. The N-terminal domain showed most sequence similarity with a 
Ca
2+ ion pump, indicating that calcium may regulate cGMP production. The 
cyclase catalytic domain is well conserved between genes and across the 
Alveolata, with both displaying the switched catalytic subunits of Paramecium 
and Tetrahymena. Interestingly, PfGCα has an amino acid insert in the catalytic 
domain in the same relative position as the ∆-subdomain of trypanosomatid ACs 
(see section 1.2.1.3); PfGCβ does not, possibly inferring some degree of 
differential regulation. Northern blot analysis of RNA from blood stages showed 
that both genes appear to be specific for the sexual stages. Immunoelectron 
microscopy localised PfGCα to either the parasitophorous vacuole or the plasma 
membrane of the gametocyte; extracellular gametes did not appear to show any 
reactivity to the specific antibodies (Carucci, D. J. et al, 2000). 
Resynthesis and expression of the catalytic domains fused with a hexahistidine 
tag on the N-terminal in E. coli allowed limited characterisation of the 
Plasmodium guanylyl cyclases (Carucci, D. J. et al, 2000). No AC activity was 
found with either Mn
2+ or Mg
2+ but PfGCα showed no GC activity either. PfGCβ 
catalytic domains did show GC activity when assayed as individual domains, 
which was greatly increased when assayed in combination and entirely 
dependent on the presence of Mn
2+. 
Recently the homologous gene to PfGCβ was identified and knocked out in 
Plasmodium berghei (PbGCβ). Sequence analysis and RT-PCR indicated PbGCβ 
had 7 introns with the fully spliced transcript encoding a 2952 amino acid 
protein with a molecular weight of approximately 348 kDA. Topologically PbGCβ 
and PfGCβ are identical having 22 transmembrane domains and a P-type ATPase-
like region at the N-terminal linked to a C1a, C2a catalytic domain at the C-
terminal. Both genes share 68% identity and 82% similarity in the ATPase-like 
region and 84% and 89% identity and similarity respectively in the C1a, C2a 
cyclase domain. The PbGCβ gene was disrupted by a double crossover with T. 
gondii DHFR/TS replacing the C1 and C2 domains. 3 knockout clones were 
obtained which showed normal development in mice and normal exflagellation 
and zygote to ookinete transformation after fertilisation in vitro. In mosquitoes, Matthew K Gould, 2009     Chapter 1, 63 
however no oocysts could be found indicating an essential role for PbGCβ in the 
insect vector stage of the parasite’s life cycle (Hirai, M. et al, 2006).  
Further investigation using confocal microscopy showed that the number of 
knockout ookinetes in the midgut of mosquitoes was approximately the same as 
for the wildtype indicating that in vivo the mutants can correctly differentiate 
to that stage. However, while the knockout mutants could cross the peritrophic 
matrix of the midgut, invasion of the epithelial cells appeared to be severely 
inhibited. Horizontal motility of the ookinetes is also inhibited with the wildtype 
moving at a velocity of 5.7 ± 1.4 µm/min and the knockout moving much slower 
at 0.6 ± 0.1 µm/min (Hirai, M. et al, 2006). In vitro the PbGCβ knockout 
parasites could form oocysts and transform into infective sporozoites indicating 
that the GC is not involved in further development. It thus seems likely that 
disruption of PbGCβ and the resultant inability to penetrate the epithelial cell 
layer of the mosquito midgut may be directly attributable to the parasite’s 
severely reduced motility, ultimately leading to an inability to complete its life 
cycle. Matthew K Gould, 2009     Chapter 1, 64 
1.4 Cyclic-nucleotide signalling in protozoa: 
phosphodiesterase (PDE) enzymes 
1.4.1 Kinetoplastids 
The first phosphodiesterase activity identified in kinetoplastids was observed in 
Trypanosoma brucei gambiense (Walter, R. D., 1974), and was subsequently 
discovered in T. b. brucei, Trypanosoma cruzi and Leishmania species (Walter, 
R. D. and Opperdoes, F. R., 1982; Goncalves, M. F. et al, 1980; Al-Chalabi, K. A. 
K. et al, 1989). Attempts to purify the PDE activity from cell lysates showed that 
the vast majority of cAMP-PDE was contained in the soluble fraction of T. cruzi 
and T. brucei and L. mexicana (Goncalves, M. F. et al, 1980; Walter, R. D. and 
Opperdoes, F. R., 1982; Rascon, A. et al, 2000) and both cAMP and cGMP 
hydrolysing PDE activity was found in the soluble fraction of L. tropica (Al-
Chalabi, K. A. K. et al, 1989).  
The T. cruzi cAMP-PDE activity from lysed epimastigote forms was active in the 
presence of divalent cations, showing a preference for Mn
2+, giving a Km of 40 µM 
for cAMP; the PDE activity was not inhibited by theophylline or caffeine 
(Goncalves, M. F. et al, 1985). Later investigators, however, found two distinct 
peaks of activity after further purification of NaCl-gradient DEAE-cellulose 
column eluent by brain calmodulin-Sepharose affinity chromatography. The 
purified PDE was activated by Ca
2+/calmodulin and displayed a dual affinity 
profile with  Km values of 2.5 µM and 100 µM in the presence of 5 mM Mg
2+ 
(Tellez-Inon, M. A. et al, 1985). The calmodulin/calcium activation could be 
inhibited by the Ca
2+ chelator EGTA and also by the calmodulin antagonists 
chlorpromazine, fluphenazine and compound 48/80 (Tellez-Inon, M. A. et al, 
1985). 
The Leishmania tropica PDE activity from promastigote cell lysates also 
separated into two peaks of activity after column fractionation and required 
Mg
2+ to function optimally but was independent of Ca
2+ (Al-Chalabi, K. A. K. et 
al, 1989). The Km values for cAMP for both peaks were reported as being very 
high: 1.43 mM and 4.1 mM respectively and both peaks were capable of utilising 
cGMP as well as cAMP with the second peak displaying a slight preference for 
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theophylline and caffeine appeared to be better inhibitors of leishmanial PDEs 
than of T. cruzi PDEs, showing similar effects as on mammalian PDEs.  
Similar studies of the PDE activity of promastigote studies of L. mexicana 
identified and characterised different activities in cytosolic and purified plasma 
membrane fractions (Rascon, A. et al, 2000). The majority of the activity (~95%), 
like that found in T. cruzi, T. brucei and L. tropica, was cytosolic; however the 
remainder found in the plasma membranes was purified and enough protein was 
produced to characterise its hydrolyzing properties. Both PDE activities were 
cAMP specific with cGMP unable to stimulate or inhibit cAMP hydrolysation up to 
1 mM; the Km for cAMP for the soluble activity was 200 µM while that of the 
particulate fraction was considerably higher at 700 µM. The sensitivities to PDE 
inhibitors were also divergent with the soluble fraction having an IC50 for PDE 
inhibition by theophylline, caffeine and zaprinast of 30 mM, >50 mM and 2.8 mM 
respectively compared to the IC50 values for the particulate fraction of 3 mM 
(theophylline), 19 mM (caffeine) and 0.04 mM (zaprinast). The most potent 
inhibitor of both fractions, cibacron blue (IC50 = 8 µM and 20 µM for soluble and 
particulate fractions, respectively), along with the pyridazine fragment of the 
methylxanthines, was used as the structural basis for the creation of a series of 
analogues which, unfortunately, were no more potent (Dal Piaz, V. et al, 2002). 
Further characterisation of the soluble fraction’s PDE activity showed increased 
cAMP hydrolysation in the presence of Mn
2+ or Mg
2+, with a slight preference for 
magnesium with no stimulation by calmodulin/Ca
2+ (Rascon, A. et al, 2000). 
The utilization of molecular techniques combined with the recent releases of the 
genome databases of a range of kinetoplastids resulted in a major spur in cyclic 
nucleotide signalling research. Many phosphodiesterase genes were identified, 
cloned, sequenced, recombinantly expressed and biochemically characterised, in 
a relatively short space of time by multiple laboratories and collaborations. 
Unfortunately each group adopted a different naming convention for the 
publication of their identified enzyme resulting in a confusion of species 
abbreviations, numbers and letters threatening to slow and obfuscate scientific 
discourse on the subject. To rectify this, a unified nomenclature was published 
(Kunz, S. et al, 2006) laying down a straight-forward naming convention based 
on grouping phosphodiesterases by gene sequence homology and biochemical 
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in kinetoplastids (PDEA-D), all of which are present as homologues in the genome 
databases of Trypanosoma brucei, T. cruzi and Leishmania. 
1.4.1.1  Kinetoplastid PDEA 
In Trypanosoma brucei, PDEA was identified by complementation screening of a 
cDNA library in a yeast mutant deficient in phosphodiesterase enzymes and 
sensitive to heat shock. A single plasmid clone was isolated containing the 
majority of the open reading frame representing TbrPDEA (formerly termed 
TbPDE1) (Kunz, S. et al, 2004). The full sequence was later determined, 
predicting a 620 amino acid protein and a molecular mass of approximately 
70,000. The gene is located on chromosome 10 and is a single copy, but allelic 
polymorphism was uncovered by restriction enzyme digestion with BamHI. 
Sequence analysis indicated that the catalytic domain was well conserved 
between TbrPDEA and human PDEs, sharing approximately 30 – 40% identity with 
the eleven class I PDEs in humans and conserving the key signature motif of all 
class I PDEs His-Asp-[Leu/Ile/Val/Met/Phe/Tyr]-X-His-X-[Ala/Gly]-X-X-Asn-X-
[Leu/Ile/Val/Met/Phe/Tyr]. The almost complete absence of sequence identity 
in the N-terminal region outside the catalytic domain confirms TbrPDEA as being 
in a distinct family of class I PDEs separate from all other PDE families identified 
(Kunz, S. et al, 2004).  
Homologues of TbrPDEA have also been identified and characterised in 
Leishmania major and T. cruzi, having similar sequence characteristics (Johner, 
A. et al, 2006; Alonso, G. D. et al, 2007). Screening of the L. major genome 
database identified LmjPDEA, which is found on chromosome 18 and is also a 
single copy gene. The gene sequence predicts a protein of 631 amino acids and 
has the class I PDE signature motif conserved in the catalytic domain (Johner, A. 
et al, 2006). TcrPDEA was also identified by genome database mining and has 
48.2% amino acid sequence identity with TbrPDEA, being a single copy gene 
coding a protein of 619 amino acids and containing the class I PDE signature 
motif (Alonso, G. D. et al, 2007). 
Northern blots and RT-PCR identified expression of TbrPDEA mRNA in the slender 
and stumpy forms of bloodstream trypanosomes isolated from infected rats, as 
well as in procyclic forms cultured in vitro. Expression of the full length gene, 
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cerevisiae mutants lacking endogenous PDEs, confirming TbrPDEA is capable of 
phosphodiesterase activity. In spite of restoring the wild type phenotype in the 
yeast strain no significant PDE activity was measurable from cell lysates with 
either TbrPDEA construct. A similar lack of PDE activity in cell lysates was also 
observed after complementation of yeast PDE mutants with LmjPDEA and 
TcrPDEA suggesting a common feature of the gene which results in low 
expression in yeast (Johner, A. et al, 2006; Alonso, G. D. et al, 2007). However, 
expression of the N-terminally truncated form of TbrPDEA in the bacteria E. coli 
did produce an active enzyme in lysates, although the presence of Mg
2+ in the 
purification steps was essential in maintaining conformational stability as well as 
enzyme activity (Kunz, S. et al, 2004).  
As inferred from the purification requirements, divalent cations are necessary 
for optimal activity of TbrPDEA, with a preference for Mn
2+ over magnesium 
shown in the kinetic assays. The Km for cAMP in the presence of 10 mM Mg
2+ was 
surprisingly high at over 600 µM; a 100-fold excess of cGMP did not inhibit or 
stimulate cAMP hydrolysis designating TbrPDEA cAMP specific (Kunz, S. et al, 
2004). Most class I PDEs characterised from other organisms have a much lower 
Km, usually below 50 µM. However, expression of the full length TcrPDEA in E. 
coli confirmed the lower than usual affinity for cAMP in Trypanosoma PDEAs: 
TcrPDEA required a divalent cation for activity and had a Km of around 200 µM 
for cAMP in the presence of 10 mM Mg
2+ which was neither inhibited nor 
stimulated by cGMP (Alonso, G. D. et al, 2007). Interestingly calmodulin/Ca
2+ did 
not affect enzyme activity either indicating that TcrPDEA is not responsible for 
the calmodulin/Ca
2+-dependent PDE activity described earlier (Tellez-Inon, M. A. 
et al, 1985). The two recombinant Trypanosoma PDEA enzymes diverge with 
respect to inhibitor sensitivities, as the N-terminal truncated TbrPDEA is 
inhibited by sildenafil, trequinsin, ethaverine, dipyridamole and papverine with 
IC50 values below 30 µM. The full length TcrPDEA, on the other hand, was 
insensitive to any inhibitor up to 100 µM, although sildenafil, the most potent 
inhibitor of TbrPDEA (IC50 = 1 µM), was not tested. Theophylline and IBMX did not 
inhibit either recombinant protein (Kunz, S. et al, 2004; Alonso, G. D. et al, 
2007). 
A double knock out of PDEA by sequentially replacing both alleles in 
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demonstrated that the gene was non-essential for in vitro differentiation of 
bloodstream forms to procyclics or for procyclic infestation of the tsetse fly 
midgut (Gong, K. W. et al, 2001). Total PDE activity was reduced by 
approximately 20 – 30% in the mutant procyclic and bloodstream forms compared 
to wild type, which was restored almost exactly to wild-type levels by the 
ectopic expression of TbrPDEA from the procyclin locus. The resultant effect of 
the TbrPDEA knockout on the steady state level of intracellular cAMP was to 
increase it by approximately one third but morphology and motility of the knock 
out mutants were indistinguishable from the wild type. However, the procyclic 
generation time was increased by around 2.5 hours. No change was observed in a 
heterozygous knock out retaining one copy of the TbrPDEA gene or in the 
bloodstream form generation time. (Gong, K. W. et al, 2001). 
In Leishmania donovani promastigotes, overexpression of PDEA produced a 3 – 
3.5 fold increase in LdPDEA mRNA and protein levels. The resultant reduction in 
intracellular cAMP concentration was concomitant with a reduction in the level 
of upregulation of genes coding for oxidative stress-protection proteins that is 
associated with the differentiation to amastigote form upon entering the 
macrophage (Bhattacharya, A. et al, 2008). What is not clear is whether the 
overexpression of any other L. donovani PDE would have had the same effect or 
if it is solely limited to that of PDEA. Curiously, the inhibition of upregulation of 
the genes after temperature and pH shift is entirely reversed on addition of 20 
µM IBMX to the overexpressing promastigotes. This is surprising considering IBMX 
does not inhibit recombinant T. cruzi or T. brucei PDEA up to 1 mM (Kunz, S. et 
al, 2004; Alonso, G. D. et al, 2007), suggesting that the effects of PDEA 
overexpression were compensated by the inhibition of an IBMX-sensitive PDE, 
increasing overall cAMP content. 
1.4.1.2  PDEB 
Old name  New name  GeneDB 
assignation 
PDE1  PDEA  Tb10.389.0510 
PDE2A  none  Not in genome 
PDE2B  PDEB2  Tb09.160.3630 
PDE2C  PDEB1  Tb09.160.3590 
PDEC  PDEC  Tb927.3.3070 
PDED  PDED  Tb927.3.3340 
Table 1.2: Trypanosoma brucei phosphodiesterase revised nomenclature Matthew K Gould, 2009     Chapter 1, 69 
 
Basic gene features and enzyme characterisation 
The PDEB family contains two tandemly arranged genes, termed PDEB1 and 
PDEB2 (previously TbPDE2C and TbPDE2B, see Table 1.2). Both 
phosphodiesterase enzymes were first cloned and sequenced from T. brucei and 
share 99.6% amino acid identity in the catalytic core region (Zoraghi, R. and 
Seebeck, T., 2002; Rascon, A. et al, 2002). The open reading frames predict 
proteins of 930 amino acids in length and contain the class I PDE signature motif 
in the catalytic domains. Highly homologous genes were identified in T. cruzi 
with TcrPDEB1 being 918 amino acids in length (Diaz-Benjumea, R. et al, 2006) 
and TcrPDEB2 (previously termed TcPDE1) having 929 amino acids (D’Angelo, M. 
A. et al, 2004); the catalytic domains share 90 and 88% amino acid identity with 
T. brucei PDEB1 and PDEB2, respectively, and even higher identity within the N-
terminal region, each displaying 93% identity (Diaz-Benjumea, R. et al, 2006). 
Similar homology is evident in the Leishmania major PDEB1 and LmjPDEB2 
proteins, being 940 and 930 amino acid polypeptides (82% identical on amino 
acid sequence), respectively, and also presenting the canonical class I PDE 
motif. Interestingly, when the catalytic domains of LmjPDEB1 and LmjPDEB2 
were compared, a small stretch of 24 divergent amino acids was observed in the 
alomost perfectly conserved remainder. The position of this non-conserved 
region, spanning predicted helices 12 and 13, is the same as a similar divergent 
sequence in T. brucei and T. cruzi (Johner, A. et al, 2006). The functional 
significance of this hypervariable patch in the middle of the highly conserved 
catalytic domain is unclear and the authors speculate that this stretch might 
confer specific regulational or functional differences in the isoenzymes (Johner, 
A. et al, 2006). 
Full length protein expression of TbrPDEB1 in the phosphodiesterase knockout S. 
cerevisiae mutant resulted in complementation of the heat shock phenotype. In 
contrast to PDEA, PDEB1 activity was readily recovered from cell lysates and 
kinetic characterisation revealed the recombinant enzyme was cAMP specific 
with a Km of ~ 8 µM; cGMP did not compete with cAMP as substrate nor did it 
stimulate enzyme activity (Zoraghi, R. and Seebeck, T., 2002). Similar heat 
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homologue, which was cAMP-specific and yielded a Km value of ~ 1 µM (Johner, 
A. et al, 2006). TcrPDEB1 was expressed in HEK-293 cells, and parameters 
similar to TbrPDEB1 were measured from the lysates: specificity for cAMP with a 
Km of ~ 11 µM and neither inhibited or stimulated by cGMP (Diaz-Benjumea, R. et 
al, 2006). 
In view of the sequence similarity of PDEB1 with PDEB2, it is not suprising that 
the kinetic parameters of expressed PDEB2 proteins are very similar to those of 
the PDEB1s. TbrPDEB2 complements heat shock sensitive yeast, is cAMP specific 
with a Km of ~ 2.5 µM, and is neither inhibited nor stimulated by cGMP (Rascon, 
A. et al, 2002). Likewise, TcrPDEB2 is cAMP specific with a Km of ~ 7 µM 
(D’Angelo, M. A. et al, 2004), as is LmjPDEB2, also with a Km of ~ 7 µM (Johner, 
A. et al, 2006). 
The inhibitor profiles for both PDEB1 and PDEB2 are also similar across the 
kinetoplastid species. TbrPDEB1 was inhibited by trequinsin and dipyridamole 
with IC50 values of 13.3 and 14.6 µM respectively, and also by ethaverine, 
etazolate and sildenafil (IC50 = 26.8, 30.6 and 42.2 µM respectively); whereas the 
non-specific PDE inhibitor IBMX displayed an IC50 in the milli-molar range 
(Zoraghi, R. and Seebeck, T., 2002). Of the compounds tested against TcrPDEB1 
only dipyridamole had an inhibitory effect (IC50 = 11.3 µM) with IBMX ineffective 
up to 300 µM (Diaz-Benjumea, R. et al, 2006). This is in good agreement with the 
values for TcrPDEB2 which is also inhibited by dipyridamole with an IC50 of 17 µM 
(D’Angelo, M. A. et al, 2004). Both LmjPDEB1 and LmjPDEB2 are inhibited more 
than 50% by 100 µM etazolate, trequinsin and dipyridamole, with the latter being 
the most effective; again IBMX does not inhibit (Johner, A. et al, 2006). There 
appears to be some divergence between TbrPDEB1 and TbrPDEB2 with respect to 
inhibitor profile as sildenafil and etazolate inhibited TbrPDEB2 with IC50 values 
greater than 100 µM and dipyridamole displayed an IC50 of 27 µM – approximately 
2-fold that of TbrPDEB1; IBMX, however, remained non-inhibitory (Rascon, A. et 
al, 2002). 
Effects of RNA-interference of the PDEB family 
RNA-interference of the TbrPDEB family demonstrated that these enzymes are 
essential in bloodstream form trypanosomes. Initial attempts to generate 
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antibiotic selection but only lived for approximately 3 weeks (Zoraghi, R. and 
Seebeck, T., 2002). Under light microscopy the cells were oddly shaped and 
multinucleated before they died. Expression of the RNAi constructs in procyclic 
trypanosomes resulted in a lower proportion of similarly misshapen, multi-
nucleated cells.  Induction of the RNAi construct against TbrPDEB1 or TbrPDEB2 
resulted in a strong and specific reduction in mRNA levels for each gene, with a 
construct designed to target all TbrPDEB genes showing a complete loss of PDEB 
mRNA. The PDE activity was lowered upon induction of interference against the 
individual genes with a cumulative reduction of activity displayed on induction 
of the pan-TbrPDEB construct. The intracellular cAMP concentrations in procyclic 
cells were unaffected, however, by induction against TbrPDEB2 or against 
TbrPDEA. In contrast, cAMP levels were increased in the TbrPDEB1 RNAi mutants 
even without induction – with a 15-fold increase after induction compared to 
wild type control cells. Global induction against the TbrPDEB genes even 
resulted in a greater than 30-fold increase in intracellular cAMP, which was not 
lethal to the procyclic trypanosomes (Zoraghi, R. and Seebeck, T., 2002). One of 
the clear conclusions from this study is that bloodstream forms are highly 
sensitive to increased levels of cAMP, whereas the insect forms are relatively 
resistant to the cyclic nucleotide. A further indication for this is the much higher 
sensitivity of bloodstream forms to membrane permeable cAMP analogues 
(Oberholzer, M. et al, 2007). 
The inability to produce stable bloodstream form trypanosomes transfected with 
RNAi constructs against either PDEB1 or PDEB2 or both was ascribed to the 
vector used being slightly ‘leaky’, in that it may have produced some RNA 
interference without induction by the addition of tetracycline. This low level 
interference seems to have been sufficient to result in the lethal phenotype in 
bloodstream forms described above. In a follow-up study a different vector was 
used that maintained a much tighter control of the induction of RNA 
interference (Oberholzer, M. et al, 2007). As in the Zoraghi and Seebeck paper, 
RNAi against TbrPDEB1, TbrPDEB2 or both, had no effect on the survival or 
proliferation of procyclic T. b. brucei. Northern blot analyses showed that the 
constructs in both procyclic and bloodstream forms were effective at reducing 
target mRNA levels, and also that the knockdown of either TbrPDEB1 or 
TbrPDEB2 does not result in the upregulation of the other PDEs to compensate 
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and TbrPDEB2 in bloodstream forms also resulted in strong reduction of both 
genes’ mRNA and no compensatory upregulation of genes from the other 
trypanosomal PDE families (PDEA, PDEC and PDED). The effect on the phenotype 
of the bloodstream forms is emphatic, with the double-RNAi construct resulting 
in the cells rounding up and becoming multinuclear, multikinetoplastic and 
multiflagellar; RNAi against TbrPDEB1 and TbrPDEB2 individually had no 
apparent phenotypic effect. The ratio of the multiple nuclei to kinetoplasts in 
the double-RNAi induced cells was maintained at one, suggesting that DNA 
replication and segregation occur as normal, but that separation of the mother 
and daughter cells is blocked, apparently as a result of a cytokinesis defect. 
Normal proliferation of the bloodstream forms was completely disrupted, 
resulting in eventual cell death approximately 50 hours after double-RNAi 
induction. The effect on intracellular cAMP mirrored that of the morphological 
phenotype in that RNAi against the individual TbrPDEB genes did not result in a 
change in cAMP level in comparison to the control, but induction of the 
construct against both genes produced an approximately 100-fold increase in 
cAMP in the bloodstream forms. In procyclics the double induction only resulted 
in an approximately 10-fold increase in intracellular cAMP (Oberholzer, M. et al, 
2007). It would thus seem that bloodstream form trypanosomes can compensate 
for (most of) the loss of either PDEB activity but not for the loss of both 
simultaneously.  
Further investigation into the effects of inducing RNAi against PDEB genes in 
infected mice elegantly highlighted the essential nature of these proteins in 
vivo. Mice were infected with bloodstream form trypanosomes transfected with 
TbrPDEB1, TbrPDEB2 or the double-RNAi construct; all strains had a similar 
virulence without antibiotic RNAi induction, producing high parasitaemias after 3 
– 4 days post inoculation. Mice pre-treated with doxycycline in the drinking 
water for 2 – 3 days before and during the course of infection had similar 
parasitaemia levels when infected with the individual-gene RNAi-induced 
trypanosomes as the parental NYSM wild type control strain. In contrast those 
mice pre-treated with doxycycline and infected with the generic PDEB-RNAi 
transfected trypanosomes had no sign of parasitaemia for the entire duration of 
the experiment (35 days). The same effect was seen when the mice were 
immunocompromised with either cyclophosphamide or rolipram before infection 
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with the double-RNAi construct. Induction of the double RNA interference after 
infection had reached a moderate level of parasitaemia also allowed the mice to 
overcome the initial wave of parasitaemia. The mice eventually relapsed, 
although analysis of trypanosomes extracted from the relapsed mice showed 
they no longer responded to RNAi induction, possibly due to spontaneous 
mutation (Oberholzer, M. et al, 2007). This study, in conjunction with the earlier 
RNAi experiments, clearly show that TbrPDEB1 and TbrPDEB2 together are 
absolutely essential for the proliferation of bloodstream form trypanosomes, in 
vitro and in vivo, and that inhibition of both proteins results in cell death, 
validating the genes as excellent drug targets for future chemotherapies. 
GAF domains of PDEB 
The N-terminal region of PDEB1 and PDEB2, of all species in which they have 
been sequenced, contain two regions known as GAF domains. These domains, 
named after the first proteins in which they were identified – cGMP-specific and 
binding phosphodiesterases, adenylyl cyclase of Anabaena and FhlA of E. coli, 
have been shown to function as regulatory, small ligand-binding entities and in 
mammalian PDEs 2, 5 and 6 binds cGMP to modulate enzyme activity (Aravind, L. 
and Ponting, C. P., 1997). Since the characterisation of the recombinantly 
expressed PDEB1 and PDEB2 proteins ruled out modulation by cGMP the 
properties of the two GAF domains (GAF-A and GAF-B) were investigated further. 
Full length TbrPDEB2 and the N-terminally truncated TbrPDEB2 catalytic domain 
were expressed with a C-terminal epitope tag, allowing immunoprecipitation. A 
filter-binding assay with radio-labelled cAMP was then conducted on the two 
proteins in the presence of > 5 mM EDTA, which inactivates the nucleotide 
hydrolysis capabilities of the proteins by chelating the divalent cations essential 
for substrate binding and enzyme function. The [
3H]-cAMP bound only to the full 
length TbrPDEB2 protein and not to the catalytic domain protein (or control cell 
lysates) indicating that the two GAF domains present in the full length enzyme 
and not just the catalytic domain, bind cAMP (Laxman, S. et al, 2005). To verify 
this, the N-terminal section of TbrPDEB2 up to the end of the GAF-A domain was 
expressed and immunoprecipitated with [
3H]-cAMP, clearly demonstrating 
binding of the nucleotide. Affinity purification and assaying with labelled and 
unlabelled cAMP in a competition binding assay showed that cAMP bound to GAF-
A with an IC50 of ~17 nM. Binding of cGMP was also observed but with a 15-fold Matthew K Gould, 2009     Chapter 1, 74 
higher IC50 of ~290 nM; subsequent competition binding assays with the full 
length enzyme under non-catalytic conditions gave an IC50 for cAMP of ~60 nM, 
whereas for cGMP the IC50 had increased to ~ 12 µM indicating that the full 
length enzyme can discriminate between nucleotides even more efficiently than 
the GAF domains alone (Laxman, S. et al, 2005). Introduction of a point 
mutation in a conserved residue in GAF-A that was thought to be critical for 
ligand binding by homology modelling with the crystal structure of murine PDE2A 
GAF-B, resulted in a total loss of cAMP binding by TbrPDEB2 in the presence of 
EDTA, and also a four fold increase in the Km of the enzyme under normal PDE 
assay conditions. Not only does this indicate that the second GAF domain, GAF-
B, does not bind cAMP as a point mutation in GAF-A completely abolishes cAMP 
binding of the whole enzyme in the presence of EDTA, but also that GAF-A can 
modulate the activity of the catalytic domain by binding cAMP resulting in more 
hydrolysis at lower concentrations of cAMP (Laxman, S. et al, 2005). 
Similar binding of cyclic nucleotides was also observed by the GAF-A domains of 
TcrPDEB1 and TcrPDEB2, albeit with lower affinities. The N-terminal region, 
including the GAF-A domain, of both genes were expressed in E. coli and purified 
and competitive binding assays carried out. TcrPDEB2 GAF-A had a binding 
affinity of ~190 nM for cAMP. No binding of labelled cAMP could be detected 
with this method for TcrPDEB1 GAF-A. However, a calorimetric binding method 
assigned TcrPDEB1 GAF-A a binding affinity of ~1 µM andTcrPDEB2 GAF-A an 
affinity of ~0.5 µM. cGMP binding was also observed for TcrPDEB2 GAF-A, again 
with a much lower affinity than for cAMP (~ 2.5 µM); no cGMP binding could be 
measured with TcrPDEB1 GAF-A, however (Diaz-Benjumea, R. et al, 2006). 
Gene expression profiles and cellular localisation 
The mRNA of PDEB1 and PDEB2 appear to be expressed in both mammalian and 
insect host forms, as determined by RT-PCR and Northern blots in Leishmania 
major and T. brucei, and by Western blots of whole cell lysates from 
epimastigotes and trypomastigote forms in T. cruzi (Johner, A. et al, 2006; 
Zoraghi, R. and Seebeck, S., 2002; Oberholzer, M. et al, 2007; Diaz-Benjumea, 
R. et al, 2006). Subcellular localization experiments were first conducted in T. 
cruzi: successive centrifugation fractions from whole cell epimastigotes lysates 
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distribution as paraflagellar rod protein from the flagellum (D’Angelo, M. A. et 
al, 2004). Confirmation of the flagellar localization of PDEB1 and PDEB2 in T. 
cruzi came from immunofluorescent microscopy. The protein remained 
associated with the flagellum after treatment with Triton X-100 to remove 
cytoplasmic enzymes and NP-40 to prepare a cytoskeleton preparation, 
consistent with TcrPDEBs being integral membrane proteins of the flagellum or 
paraflagellar rod (D’Angelo, M. A. et al, 2004).  
Similar results were also observed in T. brucei where one allele of TbrPDEB1 and 
TbrPDEB2 was tagged with a triple HA tag and a triple c-Myc tag, respectively. 
Immunofluorescence microscopy of TbrPDEB1 in procyclics showed the protein 
was localized along the flagellum but only where the flagellum had exited the 
cell body. TbrPDEB2 had a minor fraction co-localized with TbrPDEB1, however 
the majority was distributed throughout the cytoplasm. Extraction with Triton X-
100 failed to release TbrPDEB1 and the flagellar associated TbrPDEB2, whereas 
the cytoplasmic TbrPDEB2 was easily removed. RNA-interference of PFR2, a 
major structural protein of the paraflagellar rod results in proteins normally 
associated with the structure amassing at the tip of the flagellum in a droplet 
shape. Tagged TbrPDEB1 accumulates in the tip of the flagellum on induction of 
RNAi against PFR2, as does a small portion of TbrPDEB2, clearly indicating that 
both are integrated into the paraflagellar rod structure. The remainder of the 
TbrPDEB2, however, is distributed normally in the cytoplasm showing dual 
localization of this isoform (Oberholzer, M. et al, 2007). 
Further sequencing and restriction enzyme profile analysis identified two alleles 
for TbrPDEB2 in the strain used in the protein localization studies (Lister 427). 
TbrPDEB2b has its GAF-A domain apparently replaced by the GAF-A from 
TbrPDEB1, whereas TbrPDEB2a corresponds to the sequence published in the 
genome database. TbrPDEB2b has 26 base-pair changes, compared to 
TbrPDEB2a, resulting in 9 amino acid substitutions, of which seven are 
conservative and two non-conservative (Kunz, S. et al, 2009). This allelic 
variation appears to be specific to those strains derived from the Lister 427 
strain; and the triple c-Myc tag used in the localization study was shown to be 
integrated into the B2b allele leading the authors to postulate that the dual 
localization of the protein may be allele specific. However, they disproved that 
hypothesis by showing that integration of the Myc tag into the TbrPDEB2 gene in Matthew K Gould, 2009     Chapter 1, 76 
procyclic cells of the STIB 247 strain, which did not have a GAF-A identical to 
that of TbrPDEB1 as in Lister 427, resulted in an identical dual localization of the 
protein. A similar distribution was observed in bloodstream form BS221 strain 
trypanosomes, derived from Lister 427 and retaining the PDEB1 GAF-A in the 
PDEB2 gene allele. Both alleles were independently tagged giving the same 
localization for one allele as the other (Kunz, S. et al, 2009). 
The crystal structure of PDEB1 catalytic domain of L. major 
A major advance in the quest for specific inhibitors of kinetoplastid PDEB genes 
came with the solving of the crystal structure of the catalytic domain of 
Leishmania major PDEB1 in complex with the non-specific inhibitor IBMX (Wang, 
H. et al, 2007). The PDEB1 fragment forms an apparent dimer on crystallization, 
with the catalytic domain made up of 16 α-helices and no β-sheets. The bottom 
of the catalytic pocket is taken up by two divalent metal ions which were 
assigned, without verification, to be Zn
2+ and Mg
2+ and form an octahedral 
binding configuration similar to that found in human phosphodiesterases. A low 
root-mean-squared-deviation (RSMD) for the position of the Cα atoms of selected 
amino acid residues indicates similar folding of the polypeptide compared to 
those of human PDEs; however four regions have significant differences. Two of 
these are in positions that have divergent insertions or deletions in almost every 
class I PDE characterised to date, but the other two are in the H9 helix of the H-
loop (residues 729 – 752) and in the M-loop (residues 858 – 882) (Figure 1.7), 
resulting in a positional shift compared to human PDEs of up to 3 Ǻ. This is 
predicted to significantly alter interactions with inhibitors (Wang, H. et al, 
2007), which is of obvious pharmacological interest. 
The binding of IBMX with the LmjPDEB2 catalytic pocket has two elements in 
common with almost all PDEs: the H-bond formed between the O6 atom of the 
xanthine ring and the invariant glutamine (residue 887) and the π-stacking of the 
ring of phenylalanine residue 890 and the xanthine ring of IBMX. The xanthine 
ring also forms weaker van der Waals’ contacts with amino acids Tyr680, Asn838, 
Val853 and Phe857. The isobutyl group from IBMX also interacts with Tyr680, 
Asn838 and Val853 as well as His681. Interestingly, IBMX only forms one H-bond, 
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two; IBMX is bound by LmjPDEB1 in the same orientation as PDE3B, PDE5A and 
PDE9A, whereas it is rotated 180º in PDE4D and PDE7A (Wang, H. et al, 2007). 
  
Figure 1.7: Reproduced from Wang, H. et al, 2007. The structure of LmjPDEB1 bound with 
IBMX 
 
The 3-D structure of LmjPDEB1 was superimposed over those human PDEs that 
have solved crystal structures in order to identify aspects of the catalytic 
domain unique to the parasitic PDE that may be utilized in the development of 
chemical inhibitors specific to the parasite. Generally, the catalytic pockets are 
quite similar, with the metal-binding residues His685, His721, Asp722 and 
Asp835, inhibitor-interacting Phe890 and catalytically important His681 and 
His725 being well conserved. Some subtle and not so subtle differences were 
identified, however, with glycine (886) and the invariant glutamine (residue 887) 
displaying the largest positional displacement compared to representatives of all 
eleven human PDEs. The invariant glutamine is conserved across the class 1 PDEs 
and plays an essential role in substrate and inhibitor binding; large positional 
changes may allow structural engineering of inhibitors to capitalise on this 
distinctive difference and confer selectivity for that compound over human 
PDEs. Other residues with significant differences in their positions, which could 
potentially interact with inhibitors are Asn838, Val839, Ser846 and Met874.  
The most unique feature of the crystal structure of LmjPDEB1, however, is the 
identification of a sub-pocket, within the active site, unenclosed at the bottom Matthew K Gould, 2009     Chapter 1, 78 
and essentially forming a pore or channel through the enzyme. The pocket 
(dubbed the ‘L-pocket’ by the paper’s authors) is gated by the residues Thr854, 
Met874 and Gly886. The latter, being conserved in four out of the five identified 
Leishmania major phosphodiesterases but found only in PDE10 of the human 
PDEs, can bend to accommodate any conformation due to its flexible backbone. 
The walls of the channel are formed by Thr854 and Tyr858 of the H14 helix and 
Leu883 and Gly886 of helix H15, with Asn881 of the M-loop making up the third 
wall. Met874 and Gly886 are separated by 7.5 Ǻ to leave the pocket open at the 
active site. The L-pocket has hydrophobic as well as hydrophilic characteristics 
and is large enough to accommodate a structure the size of a five-membered 
ring (Wang, H. et al, 2007). 
1.4.1.3  PDEC 
The TcrPDEC gene has some unusual characteristics for a kinetoplastid 
phosphodiesterase enzyme. It was identified by screening the T. cruzi genome 
database, amplified from genomic DNA by PCR and sequenced for analysis (Kunz, 
S. et al, 2005). Two different alleles were detected with 38 amino acid residues 
different between them: 21 conservative substitutions and 17 non-conserved. 
Although six amino acid differences were located in the catalytic domain none of 
them were predicted to be essential for the catalytic function of the enzyme. 
Southern blot analysis of restriction digested genomic DNA indicate TcrPDEC is a 
single copy gene. The open reading frame predicts a polypeptide of 924 amino 
acids with the catalytic domain situated in the middle of the protein (Thr291 – 
Ser657), whereas all other class I PDEs contain a C-terminal catalytic domain. 
The catalytic core contains the canonical class I PDE signature motif, confirming 
its grouping, in spite of its non-conforming functional domain arrangement. 
Amino acids important for catalytic function are all conserved. However, one of 
the residues conferring substrate specificity (Asn395) is substituted for alanine 
which, as is the case for human PDEs 5 and 6, might allow it to hydrolyse cGMP 
instead of cAMP. Indeed, it was demonstrated that TcrPDEC displays dual 
selectivity for cAMP and cGMP in the presence of Mg
2+, with Km values of 32 ± 9 
µm and 78 ± 25 µM, respectively – a unique feature for kinetoplastid PDEs 
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The N-terminal contains a FYVE-type domain (Pro10 – Gly73), along with two 
coiled-coil regions (Asp144 – Asp179 and Lys207 – Glu264) (Kunz, S. et al, 2005). 
Classical FYVE-domains bind to phosphatidylinositol-3-phosphate (PtdIns(3)P) 
embedded in the membrane, however, the FYVE-like domain of TcrPDEC has 
significant changes resulting in a decrease of the net charge of the region, 
making it unlikely that it binds to PtdIns(3)P. This opinion appears to be 
confirmed by the recombinant FYVE-domain of TcrPDEC not binding to 
PtdIns(3)P, or to a series of other phospholipids in a dot-spot assay(Kunz, S. et 
al, 2005). Investigation of the coiled-coil regions indicate they may be important 
to the quaternary structure of the protein. Gel filtration of recombinantly 
expressed TcrPDEC’s FYVE domain on its own indicates it migrates as a stable 
dimer. When the experiment is repeated with the addition of the coiled-coil 
regions to the recombinantly expressed FYVE domain the polypeptide is eluted 
with an apparent mass of ~200 kDa (calculated mass = 30.5 kDa), indicating a 
higher order complex is formed (Kunz, S. et al, 2005). Expression of the full 
length TcrPDEC in PDE-deficient yeast mutants complemented the heat-shock 
phenotype; as did expression of the TcrPDEC catalytic domain with the N- and C-
terminals truncated (Kunz, S. et al, 2005). Not only does this confirm that 
TcrPDEC is an active phosphodiesterase enzyme that can hydrolyse cAMP, but 
also that the FYVE domain and the coiled-coil regions are not essential for 
catalytic activity. The PDE inhibitors etazolate, trequinsin and dipyridamole all 
inhibit TcrPDEC with IC50 values of 0.7 µM, 3.9 µM and 6.9 µM, respectively, with 
papaverine having an IC50 of 25 µM. Interestingly IBMX inhibits TcrPDEC with an 
IC50 of 68 µM – by a large margin the lowest value seen for any of the 
kinetoplastids characterised so far. 
A similar characterisation of TcrPDEC independently confirmed much of the data 
presented in the previous study, with a few notable exceptions. TcrPDEC (named 
in TcPDE4 in this study) contains a FYVE-like domain, complements heat-shock 
sensitive yeast, prefers Mg
2+ over Mn
2+, has a Km for cAMP of ~20 µM, is inhibited 
by etazolate, trequinsin and dipyridamole with IC50 values in the single-figure µM 
range and IBMX being a much more potent inhibitor of TcrPDEC than any other 
kinetoplastid PDE, in agreement with Kunz et al, 2005 (Alonso, G. D., et al, 
2006). The second study, however, identified rolipram as a reasonable inhibitor 
of TcrPDEC, with an IC50 of ~10 µM, in contrast to no effect observed at up to 
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lysates was localised to the membrane extracts by Western blot analysis, as well 
as PDE activity being characterised only in the membrane lysates (Alonso, G. D. 
et al, 2006); Kunz, et al, found and characterised their TcrPDEC in the soluble 
extract. However, the biggest difference between the to studies is in the 
substrate specificity; although Alonso, et al, did not directly attempt to measure 
cGMP hydrolysing activity directly, cGMP did not compete with cAMP as a 
substrate for TcrPDEC up to a concentration of 2 mM, in contrast to Kunz, et al, 
determining a Km of ~ 80 µM for cGMP. The differences highlighted here may 
represent the differences between the two alleles of TcrPDEC, with the data 
from Kunz, et al, relating to TcrPDEC-1, and that of Alonso, et al, coming from 
characterisation of TcrPDEC-2. That two alleles of the same gene might code for 
proteins with such different characteristics is curious, and further investigation 
is required to confirm and expand on the work carried out so far. 
PDEC has also been identified in the genomes of T. brucei and Leishmania 
major, although apart from a cursory analysis of the predicted amino acid 
sequence confirming its belonging to the class I PDEs, no in-depth 
characterisation has yet been published. It was noted, however, that the L. 
major version, at least, had conserved the ‘dual-specificity’ alanine residue, 
indicating that in leishmania, the protein might also be able to hydrolyse cGMP 
(Johner, A. et al, 2007). 
1.4.1.4  PDED 
So far, PDED has not been cloned and recombinantly characterised from any of 
the kinetoplastids, although it does appear to be in the genome databases of all 
those kinetoplastids published. It is predicted that PDED is a single copy gene 
coding for a protein of approximately 700 amino acids, with its catalytic domain 
containing the conserved class I PDE signature motif and being C-terminally 
located (Kunz, S. et al, 2006; Johner, A. et al, 2007). 
1.4.2 Apicomplexans 
Characterisation of apicomplexan phosphodiesterase enzymes had been fairly 
limited in the pre-genomic era, other than to infer their modulatory presence 
being necessary due to the observation of adenylyl and guanylyl cyclase activity, 
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(PKA) and protein kinase G (PKG). However, four putative Plasmodium 
falciparum PDEs have now been identified, containing the class I signature motif 
and sharing approximately 40% amino acid identity (Yuasa, K. et al, 2005; 
Wentzinger, L. et al, 2008). A general naming convention was adopted and the 
four PfPDEs are now termed PfPDEα, β, γ and δ (Wentzinger, L. and Seebeck, T., 
2007). All four genes are predicted to contain between four and six 
transmembrane domains, unique amongst the class I PDEs, suggesting that they 
are all integral membrane proteins (Wentzinger, L. et al, 2008). 
1.4.2.1  PfPDEα 
The first apicomplexan PDE to be characterised, PfPDEα, is represented by at 
least two splice variants, PfPDEαA and PfPDEαB. The first investigation found an 
open reading frame made from two exons and predicted to code for a protein of 
884 amino acids (Yuasa, K. et al, 2005), whereas a second study identified the 
ORF as starting 210 base-pairs upstream, giving a protein of 954 amino acids 
(PfPDEαA) with a splice variant of 892 amino acids (PfPDEαB) (Wentzinger, L. et 
al, 2008). PfPDEαA is predicted to have six transmembrane domains in the N-
terminal, while PfPDEαB has helices 4 and 5 removed to give four membrane-
spanning domains. Although no other functional domains were identified, apart 
from the catalytic domain, a potential phosphorylation motif was found which 
could be phosphorylated by PKA, casein kinase II and/or tyrosine kinase, as well 
as a casein kinase II-specific motif after the last transmembrane helix and before 
the catalytic domain. These motifs are also present in Plasmodium vivax, P. 
yoelii and P. knowlesi homologues, indicating a possible conserved regulatory 
function (Wentzinger, L. et al, 2008). 
Producing a recombinant version of PfPDEα proved to be difficult, with attempts 
at expression of full length or N-terminally truncated catalytic domains in S. 
cerevisiae, and COS cells failing. However, expression of the hexahistidine-
tagged catalytic domain in E. coli was successful, and partially purified proteins 
from cells transformed with this fragment of PfPDEα showed 135-fold higher 
cGMP hydrolysing activity compared to the same fractions from control cells, 
with no cAMP hydrolytic activity observed. Divalent cations were necessary for 
proper catalytic function, with Mn
2+ preferred over Mg
2+ and Ca
2+; a Km of 0.65 
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class I PDE (Yuasa, K. et al, 2005). Similar data was recorded when the catalytic 
domain was resynthesized using bacterial codon preferences and N-terminally 
tagged with GST, giving a Km of 2 µM for cGMP in the presence of 5 mM Mg
2+ 
(Wentzinger, L. et al, 2008). The PDE inhibitor profile from both approaches at 
recombinant expression were also in good agreement, with zaprinast being the 
only compound tested with an IC50 below 10 µM (~ 3.5 µM) with dipyridamole, 
E4201 and sildenafil, all three human PDE5 inhibitors, having IC50 values of 22 
µM, 46 µM and 56 µM, respectively (Yuasa, K. et al, 2005; Wentzinger, L. et al, 
2008). 
Further investigation into the inhibition of PfPDEα was carried out by individually 
mutating Asp762 and Gly788 to alanine, two residues reported to be essential for 
substrate binding as well as that of the inhibitor zaprinast, in bovine PDE5A. The 
PfPDEαD762A mutant displayed no cGMP-PDE activity, in spite of recombinant 
production of the protein at the same level as the un-mutated catalytic domain, 
suggesting Asp762 is essential for the hydrolyzing activity of the enzyme in 
PfPDEα. PfPDEαG788A, on the other hand, maintained its PDE activity unchanged 
(Km for cGMP was 0.77 µM), and was inhibited by zaprinast with similar potency 
(IC50 = 5.6 µM). Since the glycine residue in bovine PDE5A is necessary for 
zaprinast binding, and no difference in inhibition by the compound is reported in 
the alanine-substituted mutant, this observation implies that there may be 
sufficient divergence in the catalytic domain of PfPDEα to allow the chemical 
engineering of a specific inhibitor (Yuasa, K. et al, 2005). Expression in the 
intraerythrocytic stages was investigated using reverse-transcriptase PCR. The 
abundance of PfPDEα transcripts mirrored the proportion of ring stages in the 
cultures, inferring stage-specific regulation of PfPDEα production (Yuasa, K. et 
al, 2005). 
The presence of the N-terminal transmembrane domains in the Plasmodium PDEs 
is highly unusual in class I PDEs, with no other family identified so far having 
similar regions. In order to determine if the PDEs are located in the membranes, 
as predicted, cytosolic and membrane fractions were purified from mixed blood 
stage cultures. The vast majority of cGMP-PDE activity was localized in the 
membrane fraction (Yuasa, K. et al, 2005; Wentzinger, L. et al, 2008), with an 
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The endogenous cGMP-hydrolysing activity could be inhibited by zaprinast with 
an IC50 of 4.1 µM, similar to the inhibition of the recombinant PfPDEα catalytic 
fragment. Treatment of asexual blood stage P. falciparum in vitro resulted in 
growth inhibition of the parasite with an ED50 value of ~ 35 µM, implying that 
cGMP-PDE activity is essential for the development and proliferation of blood 
stage Plasmodium parasites (Yuasa, K. et al, 2005). Interestingly, the effects of 
dipyridamole on P. falciparum infected erythrocytes had been investigated 
earlier, with the compound giving an IC50 for growth and development arrest of 
just 30 nM, and also inhibiting the invasion of erythrocytes by merozoites (Akaki, 
M. et al, 2002). The authors of that paper appeared to have overlooked 
dipyridamole’s PDE-inhibitory properties as they hypothesized that the mode of 
action of the drug was for it to bind to the erythrocyte surface, preventing the 
binding of the merozoite with its erythrocyte receptor. They futher discussed 
the growth arrest of the parasites inside the host erythrocytes in terms of 
nucleoside and anion transport inhibition and antioxidant effects. However 
inhibition of PfPDEα by dipyridamole has been demonstrated (Yuasa, K. et al, 
2005), albeit with an IC50 value of 22 µM rather than in the mid-nanomolar 
range, and part of the effects described in the Akaki paper may be due to 
inhibition of one, or more, of the other three PfPDEs. 
As a means of further characterising the function of PfPDEα, knock out mutants 
were derived by a double cross-over, replacing the PDE gene with human DHFR, 
which confers resistance to dihydrofolate reductase inhibitors. Two clonal lines 
were derived with no obvious morphological changes or disruption of the blood 
stage asexual cell cycle after the knock out of PfPDEα. However, it was observed 
that ring stages always appeared slightly sooner after synchronisation of the 
culture compared with the parental strain (Wentzinger, L. et al, 2008). RT-PCR 
determined that the other three PfPDEs were not upregulated to compensate for 
the loss of PDE activity and that PfPDEγ and PfPDEδ are only expressed at very 
low levels in blood stages. These data suggest that PfPDEα is not an essential 
enzyme in blood stage Plasmodium, at least during in vitro culture, and that the 
other PDE that is highly expressed in intraerythrocytic stages, PfPDEβ, may be 
more important for controlling cyclic nucleotide levels. The effect of the knock 
out on overall PDE activity showed an approximately 20% reduction in cGMP 
hydrolysation with no effect on cAMP-PDE activity. This confirms the data from 
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specificity, and also implies that at least one other PfPDE is capable of cGMP-
PDE activity and that it is (they are) expressed at the same time. 10 µM of 
zaprinast reduces cGMP-PDE activity by ~50% in both the knock out and its 
parental strain suggesting that at least one of the remaining PDEs is not sensitive 
to the inhibitor and that one is. Furthermore, when cAMP was present in excess, 
cGMP-PDE activity was reduced by 20% in the membrane fraction of wild-type 
parasites compared to more than 60% in the knockout suggesting that at least 
one of the remaining PfPDEs is inhibitable by cAMP. When cGMP was present in 
excess cAMP-PDE activity was also reduced in both wild type and PfPDEα knock 
out strains. Taken together with the fact that PfPDEα is cGMP-specific, the 
above data suggests that at least one out of PfPDEβ, γ, or δ is a dual substrate 
phosphodiesterase enzyme (Wentzinger, L. et al, 2008). 
1.4.2.2  PfPDEβ 
The PDEβ gene is located on chromosome 13 of Plasmodium falciparum. 
Sequencing of PfPDEβ after PCR amplification from cDNA extracted from 
asynchronous blood stage culture revealed a gene of 3420 base-pairs coding for a 
protein of 1139 amino acids. The catalytic domain is located at the C-terminal 
end of the polypeptide and the N-terminal contains six transmembrane domains 
suggesting it is an integral membrane protein. Interestingly, Hidden Markov 
Modelling of the transmembrane regions predicts that PfPDEβ is oriented in the 
membrane so that the catalytic domain is not exposed in the parasite cytosol but 
is actually projecting into the parasitophorous vacuole; this may allow the 
parasite to modulate the cyclic nucleotide milieu of the host erythrocyte. RT-
PCR of total RNA extracted from blood stages, in combination with knocking out 
PfPDEα, indicates it is the predominantly expressed PDE in these stages. So far, 
recombinant expression of PfPDEβ has proved unsuccessful in numerous systems 
and with different methodologies (Wentzinger, L. et al, 2008). 
1.4.2.3  PfPDEγ 
PDEγ is also found on chromosome 13 of Plasmodium falciparum, approximately 
3000 base-pairs downstream of PfPDEβ and transcribed from the opposite strand 
of DNA. Sequencing of PfPDEγ identified an open reading frame of 2310 base-
pairs made from nine exons and coding for a protein of 769 amino acids, a 
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(Wentzinger, L. et al, 2008). PfPDEγ is predicted to have six transmembrane 
helices, with Hidden Markov Modelling indicating a normal, i.e. cytosolic, 
orientation of the catalytic domain (Wentzinger, L. et al, 2008). In an 
investigation into gametogenesis (see below), PfPDEγ was knocked out as an 
experimental control. No aberrant phenotype in gametocytes was observed, with 
normal rounding up and exflagellation upon stimulation by xanthurenic acid, and 
displayed unchanged phosphodiesterase activities for cGMP and cAMP. It was 
concluded that this protein is not essential in gametogenesis (Taylor, C. J. et al, 
2008). 
1.4.2.4  PfPDEδ 
PDEδ, an open reading frame of 2448 base-pairs made from six exons coding for 
a protein of 815 amino acids, is located on chromosome 14 of Plasmodium 
falciparum. PfPDEδ also contains six transmembrane regions in the N-terminal 
and, like PfPDEβ, is predicted to have its C-terminal catalytic domain exposed to 
the parasitophorous vacuole (Wentzinger, L. et al, 2008). 
Previous work had observed that cGMP-PDE inhibitor zaprinast could stimulate 
rounding up and exflagellation of gametocytes in the absence of xanthurenic 
acid, implicating the cGMP signalling pathway in male gametocyte exflagellation 
(McRobert, L. et al, 2008). However, knocking out guanylyl cyclase PfGCβ failed 
to produce any significant change in gametocyte phenotype, leading to the 
hypothesis that cGMP degradation rather than production was critical in 
gametogenesis.  Because of the high level of PfPDEδ mRNA expression, compared 
to the other PfPDEs, in developing and mature gametocytes, PfPDEδ knock outs 
were generated in order to investigate the involvement of cGMP metabolism 
further (Taylor, C. J. et al, 2008). Analysis of the particulate fractions of lysed 
stage V gametocytes showed an approximately 50% reduction in cGMP-PDE 
activity compared to wild type, indicating PfPDEδ does hydrolyse cGMP and also 
that at least one other cGMP-PDE is expressed in this parasite stage. Zaprinast 
reduced the wild type PDE activity by approximately 75%, whereas in the knock 
out parasites the activity was removed completely, indicating PfPDEδ is at least 
partly resistant to the inhibitor and also that the residual PDE activity is made 
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Phenotypically, the PfPDEδ
- mutants generated normal gametocytes. However, 
their ability to round up and exflagellate on stimulation by xanthurenic acid was 
significantly reduced. A similar effect was observed on treatment with zaprinast. 
On examination of the ability of the gametocytes to emerge from infected 
erythrocytes, less than 20% of the PfPDEδ
- mutants emerged after stimulation 
with XA compared to nearly 60% emergence by the control strain, as measured 
by reactivity to a Band 3 antibody. This indicates that PfPDEδ is important for 
both male and female gametogenesis (Taylor, C. J. et al, 2008). The authors of 
this study propose that xanthurenic acid stimulates guanylyl cyclase activity, 
thereby increasing the cGMP level which, in turn, activates PKG to trigger 
gametogenesis. PfPDEδ, in conjunction with other minor PDEs in this stage, 
degrade the cGMP signal allowing further gametocyte development, eventually 
resulting in full gametogenesis. A sustained increase in cGMP, for example by 
inhibiting PfPDEδ, retards development once gametogenesis has been initiated 
(Taylor, C. J. et al, 2008). A specific PfPDEδ inhibitor would have the effect of 
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1.5 Cyclic-nucleotide signalling in protozoa: protein 
kinases (PK) 
1.5.1 Kinetoplastid PKA 
1.5.1.1  Trypanosoma brucei 
Cyclic AMP-dependent protein kinase (PKA) activity has been associated with a 
number of processes in Trypanosoma brucei, but mostly by inference from the 
presence of adenylyl cyclases and cAMP-specific phosphodiesterases in the 
parasites, as well as by analogy with mammalian systems which use PKA as the 
main cAMP signalling effector protein. One such study implicates PKA in 
inhibition of disaggregation of T. brucei from anti-VSG antibodies in the 
mammalian bloodstream (O’Beirne, C. et al, 1998). Incubation of bloodstream 
forms with anti-VSG antibodies results in the cells clumping together; these 
clumps quickly disaggregate in an energy dependent fashion which does not 
result in the release of VSG nor damages the viability of the parasite. This 
disaggregation can be inhibited by the addition of extracellular cGMP or cAMP 
and its membrane-permeable analogues, and also by 5 mM of the PDE inhibitor 
theophylline and several protein kinase inhibitors. The authors concluded that 
an increase in intracellular cAMP concentration activates a cAMP-dependent 
protein kinase that inhibits the disaggregation process (O’Beirne, C. et al, 1998). 
The first actual measurement of cyclic nucleotide-dependent protein kinase 
activity in Trypanosoma brucei came with the identification and sequencing of a 
trypanosomal PKA regulatory subunit. In mammals the PKA holoenzyme is found 
in an inactive state, with two catalytic subunits (PKA-C) bound in a 
heterotetramer to two regulatory subunits (PKA-R). When cAMP binds to the 
regulatory subunits, a conformational change activates the phosphorylating 
catalytic domain by releasing the PKA-C subunit from the holoenzyme. In T. 
brucei, a fragment of protein with high homology to eukaryotic regulatory 
subunits of PKA was identified by searching the draft genome database for 
proteins containing putative cAMP-binding domains (Shalaby, T. et al, 2001). PCR 
amplification of the sequence allowed screening of genomic and procyclic cDNA 
libraries, which uncovered the entire open reading frame of the gene, as well as 
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subunit was probably a single-copy gene. The gene, named TbRSU, encodes a 
protein of 499 amino acids giving a predicted molecular weight of approximately 
57 kDa. The protein has the usual two cyclic nucleotide-binding domains 
(residues 243 – 360 and 363 – 483) which are predicted to retain all the 
conserved residues necessary for function, as well as a pseudo-inhibitor site 
which interacts with the catalytic subunit. Despite this broad homology with 
type I mammalian PKA regulatory subunits, some sequence deviations are 
apparent. Arginine residues conserved in both cyclic nucleotide-binding domains 
are replaced by threonine and asparagine (residues 318 and 442, respectively); 
also, eight residues before each of these substitutions a conserved alanine is 
replaced by glutamic acid (residues 311 and 435). A third difference in the 
nucleotide-binding region is a substitution at residue 319: in all cAMP-binding 
domains this residue is alanine, whereas in cGMP-binding domains of cyclic GMP-
dependent protein kinase (PKG) this amino acid is either a serine or threonine. 
Uniquely, this amino acid is valine in TbRSU (Shalaby, T. et al, 2001). 
The recombinant expression in E. coli, and subsequent purification, of a 
fragment of TbRSU allowed antibodies to the full-length protein to be raised. 
Immunoblots of whole cell lysates with the anti-TbRSU antibodies detected the 
protein in both bloodstream and procyclic forms; however, TbRSU protein levels 
were higher in the bloodstream forms than in procyclics. This confirmed 
Northern blot analysis of total RNA that showed an approximately five times 
higher level of messenger RNA for TbRSU in the former rather than in the latter 
trypanosome life cycle stage (Shalaby, T. et al, 2001). 
Native TbRSU was immunoprecipitated from whole cell lysates using the 
polyclonal antibodies against the protein fragment. Immunoprecipitation using 
antibodies generated against the bovine catalytic subunit of PKA co-precipitated 
a protein of approximately 40 kDa, indicating that the trypanosomal PKA-C 
subunit co-precipitates with TbRSU. The co-precipitates displayed 
phosphorylating activity, transferring a phosphate to classical PKA-specific 
substrates, as well as being inhibited by the peptide inhibitor PKI (also specific 
for PKA). Surprisingly, however, cAMP did not stimulate phosphorylating activity 
of the purified lysates, and in some assays may actually have been inhibitory. 
Even more unexpected was the finding that cGMP stimulated kinase activity by 3 
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activity, an observation unique to T. brucei out of all the eukaryotic PKA 
homologues characterised at that point (Shalaby, T. et al, 2001). 
To investigate the cNMP binding further, the binding domains were individually 
expressed in Drosophila S2 cells and purified. Domain A had a dissociation 
constant for cGMP of 7.5 µM while domain B had a Kd of 11.4 µM. cAMP did not 
compete with cGMP up to concentrations 100-fold in excess, confirming the 
binding substrate-specificity of the regulatory subunit in purified whole cell 
lysates (Shalaby, T. et al, 2001). It thus appears that T. b. brucei expresses a 
PKG activity, but no functional PKA activity has been demonstrated to date. 
1.5.1.2  Trypanosoma cruzi 
cAMP-dependent PKA activity was characterised in T. cruzi epimastigotes cell 
lysates after DEAE-cellulose and affinity chromatography with histone IIA and 
cAMP. A cAMP-stimulated protein kinase fraction was identified, with a half-
maximal effect at approximately 1 nM cAMP; the kinase was not affected by 
cGMP but its phosphate-acceptor preferences were as expected for a cyclic AMP-
dependent protein kinase (Ulloa, R. M. et al, 1988). 
The apparent holoenzyme was then separated into the catalytic and regulatory 
subunits by further chromatography in the presence of cAMP which, when bound 
by the nucleotide binding domains of the regulatory subunit, releases the 
catalytic protein from the holoenzyme. Experiments with and without the 
regulatory fraction showed that the catalytic subunit was only activated by cAMP 
in the presence of the regulatory fraction. The same results were obtained when 
the T. cruzi catalytic fraction was reconstituted with bovine heart regulatory 
subunit, and vice versa. Immunoblotting of purified epimastigote cell lysates 
using anti-bovine type-II regulatory subunit antibodies also identified a 56 kDa 
band from both bovine heart and T. cruzi extracts, confirming the kinase activity 
isolated from T. cruzi was that of PKA and that similar functional subunits are 
employed to make up similar holoenzymes in the parasite and mammalian 
systems (Ulloa, R. M. et al, 1988). 
A follow up study which further characterised the catalytic subunit of cAMP-
dependent PKA from T. cruzi confirmed the similarity of subunit makeup of the 
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the sedimentation constant, Stokes’ radius and partial specific volume, giving a 
relative molecular weight of around 40 000 (Ochatt, C. M. et al, 1993). This 
figure was substantiated by SDS-PAGE of the parasite catalytic subunit and 
Western blots using anti-bovine heart PKA-C. Similar calculations from data for 
T. cruzi PKA-C reconstituted with the PKA-R subunit estimated the holoenzyme 
in T. cruzi to have a relative molecular weight of approximately 200 000. This 
figure, when also taking into account the size of monomeric T. cruzi PKA-R being 
~ 57 kDa (Ulloa, R. M. et al, 1988), is consistent with a tetrameric molecule 
made up of two catalytic subunits bound with, and inhibited by, two regulatory 
subunits (Ochatt, C. M. et al, 1993). The kinetics of the native PKA catalytic 
subunit were observed to give Km values of 40 µM for ATP and of 48.6 µM and 26 
µM for histone IIA and kemptide as phosphate acceptors, respectively (Ochatt, C. 
M. et al, 1993). 
The gene encoding the T. cruzi PKA catalytic subunit was identified after 
degenerate PCR primers were designed from conserved domains of the ACG 
serine/threonine protein kinase family and the resulting product was used to 
screen genomic DNA libraries. The full-length TcPKA-C gene encoded a protein 
329 amino acids long, sharing 80% and 57% sequence identity with two putative 
Leishmania PKAs, as well as 67% identity with the PKA-C of Euglena gracilis 
(Huang, H. et al, 2002). Further sequence analysis identified all necessary 
residues and signature motifs of the catalytic core of a PKA; however, the FXXF 
motif is uniquely situated at the extreme C-terminal end of the parasite protein, 
and the N-terminal lacked the myristoylation motif usually found in mammalian 
PKA-Cs. A potential proteolytic cleavage site, relatively well conserved in L. 
major and E. gracilis, was also detected, and may allow another mode of 
regulation of the protein kinase activity. Northern blot analysis identified TcPKA-
C in all stages of the parasite’s life cycle albeit at a relatively low level in the 
mammalian forms. Southern blotting of restriction digests of T. cruzi DNA gave a 
banding pattern consistent with either allelic variation of a single copy of TcPKA-
C, or the presence of a second related TcPKA-C gene in the parasite’s genome 
(Huang, H. et al, 2002). A BLAST search with the original sequence for TcPKA-C 
from this paper identifies at least three separate isoforms with P values below e-
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TcPKA-C was recombinantly expressed in E. coli and cell lysates were assayed for 
phosphorylating activity. TcPKA-C could phosphorylate kemptide, and was 
inhibited by the PKA-specific peptide inhibitor PKI, suggesting the T. cruzi 
protein is a homologue of PKA. GST-tagged recombinant TcPKA-C was affinity 
purified and used to raise polyclonal antibodies against the parasite protein. The 
antibodies detected an approximately 40 kDa protein in epimastigote forms only; 
similar results were obtained using antibodies raised against a fragment from the 
PKA-C from C. elegans which also cross-reacts with mammalian PKA-Cs. 
Confirmation of the differential expression of T. cruzi PKA-C came from 
measuring the protein kinase activity in the differing life cycle forms, 
determined as the difference between phosphorylating activity with or without 
PKI in the presence of 1 mM cAMP. The PKA activity was approximately 4 times 
higher in the epimastigote forms than in mixed lysates of trypomastigote and 
amastigote forms. Immunohistology using the anti-TcPKA-C antibodies localised 
the protein to the cytosol in all life cycle stages (Huang, H. et al, 2002). The 
activity of recombinant TcPKA-C was completely inhibited by the peptide 
inhibitor PKI; specific inhibitors of PKC/CaMK had no effect on the kinase 
activity of the recombinant T. cruzi catalytic subunit (Huang, H. et al, 2006). 
Recently the T. cruzi PKA regulatory subunit was also cloned and characterised. 
The deduced open reading frame encodes a protein of 503 amino acids, 
containing all the domains and motifs of known PKA-R subunits including two 
cyclic nucleotide-binding domains and an autophosphorylation site (Huang, H. et 
al, 2006). Sequence analysis showed the protein shares 72% identity with the 
PKA-R from T. brucei and 63% identity with that from L. major. Southern blots of 
restriction digests show that in T. cruzi the PKA regulatory subunit is probably a 
single copy gene. 
TcPKA-C kinase activity was completely inhibited by the addition of the 
recombinant TcPKA-R subunit, with the catalytic activity being partially restored 
by 100 µM cAMP (Huang, H. et al, 2006), seemingly substantiating the classical 
PKA-C/R holoenzyme modulation by cAMP. However, the data presented in this 
study shows cAMP dramatically stimulating the kinase activity of the 
recombinant TcPKA catalytic subunit on its own, to many times that of the basal 
activity without cAMP. This is at odds with the native kinase characterisation 
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epimastigote lysates, and that addition of cAMP to the reconstituted catalytic 
and regulatory fractions only serves to return the kinase activity to the basal, 
catalytic subunit-only level (Ulloa, R. M. et al, 1988). It is also at variance with 
the mammalian PKA holoenzyme paradigm where cAMP does not act on PKA-C, 
but essentially de-represses the inhibitory effect of the regulatory subunit by 
binding to specific PKA-R domains. The nucleotide binding by the R-subunit 
results in conformational change and release of the catalytic subunit, thereby 
allowing the full phosphorylating activity of the catalytic peptide. It is unclear 
how cAMP would stimulate the recombinant T. cruzi PKA catalytic subunit on its 
own and what this implies for cyclic nulceotide regulation of the holo-enzyme. If 
cAMP stimulates the catalytic subunit directly, might the regulatory subunit be 
regulated by a different factor, such as cGMP in T. brucei PKA-R (Shalaby, T. et 
al, 2001), allowing cross-talk between signalling pathways. 
Evidence of cAMP-dependent protein kinase activity has also been uncovered in 
Trypanosoma evansi lysate fractions. Intriguingly, cAMP had no effect on 
phosphorylating activity of whole cell lysates or particulate fractions, but a 
doubling of kinase activity was recorded in the soluble fraction. This stimulation 
could be inhibited almost completely by the addition of PKI (Galan-Caridad, J. 
M. et al, 2004). The results could be interpreted as evidence for the presence of 
kinase inhibitory factors that are not sensitive to cAMP in whole cell lysates, but 
have been removed by fractionation of the soluble extracts. 
In order to show that the two characterised T. cruzi PKA subunits interact in 
their native state, specific monoclonal antibodies to both peptides were 
generated. Individual immunoprecipitates of epimastigote lysates using the anti-
TcPKA-C and anti-TcPKA-R antibodies pulled down complexes which were then 
immunoblotted to identiy their components. Those complexes precipitated by 
anti-TcPKA-C antibodies reacted with anti-TcPKA-R, and vice versa, 
demonstrating that the two subunits do interact with each other in T. cruzi 
whole cell lysates. Also, the complex precipitated by the anti-TcPKA-R 
antibodies was assayed for kinase activity showing stimulation on addition of 
cAMP which was greatly inhibited by the further addition of PKI, showing the 
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Immunoblots with anti-TcPKA-R antibodies of whole cell lysates from 
trypanosomes from all three life cycle stages showed differential expression. 
The highest expressing stage was the trypomastigote form, followed by the 
epimastigotes, with amastigotes having the least TcPKA-R. This pattern was 
similar as for TcPKA-C (Huang, H. et al, 2002). Immunofluorescence using anti-
TcPKA-R showed a cytosolic location in all three stages; however, in 
trypomastigotes significant fluorescence was also detected in the flagellum and 
plasma membrane (Huang, H. et al, 2006). 
The importance of PKA activity in T. cruzi was clearly demonstrated by the 
transfection of the PKA-specific peptide-inhibitor PKI into epimastigotes, which 
displayed a delayed lethal phenotype, with the majority of selected parasites 
dying within a month; control lines transfected with the empty vector, or with 
vector plus GFP, resulted in normal growth (Bao, Y. et al, 2008). Inhibition of 
PKA activity using the inhibitor H89 also resulted in slow cell death, with 10 µM 
of the inhibitor killing all parasites in 10 days. 
Having demonstrated that PKA is essential in T. cruzi the authors attempted to 
identify the proteins that it interacts with and phosphorylates using a yeast 2-
hybrid system; 38 candidate proteins were identified (Bao, Y. et al, 2008). Of 
these, 18 could not be named or given a hypothetical function as they did not 
contain any recognized functional domains, although 12 proteins of this group 
contained putative PKA phosphorylation motifs. A second group of 12 genes were 
tentatively identified from putative domains, allowing prediction of their 
function but no biochemical characterisations have been conducted to date to 
confirm or reject these preliminary annotations. Half of this second group of 
candidate PKA-C interacting proteins contained recognizable PKA 
phosphorylation motifs, with one of them predicted to be an adenylyl cyclase. A 
third group consisting of 8 out of the 38 candidate proteins had a known and 
defined function, or were deemed to have important functions for the parasite 
based on putative domains, 5 of which displayed known PKA phosphorylation 
motifs (Bao, Y. et al, 2008). 
To confirm the TcPKA-C interactions with the identified proteins were not quirks 
of exogenous expression of the partial proteins encoded by the DNA library 
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were subcloned and transformed into the yeast 2-hybrid system. Again, all 
showed positive for interaction with the ‘Bait’ TcPKA-C. The 8 genes were then 
His-tagged and recombinantly expressed and purified. Each protein could be 
phosphorylated by bovine heart PKA-C, which could be inhibited by PKI, 
demonstrating that TcPKA-C is also likely to interact with the proteins in order 
to phosphorylate them (Bao, Y. et al, 2008). 
The authors speculate that three of the identified and putative proteins that 
interact with TcPKA-C may be involved in adaptation to environmental stress. 
The T. cruzi aquaporin (TcAQP) has been shown, previously to be involved in 
osmoregulation with cAMP inducing translocation to the contractile vacuole 
complex (Rohloff, P. et al, 2004). Osmoregulation may also be aided by the 
ATPase that interacts with TcPKA-C. DNA damage due to the host’s immune 
response mounting attacks on the parasite with free radicals could be repaired 
by the DNA excision repair protein (DERP) after activation by TcPKA-C. A 
hexokinase also interacted with TcPKA-C. The T. cruzi PKA catalytic subunit has 
been shown to have a PST1 motif which may allow entry of the protein into the 
glycosome. Hexokinase is recognized as a marker for the glycosome and 
regulation of the activity of the hexokinase by TcPKA-C is likely to modulate 
glucose metabolism (Bao, Y. et al, 2008). 
Two phosphatidylinositol 3 (PI3) kinases were also detected by the yeast 2-
hybrid system as interacting with TcPKA-C. One of them is putatively annotated 
as such, however, the other is a type III PI3 kinase, termed Vps34, which has 
been demonstrated to be associated with autophagy and other intracellular 
trafficking processes (Bao, Y. et al, 2008). 
The possibility of a negative-feedback loop to modulate the cAMP signal was also 
brought to light. A putative mitogen-activated extracellular signal-regulated 
kinase (ERK) and the phosphodiesterase TcPDEC-2 were also shown to interact 
with TcPKA-C (Bao, Y. et al, 2008). In Dictyostelium, ERK activity has been 
shown to activate adenylyl cyclases and inhibit phosphodiesterases. The 
resulting rise in cAMP activates PKA which inhibits ERK and stimulates PDE 
activity, thereby lowering the cAMP concentration again (Loomis, E. F., 1998). 
The components of this kind of feedback system appear to be in place in 
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interact with each other, as well as with TcPKA-C, again using the yeast 2-hybrid 
system (Bao, Y. et al, 2008). 
In similar experiments, the localisation of the TcPKA holoenzyme was further 
investigated using the TcPKA regulatory subunit instead of TcPKA-C as ‘Bait’ in 
the yeast 2-hybrid system. Three P-type ATPases were shown to interact with 
TcPKA-R; one a putative cation-transporting ATPase, the second a putative 
calcium-motive P-type ATPase, and the third a Na
+-ATPase (Bao, Y. et al, 2009). 
Furthermore, immunocomplexes precipitated from trypomastigote lysates using 
anti-TcPKA-R monoclonal antibodies were recognized by anti-Na
+ ATPase 
antibodies in a 120 kDa band, and by anti-cation transporting ATPase antibodies 
in a 140 kDa band. Unsurprisingly, a 56 kDa band was recognized by anti-TcPKA-R 
antibodies from immunoprecipitates using anti-Na
+ ATPase and anti-cation 
transporting ATPase antibodies, confirming the interaction between the TcPKA 
regulatory subunit and the P-type ATPases. The identical experiment with the 
catalytic sub unit revealed no interactions with the ATPases. 
Immunofluorescence using anti-TcPKA-R monoclonal antibodies demonstrated 
that the regulatory subunit of TcPKA was associated with the flagellum and 
plasma membrane of trypomastigotes, as well as in the cytosol of all three T. 
cruzi life cycle stages. Subcellular fractionation analysis by immunoblot 
confirmed the presence of TcPKA-R in the membrane fraction (Bao, Y. et al, 
2009), in good agreement with previous investigations (Huang, H. et al, 2006). 
Since Na
+-ATPases are also upregulated in trypomastigotes (Iizumi, K. et al, 
2006), it was hypothesized that TcPKA-R may be localised to the plasma 
membrane and flagellum in trypomastigotes by binding to this, or the other, P-
type ATPases already located there. This would then recruit the PKA catalytic 
subunit to the same location and could serve as a useful reservoir of effector 
proteins capable of responding rapidly, and perhaps more specifically than 
cytosolically located PKA-C, to the signals induced by the stresses of being 
released from the host cell and the environmental changes associated (Bao, Y. 
et al, 2009). 
1.5.1.3  Leishmania 
A Leishmania catalytic subunit of PKA was first isolated and characterised in the 
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purified from L. donovani promastigotes by centrifugal fractionation of lysates 
and sequential column chromatography (Banerjee, C. and Sarkar, D., 1992). 
Kinase activity eluted as a single peak with SDS-PAGE analysis of the final 
preparation showing a product with a molecular weight of approximately 34 kDa. 
The purified molecule was constitutively active and shared peptide 
phosphorylation preferences with that of mammalian PKA, phosphorylating 
kemptide over histone H1 and only phosphorylating mixed histones and 
protamine at a much lower level. Acid hydrolysis of protamine phosphorylated 
by the leishmanial extract, followed by separation of the phosphoamino acids on 
cellulose-layer plates, indicated that only serine amino acids were acceptors of 
the phosphate. The fact that cAMP, cGMP, calcium and calmodulin had no effect 
on the kinase activity, combined with the size of the eluted molecule, indicated 
that the catalytic subunit of the Leishmania PKA had been purified on its own 
without a regulatory subunit. The addition of bovine heart regulatory subunit 
type II inhibited the Leishmania kinase activity; however cAMP increased the 
protein kinase activity back to the basal level. Furthermore both purified and 
cell lysate activity was inhibited by the PKA-specific peptide inhibitor PKI, 
purified from pig heart, indicating that the Leishmania enzyme is topologically 
similar to mammalian PKA (Banerjee, C. and Sarkar, D., 1992). 
A gene with high homology to other protein kinase A sequences was cloned and 
sequenced from L. major with a PCR-based strategy utilising degenerate primers 
based on conserved domains of known PKA gene sequences. This identified a 
gene, designated LmPKA-C1, which displayed 64% identity with the catalytic 
subunit of PKA from the fungi Blastocladiella and encodes a protein of 332 amino 
acids and approximately 38 kDa molecular mass (Siman-Tov, M. M. et al, 1996). 
All the important conserved features involved in ATP and phosphate-acceptor 
binding are present, including the RDLKPEN motif indicative of serine/threonine 
phosphorylating protein kinases. Some deviations from the typical PKA-C 
sequence were observed, with the LmPKA-C1 protein having a relatively short N-
terminal region of just 11 residues until the first conserved amino acid of the 
catalytic core, and lacking a site for potential myristoylation. In addition, 
LmPKA-C1 has an 8 amino acid, C-terminal extension beyond the usually final 
FXXF motif, compared to most other PKA-C subunits (Siman-Tov, M. M. et al, 
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Southern blots with genomic DNA from L. major, L. donovani and L. amazonensis 
indicate that the leishmanial PKA-C1 gene is present in all three species as a 
single copy gene. Northern blot analysis showed that expression of LmPKA-C1 by 
promastigote forms is essentially halted on change of temperature from 26 ºC to 
35 ºC, with hybridization levels dropping to less than 30% after just one hour and 
undetectable after four hours. The change in temperature also triggers 
differentiation from promastigote to amastigote forms indicating that expression 
of LmPKA-C1 is down-regulated on initiation of the transformation process and 
the kinase appears to play no role in the amastigote form (Siman-Tov, M. M. et 
al, 1996). 
Two further isoforms of PKA-C were later identified, cloned and sequenced in 
Leishmania major. LmPKA-C2a and LmPKA-C2b are highly homologous genes 
sharing 96.6% identity overall at the amino acid level, and 100% identity at the 
DNA base-pair level in the catalytic core (Siman-Tov, M. M. et al, 2002). While 
both are found on chromosome 35 they are not tandemly arranged, having 
approximately 36 kb between them. LmPKA-C1, on the other hand is located on 
chromosome 18 and shares only 59.4 % and 58.9% amino acid identity, 
respectively, with the two LmPKA-C2 isoforms, rising to 62.2% in the catalytic 
core. The open reading frames of the two isoforms predict proteins of 381 and 
371 amino acids for -C2a and -C2b, with approximate molecular masses of 43 
kDa and 42 kDa, respectively. All conserved domains and invariant residues of 
eukaryotic PKA-Cs are found in the LmPKA-C2 proteins; however, the PKI binding 
motif is somewhat different from that of mammalian PKA-C (FDDYEEE compared 
to FDKYPDS in LmPKA-C1 and FEKYPDS in LmPKA-C2 isoforms), possibly reflecting 
differences in leishmanial PKI. The C-terminal of the two isoforms is similar to 
that of the mammalian PKA-C in size, having no amino acids after the FXXF 
motif, although in LmPKA-C2a the motif is LXXF (Siman-Tov, M. M. et al, 2002) – 
possibly reducing catalytic activity, based on studies with mouse PKA-C (Batkin, 
M. et al, 2000). 
Three-dimensional models of the LmPKA-Cs based on mammalian PKA-Cα crystal 
structures indicate only minor topological differences with the majority of non-
conserved substitutions found on the protein surface and not in the catalytic 
core. The N-terminal of the LmPKA-C2 isoforms is predicted to form an α-helix 
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addition LmPKA-C1 has an extra C-terminal loop compared to typical eukaryotic 
PKA-Cs, due to its eight amino acid extension (Siman-Tov, M. M. et al, 2002). 
Attempts to identify a leishmanial PKA regulatory subunit have, so far, drawn a 
blank. Three cAMP binding proteins were isolated from promastigotes after 
separation on DEAE-cellulose columns but no protein kinase activity was 
associated with the three peaks in cAMP binding activity and the proteins did not 
cross-react with antisera against bovine type I and II PKA regulatory subunits 
(Banerjee, C. and Sarkar, D., 2001), in contrast to similar experiments using 
Trypanosoma cruzi extracts which did cross-react (Ochatt, C. M. et al, 1993). 
Yet, protein kinase A activity in L. amazonensis promastigotes was observed to 
be stimulated by cAMP in crude soluble and membrane-enriched protein 
extracts, with highest activity in metacyclic cells. Fractions obtained from 
axenic amastigote cultures of L. amazonensis displayed equivocal, at most, cAMP 
stimulation of protein kinase activity (Genestra, M. et al, 2004).  
Recent experiments appeared to confirm a role for cyclic nucleotide regulated 
protein kinase activities in promastigote proliferation and infectivity: PKA 
inhibitors PKI and H89 and PDE inhibitors dipyridamole, rolipram and IBMX all 
clearly affected both parameters. However, the addition of cAMP did not affect 
kinase activity whereas cGMP, increased activity by nearly 250%. This increase 
could not be inhibited by PKI, although PKI inhibited the base-line activity by 
more than 50% (Malki-Feldman, L. and Jaffe, C. L., 2009). This suggests that the 
cGMP stimulated kinase activity is independent of the PKI-inhibitable activity 
and that at the life cycle stages investigated a cGMP-dependent kinase activity 
may contribute more to phosphorylation of kemptide, the substrate used in this 
study. Even though cAMP itself did not detectably stimulate kemptide 
phosphorylation under the assay conditions, non-hydrolysable analogues did – 
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1.6 Aims 
This thesis will investigate the anti-trypanosomal action of putative 
phosphodiesterase inhibitors in relation to current chemotherapies against 
human African trypanosomiasis (HAT). It will devise, validate and optimise new 
techniques to aid the more efficient screening of large compound libraries; and 
it will investigate the mode of intracellular action of selected compounds 
through biochemical analyses and the characterisation of resistant trypanosome 
strains. Matthew K Gould, 2009     Chapter 2, 100 
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2.1 Introduction 
The chemotherapeutic control of African trypanosomiasis relies on a group of 
drugs that can be toxic to the patient, and are becoming less effective, with 
only pentamidine having no reliable reports of resistance arising in the field 
(Delespaux, V. and De Koning, H. P., 2007). Unfortunately pentamidine is unable 
to cross the blood-brain barrier rendering it ineffective against late-stage 
trypanosomiasis. Only one new drug has been licensed in the past 50 years for 
the treatment of sleeping sickness, eflornithine (or DFMO), which is only 
efficacious against the T. b. gambiense parasite. This compound also causes 
severe side-effects such as vomiting, diarrhoea, hair loss and convulsions (Burri, 
C. and Brun, R., 2003). The need for a new class of chemotherapy is urgent. 
The development of new lead compounds against trypanosomiasis requires 
reliable and informative in vitro assays for the screening of test compounds. This 
is equally true for the monitoring of drug resistance and the study of resistance 
mechanisms. The current assay of choice is based on the blue and non-
fluorescent dye Alamar Blue
® (resazurin) (Räz, B. et al, 1997), and is based on 
the fact that live cells take up resazurin and reduce it to resorufin (pink and 
fluorescent). Owing to the fact that resazurin can be reduced by many different 
mitochondrial and cytosolic enzymes (Gonzalez, R. J. et al, 2001), this protocol 
has been adapted to monitor viability in many different cell types, including 
hepatocytes (Slaughter, M. R. et al, 1999), neuronal cells (White, M. J. et al, 
1996), Candida (Pfaller, M. A. et al, 1994) and Leishmania promastigotes (Mikus, 
J. and Steverding, D., 2000) and amastigotes (Al-Salabi, M. I. and De Koning, H. 
P., 2005). Its results are widely accepted as accurate. The assay is considered 
cheap, versatile in that it can be used both colourimetrically and fluorescently, 
and is reproducible. In this chapter, compounds from two sources were assessed 
for their activity against trypanosomes in in vitro culture, using the standard 
whole-cell efficacy assay. 
Since strains refractory to some of the standard chemotherapies have been 
identified in the field it is essential to ascertain if cross-resistance to any 
potential new drug is likely to be displayed. In order to examine this, the test 
compounds were screened against Trypanosoma brucei brucei Tb427 wildtype, 
as well as against strains that are resistant to the diamidine and melaminophenyl Matthew K Gould, 2009     Chapter 2, 102 
arsenical class compounds and also to pentamidine. The TbAT1 knock out strain 
has a disrupted P2 adenosine transporter resulting in significant resistance to 
diamidines like diminazene, as well as having minor resistance to pentamidine 
and arsenicals (Matovu, E. et al, 2003). Resistance to current chemotherapies 
against trypanosomiasis in the field has been shown to be linked to adaptations 
in the P2 adenosine transporter (Mäser, P. et al, 1999; Matovu, E. et al, 2001), 
and so this strain can be used as a model to test for likely cross-resistance to 
new compounds by diamidine refractory strains in endemic regions. 
Some compounds were tested against the B48 strain which also has the P2 
transporter knocked out. However, this cell line has been made further resistant 
to pentamidine by gradually increasing the maximum tolerated concentration in 
in vitro cultures. The resulting strain also has additional cross-resistance to the 
melaminophenyl arsenicals (Bridges, D. J. et al, 2007). A small panel of selected 
compounds were also tested for efficacy in vivo in a murine model of 
trypanosomiasis. 
In order to test for efficacy against trypanosomiasis in domestic animals that 
result in an economic morbidity in endemic regions, compounds were screened 
against the animal infective species Trypanosoma equiperdum. As against the T. 
brucei strain, a drug resistant strain (PBR) was also be tested against. Like the 
TbAT1 knockout, the PBR strain has been shown to expresses a modified P2 
transporter thought to give rise to the diminazene resistance (Barrett, M. P. et 
al, 1995). 
For some chemotherapies merely inhibiting the increase in parasites in the host 
is sufficient to result in eventual cure, for example: eflornithine (Burri, C. and 
Brun, R., 2002). However, a fully competent host immune system is required to 
prevent relapse, meaning this treatment is inappropriate for those patients also 
infected with HIV/AIDS, or having some other immune deficiency. It is therefore 
vital to establish the effect the test compounds have on a population of 
trypanosomes to see if they kill or inhibit replication. In this chapter, two 
methods were employed to assess the action of the compounds. The first was to 
simply count the number of cells in a culture of bloodstream trypanosomes 
incubated with the test compound over a period of days. The second utilised the Matthew K Gould, 2009     Chapter 2, 103 
absorbance of light by a dense culture, with the absorbance dropping as the 
trypanosomes in suspension die. Matthew K Gould, 2009     Chapter 2, 104 
2.2 Materials and Methods 
2.2.1 Whole-cell in vitro efficacy assay 
Test compounds were provided by Otsuka Maryland Medicinal Laboratories 
(Series 1 compounds) and by Dr. Geert-Jan Sterk (GJS compounds). A test 
compound was doubly diluted in a white-bottomed 96-well plate (Greiner) in 
HMI-9 (Invitrogen) supplemented with 10% foetal calf serum (FCS; Biosera). 
Bloodstream form T. b. brucei strain 427 wild type trypanosomes, cultured in 
vitro at 37 ˚C in a 5% CO2 atmosphere, were taken at the late logarithmic phase 
of growth and the cell density measured using a haemocytometer and adjusted 
to the desired concentration in HMI-9/FCS. An equal volume (100 µl) of the 
trypanosomes was added to each well of diluted test compound to give a final 
cell density of 10
5 trypanosomes/ml. The plates were incubated for 48 hours at 
37 ºC and 5% CO2, after which 20 µl of 0.5 M resazurin sodium salt in phosphate-
buffered saline (PBS) was added to each well, followed by a further 24 hour 
incubation under the same conditions. Fluorescence was measured using either a 
LS55 luminescence spectrometer (PerkinElmer Life Sciences) with the excitatory 
wavelength set at 530 nm and the emission wavelength at 590 nm, or a FLUOstar 
OPTIMA fluorimeter (BMG Labtech) with excitation and emission filters of 544 nm 
and 590 nm respectively. Data was analyzed using GraphPad Prism software and 
EC50 values (Effective Concentration that inhibits 50% of maximal growth) were 
derived from sigmoidal dose-response curves with variable slopes. EC50 values 
reported in this thesis are the averages of at least three independent 
experiments. 
An identical protocol was employed when assaying bloodstream form TbAT1 
knockout (Matovu, E. et al., 2003) and B48 (Bridges, D. J., et al., 2007) strains 
that are derived from the wild type s427. However, for the Trypanosoma 
equiperdum wild type and PBR strains (Barrett, M. P. et al., 1995) the HMI-9 was 
supplemented with 20% FCS instead of 10%. When using Tb427 wild type 
procyclic form trypanosomes, the assays were performed using SDM79 (Gibco) 
supplemented with 7.5 µg/ml haemin (Sigma) and 10% FCS, with the incubations 
at 27 ºC and atmospheric CO2 levels. Matthew K Gould, 2009     Chapter 2, 105 
2.2.2 Proliferation assay 
Tb427 wild type bloodstream form trypanosomes were taken from culture in the 
late logarithmic phase of in vitro growth and diluted in fresh HMI-9/FCS medium 
to a cell density of 5 x 10
5 trypanosomes/ml. 10 ml aliquots were dispensed into 
25 cm
3 tissue culture flasks (Corning), to which the required volume of test 
compound, diluted in DMSO, was added so as to give the desired final 
concentration, and gently mixed. Test cultures were incubated at 37 ºC and 5% 
CO2. 10 µl samples were taken periodically by Gilson pipette, after gentle 
agitation of the culture flask to homogenize the trypanosome suspension, and 
assessed for cell density using a haemocytometer and a phase-contrast 
microscope at 40-fold magnification. 
2.2.3 Spectrophotometric lysis assay 
Tb427 wild type bloodstream form trypanosomes were taken in the late 
logarithmic phase of in vitro growth and centrifuged at 610 rcf for 10 minutes at 
room temperature. The supernatant was carefully removed and the cell pellet 
resuspended in fresh HMI-9/FCS medium. The trypanosomes were washed twice 
more by centrifugation and resuspension in HMI-9/FCS, as above, with the final 
resuspension giving a cell density between 10
7 and 10
8 cells/ml. After washing, 
the trypanosomes were left to recover in a water bath for 15 minutes at 37 ºC 
before the commencement of the lysis assay. 
The HP8453 spectrophotometer (Hewlett-Packard) was calibrated using HMI-
9/FCS medium without test compound or trypanosomes, and set to measure 
absorbance at a wavelength of 750 nm. 950 µl of the cell suspension was added 
to each heated 1 ml cuvette, continuously warmed to 37 ºC by circulating water, 
and readings were taken every 30 seconds. After 15 minutes of recording 
reference traces, 50 µl of test compound, diluted in HMI-9/FCS to 20 times the 
final desired concentration, was added to each cuvette. Absorbance 
measurements were taken every 30 seconds for approximately 8 hours. 
A similar protocol was followed when assessing the effects of the test 
compounds on trypanosome survival after short periods of exposure, with a 
deviation after the washing steps. Before starting measuring absorbance, 960 µl Matthew K Gould, 2009     Chapter 2, 106 
of cell suspension was added to pairs of eppendorfs. 40 µl of test compound, 
diluted in HMI-9 at 25 times the desired final concentration, was added to the 
eppendorf pairs and incubated for the stated period of time at 37 ºC. After 
incubation the eppendorfs were centrifuged at 610 rcf for 10 minutes at room 
temperature and the supernatant removed. One pellet was resuspended in 1 ml 
of the HMI-9-diluted test compound at the desired final concentration and the 
other was resuspended in fresh HMI-9 with no added compound, as a control. 
The cell suspensions were then transferred to the cuvettes preheated to 37 ºC 
and absorbance measuring commenced as before. 
2.2.4 In vivo compound tolerance testing 
Before efficacy trials against murine trypanosomiasis were conducted, each 
selected lead compound was assessed for tolerance by individual mice at 
increasing concentrations. 
The compounds were first tested at a dose of 1 mg/kg in a single uninfected 
mouse. All mice used were female, ICR strain (Harlan, UK), 10 – 12 weeks old 
and weighing between 25 – 30 g, and fed a normal diet throughout the tests. 
Each mouse was weighed and injected intraperitonealy with the required volume 
of compound dissolved in dimethyl sulphoxide (DMSO), and monitored 
periodically for adverse reactions. If no overt toxicity was observed after 48 
hours, a second mouse was injected with a dose of 10 mg/kg in the same 
manner, and monitored for signs of discomfort. If after 5 days none were 
observed in the second mouse, and no severe discomfort was displayed by the 
first mouse, a third mouse was then injected intraperitonealy with a dose of 50 
mg/kg. Each mouse was monitored for a total of 10 days for signs of overt 
toxicity, with the experiment being terminated at any sign of severe discomfort. 
For compounds tolerated at 10 mg/kg, but not 50 mg/kg, the dose was increased 
by 10 mg/kg for each fresh mouse until the maximum tolerated dose was 
established. 
2.2.5 In vivo efficacy testing 
Female ICR mice were infected with 10
4 Tb427 wild type bloodstream form 
trypanosomes, in 200 µl HMI-9, by intraperitoneal injection. 6 hours later the Matthew K Gould, 2009     Chapter 2, 107 
first dose of test compound at 50 mg/kg, or the maximum tolerated 
concentration, was administered by intraperitoneal injection on the opposite 
side from the parasite inoculation site. Subsequent doses were given at the same 
concentration and in the same manner, spaced 24 hours apart. 
Parasitaemia was monitored daily by sampling blood from the tail of each 
mouse. A small gauge needle was used to prick the tip of the tail which was 
gently massaged to produce a sufficient quantity of blood. 2 µl was taken using a 
Gilson pipette and mixed with an equal volume of heparin (at a concentration of 
500 International Units/ml Carter’s Balanced Salt Solution) in a microfuge tube. 
The remaining blood was smeared onto a glass microscope slide and covered 
with a cover slip. The slides were screened by light microscopy for the presence 
of trypanosomes in 40 fields of view at 40x magnification and those that were 
positive for parasites were quantified using the blood sample from the microfuge 
tube. The sample was diluted 1:25 with 0.85% ammonium chloride in PBS, which 
lyses the red blood cells but not the trypanosomes, making the quantification of 
parasitaemia using a haemocytometer markedly easier. 
A preliminary study was carried out first with groups of three mice per 
compound tested and with three doses of test compound. A larger study was 
then conducted with groups of six infected mice for compounds 37 and 48, along 
with control groups; mice were treated with four doses, 24 hours apart, instead 
of the three doses in the first trial. Matthew K Gould, 2009     Chapter 2, 108 
2.3 Results 
2.3.1 Whole-cell in vitro efficacy testing 
Over 200 compounds were identified from compound libraries as putative 
inhibitors of Trypanosoma brucei PDEB by Otsuka Maryland Medicinal 
Laboratories (Series 1 compounds), and dispatched for further screening for 
efficacy against live trypanosomes. All compounds were assayed for their effect 
on cell growth using a protocol based on the Alamar Blue
® method developed by 
Räz et al, (1997). The ability to inhibit cell growth was determined by the 
amount of fluorescence developed through metabolism of the dye resazurin by 
any surviving trypanosomes after 24 hours of incubation with the test compound. 
In cultures where parasites were killed by a particular concentration of 
compound, the amount of fluorescence measured was minimal, whereas at 
concentrations that did not kill the parasites considerable fluorescence was 
observed (Figure 2.1). Plotting the relative fluorescence against the log of the 
test compound concentration gives a sigmoidal dose response curve (Figure 2.1), 
from which the EC50 value (Effective Concentration which inhibits growth by 
50%) can be determined. 
Each compound was screened against the Trypanosoma brucei brucei Tb427 wild 
type strain, as well as the TbAT1 knockout strain which is strongly resistant to 
diminazene and some other diamidine class compounds, as well as mildly 
resistant to arsenicals and pentamidine (Matovu, E. et al, 2003). Resistance to 
current chemotherapies against trypanosomiasis in the field is linked to 
adaptations in the P2 adenosine transporter that is disrupted in the TbAT1 
knockout strain (Mäser, P. et al, 1999; Matovu, E. et al, 2001). This strain can be 
used as a model to test for likely cross-resistance to new compounds by 
diamidine refractory strains in endemic regions. As well as testing against this 
mutant strain, a panel of compounds was also tested against the B48 strain. This 
cell line exhibits additional cross-resistance to pentamidine and melaminophenyl 
arsenicals, and was derived from the TbAT1 knockout strain by gradually 
increasing the maximum tolerated concentration of pentamidine in in vitro 
cultures (Bridges, D. J. et al, 2007). Matthew K Gould, 2009     Chapter 2, 109 
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Figure 2.1: Representative graphs showing whole-cell in vitro efficacy assays for a number 
of putative phosphodiesterase inhibitors and diminazene against (A): Tb427 wild type, (B): 
TbAT1 knockout, and (C): strain B48, bloodstream form trypanosomes. Cells were 
incubated with the respective test compound at a series of concentrations for 48 hours at 37 
ºC, 5% CO2 and in the culture medium HMI-9, before the addition of resazurin and a further 
incubation of 24 hours. Cell growth was assessed as the amount of fluorescence produced 
from an excitation wavelength of 530 nm and emission wavelength of 590 nm from the 
metabolism of resazurin by living trypanosomes. 
 
Representative graphs of the whole-cell in vitro efficacy assay, for a number of 
compounds, against the three strains of T. brucei 427 are shown in Figure 2.1. 
Against Tb427 wild type, diminazene and compound 48 are the most active, with 
concentrations in the tens of nanomolars being sufficient to kill the trypanosome 
cultures as measured by the metabolism of resazurin. In the TbAT1 knockout and 
the B48 strains the curve for diminazene has moved markedly to the right in Matthew K Gould, 2009     Chapter 2, 110 
comparison to the wild type, demonstrating that these strains are resistant to 
the diamidine compound. For TbAT1 knockout, the activities of the remaining 
compounds are broadly equivalent to those against Tb427 wildtype, indicating no 
cross-resistance by the diamidine–refractory strain, whereas for the B48 strain a 
dramatic increase in sensitivity is displayed to compound 48 and slight resistance 
shown to compound 37. 
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Figure 2.2: Representative graph showing the range of average EC50 values of putative PDE 
inhibitors against Tb427 wild type bloodstream form trypanosomes. Compounds were 
ranked by ascending EC50 value, and the value of every third compound was plotted. 
 
The EC50 values were determined for each compound in a minimum of 3 
independent experiments, and the averages determined. The values ranged from 
the highly active, with an EC50 average of just 5.8 ± 3.4 nM for compound 129 
against Tb427 wild type, to the much less active compounds, such as compounds 
208 – 212, with in vitro efficacy values over 100 µM (Table 2.1, Appendix 1 and 
Figure 2.2). 32 compounds had EC50 values under 1 µM, 7 of which had activity 
below 100 nM, against Tb427 wild type bloodstream forms. Although significant 
resistance was displayed against 26 compounds by the TbAT1 knockout 
trypanosomes, only 6 showed more than 2-fold resistance, with 4-fold being the 
maximum significant resistance for any Series 1 compound (Compound 124), 
compared with the 21-fold resistance shown for diminazene (Table 2.1 and 
Appendix 1). Matthew K Gould, 2009     Chapter 2, 111 
University of 
Glasgow 
Compound Code 
EC50 Value (M) 
Tb427 WT 
EC50 Value (M) 
TbAT1 KO 
TbAT1 KO 
Resistance 
Factor 
P Value: 
Significantly 
Resistant  Average  S.E.  Average  S.E. 
129  5.8E-09  3.4E-09  7.8E-09  4.2E-09  1.3  0.373 
197  1.2E-08  2.1E-09  5.2E-08  1.8E-08  4.4  0.103 
140  3.3E-08  1.8E-08  3.0E-08  1.6E-08  0.90   
141  3.6E-08  2.1E-08  3.2E-08  1.8E-08  0.89   
48  7.0E-08  2.8E-08  4.2E-08  2.9E-08  0.60   
82  7.0E-08  1.6E-08  4.7E-08  1.4E-08  0.67   
137  8.1E-08  4.3E-08  7.2E-08  4.1E-08  0.89   
Diminazene  8.6E-08  1.2E-08  1.8E-06  1.1E-07  21  0.000 
138  1.2E-07  1.4E-08  9.1E-08  2.5E-08  0.75   
143  1.6E-07  1.9E-08  5.7E-07  5.0E-08  3.6  0.002 
198  1.6E-07  2.1E-08  2.6E-07  4.7E-08  1.6  0.064 
124  1.8E-07  2.4E-08  7.0E-07  4.4E-08  4.0  0.000 
199  1.8E-07  3.0E-08  1.5E-07  4.2E-09  0.84   
128  1.9E-07  9.7E-08  3.1E-07  3.3E-08  1.6  0.169 
114  2.0E-07  2.3E-08  4.7E-07  4.7E-09  2.4  0.004 
142  2.0E-07  9.8E-09  3.3E-07  5.1E-08  1.7  0.078 
139  2.3E-07  4.3E-08  1.9E-07  4.7E-09  0.84   
113  2.6E-07  2.7E-09  6.4E-07  2.5E-08  2.5  0.003 
80  2.7E-07  2.9E-08  3.5E-07  3.6E-08  1.3  0.113 
79  2.9E-07  4.5E-08  3.1E-07  6.2E-08  1.1  0.421 
104  3.4E-07  4.1E-08  5.3E-07  4.8E-08  1.6  0.033 
37  3.5E-07  7.5E-08  3.3E-07  8.0E-08  0.93   
111  3.9E-07  3.8E-08  4.9E-07  1.5E-08  1.3  0.058 
83  4.4E-07  1.9E-08  5.1E-07  3.6E-08  1.2  0.126 
107  4.4E-07  4.7E-09  4.9E-07  2.2E-08  1.1  0.093 
130  4.8E-07  6.8E-08  4.3E-07  2.4E-08  0.89   
158  5.7E-07  4.5E-08  5.3E-07  1.1E-08  0.92   
72  5.8E-07  4.2E-08  8.5E-07  4.8E-08  1.5  0.013 
105  5.9E-07  9.7E-08  8.5E-07  7.2E-08  1.4  0.080 
103  6.6E-07  8.6E-08  1.1E-06  1.6E-07  1.6  0.069 
77  7.6E-07  7.1E-08  5.7E-07  7.5E-08  0.75   
10  8.3E-07  1.7E-07  9.5E-07  2.0E-07  1.2  0.354 
121  9.2E-07  7.3E-08  1.2E-06  2.2E-08  1.3  0.022 
6  1.0E-06  2.3E-07  1.4E-06  4.7E-07  1.3  0.314 
74  1.0E-06  4.7E-08  8.9E-07  1.1E-08  0.86   
Table 2.1: Average EC50 values for Series 1 compounds with sub-micromolar activity against 
Tb427 wild type and TbAT1 knockout bloodstream form trypanosomes, with standard 
errors. Values were derived from whole-cell in vitro efficacy assays and calculated from 
sigmoidal dose-response curves, with variable slopes, using GraphPad Prism software. 
Averages are taken from at least 3 independent experiments. Also shown is the resistance 
factor of the TbAT1 knockout strain compared to Tb427 wild type for each compound. 
Statistical significance was calculated after an F-test was conducted to determine which 
one-tailed, unpaired Student’s T-test was most appropriate: that for equal or unequal 
variances. Those compounds for which the TbAT1 knockout strain is statistically resistant 
are highlighted with red text. 
 
The B48 strain of the TbAT1 knockout cell line showed a similar resistance 
profile to the panel of compounds assayed against it. No significant resistance 
was shown for the majority of Series 1 compounds against B48, with only 
Compound 113 having more than a 3-fold increase in EC50 value (12.8-fold Matthew K Gould, 2009     Chapter 2, 112 
increase) (Table 2.2). In spite of the large apparent resistance factor produced 
from the mean EC50 values of Compound 37, statistical analysis did not 
determine the difference as significant. Interestingly, 11 out of the 27 
compounds assayed against B48 were significantly more active compared to the 
Tb427 wild type, with 6 of them having EC50 values more than 10-fold lower than 
against the wildtype (Table 2.2). 
University of 
Glasgow 
Compound Code 
EC50 Value (M) 
TbAT1 KO B48 
Resistance 
Factor 
P Value:Significantly 
Resistant compared 
to Tb427 WT 
P Value:Significantly 
Sensitive compared 
to Tb427 WT  Average  S.E. 
129  6.7E-11  1.2E-11  0.01    0.105 
48  2.1E-09  6.8E-10  0.03    0.063 
82  2.2E-09  6.4E-10  0.03    0.038 
80  8.7E-09  1.7E-09  0.03    0.009 
111  1.8E-08  7.6E-10  0.05    0.008 
79  2.1E-08  1.4E-09  0.07    0.020 
112  1.2E-07  2.7E-08  0.08    0.000 
110  1.7E-07  3.7E-08  0.07    0.011 
139  1.8E-07  4.4E-08  0.81    0.299 
83  2.2E-07  1.3E-08  0.50    0.001 
77  4.5E-07  3.7E-08  0.60    0.018 
74  4.7E-07  7.5E-08  0.45    0.003 
114  4.8E-07  3.5E-08  2.45  0.003   
107  5.0E-07  9.4E-08  1.13  0.339   
72  5.9E-07  8.1E-08  1.01  0.485   
10  9.5E-07  1.6E-07  1.15  0.342   
84  9.6E-07  1.2E-07  0.58    0.019 
63  1.3E-06  1.2E-07  0.64    0.112 
64  1.5E-06  2.5E-08  0.72    0.189 
Diminazene  1.6E-06  6.2E-07  18.31  0.049   
73  1.7E-06  6.2E-08  0.89    0.050 
7  2.0E-06  3.9E-07  0.90    0.438 
6  2.4E-06  4.6E-07  2.29  0.051   
98  2.8E-06  3.5E-08  1.12  0.011   
113  3.3E-06  2.1E-07  12.81  0.004   
4  3.5E-06  5.5E-07  2.26  0.032   
37  3.7E-06  1.5E-06  10.50  0.106   
27  5.7E-06  1.0E-06  2.79  0.049   
Table 2.2: Average EC50 values for a panel of Series 1 compounds against the B48 strain 
derived from TbAT1 knockout cell line. Values were derived from whole-cell in vitro efficacy 
assays and calculated from sigmoidal dose-response curves, with variable slopes, using 
GraphPad Prism software. Averages are taken from at least 3 independent experiments. 
Also shown is the resistance factor of the B48 strain compared to Tb427 wild type for each 
compound. Statistical significance was calculated using the one-tailed, unpaired Student’s 
T-test after an F-test was conducted to determine which was most appropriate: that for 
equal or unequal variances. Those compounds for which the TbAT1 knockout B48 strain is 
statistically resistant are highlighted with red text and those that are statistically more 
active against the B48 strain are highlighted with blue. 
 
Since procyclic form trypanosomes had been shown to be much more resistant to 
increases in intracellular cAMP (Zoraghi, R. and Seebeck, T. 2002), it was Matthew K Gould, 2009     Chapter 2, 113 
hypothesized that phosphodiesterase inhibitors would be less active in this life 
cycle stage than in bloodstream forms. A panel of 25 Series 1 compounds was 
assayed against the procyclic form trypanosomes of the Tb427 strain (Table 2.3). 
As expected, the majority of the compounds were less active in the procyclic 
form with only Compounds 82 and 77 being more active, compared to activity 
against bloodstream forms. Five compounds were 10 – 20-fold less active, and 
Compound 129 was 175-fold less active in the procyclic form suggesting that the 
target(s) of these compounds may be differentially expressed in the life cycle 
stages of the trypanosome. 
University of 
Glasgow 
Compound Code 
EC50 Value (M) Tb427 
WT Procyclic Form 
Efficacy Factor 
(Tb427 WT PCF / 
Tb427 WT BSF) 
P Value: Significantly 
Different compared to 
Tb427 WT  Average  S.E. 
82  2.0E-08  6.2E-10  0.28  0.128 
48  1.5E-07  1.6E-08  2.08  0.130 
111  4.6E-07  5.5E-08  1.19  0.431 
80  4.6E-07  6.1E-08  1.71  0.080 
79  5.7E-07  8.4E-08  1.98  0.072 
77  6.1E-07  5.9E-08  0.80  0.249 
129  1.0E-06  6.6E-08  175.69  0.006 
114  1.1E-06  3.7E-08  5.52  0.000 
83  1.2E-06  8.9E-08  2.84  0.015 
10  2.2E-06  5.6E-07  2.67  0.127 
6  2.5E-06  1.1E-07  2.39  0.010 
110  2.5E-06  7.9E-08  1.07  0.684 
107  2.6E-06  5.3E-08  6.00  0.001 
112  3.2E-06  2.0E-07  2.17  0.003 
64  3.5E-06  2.5E-07  1.67  0.082 
139  4.3E-06  3.0E-07  19.08  0.007 
37  4.9E-06  3.1E-07  13.81  0.000 
72  5.1E-06  2.3E-07  8.71  0.003 
74  5.2E-06  1.1E-07  4.99  0.000 
98  5.5E-06  4.4E-08  2.25  0.000 
73  6.5E-06  3.1E-07  3.38  0.007 
63  7.4E-06  2.5E-07  3.62  0.001 
84  1.6E-05  8.0E-07  9.70  0.005 
4  2.5E-05  2.1E-06  15.66  0.011 
27  2.8E-05  1.2E-06  13.62  0.003 
Diminazene  9.5E-05  6.8E-06  1103.53  0.008 
Table 2.3: Average EC50 values for a panel of Series 1 compounds assayed against procyclic 
forms of the Tb427 wild type strain, with standard errors. Values were derived from whole-
cell in vitro efficacy assays and calculated from sigmoidal dose-response curves, with 
variable slopes, using GraphPad Prism software. Averages are taken from at least 3 
independent experiments. Also shown is the fold increase in EC50 value for the procyclic 
form compared to that of the bloodstream form, expressed as the efficacy factor. 
Compounds with a significantly different EC50 value compared to that against Tb427 wild 
type bloodstream forms are highlighted with red text. Statistical significance was calculated 
using the two-tailed, unpaired Student’s T-test after an F-test was conducted to determine 
which was most appropriate: that for equal or unequal variances. 
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University of 
Glasgow 
Compound Code 
EC50 Value (M) T. 
equiperdum WT 
EC50 Value (M) T. 
equiperdum PBR 
PBR 
Resistance 
Factor 
P Value: 
Significantly 
Resistant 
Efficacy Factor 
(Tb427 WT / T.  
equiperdum WT) 
P Value: 
Significantly 
Different  Average  S.E.  Average  S.E. 
82  3.5E-09  2.1E-09  3.7E-09  9.8E-10  1.0  0.478  20  0.077 
48  5.4E-09  1.3E-09  5.7E-09  1.6E-09  1.1  0.452  13  0.140 
80  1.9E-08  1.9E-09  2.0E-08  4.7E-09  1.1  0.420  14  0.019 
111  1.9E-08  2.9E-09  2.5E-08  8.2E-10  1.3  0.088  20  0.015 
Diminazene  2.8E-08  4.9E-09  2.0E-06  2.9E-07  71  0.003  3.1  0.002 
107  3.2E-08  1.4E-08  2.9E-08  1.2E-08  0.90    14  0.000 
197  3.5E-08  1.4E-08  2.5E-08  2.2E-09  0.73    0.35  0.326 
79  4.2E-08  6.8E-09  4.3E-08  2.7E-09  1.0  0.445  6.9  0.043 
199  6.2E-08  8.9E-09  6.0E-08  4.6E-09  0.97    2.9  0.037 
139  1.1E-07  4.9E-09  1.0E-07  3.2E-09  0.98    2.1  0.144 
72  1.1E-07  2.0E-08  1.7E-07  1.3E-08  1.5  0.045  5.4  0.000 
112  1.3E-07  1.4E-08  1.4E-07  1.4E-08  1.0  0.442  11  0.004 
83  1.6E-07  2.1E-08  1.4E-07  2.3E-08  0.90    2.8  0.001 
104  2.0E-07  1.5E-08  1.5E-07  4.7E-09  0.76    1.7  0.058 
198  2.0E-07  3.2E-09  1.8E-07  2.0E-08  0.88    0.80  0.151 
84  2.2E-07  2.7E-09  2.3E-07  5.4E-09  1.0  0.125  7.7  0.000 
114  2.3E-07  2.0E-08  2.1E-07  1.8E-08  0.94    0.87  0.466 
37  2.5E-07  1.4E-08  2.9E-07  2.5E-08  1.2  0.160  1.4  0.323 
110  2.5E-07  4.3E-08  2.6E-07  3.3E-08  1.0  0.469  9.3  0.023 
10  3.6E-07  1.4E-08  4.5E-07  2.7E-09  1.3  0.015  2.3  0.151 
74  3.9E-07  9.0E-08  3.7E-07  7.4E-08  0.94    2.7  0.004 
103  4.1E-07  1.2E-07  4.7E-07  1.0E-07  1.1  0.388  1.6  0.247 
105  4.3E-07  1.2E-07  3.7E-07  7.7E-08  0.85    1.4  0.437 
64  4.4E-07  3.6E-08  6.4E-07  4.8E-08  1.4  0.028  4.8  0.086 
4  4.9E-07  4.7E-08  6.7E-07  5.0E-08  1.4  0.052  3.2  0.103 
77  5.2E-07  1.2E-07  4.9E-07  1.3E-07  0.94    1.5  0.234 
113  5.2E-07  3.7E-08  6.6E-07  1.2E-08  1.3  0.022  0.49  0.027 
98  5.3E-07  3.8E-08  8.1E-07  5.9E-08  1.5  0.014  4.7  0.000 
6  8.1E-07  1.9E-07  9.3E-07  1.6E-07  1.1  0.352  1.3  0.547 
158  8.3E-07  3.4E-08  8.8E-07  3.9E-08  1.1  0.254  0.69  0.014 
63  8.5E-07  9.3E-08  1.0E-06  1.1E-07  1.2  0.206  2.4  0.072 
Table 2.4: Average EC50 values for a panel of Series 1 compounds with sub-micromolar 
activity against Trypanosoma equiperdum wild type and the diminazene resistant PBR 
strain bloodstream form trypanosomes, with standard errors. Values were derived from 
whole-cell in vitro efficacy assays and calculated from sigmoidal dose-response curves, 
with variable slopes, using GraphPad Prism software. Averages are taken from at least 3 
independent experiments. Also shown is the resistance factor of the PBR strain compared 
to T. equiperdum wild type, as well as the efficacy factor between species, comparing the 
average EC50 values against Tb427 and T. equiperdum wild type strains for each compound. 
Statistical significance for the presence of resistance was calculated using the one-tailed, 
unpaired Student’s T-test after an F-test was conducted to determine which was most 
appropriate: that for equal or unequal variances. A two-tailed, unpaired Student’s T-test was 
carried out to determine the presence of significant differences between species, again after 
the use of the F-test to determine the correct T-test to use. Those compounds for which the 
PBR strain is statistically resistant are highlighted in red text, and those showing significant 
inter-species difference in EC50 values are highlighted in blue. 
 
A selection of Series 1 compounds were also tested for in vitro efficacy against 
the wild type and diminazene resistant (PBR) strains of the animal infective 
species Trypanosoma equiperdum. Like diamidine resistant T. b. brucei, the PBR 
strain also expresses a modified P2 transporter thought to give rise to the 
diminazene resistance (Barrett, M. P. et al, 1995). The most active compound 
was Compound 82 with EC50 values of 3.5 ± 2.1 nM and 3.7 ± 1.0 nM against the 
wild type and diminazene resistant strains, respectively (Table 2.4 & Appendix 
2). For the majority of Series 1 compounds, no cross-resistance was displayed by 
the diminazene resistant PBR strain. Only five out of the sixty two compounds Matthew K Gould, 2009     Chapter 2, 115 
assayed against the T. equiperdum strains gave statistically significant increases 
in EC50 value in the PBR strain versus the wild type; however, similar to the T. 
brucei wild type versus TbAT1 knockout cell lines, none of these showed more 
than a two-fold difference in efficacy, compared to the greater than 70-fold 
resistance seen for diminazene. 
When the EC50 values against the wild type strains of the two species were 
compared 18 out of the 62 compounds assayed were significantly different from 
each other. Most notably, Compounds 80, 111, 107, and 112 were more than 10-
fold more active (P-value < 0.05) against T. equiperdum than T. brucei (Table 
2.4 & Appendix 2), suggesting either differential expression of, or significant 
modification to, the target protein(s) of these compounds across the two 
species. 
2.3.2 Effect of test compounds on trypanosome proliferation 
Since the whole-cell in vitro efficacy assay with resazurin essentially only gives a 
snapshot of metabolic activity at the end of a particular incubation period, it 
was not possible to determine, by using this method, how quickly the test 
compound acts on the cells at a specific concentration. It is also very difficult to 
establish if the effect of the test compounds is lethal to the trypanosomes, or 
merely inhibits proliferation. In order to examine these aspects of the 
compounds’ action, cell density in cultures with and without the test compounds 
was monitored over time by manually counting the trypanosomes, using a 
haemocytometer.  
Figures 2.3A and 2.3B show representative graphs of Tb427 wild type 
bloodstream form trypanosomes incubated with 15 µM of various test 
compounds. Compounds 4 and 7 are relatively slow acting at concentrations of 
approximately 10 and 7-fold the EC50 values, respectively, only killing all the 
trypanosomes after more than 3 days incubation. Similarly, diminazene is a slow 
acting compound, taking up to 34 hours to kill wild type Tb427 bloodstream 
forms at a concentration over 100-fold its EC50 value. In spite of having similar 
EC50 values, Compounds 27 and 55 appear to act much more quickly than 
Compounds 4 and 7, killing all the trypanosomes in the culture in less than 24 Matthew K Gould, 2009     Chapter 2, 116 
hours at 15 µM, suggesting either faster uptake of the compounds, or a different 
mode of action within the cell. 
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Figure 2.3: Representative graphs showing the effect of a selection of Series 1 compounds 
and diminazene on Tb427 wild type bloodstream form trypanosome proliferation. 15 µM of 
each compound was incubated with the trypanosomes, beginning at a density of 5 x 10
5 
cells/ml, at 37 ºC, 5% CO2, and cell counts conducted periodically using a haemocytometer 
for up to (A): 72 hours or (B): 24 hours. (C): The effect of Compound 72 at various 
concentrations on trypanosome proliferation over 60 hours. Insets: control cultures without 
test compound shown separately for reasons of scale. 
 
Compound 37 appears to be the fastest acting compound tested at 15 µM, with 
complete cell death within 6 hours (Figure 2.3B). However, Compound 72 killed 
all cells over the same time-frame at just 5 µM (Figure 2.3C), while having an 
EC50 value approximately twice that of Compound 37 (Table 2.1), again 
suggesting alternative modes of action within the trypanosomes. Matthew K Gould, 2009     Chapter 2, 117 
All the compounds tested in this way show that they are lethal to the 
trypanosomes and result in cell death, instead of merely inhibiting cell 
proliferation while not ultimately killing the cell. The multiple concentrations of 
Compound 72 assayed also show that, for this compound at least, there is a clear 
dose-response, with increasing concentrations resulting in faster cell death 
(Figure 2.3C). 
2.3.3 Dynamics of test compounds’ lethal effects 
One major drawback to using the proliferation assay, above, is the amount of 
time involved in conducting cell counts of the sampled cultures, thereby limiting 
the number of samples that can be taken and the number of test conditions 
assayed in any one set of experiments. 
In order to overcome this, the monitoring of the cell density of a test culture 
was automated by the use of a spectrophotometer. In a dense culture of 
trypanosomes light is absorbed or refracted by the living cells in suspension. If 
the cells die, they lose the ability to maintain their osmotic stability and swell 
up and lyse. Therefore, light absorption can be used as a proxy measure of the 
cell density of a culture: as the cell density of a suspension becomes less, the 
light absorption at a specific wavelength (750 nm) is also lowered (Fairlamb, A. 
H. et al, 1992; Bridges, D. J. et al, 2007). A potential confounding factor, 
however, is that loss of motility by the flagellated trypanosomes may produce a 
similar effect: reduced light scatter and fewer cells in the light beam due to 
slow precipitation. 
Figure 2.4A shows the effect on cell density, as measured by light absorbance, of 
incubating Tb427 wild type bloodstream form trypanosomes with various 
concentrations of Compound 48. 10 µM of the test compound appears to kill the 
majority of cells within minutes of addition to the cell suspension. 8 and 6 µM of 
Compound 48 appear to produce a biphasic curve. The first, and steepest, slope 
of the curve could be due to the killing of a sub population of the trypanosomes 
by the initial shock of the addition of the compound, followed by a period where 
the compound acts on its intracellular target(s), resulting in a more gradual 
slope later on as the secondary action of the compound takes effect. At 4 and 2 
µM of Compound 48, the concentration may not be enough to generate the Matthew K Gould, 2009     Chapter 2, 118 
initial toxic shock and the steep slope seen for the higher concentrations is 
missing resulting in a single, more gradual slope as the secondary effects begin 
to take hold. 
In Figure 2.4B, Compound 111 shows a similar lysis profile, with high 
concentrations resulting in almost immediate lysis of all the cells. However, at 
16 µM, a biphasic lysis curve is displayed, with a steep initial slope followed by a 
period of approximately 1 hour where next to no lysis occurs and a more gradual 
second slope coming later. At lower concentrations only one slope is evident, 
with a similar gradient to that of the second slope at 16 µM. The observation 
that higher concentrations of Compound 111are required to produce the same 
effects of Compound 48 is consistent with the higher EC50 value of the former 
compared to the latter (Table 2.1). 
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Figure 2.4: Representative graphs showing the effects of (A): Compound 48, (B): Compound 
111, (C): Compound 37 and (D): Compound 77, at various concentrations, on the speed of 
cell death. Between 10
7 and 10
8 cells/ml of Tb427 wild type bloodstream form trypanosomes 
were incubated at 37 ºC with the respective concentrations of test compound in HMI-9/FCS. 
Arrowheads denote the time-point when the test compound was added. The cell 
suspensions were monitored for cell death by measuring light absorbance at a wavelength 
of 750 nm every 30 seconds. 
 
In spite of having a very similar in vitro efficacy value to Compound 111 (Table 
2.1), Compound 37 appears to lyse the trypanosome suspension much more Matthew K Gould, 2009     Chapter 2, 119 
slowly (Figure 2.4C). Even at 100 µM there is a lag phase of approximately 30 
minutes from addition of Compound 37 to the beginning of the lysis of the cells, 
whereas for Compound 111, lysis occurred almost instantaneously at the same 
concentration. 
For Compounds 48, 111 and 37, a dose-response relationship is apparent, with 
higher concentrations lysing the trypanosome suspensions faster than lower 
concentrations. However, the same cannot be said for Compound 77: 
concentrations of 10 µM and above appear to lyse the cells with equal rapidity, 
beginning after approximately 3 hours incubation (Figure 2.4D). A dose-response 
relationship appears to resume below 10 µM, with 5 µM of Compound 77 
beginning lysis of the cells after approximately 5 hours incubation. 
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Figure 2.5: Representative graphs showing the effect of removing drug pressure on cell 
death after limited incubations of the test compounds with Tb427 wild type bloodstream 
form trypanosomes. Between 10
7 and 10
8 cells/ml were incubated with the various 
concentrations of test compound for the stated lengths of time in HMI-9/FCS and at 37 ºC. 
The cell suspensions were washed once by centrifugation and resuspension of the cell 
pellet in an equal volume of either (Group 1): 1 ml of the test compound at the initial 
concentration dissolved in fresh HMI-9/FCS, or (Group 2): 1 ml of fresh HMI-9/FCS only. 
After washing, the trypanosome suspension was maintained at 37 ºC and monitored for cell 
death by measuring light absorbance at a wavelength of 750 nm in a spectrophotometer 
every 30 seconds. (A): The effect of various concentrations of Compound 111 with drug 
pressure removed after 1 hour incubations in Group 2. (B) The effect of 8 µM of Compound 
111 with drug pressure removed after various incubation lengths in Group 2. (C) and (D) The 
effect of various concentrations of Compound 37 with drug pressure removed after 1 hour, 
and 45 minutes, respectively, in Group 2. Higher concentrations of the drug were used in 
panel D than in panel C.  Matthew K Gould, 2009     Chapter 2, 120 
 
The spectrophotometric lysis assay was also used to investigate whether the 
trypanosomes were committed to cell death after removing drug pressure before 
the toxic effects became apparent. For concentrations of Compound 111 at 8 
and 12 µM, a 1 hour exposure of the trypanosomes appears to be sufficient to 
commit the cells to death even if drug pressure is removed (Figure 2.5A). 
However at 4 µM, removing the drug pressure after 1 hour by centrifugation and 
resuspension in fresh HMI-9 medium appears to prevent the onset of cell lysis, at 
least over the time-frame monitored. When the concentration of Compound 111 
is maintained at 8 µM and the exposure time to the trypanosomes is varied a 
similar result is given. Exposure for 45 minutes is sufficient to result in the onset 
of cell lysis at the same time as a cell suspension with drug pressure maintained 
throughout (Figure 2.5B). Reducing the exposure time to 30 minutes results in a 
delayed onset of cell lysis, whereas a 15 minute exposure does not appear to 
have been sufficient to commit the trypanosomes to lyse over the time period 
monitored. The obvious conclusion is that Compound 111 is rapidly accumulated 
into the cells where it triggers events that will eventually lead to cell death over 
a period of several hours. 
In contrast to Compound 111, removal of drug pressure after a 1 hour exposure 
to Compound 37 appears to entirely prevent cell lysis (Figure 2.5C). Indeed, 
even removing drug pressure after the onset of cell death can prevent the 
remaining trypanosomes from lysing (Figure 2.5D). 
2.3.4 In vivo efficacy testing 
A panel of compounds with the highest in vitro activity that were available at 
the time were selected to undergo preliminary in vivo efficacy trials against 
trypanosomiasis in mice. Before investigating the effects of the compounds on 
parasitaemia in infected mice, each compound was tested to ensure the mice 
tolerated the treatment without signs of acute toxicity. Single mice were 
injected intraperitonealy with a single dose of 1 mg/kg bodyweight for each 
compound. If no adverse effects were observed after 48 hours another mouse 
was injected with a single dose of 10 mg/kg. Again, if no signs of severe 
discomfort were observed after 5 days post-injection, another mouse was given Matthew K Gould, 2009     Chapter 2, 121 
the maximum allowed dose of 50 mg/kg. Each mouse was monitored for 10 days 
in total for any adverse effects or signs of discomfort. 
Table 2.5 shows the 10 compounds tested for tolerance in mice and the 
maximum tolerated doses. For Compounds 4, 7, 24, 27, 37, 38, 43 and 55, no 
severe discomfort was observed in the mice over 10 days after a dose of 1, 10 or 
50 mg/kg. However, for Compounds 5 and 48, while well tolerated at 1 and 10 
mg/kg, a dose of 50 mg/kg resulted in severe discomfort and the test was 
aborted immediately by terminal anaesthesia with a rising concentration of CO2. 
Since Compound 5 only displayed moderate in vitro activity in the whole-cell 
efficacy assays, no further in vivo testing was carried out with this compound. 
Compound 48, on the other hand, showed remarkable activity, with an EC50 
value of just 70 nM (± 28) against Tb427 wild type (Table 2.1) so it was decided 
to determine the maximum tolerated dose by increasing the concentration by 
increments of 10 mg/kg bodyweight. The maximum dose that was well tolerated 
by the mouse was 20 mg/kg (Table 2.5) and this concentration was used in 
subsequent in vivo efficacy trials. 
1 10 20 30 50
4 OK OK OK
5 OK OK Aborted
7 OK OK OK
24 OK OK OK
27 OK OK OK
37 OK OK OK
38 OK OK OK
43 OK OK OK
48 OK OK OK Aborted Aborted
55 OK OK OK
University of 
Glasgow 
Compound Code
Compound Dose (mg/kg bodyweight)
 
Table 2.5: Panel of compounds tested for in vivo tolerance in mice. Single female ICR strain 
mice were given a single dose at the concentration stated by intraperitoneal injection and 
monitored for signs of severe discomfort for 10 days. Conditions that were tolerated by the 
mice are marked OK; those that were not tolerated are marked Aborted. 
 
A preliminary investigation into the effect of 5 compounds on the parasitaemia 
of infected mice was carried out on groups of 3 mice per compound. Female ICR 
mice were first inoculated with 10
4 bloodstream form Tb427 wild type 
trypanosomes by intraperitoneal injection. 6 hours later the first of three doses 
were given at 50 mg/kg, again by intraperitoneal injection, with the remaining 
two doses administered 24 hours apart. The parasitaemia was monitored by Matthew K Gould, 2009     Chapter 2, 122 
microscopic inspection of blood smears as well as cell counts, using a 
haemocytometer, on small samples of blood taken from each mouse. 
Three days post-infection, those mice treated with Compounds 4, 27 and 55 did 
not appear to show a difference in the level of parasites in the blood compared 
with the untreated, infected controls (Figure 2.6A). Those mice treated with 7 
mg/kg of diminazene had no sign of infection after the same time period. Mice 
treated with Compounds 37 and 7, however, did appear to have greatly reduced 
parasitaemia, but statistical testing using the 1-tailed, paired Student’s T-test 
showed the differences were not significant compared to the untreated control. 
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Figure 2.6: Histograms showing the mean parasitaemia, with standard error bars, of female 
ICR strain mice infected with Tb427 wild type bloodstream form trypanosomes and treated 
with a panel of Series 1 compounds after (A) 72 hours, and (B) 96 hours post infection. For 
each compound, 3 mice were infected and treated with 3 doses of 50 mg/kg by 
intraperitoneal injection, 24 hours apart. The mice treated with the positive control, 
diminazene, were also given 3 doses 24 hours apart but at a concentration of 7 mg/kg. 
Blood samples were taken daily and parasitaemia quantified by haemocytometer. Matthew K Gould, 2009     Chapter 2, 123 
24 hours later, the parasitaemias of mice treated with Compounds 4 and 55, 
again show no apparent difference to those of the untreated controls (Figure 
2.6B). The group of mice given Compound 27 appear to have a reduced 
parasitaemia, with those treated with Compounds 37 and 7 showing an even 
more pronounced reduction. While the average parasite levels in the blood 
appear to show an effect for these compounds, the 1-tailed, paired Student’s T-
test again showed the differences were not significant compared to the control. 
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Figure 2.7: Graphs showing the effect of treatment with Series 1 compounds on the mean 
parasitaemia of female ICR strain mice infected with Tb427 wild type bloodstream form 
trypanosomes. (A): Average parasitaemia after daily doses of Compound 37 at 50 mg/kg for 
4 days starting 6 hours post-infection. (B): Average parasitaemia after daily doses of 
Compound 48 at 20 mg/kg for 4 days starting 6 hours post-infection. The left-hand axis 
expresses the parasitaemia as the number of trypanosomes per ml of blood and the right-
hand axis expresses it as a percentage of the parasitaemia in the infected, untreated, 
control group. Each point is the mean parasitaemia, with standard errors, of 6 mice and 
those that are significantly different from the control are marked with asterisks. P-values 
were calculated using a one-tailed, unpaired, Student’s T-test. Parasitaemia levels were not 
quantifiable before 48 hours post-infection. 
 
In order to establish if there was a genuine reductive effect on the level of 
parasites in the blood of infected mice treated with Compound 37 at 50 mg/kg, Matthew K Gould, 2009     Chapter 2, 124 
a larger trial with groups of 6 mice was conducted, as well as a fourth dose of 
the compound added to the treatment regimen. After 48, 72 and 96 hours post 
infection, there was a consistently lower average number of trypanosomes 
present in the group of treated mice than in the untreated controls (Figure 
2.7A). When converted to a percentage, the parasitaemia in the treated group 
remained at approximately 60% of that of the control over the days when the 
parasite numbers were measurable. While the lower level of parasites appeared 
consistent over the course of the trial, the difference was only significant at the 
72 hour time-point (P = 0.044; 1-tailed, paired Student’s T-test). 
A similar in vivo efficacy trial was also conducted for Compound 48. 2 groups of 
6 mice were infected with bloodstream form trypanosomes: one group was left 
untreated while the mice in the other group were given 4 doses of Compound 48 
at 20 mg/kg 24 hours apart, commencing 6 hours post-infection. At all time 
points where the parasitaemia was quantifiable, the average number of 
parasites in the treated group was less than 40% of that of the control (Figure 
2.7B). At the 48, 72 and 96 hour time points, the reduction in parasitaemia was 
strongly significant, with P-values for each less than 0.005 (1-tailed, paired 
Student’s T-test), suggesting Compound 48, while not curative, can reduce the 
parasite burden in infected mice at a concentration of 20 mg/kg via the 
intraperitoneal route. 
2.3.5 Screening of putative phosphodiesterase inhibitors from a 
secondary source 
University of 
Glasgow 
Compound Code 
EC50 Value (M) Tb427 
WT 
EC50 Value (M) TbAT1 
KO 
TbAT1 KO 
Resistance 
Factor 
P Value: 
Significantly 
Resistant  Average  S.E.  Average  S.E. 
GJS-128  7.94E-08  1.03E-08  9.16E-08  5.20E-09  1.2  0.186 
GJS-446  1.31E-07  3.11E-08  1.60E-07  1.59E-08  1.2  0.248 
GJS-2011  2.11E-07  1.37E-08  2.65E-07  1.94E-08  1.3  0.083 
GJS-2358  3.67E-07  1.69E-08  3.34E-07  1.74E-08  0.91   
Table 2.6: Average EC50 values for GJS compounds assayed against Tb427 wild type and 
TbAT1 knockout bloodstream form trypanosomes, with standard errors. Values were 
derived from whole-cell in vitro efficacy assays and calculated from sigmoidal dose-
response curves, with variable slopes, using GraphPad Prism software. Averages are taken 
from at least 3 independent experiments. Also shown is the resistance factor of the TbAT1 
knockout strain compared to Tb427 wild type for each compound. Statistical significance 
was calculated after an F-test was conducted to determine which one-tailed Student’s T-test 
was most appropriate: that for equal or unequal variances. 
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A batch of four putative phosphodiesterase inhibitors, synthesized by Dr. G.-J. 
Sterk of Mercachem, The Netherlands, was made available and dispatched for 
preliminary screening against trypanosomes using the whole-cell in vitro efficacy 
assay. These compounds proved to be highly efficacious against the bloodstream 
form Tb427 wild type strain, with EC50 values in the nanomolar range and no 
cross-resistance displayed by the TbAT1 knockout cell line (Table 2.6). The most 
active compound was GJS-128 with an EC50 value of 79.4 ± 10.3 nM. 
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Figure 2.8: Representative graphs showing the effect of GJS compounds on Tb427 wild type 
bloodstream form trypanosome proliferation. Various concentrations of (A): GJS-128 and 
(B): GJS-2358 were incubated with the trypanosomes, beginning at a density of 
approximately 5 x 10
5 cells/ml, at 37 ºC, 5% CO2, and cell counts conducted periodically 
using a haemocytometer for up to 60 hours. 
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Proliferation assays with various concentrations of GJS-128 and GJS-2358 
demonstrate that the compounds are relatively slow acting compared to the 
putative PDE inhibitors of Series 1 (Figures 2.8A and 2.8B). For both compounds 
there is a dose-dependent effect, with higher concentrations of drug resulting in 
faster rate of trypanosome population decline. However there appears to be a 
considerable lag-phase between addition of compound and the beginning of cell 
lysis: for GJS-128 at least 6 hours elapses before cell density begins to decrease, 
even at over 100-fold the EC50 value (Figure 2.8A). The cell density graphs show 
a similar, if slightly longer, lag-phase for GJS-2358 (Figure 2.8B), consistent with 
it being a less active compound as determined by the whole-cell in vitro efficacy 
assays (Table 2.6). Matthew K Gould, 2009     Chapter 2, 127 
2.4 Discussion 
The Series 1 compounds display a wide range of activity against T. b. brucei and 
T. equiperdum with the most active compounds having EC50 values below 10 nM 
and the least active above 100 µM. Thus, a number of Series 1 compounds have 
activities in the same range, or better, than the current clinical or veterinary 
chemotherapies. Against T. b. brucei, seven compounds are more active than 
diminazene (Table 2.1), with Compounds 129, 197, 140 and 141 having EC50 
values roughly equivalent to those reported for pentamidine, melarsoprol and 
suramin (Lanteri, C. A. et al, 2006). Against T. equiperdum, four of the 
compounds tested were more active than diminazene (Table 2.4) with seven 
having EC50 values lower than suramin, and Compound 82 just ~ 2-fold less active 
than cymelarsen (Gillingwater, K. et al, 2007). 
Resistant T. b. brucei strains isolated from relapsing, treated animals or patients 
have been shown to have modifications in the parasite TbAT1/P2 transporter 
that takes up diamidine class drugs in addition to its physiological role in purine 
salvage (Mäser, P. et al., 1999; Matovu, E. et al., 2001b). This transporter has 
been disrupted in the TbAT1 knock out strain and has a greatly reduced 
substrate affinity in the T. equiperdum PBR strain (Barrett, M. P. et al., 1995). 
Induction of further resistance to pentamidine and melaminophenyl arsenical 
drugs resulted in the loss of the high-affinity pentamidine transporter (HAPT1) in 
the B48 strain and is a likely route for resistance to these compounds to arise in 
the field (Bridges, D. J. et al, 2007). That only a handful of compounds displayed 
significant resistance in the TbAT1 knockout and B48 strains, as well as the T. 
equiperdum PBR strain; and that even these compounds do not have more than a 
3 – 4-fold difference from the wildtype, suggests that there would be a low 
chance of cross-resistance to the Series 1 compounds from refractory strains in 
endemic foci. Compound 113 is one exception, with minor, but statistically 
significant resistance shown by the TbAT1 knockout and PBR strains, and more 
than 10-fold resistance from B48. The greater resistance in the B48 strain 
suggests that for this compound the high-affinity pentamidine transporter is a 
major route of entry into the trypanosome. Compound 98 also has statistically 
significant resistance in all three resistant cell lines, however the EC50 values are 
all less than 2-fold higher than the wildtype (Appendix 1; Tables 2.2 and 2.4). 
Since the resistance level is no different in the B48 strain than in the TbAT1 Matthew K Gould, 2009     Chapter 2, 128 
knockout cell line, HAPT1 is probably not a transporter of Compound 98, but 
TbAT1 may be one route of entry, probably alongside at least one other. Six 
compounds were more than 10-fold more active against the B48 strain than the 
wildtype (Table 2). One explanation for the greater sensitivity could be that the 
mutation in HAPT1 that lowers the affinity for pentamidine in B48 could also 
give rise to higher affinities for the Series 1 compounds. A similar phenomenon 
was observed with some curcumin analogues (Changtam, C. et al., 2009). 
Three compounds are more than 10-fold more active against T. equiperdum 
wildtype than T. b. brucei. Such large variations may be a result of differing 
expression levels of the target protein between species, or possibly due to single 
nucleotide polymorphisms in the gene sequence resulting in different affinities 
for the target protein. 
The proliferation assays highlight an apparently different mode of action 
between the two sources of putative phosphodiesterase inhibitors: the GJS 
compounds and those from Series 1. The GJS compounds have a lag phase of at 
least one generation time after the addition of test compound before the 
trypanosomes start to die, even at concentrations 100-fold higher than the EC50 
value (Figure 2.8). Some of the Series 1 compounds, on the other hand, begin to 
lower the cell density almost straight away (Figures 2.3B and 2.3C). To achieve 
the same lag period with Compound 72 the concentration must be lowered to 
just 5-fold that of the EC50, indicating that either Compound 72 enters the cell 
faster than the GJS compounds or the intracellular mode of action is different 
resulting in much faster cell death. When RNA interference was used to knock 
down the PDEB family of enzymes in bloodstream form trypanosomes, the 
intracellular cAMP concentration had risen to ~100-fold that of the basal level 
after 18 hours post-induction (Oberholzer, M. et al, 2007). In spite of the large 
increase in cAMP, cell lysis did not begin until approximately 24 – 30 hours after 
RNAi induction, and total population death was not complete until after 
approximately 50 hours. While the half-life of PDEB enzymes in trypanosomes is 
not known, and the long lag period between RNAi induction and the start of cell 
death may be a result of the slow degradation of the enzyme, the timing of cell 
death matches that caused by the GJS compounds better than that by the Series 
1 compounds tested. This indicates that the Series 1 compounds may not act by 
inhibiting the trypanosomal PDEB enzymes. Matthew K Gould, 2009     Chapter 2, 129 
This hypothesis is also supported by the efficacy data for the procyclic forms. 
This life cycle stage of the trypanosome has been shown to be resistant to knock 
down of the PDEB genes by RNAi, showing abnormalities in only a small 
percentage of the population due to the resultant increase in intracellular cAMP 
concentration (Zoraghi, R. and Seebeck, T., 2002; Oberholzer, M. et al, 2007). 
Although approximately two thirds of the compounds tested have EC50 values 
significantly higher in procyclics than bloodstream forms only 20% show greater 
than a 10-fold resistance in the insect stage, with just Compound 129 being more 
than 20-fold less active (Table 2.3). Since procyclics appear to be almost 
unaffected by the knockdown of the PDEB genes one would expect a very large 
degree of resistance to PDE inhibitors in this stage, suggesting the majority of 
Series 1 compounds tested are not trypanosomal PDE inhibitors. For the five 
compounds that do show major resistance from procyclic forms either the 
intracellular target protein or pathway is differentially expressed in the life 
cycle stages or, as is the case for diminazene, the transporter that allows entry 
to the cell is expressed at a lower level in the insect form (De Koning, H. P. et 
al., 1998; De Koning, H. P. et al., 2004). 
Both the proliferation assay and the spectrophotometric lysis assay suggest that 
differing modes of action or of cellular entry are utilised by different Series 1 
compounds. Compounds 7 and 27 have almost identical EC50 values (Appendix 1); 
however Compound 27 only takes approximately nine hours to kill all the 
trypanosomes whereas Compound 7 takes three days (Figures 2.3A and 2.3B). 
Either Compound 27 is accumulated to a lethal concentration inside the cell 
much faster than Compound 7, or the target proteins/pathways of the two 
compounds are different resulting in slower death for those trypanosomes 
incubated with Compound 7. Similarly, Compounds 37 and 111 have statistically 
identical EC50 values (Table 2.1); however, at 20 µM, cell lysis begins after 2 
hours of incubation with Compound 37, whereas lysis begins mere minutes after 
the addition of the same concentration of Compound 111 (Figures 2.4B and 
2.4C). There also appears to be a difference in the length of exposure time 
necessary to result in cell death for these two compounds. While exposure to 8 
µM of Compound 111 for 1 hour is sufficient to bring about the onset of cell 
death 2 hours later, toxic pressure needs to be maintained right up until the 
trypanosomes lyse for Compound 37 (Figures 2.5A, 2.5B and 2.5C). Again, the Matthew K Gould, 2009     Chapter 2, 130 
lysis assays could indicate alternative modes of action or of uptake of the 
compounds. 
At high concentrations, both Compounds 48 and 111 appear to be acutely toxic 
to the trypanosome (Figures 2.4A and 2.4B); however, after some time, the rate 
of population lysis appears to slow before gathering pace again. At low 
concentrations the lysis curve has one slope instead of the two seen at high 
concentrations. This could be the result of the compounds disrupting multiple 
proteins or pathways within the cell with differing affinities. The acute toxicity 
could be the result of a low affinity target which, possibly after some response 
to the toxin, can be overcome to halt or retard the lethal effects. The later 
slope may be due to the inhibition of a second target protein or pathway with a 
higher affinity for the inhibitor but which kills the cell more slowly than the 
acute mode. At high concentrations both routes to cell death can be taken, but 
at lower concentrations only the high affinity target may be disrupted, giving 
the single slope. Another explanation for the biphasic lysis curves could be that 
instead of the initial lowering of absorbance being due to cell death, the 
compounds may be paralysing the cells resulting in less diffraction of light from 
the non-motile flagella compared to the moving, unaffected flagella. In this 
instance the second slope would correspond to either the trypanosomes falling 
below the light beam through the effect of gravity on the non-motile cells, or 
actual cell death as a result of the toxic effects of the compounds. 
Compound 77 also appears to display a unique lysis profile compared to the 
other compounds, with the lack of a dose-response above 10 µM (Figure 2.4D). 
This could be due to the target being saturated at that concentration, with 
higher concentrations having no greater impact on the target and the onset of 
cell lysis. A more likely alternative is that Compound 77 is not entirely soluble in 
the HMI-9 medium at higher concentrations. It was observed that on addition of 
the compound stock, dissolved in DMSO, to HMI-9, the medium would initially 
turn cloudy before the compound apparently went back into solution as the 
medium was heated to 37 ºC. It may be that at higher concentrations some of 
Compound 77 was merely in a fine suspension and not available for uptake or 
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While both the proliferation and spectrophotometric lysis assays provide 
valuable information on the relative speeds of action of particular compounds 
against trypanosomes, there are a number of drawbacks and confounding factors 
that limit their usefulness. Using a haemocytometer to assess the effects of 
compounds on cell density is slow and labour-intensive; because of this it is not 
possible to assay many variations on incubation conditions at one time. It is also 
difficult to provide accurate timings for compounds that act in minutes as 
opposed to hours. The spectrophotometric lysis assay overcomes some of these 
problems by automating the cell density assessment meaning many more 
readings can be taken than by haemocytometer. This gives higher resolution and 
accuracy for fast acting compounds as to the beginning of cell lysis in the 
population of trypanosomes, providing useful information for the set up of future 
biochemical analyses of the compounds’ intracellular effects. However, since 
the cell densities required to provide a measurable drop in absorbance due to 
cell lysis are an order of magnitude higher than can be achieved through normal 
in vitro culture, questions are raised as to whether the effects observed can be 
directly translated to experiments conducted at lower cell densities. Another 
confounding factor already alluded to is whether the lowering of absorbance is 
always due to cell lysis or to loss of motility, which would result in the cells 
accumulating at the bottom of the cuvette and below the beam of measured 
light. A higher through-put assay that can more accurately determine the point 
of cell lysis at less physiologically stressful trypanosome densities is much 
needed and we describe the development and characterization of such an assay 
in Chapter 3. 
The in vivo trials indicate that at least for Compound 48, the Series 1 compounds 
can have an effect on the parasitic burden in the host. Pharmacokinetic analysis 
of the half-life of the compound in the blood plasma indicates that at 10 mg/kg 
bodyweight, the concentration of Compound 48 rapidly drops below the in vitro 
EC50 value (Shota Yamanaka, personal communication, Otsuka Japan). This 
suggests that at the maximum tolerated dose, Compound 48 does not stay at a 
high plasma concentration for long enough to kill all of the trypanosomes and 
result in a cure. Chemical modification of the compound to prevent rapid 
clearance by the host could be possible, although this may result in a compound 
more toxic to the mammalian host. Matthew K Gould, 2009     Chapter 2, 132 
Compound 37 did not suffer from the same problem of toxicity and appeared to 
be well tolerated by the mice. The maximum dose allowed under the Home 
Office Project license of 50 mg/kg, while consistently lowering the parasitaemia 
compared to untreated mice, was not sufficient to produce a statistically 
significant difference from the controls. Although far from ideal, higher 
concentrations may provide statistical evidence for an effect for Compound 37 in 
vivo and possibly cure. As a comparison, the current treatment regimen for 
Eflornithine stipulates a daily dose of 400 mg/kg per day for two weeks to 
provide a cure for late stage T. b. gambiense infections (Bouteille, B. et al, 
2003). Matthew K Gould, 2009     Chapter 3, 133 
 
 
 
 
 
 
 
Chapter III 
3  Validation of a propidium iodide based method 
for monitoring drug action on the 
kinetoplastidae Matthew K Gould, 2009     Chapter 3, 134 
3.1 Introduction 
As has been described in the previous chapter (2.1) the Alamar Blue
® assay is the 
standard assay used to determine in vitro efficacy of test compounds. Based on 
the method developed by Räz, et al (1997), the metabolism of non-fluorescent 
resazurin to its fluorescent metabolite resorufin by living cells is utilised as a 
means of monitoring the effects of test compounds on trypanosome growth in 
vitro. It is cheap, versatile and reproducible, yet it suffers from a number of 
limitations that are not always appreciated. 
The rate of resorufin formation logically depends on both the rate by which 
resazurin enters the cell and the rate by which this dye is reduced once inside. 
Neither parameter can be assumed to be constant between different cell types 
or species, leading to different incubation conditions that make comparisons 
difficult. For instance, Mikus and Steverding (2000) noted that Leishmania 
promastigotes metabolise resazurin much more slowly than bloodstream form 
trypanosomes, and assume the difference stems from different incubation 
temperatures (27 versus 37 °C). However, Al-Salabi and De Koning (2005) found 
that in order to produce a sufficient fluorescent signal they had to incubate L. 
mexicana amastigotes (seeded at 10
6/ml, 32 °C in a CO2 incubator) for 72 hours 
in the presence of the dye, as opposed to a two-hour incubation with 
Trypanosoma brucei bloodstream forms, seeded at 2×10
3 cells/ml and cultured 
at 37 °C Räz, B. et al, 1997). In addition, Rolón et al. (2006) found a resazurin 
incubation time of 5 hours at 28 °C sufficient for Trypanosoma cruzi 
epimastigotes. 
More importantly, in some cases the test substance itself can reduce resazurin 
(Eichler, H., 1934) yielding a false positive. In addition, the fluorescent resorufin 
can be further reduced to the colorless, non-fluorescent metabolite 
hydroresorufin. This can result in metabolically active, living cells that produce 
hardly any fluorescent signal as a result of over-incubation. On the other hand, 
dead cells that fail to further reduce resorufin can produce a strong fluorescent 
signal, normally taken to indicate live cells (O’Brien, J. et al, 2000). Moreover, 
resazurin lends itself poorly to analysis of the dynamics of drug action, being 
very much an end-point indicator (O’Brien, J. et al, 2000; personal observations) 
and monitors metabolic activity rather than cellular survival. It is thus very hard, Matthew K Gould, 2009     Chapter 3, 135 
using this assay, to distinguish between test compounds that induce growth 
arrest or cell death (Rodenko, B. et al, 2007). A test compound might also affect 
the metabolic activity or growth rate of cells rather than their survival, creating 
further uncertainty. Finally, the validity of comparison of different strains of the 
same species relies on the assumption that they metabolize resazurin at the 
same rate. However, in two different isogenic pairs of melarsen-resistant 
trypanosomes, the resistant cells’ capacity to reduce resazurin was diminished 
and there was no clear correlation between cell survival and fluorescence 
(Foucher, A. L., 2003). 
While the resazurin reduction assay has undoubtedly allowed the screening of 
potential new lead compounds against diverse protozoan pathogens and cancer 
cell lines, it would be highly beneficial to have a well-validated alternative 
protocol that does not suffer from the same drawbacks. In this chapter the 
fluorescent dye propidium iodide (PI) is evaluated as an alternative monitor for 
assessing drug action on trypanosomes. This dye, which becomes fluorescent 
upon binding to nucleic acids and which does not cross intact plasma membranes 
or even membranes of cells in the early stage of apoptosis (Ferlini, C. et al, 
1996), can be used either in an end-point or a real-time assay.
 
3.2 Materials and Methods 
3.2.1 Materials and Culturing 
Propidium iodide was supplied by Fluka; digitonin, resazurin sodium salt and 
pentamidine were obtained from Sigma Aldrich; melarsen oxide was a gift from 
Sanofi-Aventis. 
Bloodstream forms of Trypanosoma brucei brucei strain 427 were grown at 37 ºC 
in a 5% CO2 atmosphere in HMI-9 medium (BioSera) supplemented with 10% 
foetal bovine serum (FBS, Biosera). Cells in the mid to late logarithmic stage of 
growth were collected and centrifuged at 610 rcf for 10 minutes and either 
resuspended in HMI-9 to the required cell density, or washed once and 
resuspended in assay buffer (AB) (33 mM Hepes, 98 mM NaCl, 4.6 mM KCl, 0.3 
mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, and 14 mM glucose, pH 7.3) for Matthew K Gould, 2009     Chapter 3, 136 
those experiments not conducted in HMI-9 medium. Cell counts were carried out 
using a haemocytometer.  
T. b. brucei procyclics were grown in SDM79 (Gibco) supplemented with 7.5 
µg/ml haemin (Sigma) and 10% FBS at 27 ºC. Leishmania mexicana promastigotes 
were grown at 25 ºC in HOMEM (Gibco) supplemented with 10% FBS and 
harvested for experiment at a density of ~10
7 cells/ml. L. mexicana amastigotes 
were cultured at 32 ºC in Schneider’s Drosophila medium (Gibco) supplemented 
with 20% FBS. 
3.2.2 Standard Curves 
Genomic DNA from bloodstream form T. b. brucei strain 427 was extracted using 
a method based on that described by Medina-Acosta and Cross (1993). A 50 ml 
culture was centrifuged at 610 rcf and resuspended in 1 ml HMI-9 before being 
transferred to a 1.5 ml eppendorf; this was centrifuged again at 380 rcf for 10 
minutes. The supernatant was discarded and the pellet gently resuspended in 
150 µl of TELT lysis buffer (50 mM Tris-HCl (pH 8.0), 62.5 mM EDTA (pH 9.0), 2.5 
M LiCl, 4% (v/v) Triton X-100) and left for 5 minutes at room temperature. 150 µl 
equilibrated phenol:chloroform (Sigma-Aldrich) was added and mixed, then the 
eppendorf was centrifuged at 16060 rcf for 5 minutes. The upper, aqueous phase 
was removed and placed in a new eppendorf to which 300 µl of absolute ethanol 
was added, gently swirled and left for 5 minutes to precipitate the DNA. The 
eppendorf was then centrifuged at 16000 rcf for 10 minutes and the supernatant 
removed; the pellet was washed once with 70% (v/v) ethanol and re-pelleted at 
16000 rcf for 10 minutes after which the ethanol was removed by pipette and 
the pellet left to air dry. The DNA was then dissolved in 100 µl TE buffer (10 mM 
Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)) with RNaseA. The DNA was quantified 
using a Nanodrop spectrophotometer (Thermo Fisher Scientific) and stored at 4 
ºC.  
The Tb427 gDNA was doubly diluted in assay buffer in a 96-well plate and an 
equal volume (100 µl) of assay buffer containing propidium iodide at twice the 
final desired concentration was added to each well. Fluorescence was measured 
using a PerkinElmer LS55 Luminescence Spectrometer at an excitation 
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Live Tb427 bloodstream forms were harvested as described above and 
resuspended to a cell density of 4 x 10
8 trypanosomes/ml in either assay buffer 
or HMI-9 medium, as indicated. Serial two-fold dilutions of the cell suspension 
were made in a 96-well plate and to each well an equal volume (100 µl) of assay 
buffer or HMI-9 containing twice the desired concentration of propidium iodide 
and 40 µM digitonin was added. The 96-well plate was incubated at 37 ºC for 2 
hours to allow the digitonin to permeabilize the cell membranes to the 
propidium iodide; full lysis was confirmed by microscope. Fluorescence was then 
measured using a FLUOstar OPTIMA (BMG Labtech) fluorimeter with excitation 
and emission filters at 544 nm and 620 nm respectively. 
3.2.3 Effect of Propidium Iodide on Bloodstream Form T. b. brucei 
Propidium iodide was doubly diluted in HMI-9 medium in a 24-well plate. An 
equal volume (500 µl) of HMI-9 containing  bloodstream form T. b. brucei strain 
427 trypanosomes was added to each well to give a final cell density of 2x10
5/ml 
and the plate was incubated at 37 ºC and 5% CO2. Cell counts for each well were 
carried out in duplicate at various time points using a haemocytometer and the 
ED50 values (the effective dose at which 50% of the cells were killed) were 
calculated by non-linear regression using the Prism 4 software package 
(GraphPad). 
3.2.4 Cell Lysis Assays 
100 µl of HMI-9 containing twice the desired concentration of melarsen oxide or 
pentamidine and 12 µg/ml (18 µM) propidium iodide was pipetted into a well of 
a 96-well plate; a well containing 100 µl HMI-9 with propidium iodide only was 
set up as a control. An equal volume of HMI-9 containing  bloodstream form 
Tb427 trypanosomes was added to each well to give a final cell density of 
5x10
6/ml and PI concentration of 6 µg/ml (9 µM)and fluorescence was monitored 
over time at 37 ºC and 5% CO2 using a FLUOstar OPTIMA fluorimeter with the 
excitation and emission filters stated above. This method was compared to the 
standard spectrophotometric lysis assay monitored at 750 nm in a 1 ml cuvette, 
using 1-3 x 10
7 bloodstream form trypanosomes/ml in HMI-9/10% FBS, exactly as 
described (Chapter II). Matthew K Gould, 2009     Chapter 3, 138 
3.2.5 Comparison of the use of propidium iodide as an endpoint 
assay with the whole-cell resazurin reduction assay for in 
vitro compound efficacy 
The resazurin reduction assay was performed essentially as described (Chapter 
II) with minor modifications. Briefly, melarsen oxide was doubly diluted in HMI-9 
in a 96-well plate; an equal volume (100 µl) of HMI-9 containing bloodstream 
form Tb427 trypanosomes was added to give a final cell density of 10
5 
trypanosomes/ml. This was repeated with final cell densities of 5 x 10
4, 1 x 10
4, 
and 5 x 10
3 trypanosomes/ml and the plate was incubated at 37 ºC and 5% CO2 
for 48 hours. After which, 20 µl of 0.5 mM resazurin sodium salt in phosphate-
buffered saline (PBS) was added to each well and the plate was incubated for a 
further 24 hours. Fluorescence was measured using a FLUOstar OPTIMA 
fluorimeter with excitation and emission filters of 544 nm and 590 nm 
respectively. 
The propidium iodide endpoint assay was set up in exactly the same manner as 
the whole-cell in vitro efficacy assay except that, after the trypanosomes were 
added to the drug dilutions, the 96-well plate was incubated for 72 hours. 
Subsequently, 20 µl of 90 µM propidium iodide and 200 µM digitonin in PBS was 
added to each well and, after a further incubation of 1 hour to ensure all the 
trypanosomes were permeabilized, the fluorescence of the propidium iodide was 
measured with a FLUOstar OPTIMA fluorimeter with the excitation and emission 
filters at 544 nm and 620 nm respectively.  
3.2.6 Rates of Resazurin Metabolism. 
T. b. brucei procyclics and bloodstream forms, and L. mexicana promastigotes 
and axenic amastigotes were grown and harvested as described above, washed 
twice and resuspended in their respective culture media supplemented with FBS. 
Doubling dilutions of the cells in the same media were set up in 96-well plates, 
starting at 1 or 2 x 10
8 parasites/ml in a final volume of 200 µl. At the start of 
the incubation, 20 µl of 0.5 mM resazurin sodium salt in PBS was added to each 
well and the plate was incubated for a further 24 hours at 28 ºC (procyclics and 
promastigotes), 32 ºC (amastigotes) or 37 ºC (T. b. brucei bloodstream forms). 
The bloodstream forms were also kept under a 5% CO2 atmosphere throughout. Matthew K Gould, 2009     Chapter 3, 139 
Fluorescence was monitored in real time using a FLUOstar OPTIMA fluorimeter 
with excitation and emission filters of 544 nm and 590 nm respectively. Initial 
rates of resazurin metabolism were determined using linear regression over the 
linear phase (r2 ≥ 0.99) and expressed as artificial fluorescence units (A.U.) per 
hour. Matthew K Gould, 2009     Chapter 3, 140 
3.3 Results 
3.3.1 Standard Curves and Assay Sensitivity. 
To test whether propidium iodide could be a suitable fluorophore to use in the 
monitoring of a culture of trypanosomes, standard curves of fluorescence when 
bound to doubly diluted genomic DNA extracts or whole trypanosomes lysed with 
digitonin were generated. PI generates a dose-dependent fluorescence when 
bound to trypanosomal gDNA (Figure 3.1), with a detection limit (using a Perkin-
Elmer LS55 fluorimeter) of approximately 0.5 pg/ml. At 12 µg/ml or 6 µg/ml PI 
the linear range was up to 12.5 pg/ml (Figure 3.1, inset) although fluorescence 
continued to increase up to 100 ng/ml T. b. brucei gDNA.  
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Figure 3.1: Standard curves of fluorescence signal generated by the interactions of various 
concentrations of T. b. brucei genomic DNA with propidium iodide: (n n n n) 12 µg/ml; (￿ ￿ ￿ ￿) 6 
µg/ml; (l l l l) 3 µg/ml; and (￿ ￿ ￿ ￿) 1.5 µg/ml. The inset shows the linear part of the dose-response 
curve for each propidium iodide concentration, with correlation coefficients of 0.99, 0.98, 
0.99 and 0.94, respectively, calculated by linear regression. 
 
A similar signal was generated when PI was added to whole cell Trypanosoma 
brucei suspensions, lysed by digitonin (Figure 3.2A). Using the Perkin-Elmer LS55 
fluorimeter, and a concentration of 6 µg/ml PI, the detection limit was below 
10
6 trypanosomes/ml and the assay is linear between 1 x 10
6 and 5 x 10
7 
trypanosomes/ml (r2 = 0.98).  Matthew K Gould, 2009     Chapter 3, 141 
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Figure 3.2: Standard curves of trypanosome-associated propidium iodide fluorescence after 
cell permeabilisation with digitonin. Propidium iodide concentrations: (n n n n) 12 µg/ml; (￿ ￿ ￿ ￿) 6 
µg/ml; (l l l l) 3 µg/ml; and (￿ ￿ ￿ ￿) 1.5 µg/ml. (A): T. b. brucei bloodstream forms, suspended in 
assay buffer: fluorescence read using a Perkin-Elmer LS55. Inset shows the linear phase of 
the dose-response curve for each propidium iodide concentration, with correlation 
coefficients of 0.99, 0.95, 0.96 and 0.95, calculated by linear regression. (B), (C): T. b. brucei 
bloodstream forms suspended in assay buffer (B) or HMI-9 medium with 10% FBS (C): 
fluorescence read using FLUOstar OPTIMA. Insets shows fluorescence after the gain was 
readjusted to enhance resolution at low fluorescence levels. 
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Optimising the signal strength by adjusting the gain settings at 6 µg PI/ml and in 
assay buffer (AB) resulted in the operational range being extended to 1.2 x 10
5 – 
2.5 x 10
8 trypanosomes/ml (Figure 3.2B) and linear up to 7 x 10
7 
trypanosomes/ml (r 2>0.98 at 12 and 6 µg/ml PI). Indeed, the improved 
sensitivity also allowed similar measurements in HMI-9 (Figure 3.2C), with a 
lower limit of ~1 x 10
6 trypanosomes/ml. 
3.3.2 Effect of propidium iodide on cell viability and growth. 
The effect of propidium iodide on trypanosome viability was tested next, in 
order to confirm whether the dye can be used to monitor drug effects on 
viability without affecting this itself. The effects of varying concentrations of 
the compound on cultures of bloodstream trypanosomes were monitored over 34 
hours by cell counts using a haemocytometer and phase-contrast microscopy. At 
high concentrations, PI was found to be toxic to trypanosomes over a period of 9 
hours, yielding an extrapolated IC50 value of 76 ± 3 µM or 51 ± 3 µg/ml (n = 3; 
Figure 3.3). Below 10 µg/ml no discernible growth effect was observed over 9 
hours, or any effect on viability for up to 34 hours (data not shown). However, 
concentrations as low as 0.5 µg/ml PI appeared to inhibit cell proliferation over 
24 or 34 hours (data not shown). 
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Figure 3.3: Effect of the continuous exposure to propidium iodide on trypanosome viability. 
T. b. brucei in HMI-9 with 10% FBS were incubated with serial two-fold dilutions of 
propidium iodide for 9 hours. Cell counts were performed in duplicate using a 
haemocytometer. IC50 value was estimated using a non-linear regression (Prism 4.0, 
GraphPad) and extrapolation of the sigmoidal curve to a minimum value of zero. 
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3.3.3 Real-time monitoring of cell lysis. 
Since propidium iodide is unable to cross intact cell membranes, it can only bind 
to intracellular RNA and DNA and fluoresce when the cell membrane has been 
disrupted. Therefore, in suspensions of live cells, fluorescence of propidium 
iodide can be an accurate signal of the moment the cell membrane is breached 
and, by inference, cell death occurs. This gives an accurate depiction of the 
dynamics of drug action on the trypanosome. 
When incubated with 10 µM of melarsen oxide, the onset of T. brucei cell lysis 
started to occur after as little as 15 minutes and was complete within 30 
minutes (Figure 3.4A). The assay clearly shows a dose-dependent response to the 
arsenical drug: at 2.5 µM the start of cell lysis has been delayed by 15 minutes, 
with full lysis of the culture reached at approximately 40 minutes. With 0.5 µM 
melarsen oxide, 50% of trypanosomes were lysed in ~100 minutes. The action of 
pentamidine (a compound with an almost identical EC50 value to melarsen oxide 
as determined in a resazurin reduction assay (Matovu, E. et al, 2003)) on 
trypanosome viability was very much slower; the extremely high concentration 
of 100 µM (i.e. 50,000 x IC50 (Bridges, D. J. et al, 2007)) only bringing about the 
onset of cell lysis after 2 hours of incubation and 25 µM of pentamidine having no 
apparent effect on cell survival over 6 hours (Figure 3.4A). At the end of the 
assay, samples from each of the cultures were inspected by microscope: no 
living trypanosomes were observed in any of the samples containing melarsen 
oxide. In contrast, no ill effects on the cells were noticeable in the 5 µM 
pentamidine sample or in the no-drug control. The traces due to PI fluorescence 
in figure 3.4A mirror those derived from the spectrophotometric assay in figure 
3.4B demonstrating that the PI lysis assay produces data consistent with that 
from the alternative method. 
Figure 3.4C shows the acute effects of melarsen oxide and pentamidine on these 
cells in the presence and absence of 3, 6 and 12 µg/ml PI. No difference is 
shown for the onset of cell lysis due to either drug in the presence or absence of 
propidium iodide. Similarly, the rate of cell lysis is unaffected by the addition of 
PI, in comparison to drug action without the dye. This demonstrates that over at 
least eight hours PI did not alter the rate by which standard trypanocides cause 
cell death in bloodstream T. b. brucei. Matthew K Gould, 2009     Chapter 3, 144 
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Figure 3.4: Effects of pentamidine and melarsen oxide on T. b. brucei survival. (A): Survival 
monitored by measuring fluorescence of 6 µg/ml propidium iodide in HMI-9 with 10% FBS 
using a FLUOstar OPTIMA fluorimeter. All traces recorded simultaneously in a white-
bottomed 96-well plate using 5 x 10
6 bloodstream form trypanosomes/ml. (B), (C): Survival 
monitored by measuring light scatter or absorbance at 750 nm. 
 
The propidium iodide lysis assay validated in Figure 3.4 was used to monitor the 
effects of a number of test compounds on the survival of populations of 
bloodstream form trypanosomes. The timings for the onset of cell death with 
Compound 37 is almost identical to the data generated by the 
spectrophotometric lysis assay (Chapter 2, Figure 2.4C; Figure 3.5A), further 
validating the PI assay as a reliable means of monitoring cell death. Compound Matthew K Gould, 2009     Chapter 3, 145 
48, on the other hand, appears to be much more active in the PI method in 
comparison to the spectrophotometric assay. In the PI assay Compound 48 kills 
trypanosomes almost instantaneously at concentrations as low as 6.25 µM (Figure 
3.5B), whereas similar concentrations in the light absorbance assay result in a 
biphasic curve with the initial drop in absorbance becoming less steep taking 
approximately 3 hours to reach the base-line absorbance of total cell death 
(Chapter 2, Figure 2.4A). The Compound 48 analogue, Compound 139, appears to 
kill trypanosomes more slowly than Compound 48 (Figure 3.5C), consistent with 
the former having a lower EC50 than the latter. GJS-128, in spite of having an 
almost identical EC50 value with Compound 48, is a much slower acting 
compound with concentrations hundreds of times higher than the in vitro 
efficacy value not killing the trypanosomes within 8 hours (Figure 3.5D). This 
difference in speed emphasises a probable different mode of action between the 
two series of compounds. 
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Figure 3.5: Effects of various concentrations of Series 1 compounds and GJS-128 on T. b. 
brucei survival. Survival was monitored by measuring fluorescence of 6 µg/ml propidium 
iodide in HMI-9 with 10% FBS using a FLUOstar OPTIMA fluorimeter. All traces recorded 
simultaneously in a white-bottomed 96-well plate using 5 x 10
6 bloodstream form 
trypanosomes/ml. (A): Compound 37; (B): Compound 48; (C): Compound 139; (D): GJS-128. 
 Matthew K Gould, 2009     Chapter 3, 146 
3.3.4 Resazurin metabolism by protozoan parasites. 
As part of the comparison between the whole-cell in vitro and PI assays, it was 
investigated whether, as reported for some mammalian cell types (O’Brien, J. et 
al, 2000), protozoa are able to reduce resazurin to resorufin and onwards to the 
non-fluorescent hydroresorufin. Figure 3.6 shows that bloodstream form T. b. 
brucei, but not L. mexicana amastigotes, do seem to rapidly metabolize the 
fluorescent compound generated upon incubation with resazurin, especially at 
high cell numbers, leading to a rapid decrease in net fluorescence. Some 
reduction in resazurin fluorescence after more than 6 hours was also noticeable 
with high density cultures of T. b. brucei procyclics and L. mexicana 
promastigotes, but this was less pronounced than with bloodstream forms (data 
not shown). 
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Figure 3.6: Development of fluorescence due to resazurin metabolism over 24 hours. (A): T. 
b. brucei bloodstream forms at 37 ºC under 5% CO2 atmosphere at stated seeding cell 
densities. (B): L. mexicana amastigotes at 32 ºC at stated seeding cell densities. 
Fluorescence was measured using a FLUOstar OPTIMA fluorimeter with identical gain 
settings for both organisms. 
 Matthew K Gould, 2009     Chapter 3, 147 
The perceived differences in resazurin metabolic rates in the various parasites 
were addressed next. Initial rates of metabolism, rather than levels of 
fluorescence after a predetermined number of hours, were plotted for T. b. 
brucei procyclics and bloodstream forms as well as L. mexicana promastigotes 
and axenic amastigotes. The rate of resazurin metabolism was virtually identical 
in T. b. brucei procyclics and bloodstreams forms (Figure 3.7A), and the rate is 
directly proportional to cell density for all four cell types over at least three 
orders of magnitude (Figures 3.7A and 3.7B). However, resazurin metabolism 
was notably slower in L. mexicana amastigotes than in promastigotes (Figure 
3.7B), although not to the extent expected on the basis of the incubation times 
required for the standard whole-cell in vitro efficacy assay (Al-Salabi, M. I. and 
De Koning, H. P., 2005; Papageorgiou, I. G. et al, 2005). 
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Figure 3.7: Rate of fluorescence development during incubation of parasites with resazurin. 
Fluorescence was monitored over 24 hours in the presence of various cell densities, the 
initial rate of resazurin metabolism was determined by linear regression of the first phase of 
increasing fluorescence (correlation coefficient ≥ ≥ ≥ ≥0.99). (A): T. b. brucei procyclics or 
bloodstream forms; (B): L. mexicana promastigote or amastigote forms. Matthew K Gould, 2009     Chapter 3, 148 
3.3.5  Propidium iodide as an endpoint-assay indicator; 
comparison with the whole-cell in vitro efficacy assay. 
In order to assess the potential for using propidium iodide fluorescence (in 
conjunction with digitonin as a cell lysis agent) in an in vitro high-throughput 
screening assay, a comparison with the commonly used resazurin reduction 
method was conducted using melarsen oxide as the test compound. Since 
different laboratories use differing seeding densities of trypanosomes to start 
their efficacy evaluations (e.g. Räz, B. et al, 1997; Wallace, L. J. M. et al, 
2002), potentially leading to different outcomes (Chris Ward and Professor Mike 
P. Barrett (University of Glasgow), personal communication), a range of starting 
densities was compared. For both assays, T. b. brucei bloodstream forms of 
strain 427 were incubated for 72 hours in HMI-9 media. To one set of cultures, 
resazurin was added after 48 hours, and fluorescence was read after an 
additional 24 hours incubation. To the second set, PI and digitonin were added 
to a final concentration of 6 µg/ml (9 µM) and 20 µM respectively after the cells 
were incubated with the differing concentrations of melarsen oxide for 72 hours. 
Fluorescence was then read after a further 60 minutes incubation. 
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Figure 3.8:Trypanocidal effects of melarsen oxide on T. b. brucei bloodstream forms 
measured by propidium iodide or resazurin reduction assay at different seeding densities. 
Melarsen oxide concentrations reducing fluorescence by 50% (EC50 values) were 
determined using the standard resazurin reduction protocol (red bars) or the propidium 
iodide-based protocol (blue bars), using different trypanosome densities at the start of the 
experiment. Results are the average of three independent determinations and error bars are 
standard errors. 
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The melarsen oxide EC50 values derived from the PI/digitonin method were in 
close agreement with those derived from the whole-cell in vitro method (Figure 
3.8) and also similar to data previously published (Matovu, E. et al, 2003). 
Although some disparity was apparent when the efficacy values were compared 
between the differing trypanosome seed densities, the degree to which this 
affected the actual EC50 values was the same for both methods. Thus, the results 
derived using the propidium iodide method appear to be directly comparable to 
those from the whole-cell in vitro method as long as the starting density of 
trypanosomes is the same. Matthew K Gould, 2009     Chapter 3, 150 
3.4 Discussion 
The data generated from the standard curves demonstrate that propidium iodide 
produces a strong fluorescent signal when incubated with trypanosomal genomic 
DNA. There is also enough genetic material in lysed whole trypanosomes to 
provide PI with a substrate with which to bind and fluoresce. Based on an 
estimated DNA content of 7.8 x 10
7 bp per nucleus of T. b. brucei s427 (Melville, 
S. E. et al, 2000) and a G+C content of 46.4% (Berriman, M. et al, 2005), it can 
be worked out that 10
7 trypanosomes of T. b. brucei s427 have a theoretical 
content of 0.88 µg nuclear DNA. Figures 3.1 and 3.2A show that, using 6 µg/ml 
PI, the fluorescence signal of 10
7 trypanosomes was almost identical to that of 4 
µg of T. b. brucei genomic DNA. This probably indicates that PI binds to 
additional T. b. brucei material, possibly including RNA and kinetoplast DNA. It 
can be concluded that the assay is highly sensitive and linear and thus can be 
used for quantitative analysis of cell numbers. 
The preliminary measurements were performed in a standard serum-free Assay 
Buffer (AB) (De Koning, H. P. et al, 1998), as sensitivity in the HMI-9 culture 
medium was much reduced, apparently as a result of quenching of the 
fluorescent signal. The use of a FLUOstar OPTIMA fluorimeter (BMG Labtech, 
Aylesbury, UK) greatly increased sensitivity, with the highest sensitivity achieved 
by using a clear buffer, such as AB, and a sensitive instrument with adjustable 
signal gain. This results in an operational range over three orders of magnitude 
and, importantly, encompassing physiologically relevant cell densities. 
The observations using PI monitoring of cell survival are entirely consistent with 
the effects of the same drugs monitored using the classical spectrophotometric 
lysis assay (Fairlamb, A. H. et al, 1992) performed in parallel. However, the PI 
assay has several advantages over this alternative. The traditional assay 
monitors the scatter/absorbance of light by the rapidly moving flagellates, 
whereas the PI assay monitors plasma membrane integrity, which is a much 
better proxy for parasite survival and more universal, as well as also applicable 
to non-motile cells including Leishmania amastigotes. While the light scatter 
assay works well for arsenicals (Matovu, E. et al, 2003; Fairlamb, A. H. et al, 
1992) and could possibly be used for the slow-acting diamidines, any test 
compound that depletes the parasite of ATP or otherwise acts on the flagellar Matthew K Gould, 2009     Chapter 3, 151 
motion is indistinguishable from one that actually kills the cell. This is because 
loss of motility will result in live parasites disappearing from the 
spectrophotometer beam, as well as those cells killed outright by drug action, 
due to gravity-assisted precipitation. The PI assay does not suffer this drawback. 
Moreover, this assay is much more sensitive: the data in Figure 3.4A were 
obtained using 5 x 10
6 cells/ml or 1 x 10
6 cells/trace, whereas the data in Figure 
3.4B were obtained using 2.7 x 10
7 cells/ml in a 1 ml volume.  
However, it is clear that even in the absence of drug-induced cell death, a slow 
increase in fluorescence is observed over the course of the PI assay (Figures 3.4A 
and 3.5). This could be the result of either a slow rate of uptake by the parasites 
through endocytosis or perhaps the same transporters that mediate uptake of 
the dications isometamidium and pentamidine (Delespaux, V. and De Koning, H. 
P., 2007), or because of natural turnover of cells in the population, leading to 
some spontaneous cell death in the population over six hours. 
The PI assay is more suited to a 96-well plate format and higher throughput, 
than the light scatter/absorbance assay which is performed in 1 ml cuvettes. In 
the case of a plate reader spectrophotometric assay the cells would still 
precipitate to the bottom of the well upon loss of motility as well as cell debris 
from lysed cells, but this would not remove them from the beam and thus 
reduce the observed change in absorbance in comparison to measuring 
horizontally through a cuvette. The PI assay is superior to the light scatter assay 
by more accurately monitoring cell death, requiring far fewer cells and allowing 
a much more efficient high-throughput system. The acute effects on parasite 
viability can be determined for 47 compounds (alongside positive and negative 
controls, and controls for autofluorescence of the test compound with PI) on a 
single 96-well plate. 
The increased capacity of the PI assay compared to the spectrophotometric 
assay was utilised to help determine protocols for a large number of test 
compounds for further biochemical analysis (Chapter 4). The assay provided 
valuable information on the most appropriate concentrations and incubation 
times to give the best opportunity to detect intracellular changes. It also 
demonstrated, through the obviously different speeds of action, either 
alternative intracellular targets or modes of compound uptake between the Matthew K Gould, 2009     Chapter 3, 152 
Series 1 and GJS compounds (Figure 3.5). The differences in timings between the 
PI and light scatter/absorbance assay for Compound 48 are probably due to the 
length of time required for the cell debris of the immediately lysed 
trypanosomes sinking below the light beam. This highlights the superiority of an 
assay that cannot be confounded by the time between cell death and 
sedimenting on the floor of the cuvette. 
The metabolism of resazurin data shows that, for the endpoint in vitro efficacy 
assay, the different incubation times required for various organisms with this 
compound probably reflect differences in the rate of resazurin metabolism 
(influenced by temperature of culturing), rate of hydroresorufin formation and 
the doubling time of the particular cell type in culture. The rather complex 
interplay of these parameters makes the adaptation of this assay for new cell 
types rather cumbersome. The resazurin in vitro efficacy assay cannot be used 
to assess acute effects, yielding insufficient signal over short time intervals and 
being insufficiently sensitive to record relatively small changes in cell survival 
that are immediately apparent with the PI real-time assay. In addition, the 
resazurin-based end-point assays require a dilution range of test compound in 
order to yield usable information, a single concentration not distinguishing 
between, for instance, (a) all cells dead at the end of the assay but having 
survived long enough to generate a considerable signal, (b) few cells surviving to 
the end of the incubation time, and (c) inhibition of growth, resulting in fewer 
cells and hence a lower signal. The robustness of a PI based approach to 
assessing cell numbers allows more flexibility in assay design, with the 
compound being equally reliable when used as an endpoint in vitro efficacy 
assay compared to the resazurin assay. Matthew K Gould, 2009     Chapter 4, 153 
 
 
 
 
 
 
 
Chapter IV 
4  cAMP levels in trypanosomes incubated with 
putative PDE inhibitors Matthew K Gould, 2009     Chapter 4, 154 
4.1 Introduction 
In this chapter the effect on the intracellular concentration of cAMP in 
bloodstream form trypanosomes is monitored to determine whether the putative 
phosphodiesterase inhibitors can impact on the cAMP signalling pathway. 
cAMP, produced by the adenylyl cyclase enzymes from ATP, activate 
downstream effector proteins. In mammalian cells this allows them to respond 
to an extracellular stimulus. In order to control the activation of these effector 
proteins, phosphodiesterase enzymes modulate and contain the cAMP signal by 
hydrolysing cAMP to the linear AMP (Seebeck, T. et al, 2001). Although it is not 
currently known whether the adenylyl cyclases of T. brucei are constitutively 
active or need to be activated by a stimulus to produce cAMP, it has been shown 
that genetic disruption to the PDEs in trypanosomes results in an elevated 
intracellular cAMP concentration (Zoraghi, R. and Seebeck, T., 2002; 
Oberholzer, M., et al, 2007). An increase in cAMP on incubation with a test 
compound is strong evidence that that compound is inhibiting the 
phosphodiesterase enzymes in the trypanosome. 
Two methods were employed to monitor the intracellular cAMP concentration. 
The first was based on an assay developed by Salomon, Y. et al, (1974), using 
tritiated adenine to label the intracellular adenine pool (including cAMP) after a 
pre-experiment incubation period with the bloodstream form trypanosomes. 
After incubation with test compound, metabolic activity in the cells can be 
stopped immediately by adding the sample to an acidic ice-cold stop solution. 
The cAMP is then separated from the cell contents via a series of Dowex and 
alumina columns and the radioactivity measured by a scintillation counter, 
allowing the intracellular concentration of cAMP to be expressed as a ratio of 
labelled-cAMP to labelled-adenine pool. Using this protocol allows the rapid 
sampling of the radio-labelled intracellular cAMP over short periods of time 
giving information on the immediate response of the trypanosomes to the 
putative PDE inhibitors. 
The second method uses a commercially available enzyme-linked immunosorbant 
assay (ELISA) kit to directly quantify the cAMP concentration from a standard 
curve of known cAMP concentrations. While this method is much more sensitive Matthew K Gould, 2009     Chapter 4, 155 
and accurate than the other, the protocol does not stop metabolic activity until 
after a centrifugation step. This means the assay is only appropriate to assess 
cAMP levels over a long incubation time. 
Inducing resistance to a compound or drug under controlled circumstances can 
further the understanding of how the compound kills the trypanosome, and also 
how resistance may arise in the field (Bridges, D. J. et al, 2007; Barret, M. P. et 
al, 1995; Matovu, E. et al, 2003). A selection of compounds was cultured with 
bloodstream form trypanosomes at sub-lethal concentrations. Over a prolonged 
period of time, attempts were made to increase the maximum tolerated 
concentration of the compounds. A second approach started with the screening 
of a chemically mutagenised culture of trypanosomes with lethal concentrations 
of test compound. Those trypanosomes that survived were resistant to the 
compound and further resistance was induced by gradually increasing the 
concentration of the compound as in the first method. The resultant resistant 
cell lines were then assayed for cross-resistance by the standard whole-cell in 
vitro efficacy assay, as well as comparing the cAMP profile on incubation with 
PDE inhibitors to that of the parental wildtype strain. Matthew K Gould, 2009     Chapter 4, 156 
4.2 Materials and Methods 
4.2.1 Materials and trypanosome culturing 
Test compounds were provided by Geert Jan Sterk of Mercachem, The 
Netherlands (GJS compounds) and by Otsuka Maryland Medicinal Laboratories 
(Series 1 compounds). Etazolate, dipyridamole, dibutyryl cAMP, 8-bromo-cAMP, 
cholorophenylthio-cAMP were obtained from Sigma Aldrich and Fluka; melarsen 
oxide was a gift from Sanofi-Aventis; pentamidine, phenylarsine oxide and 
diminazene were purchased from Sigma, Suramin was a gift from Brian Cover 
(University of Kent at Canterbury), nifurtimox was a gift from Mike Barrett 
(University of Glasgow), and cymelarsan a gift from Mike Turner (University of 
Glasgow). [
3H]-adenine was obtained from either GE Healthcare or Moravek 
(specific activity 20-40 Ci/mmol) and the Direct Cyclic AMP Enzyme 
Immunoassay kits came from Assay Designs. Resazurin sodium salt was purchased 
from Sigma Aldrich and DE52 cellulose came from Whatman. 
Bloodstream form Trypanosoma brucei brucei strain 427 wildtype were cultured 
in vitro as described previously (Chapter 2.2.1) in HMI-9 (Biosera). After the GJS-
128 resistant R0.8 line, derived from T. b. brucei strain 427 wildtype, was 
obtained it was also cultured under the same conditions as the wildtype except 
that 0.4 µM GJS-128 was added to the HMI-9 to maintain drug pressure. Before 
assaying, the trypanosomes were grown in HMI-9 without GJS-128 for at least 6 
days (approximately 18 generations). Cells were either taken directly from a 
culture in the late logarithmic growth phase for experimentation or centrifuged 
for 10 minutes at 610 rcf and room temperature with resuspension of the pellet 
in fresh HMI-9 to increase the cell density above that which can be reached 
unassisted. 
Ex vivo T. b. brucei strain 427 wildtype parasites were obtained from infected 
Wistar rats with high parasitaemia and purified from the whole blood using DE52 
cellulose columns (Lanham, S. M., 1968): DE52 cellulose was washed three times 
with PSG (20.21 g/l Na2HPO4.12H2O; 0.47 g/l NaH2PO4.2H2O; 2.49 g/l NaCl; 10 
g/l glucose; pH = 8.0, phosphoric acid) and the pH adjusted to 8.0. The plunger 
was removed from a 50 ml syringe and a fine layer of glass wool was packed in to 
form the base for an approximately 3 cm layer of washed DE52 cellulose; the Matthew K Gould, 2009     Chapter 4, 157 
cellulose was then washed again in the column with 100 ml of PSG. Whole blood 
from an infected rat was centrifuged for 10 minutes at room temperature and 
610 rcf before removal of the Buffy Coat layer containing the parasites. This was 
then resuspended in PSG (pH 8.0) and loaded onto the DE52 cellulose column to 
remove any remaining blood cells. After the mixture had entered the cellulose 
matrix approximately 50 ml of PSG (pH 8.0) was carefully added and the eluate 
containing the purified trypanosomes collected. This cell suspension was 
centrifuged once, as above, the supernatant removed and the cell pellet 
resuspended in HMI-9/10% FCS culture medium for assaying. 
4.2.2 Monitoring of intracellular cAMP using tritiated adenine 
4.2.2.1  Cell preparation 
T. b. brucei strain 427 wildtype trypanosomes were obtained ex vivo as 
described above and resuspended in HMI-9 medium. In order to ensure the 
maximum uptake of radio-labeled adenine, 100 µM inosine was substituted as 
the purine source instead of hypoxanthine in the HMI-9 medium, as hypoxanthine 
can be metabolized to adenine. Cell density was established with a 
haemocytometer and sufficient trypanosomes for the entire experiment were 
added to more HMI-9 (+ inosine, -hypoxanthine) to give two 100 ml cultures in 
150 cm
2 flasks. 1.48 MBq (40 µCi) of [
3H]-adenine was added to each flask and 
the cultures incubated at 37 ºC, 5% CO2 for 2 hours. After incubation the cultures 
were poured into 50 ml falcon tubes and centrifuged at room temperature for 10 
minutes at 610 rcf. The supernatant was carefully removed and reserved for 
appropriate disposal and the pellets were resuspended in 10 ml HMI-9 (+inosine, 
-hypoxanthine) to wash the trypanosomes. Centrifugation and washing was 
repeated twice more, with the final pellet being resuspended in HMI-9 (+inosine, 
-hypoxanthine) so as to give a cell density of 1 x 10
8 trypanosomes/ml. The cell 
suspension was then left to recover in a water-bath at 37 ºC before the 
commencement of the assay. Due to the trypanosomes having been radio-
labeled with [
3H]-adenine it was deemed unsafe to conduct cell counts with a 
haemocytometer; it was assumed that there was no loss of cells during the wash 
and centrifugation steps and the required cell density was obtained by using the 
cell counts from before the addition of [
3H]-adenine. Matthew K Gould, 2009     Chapter 4, 158 
4.2.2.2  Assay set up 
Assays were carried out independently on at least three separate occasions; 0.5 
ml samples were taken in triplicate at each time-point for both the control 
culture and the culture incubated with the test compound. Metabolic activity 
was halted by dispensing the sample into an equal volume of ice cold STOP 
solution (5% trichloroacetic acid (TCA), 1 mM ATP, 1 mM cAMP) in a 1.5 ml 
microfuge tube and vortexing briefly. Samples were placed in the refrigerator 
for at least 30 minutes to complete the lysis of the trypanosomes and then 
centrifuged at maximum speed in a bench-top microfuge for 2 minutes (13,000 
rpm). The supernatant was carefully pipetted into a fresh eppendorf and stored 
in a freezer at -20 ºC until [
3H]-cAMP extraction was commenced. The cell debris 
pellets and contaminated eppendorfs were disposed of as appropriate for 
tritiated radioactive waste. 
4.2.2.3  [
3H]-cAMP extraction 
The isolation of [
3H]-cAMP from the [
3H]-adenine and its metabolites was 
achieved by sequential chromatography on Dowex and alumina columns. The 
[
3H]-cAMP migrates more slowly through the Dowex ion-exchange column than 
the adenine metabolites [
3H]-ATP and [
3H]-ADP, and so can be retained in the 
Dowex after the careful elution of the latter. The [
3H]-cAMP portion of the 
sample is further purified from any contaminants by further chromatography 
through an alumina column. When the sample is eluted from the Dowex onto the 
alumina, the solution is slightly acidic which results in the retardation of the 
[
3H]-cAMP. Neutralizing the alumina with imidazole allows the release of the 
tritiated cAMP giving a more accurate assessment of the compounds relative 
concentration than by Dowex or alumina chromatography alone (Salomon, Y. et 
al, 1974). 
Columns loaded with 2 ml Dowex 50WX4-400 ion-exchange resin (Sigma) were 
placed above 20 ml scintillation vials and the thawed out supernatant samples 
were loaded onto individual columns. 3 ml of water was gently added to the 
column and 4 ml of scintillation fluid was added to the vials once all the eluate 
had been collected below, after which they were capped and vortexed; these 
vials now contained the [
3H]-ATP and [
3H]-ADP fraction. The Dowex columns 
were then placed directly above a corresponding set of regenerated alumina Matthew K Gould, 2009     Chapter 4, 159 
columns washed with 0.1 M imidazole and 10 ml water was added to each. Once 
the water had dripped through both sets of columns the Dowex columns were 
removed and the alumina columns were mounted above a fresh set of 20 ml 
scintillation vials. The [
3H]-cAMP was eluted from the alumina by adding 6 ml of 
0.1 M imidazole to each column. 8 ml of scintillation fluid was added to each vial 
and these were then capped and vortexed. All the scintillation vials were 
transferred to a Becton-Dickson beta counter for determination of radioactivity. 
Intracellular [
3H]-cAMP levels were expressed as a percentage of the total pool 
of [
3H]-adenine nucleotides. 
4.2.3 Direct quantification of intracellular cAMP concentration 
using enzyme-linked immunosorbant assay (ELISA) kits 
Intracellular cAMP concentrations were quantified by using the Direct Cyclic AMP 
Enzyme Immunoassay kit made by Assay Designs. Bloodstream form 
trypanosomes were cultured in vitro, as described above, and incubated at 37 ºC 
with or without test compound at the concentrations specified at a cell density 
of 5 x 10
6 trypanosomes/ml. At specific time points 2 ml samples were pipetted 
into microfuge tubes and centrifuged at 855 rcf for 10 minutes at 4 ºC in a 
Heraeus Biofuge centrifuge. The supernatant was removed, the cell pellet was 
resuspended in 100 µl 0.1 M HCl and left on ice for 20 minutes to complete cell 
lysis. The samples were centrifuged at 16,000 rcf for 10 minutes and the 
supernatant transferred to a new eppendorf and stored in a freezer at -20 ºC. 
cAMP content was assessed exactly as per the ELISA kit instructions from the 
manufacturers. Samples were taken in duplicate and all assays were conducted 
independently at least 3 times. 
4.2.4 Induction of resistance to a panel of selected putative 
phosphodiesterase inhibitors. 
Series 1 compounds 37, 72, 139 and 48 were doubly diluted in HMI-9 in 24-well 
plates and bloodstream trypanosomes of strain Tb427 wildtype were added to 
give a final volume of 1 ml and cell density of ~ 5 x 10
4 cells/ml. These were 
then incubated at 37 ºC and 5% CO2 for 48 hours. After the first incubation the 
compounds were again doubly diluted in HMI-9 in 24-well plates as before to a 
final volume of 1 ml; 40 µl of culture from each well of the incubated plates was Matthew K Gould, 2009     Chapter 4, 160 
then transferred to the corresponding well of the fresh dilutions which were 
subsequently incubated for a further 48 hours under the same conditions as 
above. After the second incubation the 24-well plates were inspected by light 
microscopy for cell viability: the highest concentration of each compound which 
allowed apparently normal cell growth was taken as the initial maximum 
tolerated concentration. For each compound trypanosomes from these cultures 
were passaged into wells in 24-well plates containing 1ml of HMI-9 only, HMI-9 
plus the initial maximum tolerated concentration and HMI-9 plus 2x the 
tolerated concentration and incubated for 48 hours.  The cultures were then 
visually inspected for cell viability and passaged again into wells containing the 
(new) maximum tolerated concentration and 2x the tolerated concentration, as 
well as a no drug control well. The cultures were maintained in this way 
continuously for over 24 months. 
However, after 12 months of continuous culturing in sub-lethal concentrations of 
test compound it became apparent that gradual accumulation of resistance to 
these compounds was not progressing quickly. Therefore a new approach was 
taken using chemical mutagenesis. Methylmethanesulphonate (MMS; Sigma) was 
added to a 50 ml culture of Tb427 wildtype trypanosomes in late logarithmic 
growth phase to give a final concentration of 0.001% (v/v) and incubated at 37 
ºC and 5% CO2 for 1 hour. The culture was then centrifuged at room temperature 
at an RCF of 610 for 10 minutes and the supernatant carefully removed and 
discarded in 1 M NaOH (to deactivate the mutagen). The pellet was resuspended 
in fresh HMI-9 and washed twice by centrifugation and resuspension in fresh HMI-
9 as above. After the final wash the pellet was resuspended in 50 ml HMI-9 and 
incubated at 37 ºC and 5% CO2. During this incubation approximately 95% of the 
trypanosomes died due to the exposure to MMS. The remaining trypanosomes 
proliferate, some of which will have been mutagenised.  
Once the surviving culture reached the late logarithmic phase of growth the cells 
were washed once, as above, and resuspended in fresh HMI-9 to a final cell 
density of approximately 1 x 10
5 cells/ml. The Series 1 compounds 37, 72, 139 
and 48 were diluted in HMI-9 to 2x the final desired concentration (the 
approximate EC50 value) and GJS-128 was diluted to 2x the desired final 
concentration of 0.1 µM. Mutagenised trypanosomes (0.5 ml at ~ 5 x 10
4 
cells/ml) were added to an equal volume of test compound dilution in multiple Matthew K Gould, 2009     Chapter 4, 161 
24-well plates and incubated at 37 ºC and 5% CO2. The plates were inspected by 
light microscopy every 24 hours for 5 days for cell viability. Once the 
trypanosomes in a well reached the late logarithmic phase of growth they were 
passaged into a 24-well plate with fresh HMI-9 containing the test compound at 
the screening concentration as well as at 2x the screening concentration; a no 
drug control was also included. The cultures were then continuously maintained, 
as in the first resistance induction method, under gradually increasing, sub-
lethal concentrations of the test compound.  
4.2.5 Resistance and cross-resistance profiling using the 
resazurin reduction assay 
Resazurin reduction assays were conducted, exactly as described previously 
(Chapter 2.2.1), using the GJS-128 resistant R0.8 cell line and its parental T. b. 
brucei 427 wildtype strain to establish the EC50 values for GJS-128 and a range of 
other compounds. Matthew K Gould, 2009     Chapter 4, 162 
4.3 Results 
4.3.1 Monitoring of the immediate cAMP response after treatment 
with potential PDE inhibitors 
In order to establish whether the compounds inhibited the trypanosomal 
phosphodiesterase (PDE) enzymes in live trypanosomes, changes in intracellular 
cAMP levels were monitored after incubation with a selected panel of putative 
PDE inhibitors using a method based on the uptake of tritiated adenine and the 
isolation of [
3H]-cAMP from cell extracts. A pre-experiment incubation period, 
where the cells are labelled with [
3H]-adenine, allows the trypanosomes to take 
up and incorporate the radio-labelled adenine into its many metabolites 
including cAMP and its precursor ATP. After incubation with the putative PDE 
inhibitors the cAMP is separated from the rest of the tritiated adenine pool by a 
series of columns, as described above (4.2.2). The radioactivity of the cAMP 
sample is then appraised in relation to that of the whole adenine pool and this 
ratio can then be monitored in samples from the same experiment taken over 
time or compared to those of a control culture. 
On incubation with GJS-128 at 0.3 µM there is a statistically significant rise in 
the intracellular cAMP concentration over the first 10 minutes (Figure 4.1A), 
compared to the control which was incubated with the drug solvent (DMSO) only. 
After just 5 minutes incubation with GJS-128 the cAMP concentration has risen 
by approximately 2-fold compared to the control (P<0.01; unpaired, 1-tailed 
Student’s T-test) and after 10 minutes the cAMP is approximately 3 times higher 
than that of the control (P<0.001). 
Each of the GJS compounds show a statistically significant increase in the 
intracellular cAMP concentration after 20 minutes incubation at a concentration 
of 1 µM compared to the control sample, with GJS-128 giving the largest rise 
(Figure 4.1B). Compounds 212 and Lmj-61 also significantly raised the cAMP 
levels over 20 minutes (Figure 4.1B); however, a much higher compound 
concentration, in comparison to that used for the GJS compounds, is required for 
an effect to be measureable. Matthew K Gould, 2009     Chapter 4, 163 
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Figure 4.1: (A) Effect of 0.3 µM GJS-128 on intracellular cAMP levels in bloodstream-form 
Tb427 wildtype trypanosomes pre-labelled for 2 hours with tritiated adenine. Intracellular 
cAMP was assessed by separating and comparing the tritiated cAMP to the total tritiated 
adenine pool by Dowex and alumina columns. The cells were incubated with or without 
GJS-128 at a cell density of 1 x 10
8 trypanosomes/ml in HMI-9 medium at 37 ºC. The graph 
shown is representative of 3 separate experiments and the data expressed as –fold 
difference to the 0 minute Control value, with Standard Error bars for the triplicate data. The 
time-points showing statistically significant increases in cAMP from the control on average 
over the 3 experiments are also shown (asterisked), with the P-values calculated using the 
unpaired, 1-tailed, Student’s T-test. (B) Bar-chart showing the average intracellular cAMP 
levels on incubation with various compounds for 20 minutes in bloodstream-form Tb427 
wildtype cells, prepared as described in (A), at a cell density of 1 x 10
8 trypanosomes/ml in 
HMI-9 medium at 37 ºC. The averages are from 3 separate experiments, sampled in triplicate, 
with Standard Error bars shown, with those compounds showing statistically significant 
increases in cAMP from the control asterisked. The P-values were calculated as described 
in (A) above. *, P<0.05; **, P<0.01; ***, P<0.001. 
 
The concentrations used when assaying the Series 1 compounds were determined 
by the highest, but eventually lethal, concentration that the trypanosomes could 
tolerate for 3 hours under normal culturing conditions. Even with these Matthew K Gould, 2009     Chapter 4, 164 
relatively high compound concentrations with regards to their in vitro 
typanocidal activity, only moderate increases in the intracellular cAMP were 
measured and only Compounds 72 and 37 showed a statistically significant 
difference at the P-value threshold of 0.05 (Figure 4.1B). 
4.3.2 Long-term effects of PDE inhibitors on intracellular cAMP 
The tritiated adenine method of monitoring intracellular cAMP has a number of 
limitations that preclude its use for measuring cAMP concentrations over a 
period of hours. The most important of these is that after the trypanosomes 
have been removed from the pre-experiment incubation medium containing the 
[
3H]-adenine, the radioactivity of the incorporated adenine pool diminishes by 
approximately one third every 30 minutes (personal observations). Conducting a 
cAMP monitoring experiment over a number of hours would result in 
radioactivity counts too low to provide accurate assessment unless an unfeasibly 
large cell number was sampled at each time-point. 
In order to investigate the effects of the putative PDE inhibitors on the 
intracellular cAMP concentration over a longer period of time, enzyme-linked 
immuno-sorbent assay (ELISA) kits were used. These kits directly measure the 
concentration of cAMP in a sample from a standard curve made from known 
concentrations of cAMP thereby avoiding the need to radiolabel the adenine 
pool. As the kits measure the whole amount of cAMP in a sample instead of just 
the radio-labeled portion they can accurately quantify the intracellular 
concentration in a sample of trypanosomes of known quantity, which can be 
directly compared with results from separate experiments. The high sensitivity 
of the ELISA kits also means that a lower number of trypanosomes is needed for 
a detectable level of cAMP. This allows the cell density of the experimental 
culture to be greatly reduced, limiting environmental stress on the cells 
compared to the [
3H]-adenine method. 
A panel of putative trypanosomal PDE inhibitors, along with some known 
mammalian PDE inhibitors and trypanocides, were incubated with Tb427 
wildtype trypanosomes for 3 hours, after which samples were assessed for cAMP 
content as described above (4.2.3). The control samples with just DMSO added, 
the solvent used to dissolve the test compounds, produced an average basal Matthew K Gould, 2009     Chapter 4, 165 
intracellular cAMP content of 3.3 ± 0.2 pmol/10
8 trypanosomes (Table 4.1), 
which is consistent with data produced at other laboratories using similar 
methods (Zoraghi, R. and Seebeck, T., 2002; Oberholzer, M. et al, 2007). GJS-
128 appears to be the most active compound tested with a 44-fold increase in 
intracellular cAMP (to 146 ± 12 pmol cAMP/10
8 trypanosomes) after incubation 
with 1 µM of the compound (Figures 4.2A and 4.2B; Table 4.1). 
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Figure 4.2: (A) Bar-chart showing the average intracellular cAMP concentration in 
bloodstream-form Tb427 wildtype cells incubated with various compounds for 3 hours. 
cAMP was measured in duplicate using an enzyme-linked immunosorbant assay (ELISA) kit 
as per kit instructions. The cells had been incubated with or without test compound at a cell 
density of 5 x 10
6 trypanosomes/ml in HMI-9 medium, at 37 ºC. Averages are from at least 3 
independent experiments and the P-values were calculated using the 2-tailed, paired 
Student’s T-Test. ***, P<0.001; *****, P<0.00001. (B) Graph showing the increase in 
intracellular cAMP in bloodstream-form Tb427 wildtype cells incubated with 1 µM GJS-128 in 
comparison with a control culture incubated with the test compound solvent DMSO only. 
The trypanosomes were incubated and cAMP measured under the same conditions as in 
(A). The data shown is the average of 3 independent experiments and analysed by linear 
regression using GraphPad Prism software. Error bars indicate Standard Errors. 
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University of 
Glasgow 
Compound Code 
Concentration 
(µM) 
cAMP concentration 
(pmol/10
8 cells) 
Percentage 
of Control 
P-values 
(Different from 
Control)  Average  S. E. 
No Drug Control    3.3  0.2  100   
Etazolate   100  1.9  0.2  58  0.026 
Dipyridamole  40  3.2  0.2  97  0.924 
Dipyridamole  100  0.29  0.1  9  0.00025 
GJS 446  1  12.4  0.4  377  <0.00001 
GJS 446  0.1  4.8  0.3  146  0.0002 
GJS 2011  1  24.9  0.6  758  <0.00001 
GJS 2011  0.1  7.5  0.3  227  0.0001 
GJS 128  1  146  12  4446  <0.00001 
GJS 128  0.3  64.4  6.2  1958  <0.00001 
GJS 128  0.1  40.6  2.4  1236  <0.00001 
GJS 128  0.03  9.9  0.8  302  0.002 
GJS 2358  1  5.0  0.2  152  0.0001 
GJS 2358  0.1  3.0  0.3  90  0.359 
37  6  2.1  0.1  63  0.005 
37  0.6  1.4  0.1  41  0.0006 
48  0.5  1.6  0.3  48  0.049 
48  0.1  3.2  0.2  98  0.523 
139  3  1.0  0.5  30  0.085 
139  0.3  3.4  0.2  102  0.119 
Pentamidine  1  3.1  0.1  93  0.993 
Pentamidine  0.025  3.2  0.2  97  0.745 
Melarsen Oxide  0.1  2.9  0.2  88  0.595 
Melarsen Oxide  0.01  3.2  0.1  98  0.503 
72  10  4.4  0.2  133  0.048 
72  5  4.6  0.3  139  0.001 
149  3  3.1  0.2  94  0.710 
149  1  3.8  0.7  117  0.222 
173  25  3.4  0.3  104  0.618 
197  0.75  2.0  0.2  61  0.0004 
197  0.15  3.1  0.3  94  0.093 
197  0.015  3.1  0.3  95  0.343 
198  0.75  3.7  0.1  112  0.314 
198  0.15  3.0  0.4  90  0.101 
200  100  1.5  0.1  46  0.002 
201  25  3.7  0.2  113  0.043 
201  5  3.4  0.2  103  0.619 
204  25  4.7  0.3  142  0.006 
204  5  3.8  0.6  115  0.212 
Lmj-61  25  6.9  0.4  211  0.00001 
212  25  3.7  0.3  112  0.00006 
Table 4.1: Table showing the average intracellular cAMP concentration in bloodstream-form 
Tb427 wildtype trypanosomes after incubation with various compounds for 3 hours. cAMP 
was measured in duplicate using an ELISA kit  as per manufacturer’s instructions. 
Trypanosomes were incubated at 37 ºC in HMI-9 at a starting cell density of 5 x 10
6 
trypanosomes/ml. cAMP concentrations are averages of at least 3 independently performed 
experiments and the P-values are derived using the 2-tailed, paired Student’s T-test for 
significant difference from the no drug Control: those values in green are significantly 
increased from Control and those in red are significantly decreased. 
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The rise in cAMP due to GJS-128 appears linear over 9 hours incubation at 1 µM 
(P<0.0001; 2-tailed, paired Student’s T-Test) (Figure 4.2B) with the intracellular 
cAMP concentration increasing 18 fold per hour (from 0 minute basal level) 
compared with an increase of just 1.24 fold per hour for the no drug control. 
The increase in cAMP after 3 hours incubation with GJS-128 is dose-dependent, 
with concentrations as low as just 30 nM enough to significantly raise the 
intracellular concentration 3 fold relative to the control (to 9.9 ± 0.8 pmol 
cAMP/10
8 trypanosomes, P<0.005) (Table 4.1). 
After 3 hours incubation at 1 µM, GJS-2011, -446 and -2358 also significantly 
increased intracellular cAMP, to 25 ± 0.6, 12 ± 0.4 and 5.0 ± 0.2 pmol cAMP/10
8 
trypanosomes respectively (Table 4.1), as did Lmj-61 and Compound 212 at 25 
µM (6.9 ± 0.4 and 3.7 ± 0.3 pmol cAMP/10
8 trypanosomes respectively), as well 
as Compound 72 at 10 and 5 µM (4.4 ± 0.2 and 4.6 ± 0.3 pmol cAMP/10
8 
trypanosomes, respectively). This confirms the increases observed over 20 
minutes using the [
3H]-adenine method of monitoring cAMP changes. The only 
aberration from the radio-labeling method is with Compound 37 which appears 
to lower the intracellular cAMP concentration at 6 µM and also at 0.6 µM to 2.1 ± 
0.1 and 1.4 ± 0.1 pmol cAMP/10
8 trypanosomes (P<0.005 and <0.001) 
respectively after 3 hours incubation. 
Of the other Series 1 compounds tested only 201 and 204 showed a slight, but 
statistically significant increase in cAMP levels when incubated at 25 µM (3.7 
±0.3 (P<0.05) and 4.7 ±0.4 (P<0.01) pmol cAMP/10
8 trypanosomes, respectively).  
The trypanocides pentamidine and melarsen oxide, compounds used in 
chemotherapy against African trypanosomiasis today, appeared to have no effect 
on cAMP concentrations at all, in spite of being assayed at concentrations many 
times their lethal threshold. Neither did the Series 1 compounds 139, 173 and 
198. However Compounds 48, 197 and 200 each significantly lowered the cAMP 
concentration compared to the control at their highest concentrations tested to 
1.6 ± 0.3 (P<0.05); 2.0 ± 0.2 (P<0.0005) and 1.5 ± 0.1 (P<0.005) pmol cAMP/10
8 
trypanosomes, respectively. Surprisingly, the mammalian phosphodiesterase 
inhibitors etazolate and dipyridamole, incubated at a concentration of 100 µM, 
also significantly lowered the intracellular cAMP levels in relation to the control Matthew K Gould, 2009     Chapter 4, 168 
(to 1.9 ± 0.2 and 0.3 ± 0.1 pmol cAMP/10
8 trypanosomes (P<0.05 and <0.0005) 
respectively. 
4.3.3 Induction of resistance to a panel of putative 
phosphodiesterase inhibitors. 
After 2 years of continuous culturing in sub-lethal concentrations of test 
compound and attempting to gradually increase the tolerated concentration, no 
resistance to Compounds 72, 48 and 139 had developed. Only Compound 37 had 
induced a slight increase in the maximum tolerated concentration to, 1.4 µM: 
just 4 times the EC50 value for that compound. However, when Compound 37 was 
assayed for its in vitro efficacy against this adapted culture, no significant 
difference from the parental Tb427 wildtype strain was observed (EC50 values = 
1.0 µM versus 0.41 µM, respectively; P>0.05, unpaired Student’s T-test). 
Attempts to induce resistance to the Series 1 compounds by using the chemical 
mutagen methylmethanesulphonate (MMS) were also negative with no 
mutagenised trypanosomes surviving screening at the EC50 value for any of the 
compounds. 
However, this method of inducing resistance was successful for GJS-128, with 
mutagenised trypanosomes surviving screening at 0.1 µM (GJS-128 EC50 value = 
0.08 µM). After just 2 months of continuously culturing the resistant cell line in 
sub-lethal, but gradually increasing concentrations, the maximum tolerated 
concentration for GJS-128 was above 0.8 µM (10-fold the EC50 value) and was 
termed the R0.8 cell line. After the resistant strain was cloned out by limiting 
dilutions under 0.8 µM drug pressure (2 clonal lines were obtained) and 
maintained with GJS-128 free medium, no loss of resistance was noted after 3 
months of continuous culturing and experimenting. Resistance was also stable 
after storage in liquid nitrogen and subsequent thawing and culturing in HMI-9 
medium. While biochemical and resistance characterization was performed with 
the R0.8 clonal line, further adaptation was attempted and after 4 months a 
culture tolerating 6.4 µM GJS-128 was obtained and stored in liquid nitrogen for 
future analysis. Matthew K Gould, 2009     Chapter 4, 169 
4.3.4 Resistance and cross-resistance characterization of the 
GJS-128 resistant R0.8 cell line 
University of Glasgow 
Compound Code 
Tb427 WT EC50 
Values (µM)  
R0.8 EC50 Values 
(µM)  
Resistance 
Factor 
P-values 
(Different from 
Tb427 WT)  Average  SE  Average  SE 
GJS-128  0.08  0.01  1.37  0.19  17.2  0.004 
GJS-2358  0.37  0.02  5.39  1.55  14.7  0.045 
GJS-2011  0.21  0.01  0.83  0.15  3.93  0.023 
GJS-446  0.13  0.03  1.28  0.25  9.74  0.016 
Dipyridamole  17.9  2.7  9.2  0.8  0.51  0.059 
Dibutyryl cAMP  263  13  1890  310  7.19  0.011 
8-Bromo cAMP  271  8  1130  180  4.18  0.014 
Chlorophenyl Thio cAMP  1.24  0.43  0.25  0.05  0.20  0.201 
Suramin  0.021  0.001  0.016  0.000  0.74  0.001 
Diminazene  0.022  0.007  0.011  0.001  0.48  0.133 
Pentamidine  0.0016  0.0004  0.0014  0.0002  0.85  0.683 
Cymelarsen  0.0038  0.0004  0.0038  0.0003  1.00  1.000 
Phenylarsine Oxide  0.0008  0.0001  0.0009  0.0001  1.06  0.783 
Nifurtimox  2.01  0.24  1.61  0.08  0.80  0.247 
48  0.008  0.001  0.005  0.001  0.62  0.262 
72  0.62  0.05  0.22  0.03  0.36  0.005 
37  0.16  0.02  0.13  0.02  0.82  0.441 
139  0.100  0.004  0.048  0.003  0.48  0.002 
73  1.21  0.22  1.05  0.23  0.87  0.362 
149  6.19  0.37  6.39  0.14  1.03  0.595 
153  6.14  1.79  5.68  0.44  0.92  0.839 
154  6.49  0.46  5.90  0.32  0.91  0.250 
155  23.8  4.7  28.2  0.3  1.19  0.525 
156  25.7  3.8  16.2  2.4  0.63  0.334 
157  2.01  0.14  1.66  0.07  0.83  0.209 
158  0.52  0.02  0.49  0.00  0.94  0.440 
159  1.84  0.04  1.59  0.03  0.87  0.084 
160  16.0  1.5  12.6  0.9  0.79  0.371 
Table 4.2: In vitro efficacy values of putative phosphodiesterase inhibitors, and a range of 
known trypanocides and cAMP analogues, against Tb427 wildtype and the GJS-128-
resistant R0.8 strain, as assessed by the resazurin reduction method. Trypanosomes were 
incubated with doubly diluted concentrations of the test compound for 48 hours in HMI-9 at 
37 ºC and 5% CO2. Resazurin was then added and plates were incubated for a further 24 
hours before fluorescence was measured. Data was graphed and EC50 values (effective 
concentration that reduces fluorescence (resazurin metabolism) by 50%) were calculated 
using a non-linear regression sigmoidal curve fit (variable slope) on GraphPad Prism 
software. EC50 values shown are averages of at least 3 independent experiments. Also 
shown is the fold-resistance displayed by the R0.8 cell line for each compound; P-values 
were calculated using the two-tailed, paired Student’s T-Test (values shown in green are 
significantly resistant compared to the Tb427 wildtype and those in red are significantly 
sensitized). 
 
To investigate the level of resistance achieved by the Tb427 wildtype-derived 
R0.8 cell line and to establish the presence, or otherwise, of cross-resistance to 
any known trypanosomiasis chemotherapies, in vitro efficacy values were Matthew K Gould, 2009     Chapter 4, 170 
obtained using the resazurin reduction assays for both the parental and resistant 
strains against a panel of test compounds. 
The R0.8 cell line displayed significant resistance to each of the GJS compounds: 
unsurprisingly the highest resistance was displayed against GJS-128, showing a 
17.2-fold increase in the EC50 value from 0.079 ± 0.01 µM against Tb427 wildtype 
to 1.4 ±0.2 µM against the R0.8 strain (P<0.005) (Table 4.2). The compound 
showing the next highest increase in EC50 was GJS-2358 with a 14.7-fold increase 
from 0.37 ± 0.02 µM to 5.4 ±1.5 µM in the R0.8 line (P<0.05); GJS-446 and GJS-
2011 displayed a 9.7 and 3.9-fold resistance, respectively (P<0.05 for both). 
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Figure 4.3: Graph of in vitro efficacy of selected compounds against the GJS-128 resistant 
R0.8 cell line and the parental Tb427 wildtype strain. Cell viability at various concentrations 
of test compound was assessed by measuring the fluorescence due to the reduction of the 
non-fluorescent resazurin by living cells to its fluorescent resorufin metabolite. 
Trypanosomes were incubated for 48 hours at 37 ºC, 5% CO2 in the presence of drug, after 
which resazurin was added with a further incubation of 24 hours under the same conditions 
before fluorescence was measured. Data was analysed by non-linear regression using a 
sigmoidal curve fit (variable slope) using GraphPad Prism software. The graph shown is 
representative of at least 3 independent experiments for each trypanosome strain with data 
generated from the resistant R0.8 cell line represented by a solid line and for the Tb427 
wildtype by a dashed line. 
 
Figure 4.3 shows a representative graph of the in vitro efficacy data from which 
the EC50 values were derived, with curves from the parental Tb427 wildtype and 
the R0.8 strains shown side by side for some selected compounds. For GJS-128 
and GJS-2011 the curves produced when assayed against the R0.8 cell line have 
clearly shifted to the right compared to those from the Tb427 wildtype signifying 
an increase in the concentration of the compounds required to kill, or inhibit the 
growth of, the cells. The curves for the cAMP analogues dibutyryl cAMP and 8-Matthew K Gould, 2009     Chapter 4, 171 
bromo cAMP for the R0.8 line have also moved markedly to the right: these 
compounds showed a 7.2 and 4.2-fold increase in EC50 values, respectively 
(Table 4.2) rising from 260 µM ± 13 against Tb427 wildtype to 1900 ± 310 µM for 
dibutyryl cAMP (P<0.05) and from 270 ± 8 µM to 1100 ± 190 µM for 8-bromo cAMP 
(P<0.05). Curiously, another cAMP analogue, chlorophenyl-thio cAMP, appeared 
to show a 5-fold increase in sensitivity against the R0.8 trypanosomes. However, 
this proved not to be statistically different from the Tb427 wildtype data 
(P>0.2). 
There was no significant cross-resistance shown by the R0.8 trypanosomes to any 
of the current trypanosomiasis chemotherapies. However, a slight but 
statistically significant increase in sensitivity to suramin was observed, with the 
EC50 value reduced from 0.021 ±0.001 µM against the Tb427 wildtype to 0.016 ± 
0.0005 µM against R0.8 (P<0.005). 
Of the Series 1 compounds assayed against the R0.8 line there appeared to be no 
significant resistance displayed, however an increased sensitivity by the resistant 
strain was apparent with Compounds 72 and 139 (P<0.005 for both) (Table 4.2). 
4.3.5 cAMP response in T. b. brucei lines adapted to high 
concentrations of GJS-128 
Since GJS compounds dramatically increase the intracellular cAMP concentration 
it was speculated that the resistance shown by the R0.8 line may have come 
about by an adaptation that allowed the strain to better control the cAMP levels 
on exposure to these compounds. To investigate whether this was the case the 
intracellular cAMP levels in the resistant trypanosomes and their parental Tb427 
wildtype strain were determined after exposure to the GJS compounds as 
described, using the same ELISA-based protocol as before (4.2.3).  
On incubation with various concentrations of GJS-128 over 3 hours there 
appeared to be no significant difference between the resistant and the Tb427 
wildtype cell lines with respect to the levels of cAMP attained, nor in the speed 
with which they were reached (Figure 4.4A).  
In a separate experiment, no statistical difference in cAMP levels in WT and R0.8 
lines was observed after 3 hours incubation with a concentration of 1 µM of any Matthew K Gould, 2009     Chapter 4, 172 
of the GJS compounds (Figure 4.4B). Yet, in both lines increases in cAMP levels 
compared to the no-drug control were highly significant, and similar to increases 
observed earlier (4.3.2). Incubations with both cell lines were performed in 
parallel so as to minimise inter-assay variation and there was no significant 
difference between the basal cAMP levels of the control samples for each strain. 
Also as before, the intracellular cAMP levels in both lines were unaffected by 3 
hour incubations with 40 µM of the mammalian PDE inhibitor etazolate  
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Figure 4.4: (A) The effect of various concentrations of GJS-128 on the intracellular cAMP 
concentration in Tb427 wildtype (left panel) and the GJS-128 resistant R0.8 cell line (right 
panel) over 3 hours. Graphs shown are representative of 3 paired, independent experiments 
performed in parallel. (B) Bar-chart showing the intracellular cAMP concentration in Tb427 
wildtype (red bars) and GJS-128-resistant R0.8 trypanosomes (green bars) after 3 hours 
incubation with various compounds at specified concentrations. cAMP concentrations 
shown are averages of at least 3 independently performed experiments. For both (A) and (B) 
cAMP was measured in duplicate using an ELISA kit as per manufacturer’s instructions. 
Trypanosomes were incubated at 37 ºC in HMI-9 at a starting cell density of 5 x 10
6 
trypanosomes/ml.  Matthew K Gould, 2009     Chapter 4, 173 
4.4 Discussion 
It is apparent from the long and short term monitoring of intracellular cAMP 
concentrations that the majority of Series 1 compounds tested do not increase 
cAMP levels, even when incubated at concentrations lethal to trypanosomes. 
This strongly indicates that they are not phosphodiesterase enzyme inhibitors 
and kill trypanosomes via an alternative target. Of the four that did manage to 
significantly raise cAMP levels above that of the control the maximum increase 
was only around 40% (Table 4.1). For Compounds 72, 201 and 204 the 
concentration required to bring about the slight cAMP elevation was many times 
that of their in vitro EC50 values, suggesting that, while they may inhibit PDEs at 
high concentrations, this is not their primary mode of action in the trypanosome. 
Although Compound 212 does inhibit recombinant TbrPDEB2 (Dr. Yasmin Shakur, 
Otsuka Maryland Medicinal Laboratories, personal communication), the fact that 
25 µM only raised intracellular cAMP levels by 12% after 3 hours of incubation 
(Table 4.1), combined with an in vitro EC50 value greater than 100 µM (Appendix 
1), indicates that this compound may have difficulty entering the cell and 
reaching the PDEs inside the trypanosome. 
Four Series 1 compounds significantly reduced the intracellular cAMP 
concentration compared to the control, suggesting that they either inhibited the 
production of cAMP by the adenylyl cyclases or stimulated its degradation by the 
phosphodiesterases. An alternative explanation, however, is that these 
compounds, while not at a concentration that would kill the cells over the length 
of the incubation, may have caused enough damage to a proportion of the 
trypanosomes to render them incapable of withstanding the stress of 
centrifugation after sampling. This would result in the content of these cells 
being lost to the ELISA measurement thereby lowering the apparent cAMP level 
of the sample. 
Attempts to induce resistance to a panel of Series 1 compounds, by gradually 
increasing the maximum concentration tolerated by trypanosomes in in vitro 
culture, was unsuccessful after more than 2 years of continuous passaging. Even 
the use of chemical mutagens to increase the mutation rate did not result in 
resistance arising. This suggests that either there are multiple targets for these 
compounds – meaning that more than one mutation would have to occur Matthew K Gould, 2009     Chapter 4, 174 
simultaneously for resistance to develop - or that the target(s) of these 
compounds is/are essential to parasitic survival. Clearly, if any of these 
compounds are deployed as clinical chemotherapies, the difficulty inducing 
resistance in vitro indicates resistance is unlikely to arise quickly in the field. 
In contrast to those from Series 1, all four GJS compounds significantly raised 
intracellular cAMP concentrations in bloodstream form trypanosomes. These 
compounds were identified from a series developed at ALTANA Pharma for the 
inhibition of T. b. brucei PDEB1 and PDEB2, and displayed high affinity for the 
target recombinant enzyme which correlated very well with in vitro trypanocidal 
activity (conducted by Dr. Herrmann Tenor, ALTANA Pharma, and Prof. Thomas 
Seebeck, University of Bern; data not shown).  
These data led to the testing of the effects of a subset of these compounds (GJS 
compounds) on intracellular cAMP levels and found that their dose-dependent 
effects (Table 4.1) again correlated well with their TbrPDEB2 Ki values (data not 
shown) and anti-trypanosomal EC50 values in vitro (Table 4.2 and Chapter 2, 
Table 2.6). GJS-128 acts quickly on the trypanosomes, significantly increasing 
cAMP levels after just 5 minutes incubation at 1 µM, with the other GJS 
compounds significantly raising cAMP after 20 minutes incubation at the same 
concentration (Figures 4.1A and 4.1B). This indicates that the compounds can 
rapidly enter the cell to reach the trypanosomal PDEs. The rise in cAMP 
concentration is maintained for over 3 hours of incubation (Figure 4.2A and 
Table 4.1), and increases in an apparently linear manner over at least 9 hours 
with GJS-128 (Figure 4.2B) raising the intracellular cAMP concentration to levels 
only seen when both PDEB1 and PDEB2 are simultaneously knocked down by RNAi 
in bloodstream form trypanosomes (Oberholzer, M. et al, 2007). 
This leads to the conclusion that the GJS compounds are genuine inhibitors of 
trypanosomal PDEs and that this inhibition results in an uncontrolled increase in 
cAMP, eventually leading to the death of the trypanosome. The fact that none of 
the Series 1 compounds, or known trypanocides such as pentamidine and 
melarsen oxide, do not increase cAMP, reinforces the conclusion that the effect 
seen by the GJS compounds is not just a response to general toxic stress. The 
lack of increase in cAMP levels by the mammalian PDE inhibitors dipyridamole 
and etazolate, even at very high concentrations, highlights the inherent Matthew K Gould, 2009     Chapter 4, 175 
differences between the PDEs of the host and parasite cells. The observation 
that compound Lmj-61 also has an effect on trypanosomal cAMP levels (Figure 
4.1B and Table 4.1) raises the possibility of the development of a chemotherapy 
effective against a broad spectrum of kinetoplastid species. Lmj-61 is an 
inhibitor of Leishmania major PDEs that was identified in silico by docking 
compound structures into the active site of the three-dimensional model 
developed from the crystal structure of Leishmania major PDEB2 (Prof. 
Hengming Ke, University of North Carolina, Chapel Hill, NC, USA: personal 
communication; Wang, H. et al, 2007). 
Although an initial low level of resistance to GJS-128 was induced by heavily 
mutagenising a culture of trypanosomes with the mutagen MMS, passaging the 
resultant mutant line in gradually increasing concentrations of GJS-128 resulted 
in additional resistance arising remarkably quickly in comparison to the Series 1 
compounds. After just two months of continuous culturing, a cell line (termed 
R0.8) was developed that could tolerate more than 10-fold the original in vitro 
EC50 value, and after four months the maximum tolerated concentration was 80-
fold that of the EC50. This suggests that major resistance to a PDE inhibitor-
based chemotherapy in the field might be problematic fairly quickly, however, 
for a more accurate assessment the induction of resistance to GJS-128 would 
need to be repeated without the assistance of the chemical mutagen. 
The R0.8 cell line was characterised further, demonstrating that the resistance 
to GJS-128 was stable without drug pressure and not merely the result of a 
metabolic adaptation to the toxic stress. The cross-resistance profiling using the 
whole-cell in vitro efficacy assay indicates that all the GJS compounds likely hit 
the same target protein since resistance to GJS-128 results in resistance to the 
other GJS compounds as well (Table 4.2). No cross-resistance was observed for a 
panel of current trypanocides, or for the Series 1 compounds, which might open 
up the possibility of using a GJS compound in a combination therapy in endemic 
areas where resistance to current chemotherapies is prevalent.  
Interestingly, significant resistance is displayed by the R0.8 line to the cAMP 
analogues dibutyryl cAMP and 8-bromo cAMP (Table 4.2 and Figure 4.3). This 
provides some evidence that the modification in R0.8 that gives resistance to 
GJS-128 may lie downstream of the phosphodiesterase enzymes in the cAMP Matthew K Gould, 2009     Chapter 4, 176 
signalling pathway. If it were the enzymatic properties of the PDE enzymes that 
were altered in R0.8, then the hydrolysis-resistant cAMP analogues that bypass 
PDEs should have the same effect on the GJS-128 resistant trypanosome as 
against the wildtype. Further support for the source of resistance not coming 
from the PDEs comes from the examination of the cAMP profiles of the R0.8 and 
wildtype trypanosomes on addition of GJS-128 over 3 hours. There is no 
significant difference in increase of intracellular cAMP between the resistant and 
sensitive cell lines with 1 µM GJS-128 at any of the time points sampled (Figures 
4.4A and 4.4B) (2-tailed, paired Student’s T-test). Neither is there any 
significant difference for any of the other GJS compounds after 3 hours 
incubation with 1 µM, nor between the no-drug controls (Figure 4.4B). If 
resistance in the R0.8 line to the PDE inhibitor had arisen by modification to the 
PDE enzymes then one would expect either no, or a reduced, increase in 
intracellular cAMP on incubation with GJS-128 or the other GJS compounds. 
Since the speed of accumulation of cAMP appears to be the same in the resistant 
and wildtype trypanosomes one might assume that total adenylyl cyclase activity 
is also acting unaltered. 
A further point of interest from the monitoring of intracellular cAMP on addition 
of GJS-128 is the difference in the dynamics of the response produced when 
sampled over different timescales. In Figure 4.2B the increase in cAMP 
concentration is apparently linear over 9 hours, however, for both the wildtype 
and the R0.8 cell lines the increase in cAMP appears to plateau after just 20 
minutes (Figure 4.4A). One explanation for this apparent discrepancy is that 
there are two types of adenylyl cyclases activity present at the same time: one 
regulated by a negative feedback system, as seen for adenylyl cyclase A (ACA) in 
Dictyostelium (Saran, S. et al, 2003), and one that is not. The graphs in Figure 
4.4A might depict the former AC type: when the cAMP rises rapidly on addition 
of the PDE inhibitor a negative feedback is activated, halting the production of 
further cyclic nucleotide. This would result in a plateau in cAMP concentration, 
rather than a return to basal levels, since the PDEs can no longer degrade it. The 
second AC type appears to produce cAMP more slowly than the first, or is merely 
the basal activity of the downregulated adenylyl cyclase. The resulting, slower 
rise in cAMP by this AC activity, once the PDEs are inhibited, is only detected 
when the former AC activity is deactivated, and measurements taken over long 
periods of time. Matthew K Gould, 2009     Chapter 5, 177 
 
 
 
 
 
 
 
Chapter V 
5  Further investigations into the mode of action of 
a panel of compounds & mode of resistance of 
the GJS-128 resistant R0.8 cell line Matthew K Gould, 2009     Chapter 5, 178 
5.1 Introduction 
This chapter investigates the effects of selected compounds on the cell cycle of 
bloodstream form trypanosomes, as well as on the gross intracellular morphology 
of the cells. Further examinations into the mode of resistance of the R0.8 strain 
of Tb427 trypanosomes, that is resistant to the PDE inhibitor GJS-128, are also 
undertaken. 
Flow cytometry and fluorescent microscopy were performed to assess the impact 
on the replication cycle of trypanosomes exposed to selected test compounds. 
Flow cytometry is an automated method which, in this case, assesses the DNA 
content of individual fixed cells in samples stained with propidium iodide. The 
amount of fluorescence generated by propidium iodide binding to DNA is 
proportional to the amount of DNA contained within the cell. Trypanosomes 
maintain DNA in two organelles: the nucleus and the kinetoplast. Flow cytometry 
can quantify the proportion of cells in particular phases of cell replication; 
however it cannot distinguish between DNA in the nucleus and DNA in the 
kinetoplast. Using this method, trypanosomes are categorises into replication 
phases based on DNA replication of the nucleus outlined in Figure 5.1A. G1 is the 
non-dividing phase, S is where the DNA is replicated, G2/M is where the DNA 
segregate into the two nuclei and kinetoplasts before cytokinesis returns the 
mother and daughter cells to the G1 phase (McKean, P. G., 2003; Hammarton, T. 
C. et al, 2003). 
In order to probe the effects of test compounds on kinetoplast replication, fixed 
trypanosomes were stained with DAPI and assessed for the configuration of the 
DNA containing organelles in relation to the rest of the dividing cell using a 
fluorescent microscope. Cells were categorised according to the number of 
nuclei and kinetoplasts as well as progression of the cleavage furrow as shown in 
Figure 5.1B. 
The effect of the test compounds on the intracellular organelles was 
investigated using transmission electron microscopy. The trypanosomes were 
incubated with lethal concentrations of the compounds and cells were sampled 
before the trypanosomes were killed by the toxic effects of the compounds and 
fixed using a protocol based on standard methods (Hammarton, T. C. et al, Matthew K Gould, 2009     Chapter 5, 179 
2007). Sections were viewed for gross abnormalities in the organelles or 
cytoplasm for clues as to the specific target(s) of the test compounds. 
 
Figure 5.1: Cell division in procyclic form Trypanosoma brucei. Reproduced from McKean, 
P. G., 2003. (a) The trypanosome cell cycle is separated into nuclear and kinetoplast 
components. Cell cycle duration for exponentially growing procyclic trypanosomes is 8.5 h. 
Kinetoplast replication (SK) initiates before the nuclear phase (SN), but is considerably 
shorter and consequently kinetoplast segregation (D) occurs before the onset of nuclear 
mitosis (M). The phase annotated on the kinetoplast cycle as ‘A’ refers to the ‘apportioning’ 
phase during which basal bodies continue to move apart. (b) Schematic representations of 
trypanosome cells taken from various time points through the cell cycle. The black arrow 
indicates the direction and position of the cleavage furrow. 
 
Finally, the phosphodiesterase B genes were both sequenced in the GJS-128 
resistant R0.8 trypanosome strain. Evidence from Chapter 4 suggested the 
adaptation resulting in resistance to the PDE inhibitor lay downstream of the 
phosphodiesterase enzymes. In order to confirm this, the genes of the target 
proteins were cloned and sequenced and compared to those from the parental 
wildtype strain for any mutations that might affect enzyme function or inhibitor 
binding. Matthew K Gould, 2009     Chapter 5, 180 
5.2 Materials & Methods 
5.2.1 Electron microscopy 
Tb427 wildtype bloodstream-form trypanosomes were cultured under normal 
conditions (37 ºC, 5% CO2) in a large volume of HMI-9 until the late logarithmic 
phase of population growth was achieved (approximately 1–2 x 10
6 
trypanosomes/ml). The cells were washed once by centrifugation at room 
temperature and 610 rcf, after which the cell pellet was resuspended in fresh 
HMI-9 to give a final cell density of 1 x 10
6 trypanosomes/ml. After 15 minutes 
incubation at 37 ºC and 5% CO2 to allow the cells to recover, the culture was 
aliquoted into 150 cm
2 tissue culture flasks and the relevant volume of test 
compound dissolved in dimethylsulphoxide (DMSO) was added and mixed well to 
give the desired final compound concentration. For the control culture, an equal 
volume of DMSO without test compound was added to the flask. Series 1 
compounds 37, 72, 48 and 139 were incubated at 0.625 µM, 1 µM, 0.25 µM and 
0.5 µM respectively; GJS-128 was also incubated at 1 µM. The trypanosome 
cultures were then maintained at 37 ºC and 5% CO2 overnight. 
After 20 and 24 hours incubation, a 10 ml sample of each culture was 
centrifuged at room temperature and 610 rcf, in a 15 ml tissue culture 
centrifuge tube, and the supernatant carefully removed. In a fume hood, 0.5 ml 
of 2.5% gluteraldehyde (diluted from 25% stock; Sigma) in 0.1 M phosphate buffer 
was carefully added down the wall of the tube (to avoid resuspension of the cell 
pellet) and left at room temperature for 10 minutes. The pellet was then gently 
detached from the wall of the tube and carefully agitated in the fixative before 
being left for a further 30 minutes at room temperature, after which the fixative 
was removed by pipette and 0.5 ml of the 0.1 M phosphate buffer added to rinse 
the pellet of any remaining gluteraldehyde fixative and the samples were stored 
overnight at 4 ºC.  
Further sample preparation was carried out by the Integrated Microscopy Facility 
within the university. The fixed pellet was broken into < 1 mm pieces , rinsed in 
fix buffer twice to remove aldehyde and fixed in 1% aqueous osmium tetroxide 
for 1 hour.  Non-bound osmium residues were removed with several distilled 
water washes over 15 minutes, and 0.5% aqueous uranyl acetate added for 30 Matthew K Gould, 2009     Chapter 5, 181 
minutes. Cells were washed briefly in distilled water, dehydrated via an alcohol 
series (30,50,70,90 - 100% ethanol, 10 minutes each) then finally infiltrated in 
Epon/Araldite epoxy resin overnight, rotating at 200 ºC. This was followed by 
fresh resin embedding and polymerisation of cells at 600 ºC for 24 hours in 
silicon block moulds. 60 – 80 nm thick sections were routinely stained in uranyl 
and lead solutions and were then inspected by transmission electron microscopy 
(TEM) using a 120 kV Zeiss 912 energy filtering Transmission Electron Microscope. 
5.2.2 Cell cycle analysis using flow cytometry 
Tb427 wildtype trypanosomes were cultured under normal conditions until the 
late logarithmic phase of growth was reached. The cells were then washed once 
by centrifugation at room temperature for 10 minutes at 610 rcf, removal of the 
supernatant and resuspension of the cell pellet in HMI-9 with the cell density 
adjusted to 1 x 10
6 trypanosomes/ml. 
After the cells had recovered for 15 minutes under normal culturing conditions, 
the experiment was started by the addition of the relevant concentration of test 
compound dissolved in DMSO (or equal volume of DMSO solvent without test 
compound for the control culture) and a 1 ml sample taken. The test culture was 
then maintained at 37 ºC and 5% CO2 for the duration of the experiment, except 
to allow further sampling. The sample was then centrifuged at 855 rcf for 10 
minutes and at 4 ºC in a Heraeus Biofuge centrifuge, after which the supernatant 
was removed and the pellet resuspended in a 1 ml solution of 70% methanol and 
30% PBS straight from the fridge in order to fix the cells. Samples were taken at 
subsequent time-points and treated as described above and stored at 4 ºC. 
After storage, the samples were washed twice by centrifugation at 855 rcf for 10 
minutes at room temperature, the removal of the supernatant and resuspension 
of the cell pellet in PBS. After the final centrifugation the cell pellet was 
resuspended in PBS containing 10 µg/ml of propidium iodide and RNaseA and 
incubated protected from light at room temperature for an hour. Flow cytometry 
analysis was performed using a Becton Dickinson FACSCalibur and using the FL2-A 
detector with an AmpGain of 1.75. Some data was further analysed using the 
ModFit LT software (Verity Software House). Matthew K Gould, 2009     Chapter 5, 182 
5.2.3 DNA configuration assessment using fluorescence 
microscopy 
Tb427 wildtype cells, cultured at 37 ºC and 5% CO2, were taken at the late 
logarithmic phase of growth and centrifuged at 610 rcf for 10 minutes at room 
temperature, the supernatant removed and the cell pellet resuspended in HMI-9 
to give a cell density of 1 x 10
6 trypanosomes/ml.  
After recovering for 15 minutes, the experiment was started by the addition of 
the test compound dissolved in DMSO at the required concentration (or equal 
volume of DMSO solvent only for the control cultures). 50 µl samples were taken 
at regular time points and spread onto a glass microscope slide using a coverslip 
and allowed to air-dry. Once dry they were submerged in methanol at -20 ºC in a 
Copelin jar and left to fix over night, after which the slides were removed, the 
methanol allowed to evaporate and stored in a slide box at 4 ºC. 
When required for DNA configuration assessment, the slides were rehydrated 
with approximately 1 ml of PBS for 10 minutes then the excess liquid was 
removed by tilting the slide onto a paper towel. 50 µl of PBS containing 1 µg/ml 
4,6-diamidino-2-phenylindole (DAPI) and 1% (w/v) 1,4-diazabicyclo[2.2.2]octane 
(DABCO) was added to the slide and spread over the surface by affixing a 
coverslip and sealing with clear nail varnish. Slides were examined using a Zeiss 
Axioskop microscope with the requisite filters and images processed by a 
Hamamatsu digital camera with Openlab software. More than 500 trypanosomes 
in each sample were scored for their DNA configuration and placed into the 
following categories: 1N1K – having 1 nucleus and 1 kinetoplast; 1N2K – having 1 
nucleus and 2 kinetoplasts; 2N2K (Early) – having 2 distinct nuclei and 
kinetoplasts but without an apparent cleavage furrow starting to divide mother 
and daughter cells; 2N2K (Late) – having 2 distinct nuclei and kinetoplasts, and 
with the cleavage furrow having made progress to division of mother and 
daughter cells but not having achieved full cytokinesis; and >2N2K – were cells 
have more than 2 nuclei and 2 kinetoplasts. Matthew K Gould, 2009     Chapter 5, 183 
5.2.4 Sequencing of the TbrPDEB1 and TbrPDEB2 genes in the 
R0.8 cell line and its parental T. b. brucei 427 wildtype strain 
5.2.4.1  Genomic DNA extraction 
To provide cultures of trypanosomes that had been derived from a single 
parasite the T. b. brucei strain 427 wildtype and the R0.8 cell line were cloned 
out by limiting serial dilutions, with that of the R0.8 cell line conducted under 
selective pressure of 0.4 µM GJS-128. The genomic DNA was extracted from both 
strains in exactly the same way: a 50 ml culture was centrifuged at 610 rcf and 
resuspended in 1 ml HMI-9 before being transferred to a 1.5 ml eppendorf; this 
was centrifuged again at 380 rcf for 10 minutes. The supernatant was discarded 
and the pellet gently resuspended in 150 µl of TELT lysis buffer (50 mM Tris-HCl 
(pH 8.0), 62.5 mM EDTA (pH 9.0), 2.5 M LiCl, 4% (v/v) Triton X-100) and left for 5 
minutes at room temperature. 150 µl equilibrated phenol:chloroform (Sigma-
Aldrich) was added and mixed, then the eppendorf was centrifuged at 16060 rcf 
for 5 minutes. The upper, aqueous phase was removed and placed in a new 
eppendorf to which 300 µl of absolute ethanol was added, gently swirled and left 
for 5 minutes to precipitate the DNA. The eppendorf was then centrifuged at 
16060 rcf for 10 minutes and the supernatant removed; the pellet was washed 
once with 70% (v/v) ethanol and re-pelleted at 16060 rcf for 10 minutes after 
which the ethanol was removed by pipette and the pellet left to air dry. The 
DNA was then dissolved in 100 µl TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA 
(pH 8.0)) with RNaseA then quantified using a Nanodrop spectrophotometer 
(Thermo Fisher Scientific) and stored at 4 ºC. 
5.2.4.2  Amplification of TbrPDEB1 and TbrPDEB2 
Primers to amplify each gene by polymerase chain reaction (PCR) were designed 
by using the genome sequence for Trypanosoma brucei strain TREU927/4 
GUTat10.1 from GeneDB as a reference sequence, since that of the 427 strain 
had not been completed. The sequences of both genes (+/- 500 bp) was 
downloaded and sections of DNA, approximately 20 bp in length, upstream and 
downstream of the genes were identified that gave only one region of 100% 
identity when the T. brucei contigs database was searched using BLAST. These 
sequences were used as the forward and reverse primers to amplify TbrPDEB1 Matthew K Gould, 2009     Chapter 5, 184 
and TbrPDEB2. For TbrPDEB1 the primer sequences were  
5'-GAGCATCGGCAGCATAACCT-3' and 5'-TACATCTACCACCGGTCAAC-3' for forward 
and reverse primers respectively, with the forward primer’s DNA annealing site 
located 89 bp upstream of the gene’s open reading frame (ORF) and that of the 
reverse primer’s located 38 bp downstream. For the amplification of TbrPDEB2, 
the forward primer sequence used was 5'-TGCAGATCCAGATAGCTGGGA-3', which 
annealed 34 bp upstream of the ORF, and that of the reverse primer was 5'-
GCCTATCTTCGTCAACCAGG-3', which annealed 42 bp downstream.  
The PCR reaction conditions were optimized so as to give a single product when 
run on an agarose gel by electrophoresis and the proof-reading polymerase 
enzyme KOD (Novagen) was used to limit the possibility of introducing errors into 
the product amplification. The exact reaction conditions differed only at the 
annealing temperatures for the amplification of each of the two genes 
(TbrPDEB1: 54.3 ºC; TbrPDEB2: 56.7 ºC) and closely followed the supplier’s 
suggested reaction conditions with the addition of one extra step: after the final 
cycle, 0.2 µl of Taq polymerase was added to the reaction mix and maintained at 
72 ºC for 10 minutes. This final step was included because KOD produces a DNA 
reaction product with blunt ends, making it more difficult to ligate into a 
convenient vector; the inclusion of Taq for 10 minutes results in the addition of 
an ‘A-overhang’ allowing a simple ligation into the efficient vector pGEMT-easy, 
without compromising the fidelity of the proof-reading enzyme’s amplification. 
The PCR reactions’ products were separated from the primers and visualized by 
electrophoresis on a 1% (w/v) agarose gel; the appropriate bands were then 
excised after confirming the DNA was of the expected size. The DNA was purified 
from the gel using a Gel purification kit from Qiagen, exactly as per the 
manufacturer’s instructions, and ligated into the vector pGEMT-easy (Promega), 
again, as per the supplier’s instructions.  E. coli JM109 bacteria (Stratagene) 
were transformed with the pGEMT-easy vector containing the TbrPDEB1 or 
TbrPDEB2 gene, as directed by the suppliers, and plated out onto a Petri dish 
containing LB media agar supplemented with a selective concentration of 
ampicillin (Sigma) at 100 µg/ml. This resulted in only those bacteria transformed 
with the insert being able to tolerate the antibiotic and grow to form a colony 
overnight. Multiple colonies were picked and screened by PCR with Taq 
polymerase for the inclusion of TbrPDEB1 or TbrPDEB2, as appropriate, with the Matthew K Gould, 2009     Chapter 5, 185 
positive colonies grown overnight in 5ml LB broth. The cultures were pelleted 
and the plasmid DNA extracted and purified using the ‘mini-prep’ function on a 
Qiacube robot, after which the product was again screened for the presence of 
the appropriate TbrPDE gene of interest by PCR. 
5.2.4.3  Sequencing of the amplified TbrPDEB1 and TbrPDEB2 DNA 
Samples of the purified plasmid DNA were prepared as directed and sent to 
Eurofins-MWG-Operon for sequencing. The maximum length of DNA they could 
sequence in one reaction was approximately 900 - 1000 bp so to sequence the 
genes in their entirety 4 over-lapping reactions were required for both TbrPDEB1 
and TbrPDEB2. The first sequencing reactions were carried out using MWG’s 
standard T7 and SP6 primers (T7: TAATACGACTCACTATAGGG; SP6: 
CATTTAGGTGACACTATAG), which anneal to the pGEMT-easy vector DNA that 
flank the insertion site of the ligated DNA. More primers were designed from the 
sequences that were returned for both genes to allow the completion of the 
sequencing of the full open reading frames. Sequencing Primer A (5'-
TGGCCCGTGACAATCTTGATGAA-3') anneals to TbrPDEB1 starting at base-pair 683 
of the ORF and Sequencing Primer C (5'-GATTACCACGCCTCTACGATGC-3') anneals 
to TbrPDEB2 starting at base-pair 550 of it’s ORF. Due to the high degree of 
identity between TbrPDEB1 and TbrPDEB2, Sequencing Primer B (5'-
GGCATACATCCACAACATGGT-3') bound to both genes (base-pair 2015 – 2035) and 
so was used in both sets of sequencing reactions for the two genes (see Figures 
5.13 and 5.14 for diagrams showing the relative annealing positions for each 
primer). 
In order to obtain the sequences of both alleles of the two genes the full open 
reading frame was sequenced from 9 bacterial clones containing the TbrPDEB1 
and 9 clones with TbrPDEB2 from the R0.8 cell line; and from 9 clones containing 
the Tb427 wildtype TbrPDEB1 and 8 clones with TbrPDEB2. Each set of 4 
sequence fragments was contig-ed and aligned using the Vector NTI Advance 10 
software suite (Invitrogen). Matthew K Gould, 2009     Chapter 5, 186 
5.3 Results 
5.3.1 Electron Microscopy 
The morphology of Tb427 wildtype bloodstream form trypanosomes incubated 
with lethal concentrations of test compounds was examined by transmission 
electron microscopy (TEM) in an attempt to identify any particular organelle or 
cellular process specifically targeted by the compound. After 24 hours of 
incubation under normal culturing conditions samples were taken and fixed, as 
described above (5.2.1), and delivered to the Integrated Microscopy Facility 
within the Biological and Life Sciences Faculty for specimen sectioning and 
staining. The ultrastructure of the treated trypanosomes was then inspected for 
any obvious intracellular disruption. 
Figure 5.3 shows an electron micrograph of a trypanosome incubated with 0.625 
µM Compound 37 for 20 hours, and is representative of a large number of cells 
inspected. The two most obvious aspects of the cell that appear abnormal are 
the massively enlarged flagellar pocket and the area of gross cellular disruption 
immediately to its right. A normal flagellar pocket and cytosol can be observed 
in the control image taken of trypanosomes incubated with DMSO only (Figure 
5.2). It appears that incubation with Compound 37 induces the flagellar pocket 
to swell massively and also for part of the cytosol to become disorganised, 
possibly due to disruption to the acidocalcisomes, with evidence of their 
structural integrity being compromised at the bottom of figure 5.3. 
Inspection of samples of trypanosomes incubated with 0.25 µM Compound 48 and 
1 µM Compound 72 for 24 hours did not yield any pathology to the intracellular 
morphology (Figures 5.4 and 5.5). All of the sections investigated showed the 
organelles apparently intact and seemingly unaffected by exposure to a lethal 
concentration of the respective compounds, with those treated with Compound 
72 apparently capable of undergoing cell division (Figure 5.5). However, cells 
incubated with 0.5 µM Compound 139 for 24 hours did show some disruption in 
the cytosol (Figure 5.6), but none of the organelles appeared affected. 
1 µM GJS-128 has a very clear affect on the ultrastructure of trypanosomes. 
After 20 hours incubation a large number of cells displayed the components of Matthew K Gould, 2009     Chapter 5, 187 
one or more flagellum inside the cytosol instead of extending out of the 
trypanosome from the flagellar pocket. Figure 5.7 shows an example of a cell 
incubated with GJS-128: the paraflagellar rod (PFR) and associated axoneme (A) 
of a flagellum can clearly be seen in longitudinal section towards the bottom left 
of the micrograph. Apparently separate PFR and axoneme assemblies can be 
identified at the extreme bottom and top of the cell. However, they all may be 
from the same flagellum undulating in and out of the section. Also observable 
are what appear to be microtubules from the flagellar attachment zone (FAZ) 
completely disassociated from both the flagellum and the subpellicular 
microtubule array. Another abnormal feature present is the large round vacuole-
like structure in the centre of the image: this could be an enlarged flagellar 
pocket like that shown in figure 5.3 but not displaying its associated flagellum 
due to the angle of the section. 
 
Figure 5.2: Transmission electron micrograph of a Tb427 wildtype bloodstream form 
trypanosome incubated for 20 hours with DMSO only as a No-Drug Control. (F) flagellum, 
(FP) flagellar pocket, (BB) basal body (Gly) glycosome, (ER) endoplasmic reticulum, (SMA) 
subpellicular microtubule array, (G) Golgi apparatus, (N) nucleus. Magnification: x 4000. 
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Figure 5.3: Transmission electron micrograph of a Tb427 wildtype bloodstream form 
trypanosome incubated for 20 hours with 0.625 µM Compound 37. (F) flagellum, (SMA) 
subpellicular microtubule array, (A) axoneme (PFR) paraflagellar rod, (FP) flagellar pocket, 
(Gly) glycosome, (ER) endoplasmic reticulum, (AC) acidocalcisome. Magnification: x 4000. Matthew K Gould, 2009     Chapter 5, 189 
 
Figure 5.4: Transmission electron micrograph of a Tb427 wildtype bloodstream form 
trypanosome incubated for 24 hours with 0.25 µM Compound 48. (F) flagellum, (BB) basal 
body, (A) axoneme (PFR) paraflagellar rod, (FP) flagellar pocket, (K) kinetoplast, (N) nucleus, 
(V) clathrin coated vesicle, (Gly) glycosome, (ER) endoplasmic reticulum, (AC) 
acidocalcisome, (SMA) subpellicular microtubule array. Magnification: x 4000. Matthew K Gould, 2009     Chapter 5, 190 
 
Figure 5.5: Transmission electron micrograph of a Tb427 wildtype bloodstream form 
trypanosome incubated for 24 hours with 1 µM Compound 72 and undergoing cell division 
with two nuclei and basal bodies of separate flagella apparent. (F) flagellum, (BB) basal 
body, (A) axoneme (PFR) paraflagellar rod, (FP) flagellar pocket, (G) Golgi apparatus, (N) 
nucleus, (Gly) glycosome, (ER) endoplasmic reticulum, (AC) acidocalcisome, (SMA) 
subpellicular microtubule array. Magnification: x 4000. Matthew K Gould, 2009     Chapter 5, 191 
 
Figure 5.6: Transmission electron micrograph of a Tb427 wildtype bloodstream form 
trypanosome incubated for 24 hours with 0.5 µM Compound 139. (BB) basal body, (FP) 
flagellar pocket, (K) kinetoplast, (N) nucleus, (V) clathrin coated vesicle, (Gly) glycosome, 
(ER) endoplasmic reticulum, (SMA) subpellicular microtubule array, (G) Golgi apparatus, 
(CD) cytosolic disruption. Magnification: x 4000. Matthew K Gould, 2009     Chapter 5, 192 
 
Figure 5.7: Transmission electron micrograph of a Tb427 wildtype bloodstream form 
trypanosome incubated for 20 hours with 1 µM GJS-128. (F) flagellum, (A) axoneme (PFR) 
paraflagellar rod, (FP) flagellar pocket, (Gly) glycosome, (ER) endoplasmic reticulum, (AC) 
acidocalcisome, (SMA) subpellicular microtubule array, (FAZ) flagellar attachment zone (G) 
Golgi apparatus. Magnification: x 4000. 
 
5.3.2 Cell cycle analysis using flow cytometry 
In order to establish whether the Series 1 and GJS compounds had an effect on 
the cell cycle of trypanosomes the DNA content of Tb427 wildtype trypanosomes 
was monitored over time, with and without a panel of test compounds, using 
flow cytometry. Tb427 bloodstream form trypanosomes have a doubling time of 
around 6 hours (Forsythe, G. R., et al, 2009) but the cultures are asynchronous Matthew K Gould, 2009     Chapter 5, 193 
with regards to cell-cycle stage so any block or specific disruption to replication 
may affect each individual cell at different incubation times. To account for 
this, samples were taken from test cultures up 16 hours, and in some cases 24 
hours, after the addition of test compound. The trypanosomes were assayed at a 
cell density of 1 x 10
6 cells/ml and, after the cells were fixed overnight with a 
methanol/phosphate-buffered saline solution, stained with propidium iodide. 
Propidium iodide binds to the nucleic acids of a cell and the intensity of its 
fluorescence is correlated to the amount of DNA, as the fixed cells are treated 
with RNAse.  
In Figure 5.8 the Tb427 wildtype cells were incubated with the highest, 
ultimately lethal concentration of Series 1 compound that did not kill the cells 
within 16 hours (Compound 48: 0.25 µM; Compound 72: 1 µM; Compound 139: 0.5 
µM), with the no drug control receiving an equal volume of the solvent, DMSO. 
After 16 hours incubation samples were taken and DNA content was assessed. 
 
Figure 5.8: Flow cytometry analysis of the DNA content of Tb427 wildtype trypanosomes 
treated and untreated with 0.25 µM Compound 48, 1 µM Compound 72 and 0.5 µM 
Compound 139 and incubated under normal culturing conditions for 16 hours. The 
histograms show the number of cells with a particular fluorescence intensity which 
correlates with the amount of DNA in the cell. The peaks labelled 2C represent the number 
of cells in the sample with a complete diploid complement of DNA, having 2 copies of the 
genome; the peaks labelled 4C represent the cells which have replicated their DNA but not 
yet undergone cell division therefore having 4 copies of the genome. 
 
Compounds 72 and 139 appear to have no direct impact on DNA replication after 
16 hours incubation at a lethal concentration (Figure 5.8). Both the peaks 
corresponding to cells with one complete diploid genome (G1 phase of the cell 
cycle corresponding to the 2C peak) and those having completed a round of DNA 
replication and are undergoing mitosis (G2/M phase corresponding to the 4C 
peak) are very similar to those produced by the control culture.  Matthew K Gould, 2009     Chapter 5, 194 
Compound 48, however, appears to have a decreased 2C peak with a fractionally 
larger 4C peak compared to the control. This might suggest an impediment in 
the cell cycle during mitosis, resulting in trypanosomes in the G2/M phase 
increasing in number and those in G1 phase being depleted as cells progressing 
into S phase are not being replaced fast enough by others completing mitosis. 
Unfortunately further sampling of the Compound 48 culture was not possible due 
to the compound’s toxic effects killing the trypanosomes shortly after 16 hours 
of incubation. This being the case it seems unlikely that the relatively minor 
effect on cell division itself caused the death of the cell population. Rather, it 
may be that cells in G1 phase are more sensitive to Compound 48 than those 
undergoing mitosis. 
In Figure 5.9 it is shown that Compound 37 has a very different DNA content 
profile from the other Series 1 compounds tested. Over a period of 16 hours of 
incubation at 0.625 µM the 2C peak has been drastically reduced, compared to 
the no drug control, with the 4C peak appearing larger. There is also a large 
peak at the left-hand side of the histogram which is not present in the control 
data. This probably represents DNA debris from cells too structurally weakened 
to withstand the centrifugation steps of the sample preparation; however, it 
may be caused by a proportion of the cell population having gone through 
cytokinesis before proper DNA segregation occurred resulting in cells without a 
full diploid genome. Alternatively, this could reflect extensive DNA degradation. 
Even after just four hours incubation with Compound 37 the 4C peak is 
noticeably larger than that of the no drug control’s; a picture mirrored at 8 and 
12 hours incubation, with the 2C peak gradually diminishing and the ‘debris 
peak’ (<2n chromosomes) increasing.  
These data suggest that Compound 37 disrupts the cell cycle of trypanosomes 
resulting in an accumulation of the cell population in the G2/M phase. This may 
lead to cell death through blocked, or improper, DNA segregation and cell 
division. The incubation time of at most two replication cycles is not long 
enough to assess whether longer treatment with this compound would lead to 
the appearance of cells with higher ploidy but the increasing prominence of the 
<2C peak makes this seem unlikely. One assessment of these data is that cell 
division was disrupted because of extensive damage/fragmentation of nuclear 
DNA, rather than the other way around.  Matthew K Gould, 2009     Chapter 5, 195 
 
Figure 5.9: Flow cytometry analysis of the DNA content of Tb427 wildtype trypanosomes 
treated and untreated with 1 µM GJS-128 and 0.625 µM Compound 37, incubated under 
normal culturing conditions with samples taken every 4 hours for 16 hours. The histograms 
show the number of cells with a particular fluorescence intensity which correlates with the 
amount of DNA in the cell. The peaks labelled 2C represent the number of cells in the 
sample with a complete diploid complement of DNA, having 2 copies of the genome; the 
peaks labelled 4C represent the cells which have replicated their DNA but not yet undergone 
cytokinesis therefore having 4 copies of the genome. The peaks that are suggestive of cells 
with 8 copies of the genome are labelled 8C? and arrowed.  
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When incubated with 1 µM GJS-128 the G1 phase (2C) peak is reduced after just 
4 hours (Figure 5.9), in comparison with the no drug control, with a marked 
increase in the 4C G2/M phase peak. After 8 hours the two peak sizes have 
remained approximately the same size with perhaps a slight increase in the 
debris peak at the left-hand side. At 12 hours incubation both the 2C and 4C 
peaks appear reduced relative to the 4 hour time point and the 2C peak is now 
only a small fraction of the corresponding peak in the control sample. However, 
this is not attributed to cell death as a shallow peak is beginning to emerge 
towards the right-hand side of the histogram at the expected intensity for 8C 
ploidy. This third peak is more pronounced after 16 hours incubation, with the 
2C, 4C and debris peaks remaining approximately the same size as at 8 hours. 
The rapid increase in the 4C peak combined with the decrease in the 2C peak 
relative to the no drug control after 4 and 8 hours incubation with GJS-128 
suggest that this compound also disrupts the cell cycle; however, the 
appearance of the third peak after 12 hours incubation indicate that the DNA 
synthesis component of the cell cycle has not been halted but that either mitosis 
or cytokinesis, or both, have been skipped over. This would result in a proportion 
of the cells having gone through one round of DNA replication, then had mitosis 
and/or cytokinesis disrupted, halting physical cell division, but not a further 
round of DNA replication. This implies that a trypanosome affected by GJS-128 
might replicate its diploid genome from 2C to 4C, and then undergo further DNA 
replication from 4C to 8C without finishing the cell division as expected. 
Further analysis of the flow cytometry data by ModFit LT software (Verity 
Software House), which can model the histogram peaks to find the percentages 
of the population in diploid and other ploidy cell cycle phases, was carried out to 
shed further light on the particular stage of cell replication disruption. 
The modelled percentages of the trypanosome population in diploid (2C), 
tetraploid (4C) and aneuploid (less than 2C, or less than a multiple of 2C) cell 
cycles were plotted for those cells incubated with and without GJS-128 (Figure 
5.10A) and with and without Compound 37 (Figure 5.10B) against time. Cultures 
treated with 1 µM GJS-128 show that the percentage of trypanosomes in a 
normal diploid state declines over the course of 24 hours, falling from almost 
95% to just over 30%; while the percentage of tetraploid cells steadily rises from Matthew K Gould, 2009     Chapter 5, 197 
4% to nearly 60% over the same period. Tetraploid cells become the dominant 
cell cycle state in the culture after approximately 16 hours exposure to the 
compound. In contrast, in the control culture the percentage of trypanosomes in 
a diploid cell cycle barely drops below 70% over the 24 hour period, with those 
cells in a tetraploid cell cycle reaching a maximum of 27% after 16 hours 
incubation before falling again. For both the cultures the percentage of the cells 
in an aneuploid cell cycle does not differ greatly from each other: rising 
gradually from a negligible percentage to around 10% of the population after 24 
hours. 
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Figure 5.10: Graphs showing the percentage of the Tb427 wildtype culture in particular 
ploidy cell cycles. Diploid (red), tetraploid (green) or aneuploid (blue) cell cycle after 
incubation with or without 1 µM GJS-128 (A) or 0.625 µM Compound 37 (B) over 24 hours. 
The continuous lines with filled symbols represent the test compound treated cultures and 
the dashed lines with empty symbols represent the no-drug control culture. In graph A the 
thin dotted lines represent the linear regression of the GJS-128 treated culture’s data with 
their respective P values for significance boxed on the right. 
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Cultures treated with 0.625 µM Compound 37 also show a more rapid decrease in 
the proportion of cells in a diploid cell cycle in comparison with the control, 
having fallen from 95% to 60% after 8 hours incubation compared to a decline to 
88% for the control. The percentage of the culture in a tetraploid cell cycle also 
rises much faster than the control, reaching nearly 40% after 8 hours compared 
to just 9% for the control. The percentages in the Compound 37 treated culture 
then remain at the 8 hour levels for at least the next 8 hours; the samples taken 
after 16 hours had too much cell debris to allow for reliable modelling by the 
ModFit LT software.  
The ModFit LT analysis suggest that GJS-128 and Compound 37 both have an 
affect on the cell cycle of Tb427 wildtype trypanosomes but act on the cell cycle 
in different ways. Compound 37 appears to block the cell cycle of the 
trypanosomes by disrupting either mitosis or cytokinesis after the genome of the 
cell has been replicated. The trypanosomes then stay in the 4C state until cell 
death, or die as a result of DNA damage. As a considerable percentage of 
Compound 37-treated cells remain diploid it is likely that DNA degradation 
rather than the block in cell division causes the demise of the trypanosome 
population. GJS-128 also appears to impede the cell cycle at either mitosis or 
cytokinesis however, instead of stopping the cell cycle, the trypanosomes appear 
to be able to undergo a further round of DNA replication without the mother and 
daughter cells dividing, resulting in the diminishing diploid cell population and 
an increasing number of tetraploid cells. 
5.3.3 Assessment of DNA configuration using the fluorescent 
stain DAPI 
In an attempt to pinpoint more precisely the location of the disruption to the 
cell cycle, the configuration of the nuclei and kinetoplasts in trypanosomes was 
investigated after incubation with the test compounds. 
Tb427 wild-type trypanosomes were incubated with and without test compound 
for 12 hours under normal culturing conditions. Samples were then fixed onto a 
microscope slide and stained with 4,6-diamidino-2-phenylindole (DAPI) which 
fluoresces when bound to DNA. The samples were then inspected using a 
fluorescent microscope fitted with the appropriate filters, and the fixed Matthew K Gould, 2009     Chapter 5, 199 
trypanosomes then assessed for the configuration and number of nuclei and 
kinetoplasts. The cells were scored and counted in the following categories: 
1N1K – having 1 nucleus and 1 kinetoplast; 1N2K – having 1 nucleus and 2 
kinetoplasts; 2N2K (Early) – having 2 distinct nuclei and 2 kinetoplasts but 
without an apparent cleavage furrow starting to divide mother and daughter 
cells; 2N2K (Late) – having 2 distinct nuclei and 2 kinetoplasts, and with the 
cleavage furrow having almost divided the mother and daughter cells, but not 
having achieved full cytokinesis; and >2N2K –cells with more than 2 nuclei and 2 
kinetoplasts (see Figure 5.11 for examples). 
 
Figure 5.11: Example images of Tb427 wildtype trypanosomes, and the categories they were 
scored as, with their DNA stained with DAPI and inspected by fluorescent microscope. (A) 
Shows a trypanosome with 1 nucleus and 1 kinetoplast; (B) a trypanosome with 1 nucleus 
and 2 kinetoplasts; (C) a cell with 2 nuclei and 2 kinetoplasts but before an cleavage furrow 
has started to divide the mother and daughter cells; (D) another cell with 2 nuclei and 2 
kinetoplasts but with the cleavage furrow having almost completed its progress to cell 
division; (E) an undivided cell with  pronounced cleavage furrow, apparently halted close to 
completion, with 2 nuclei and 4 kinetoplasts; (F) a cell with 4 nuclei and 4 kinetoplasts with 
an cleavage furrow apparently halted near completion and at least one more (left side of 
image) having made progress to dividing the cell further. 
 
The number and configuration of nuclei and kinetoplasts was significantly 
different from the control for those cultures incubated with GJS-128, Compound 
37 and Compound 48 for 12 hours (P < 0.001; Chi-squared test). For 
trypanosomes incubated with GJS-128, the percentage of cells in the 1N1K 
category was reduced, in comparison to the control, from 74.4% to 34% after 12 
hours incubation (Figure 5.12) however, the percentages of the 2N2K (Late) and Matthew K Gould, 2009     Chapter 5, 200 
>2N2K both increased, from 8.7% and 1% respectively, in the control culture, to 
39.3% and 17.8% respectively, in the GJS-128 treated population. When the 
categories that correspond to the diploid cell cycle are combined (1N1K, 1N2K 
and 2N2K (Early)) there is a statistically significant decrease, compared to the 
control, from a total of 90.3% to 42.9% in the GJS-128 incubated culture; this 
results in a corresponding increase in the percentage of cells in a tetraploid (or 
greater) cell cycle (2N2K (Late) + >2N2K) in the compound treated culture from 
9.7% in the control to 57.1%. 
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Figure 5.12: Graphs showing the percentage of Tb427 wildtype trypanosomes, in categories 
scored for number and configuration of nuclei and kinetoplasts, after 12 hours of incubation 
with or without test compound. From each culture more than 500 cells were assessed and 
scored for content of nuclei and kinetoplasts. (A) Control culture incubated with no test 
compound; (B) incubated with 1 µM GJS-128; (C) incubated with 0.625 µM Compound 37 and 
(D) incubated with 0.25 µM Compound 48. N = nuclei, K = kinetoplasts, (E) = early stage 
before cleavage furrow, (L) = late stage after cleavage furrow halted near complete cell 
division. *** = P-value is less than 0.001 for no significant difference between the bracketed 
categories combined from those of the control; ** = P-value is less than 0.01 for no 
significant difference from control; * = P-value is less than 0.05 for no significant difference 
from control. P-values were calculated by using the Chi-squared statistical test. 
 
These data indicate that treating trypanosomes with GJS-128 results in a specific 
block in the cytokinesis stage of the cell cycle. DNA replication, and segregation 
into two nuclei and two kinetoplasts during mitosis, appears to have occurred as 
normal; the cell has begun the process of physically dividing its contents with 
the cleavage furrow forming two compartments, each containing one nucleus Matthew K Gould, 2009     Chapter 5, 201 
and one kinetoplast as well as a flagellum each (Figure 5.11D), and are 
apparently connected by only a very small region of cell membrane. On further 
incubation the cell can undergo another round of apparently co-ordinated DNA 
replication, with the third and fourth nuclei never appearing without the third 
and fourth kinetoplasts (personal observations; Figures 5.11E and 5.11F); the cell 
then tries to physically divide itself again with more cleavage furrows beginning 
to progress towards division (Figure 5.11F). Following the number and 
configuration of nuclei and kinetoplasts beyond the 12 hour time-point was not 
feasible as accurate scoring of the cells was compromised by the sheer number 
of nuclei obscuring other nuclei, as well as the much smaller kinetoplasts; 
however, it was apparent further DNA replication did take place but it was not 
possible to say if it was by co-ordinated replication followed by an orderly 
mitosis (personal observations). 
Treatment with either Compound 37 or 48 significantly increased the percentage 
of trypanosomes with two nuclei and two kinetoplasts but no visible cleavage 
furrow (2N2K (Early)), compared to that of the control culture (Figure 5.12). 
There was also a significantly lower percentage with one nucleus and one 
kinetoplast (1N1K) compared to the control, but the other categories remained 
broadly the same. This suggests that for both Compounds 37 and 48 the 
disruption to the cell cycle lies after the replicated DNA has been segregated 
into the mother and daughter nuclei and kinetoplasts, but before the cleavage 
furrow starts to physically divide the cell, since the 2N2K (Late) percentages 
remained roughly the same. 
5.3.4 Comparison of the gene sequences of TbrPDEB1 and 
TbrPDEB2 between the resistant R0.8 cell line and its 
parental Tb427 wildtype strain 
The loss of sensitivity of the GJS-128 resistant R0.8 cell line to two cAMP 
analogues (4.3.4), combined with the apparent lack of a change in the profile of 
the production or degradation of cAMP on incubation with GJS-128 (4.3.5) 
suggest that the adaptation resulting in increased tolerance to the GJS 
compounds (and the resultant increased cAMP concentration) lies, at least in 
part, downstream of the phosphodiesterase enzymes in the cAMP signalling 
cascade. If, however, the mode of resistance is solely due to changes to the Matthew K Gould, 2009     Chapter 5, 202 
target trypanosomal PDE enzymes then one would expect to find those changes 
in the DNA sequences of the genes coding for them. To investigate this 
hypothesis further the open reading frames of the two essential trypanosomal 
PDEs (TbrPDEB1 and TbrPDEB2) were sequenced in the R0.8 cell line and 
compared to that of the parental Tb427 wildtype strain for any possible 
mutations that may result in a change in the action of the proteins. 
The R0.8 and the Tb427 wildtype cell lines were cloned out by serial dilutions in 
96-well plates so that cultures of each strain were obtained that had been 
derived from a single trypanosome. Primers flanking TbrPDEB1 and TbrPDEB2 
were designed from the GeneDB Trypanosoma brucei genome sequence (which is 
that of strain TREU927/4 GUTat10.1) and used to amplify the genes of interest 
from the R0.8 and Tb427 wildtype strains by the proof-reading polymerase KOD. 
After ligation into the pGEMT-easy vector and transformation into JM109 E. coli, 
the plasmid DNA containing the respective genes was extracted by mini-prep and 
samples sent to Eurofins-MWG-Operon for sequencing. According to GeneDB 
(www.genedb.org/genedb/tryp/) the T. b. brucei genome contains only one 
copy each of PDEB1 and PDEB2. In order to be confident of obtaining sequences 
for both possible alleles of the genes, plasmid DNA from multiple bacteria clones 
screened for the insertion of TbrPDEB1 or TbrPDEB2 was sent for sequencing.  
The data returned was analysed using the Vector Nti Advance 10 software suite 
which allowed the short, over-lapping partial DNA sequences to be ‘contig-ed’, 
or stitched together, to form the full open reading frame for the entire gene. 
The sequences from the multiple bacterial clones can be seen in Appendices 3 to 
6 with those from the R0.8 strain and the Tb427 wildtype aligned alongside the 
reference sequence from GeneDB for both TbrPDEB1 and TbrPDEB2. A diagram of 
both genes showing the relative positions of specific features can be seen in 
Figures 5.13 and 5.14. 
The sequences for TbrPDEB1 from the R0.8 and Tb427 wildtype strains differ 
from each other in just three base-pairs (Appendix 3). At base-pair 738 of the 
ORF the base is guanine for all of the bacteria clones transformed with DNA from 
R0.8, while for the Tb427 wildtype, five out of nine clones have a cytosine with 
the other four clones matching the R0.8 and having guanine. Similarly, at base-
pair 1602 all the R0.8 clones have guanine while the same five out of nine Tb427 Matthew K Gould, 2009     Chapter 5, 203 
wildtype clones have cytosine with the remaining four having guanine; and at 
base-pair 1362 the R0.8 clones have thymine while the same five out of nine 
Tb427 clones have guanine and the remainder, again matching the R0.8, 
thymine. This strongly suggests that in the Tb427 wildtype strain there are two 
heterozygous alleles of the TbrPDEB1 gene, with the allelic variation apparent in 
the DNA sequence at base-pairs 738, 1362 and 1602 (Figure 5.13); whereas R0.8 
has two homozygous alleles that match identically with one of the Tb427 
wildtype’s. When the DNA sequences are translated into their corresponding 
amino acid sequence (Appendix 4) only one of the three base-pair variations 
results in a change in amino acid: the change at base pair 1602 from guanine to 
cytosine changes the amino acid at residue 534 from a glutamic acid to the 
similarly charged aspartic acid. 
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Figure 5.13: Diagram showing the open reading frame of TbrPDEB1 (+/- 200 base pairs). 
Black arrows indicate the annealing positions of the primers used in amplifying the gene for 
sequencing the versions in the Tb427 wildtype and the GJS-128 resistant R0.8 cell lines. 
Blue bars indicate the position of allelic variations present in the Tb427 wildtype gene but 
absent in the R0.8 line. The catalytic domain and GAF domains are represented by green 
blocks. The figures in brackets are the location of each feature relative to the starting base 
pair in the open reading frame (- or + indicate feature locations upstream or downstream of 
the open reading frame). 
 
There are two other slight discrepancies observed in the sequences of the R0.8 
and Tb427 wildtype TbrPDEB1 gene when all the clones are aligned. At bp 2338 
there is a guanine in all clones except one, which has an adenine; and at bp 2658 
one out of the 18 clones has an extra thymine inserted that results in a frame 
shift and corresponding amino acid changes (Appendices 3 & 4). Since these 
differences only appear in a single clone they are probably the result of an error Matthew K Gould, 2009     Chapter 5, 204 
either in the sequencing reaction or in the initial PCR amplification by the 
polymerase enzyme. The differences between the sequences of the GeneDB 
strain and that of the R0.8 or Tb427 wildtype merely reflect the adaptations 
made by the diverging TREU927 and Tb427 strains of Trypanosoma brucei and 
would have no impact on the mode of resistance in the R0.8 cell line compared 
to the Tb427 wildtype. 
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Figure 5.14: Diagram showing the open reading frame of TbrPDEB2 (+/- 200 base pairs). 
Black arrows indicate the annealing positions of the primers used in amplifying the gene for 
sequencing the versions in the Tb427 wildtype and the GJS-128 resistant R0.8 cell lines. 
Blue bars indicate the position of allelic variations. The catalytic domain and GAF domains 
are represented by green blocks. The figures in brackets are the location of each feature 
relative to the starting base pair in the open reading frame (- or + indicate feature locations 
upstream or downstream of the open reading frame). 
 
For TbrPDEB2, two alleles (A and B) were also detected (Appendices 5 and 6), 
indicating heterozygosity; however they are both unambiguously present in the 
R0.8 and the Tb427 wildtype. The allelic sequence variations appear to cluster 
into four distinct regions. The first region begins at base-pair 780 and ends at bp 
792 with allele A’s sequence being CAGGGGTGACGTA and B’s being 
GAAAGACGACAAG, having eight out of the thirteen bases different (red text). 
The second region is just 28 base-pairs downstream beginning at bp 822 and 
ending at bp 855 with the sequence of allele A being 
TGTTACAATCCCTAGGGGTGCAGGTATTGCCGGA and allele B being 
CGTTTCCATACCCAAGGGAACAGGCATTGTAGGG, with 13 out of 34 bases differing 
(red text). The other two regions are much smaller being just 7 and 8 base-pairs 
in length with just three differences each: allelic region 3 begins at bp 1002 and Matthew K Gould, 2009     Chapter 5, 205 
ends at 1008 (allele A: TGCCCAA; allele B: AACCCAG) and region 4 beginning at 
bp 1070 and ending at bp 1077 (allele A: GGCGTGAT; allele B: AACGTGAC). 
When the TbrPDEB2 open reading frame has been translated (appendix 6) the 
single letter amino acid code for region one is RGDV for allele A and KDDK for 
allele B; the amino acid sequence for region two is TIPRGAGIA for allele A and 
SIPKGTGIV for allele B. The remaining two regions of allelic variation result in 
just one amino acid difference each when translated: region three has an 
alanine in allele A and a threonine in allele B at position 335; region four has an 
arginine in allele A and a lysine in allele B at position 357. Interestingly, all four 
of these regions of allelic variation lie within the GAF A domain (Figure 5.14). 
Tb427 wildtype has one further allelic difference in sequence which the R0.8 
line appears to have lost: a single base variation at bp 2365 which lies almost in 
the middle of the catalytic domain (Figure 5.14). In allele A the base is adenine, 
but in allele B it is thymine; in the R0.8 line the base pair in allele B has 
reverted to the adenine of allele A in that position. This allelic difference results 
in the amino acid sequence changing from a cysteine to a serine at residue 789, 
a relatively conservative substitution, however. 
There are four other discrepancies in the sequences where only a single clone 
from all of those sequenced has a difference at a single base position: bp 1656 
(G – A); bp 2160 (C – T); bp 2162 (A – C) and bp 2174 (A – T). These differences 
are probably a result of sequencing error or PCR error by the polymerase. Matthew K Gould, 2009     Chapter 5, 206 
5.4 Discussion 
Electron microscopy, analysis of DNA and cell replication identify two different 
types of toxic action for Compound 37. The microscopy observes severe 
enlargement of the flagellar pocket and disruption in the cytosol, whereas the 
flow cytometry analysis and DAPI staining indicate that Compound 37 blocks the 
cell cycle after DNA replication. While Compound 37 may have multiple targets 
within the trypanosome, one possible pathway that interference of which might 
give rise to both phenotypes is intracellular transport. The flagellar pocket is the 
only site of endocytosis and exocytosis in trypanosomes (Ralston, K. S. and Hill, 
K. L., 2008) and actin has been demonstrated to play an important role in these 
cellular processes (McPherson, P. S., 2002; Qualmann, B. et al, 2000). RNAi 
knockdown of actin in bloodstream form trypanosomes appeared to block the 
normal formation of vesicles from the flagellar pocket membrane and resulted in 
the flagellar pocket swelling dramatically (Garcia-Salcedo, J. A. et al, 2004). In 
the same study it was also observed that cell division ceased within 24 hours of 
induction of the actin RNAi. The similarities in cellular pathology between actin 
RNAi and Compound 37 suggest that this Series 1 compound may inhibit actin, or 
another key protein in the endo/exocytic pathway. 
In contrast to Compound 37, GJS-128 appears to block the cell replication cycle 
at a more specific point. The flow cytometry analyses demonstrate that while 
incubation with 1 µM GJS-128 results in a build up of trypanosomes with two 
diploid genomes, suggesting a block after DNA replication, prolonged incubation 
with the compound gives rise to another peak with a higher ploidy, possibly four 
diploid genomes. This suggests that while GJS-128 inhibits cell replication, DNA 
synthesis is apparently unaffected. 
Staining trypanosomes exposed to GJS-128 with DAPI and assessing the 
configuration of the DNA-containing organelles by fluorescence microscopy 
allowed us to determine the precise stage of the cell cycle being inhibited. 
While the uninterrupted DNA replication revealed by flow cytometry was 
confirmed, the microscopic assessment showed that the duplicated DNA also 
segregated into two separate nuclei and kinetoplasts as normal, allowing the 
formation of apparently complete daughter cells. However, repeating the 
microscopy with a panel of stains specific for individual organelles would help to Matthew K Gould, 2009     Chapter 5, 207 
determine if all the single organelles are also replicated and segregated as 
normal. After DNA replication, the trypanosomes then attempted to physically 
divide the mother and daughter cells, with the cleavage furrow moving along the 
flagella. The division of the cells proceeded right up until the point of 
abscission, with only a very small section of plasma membrane connecting the 
two almost separated trypanosomes, before the process was halted. This type of 
cell cycle block appears to be unique and suggests that the uncontrolled 
elevation of cAMP inhibits a specific process, as yet undocumented, that 
completes cytokinesis. 
The prolonged exposure to GJS-128 eventually resulted in the breakdown of 
normal flagellar replication, as observed by electron microscopy. This process is 
strictly coordinated and is supposed to progress along a path defined by the old 
flagellum (Ralston, K. S. and Hill, K. L., 2008). The presence of unattached 
components of a flagellum within the cytosol indicates that by this stage of PDE 
inhibitor exposure the replication of organelles has broken down. The flagella of 
a replicating cell are intimately linked with organelle segregation as well as 
initiation and progression of cytokinesis (Ralston, K. S. and Hill, K. L., 2008). If 
cAMP signalling plays a role in cytokinesis, and the PDE targets of GJS-128 are 
localised to the flagellum (Oberholzer, M. et al, 2007), then disruption to 
flagellar replication is not an inconsistent phenotype. 
Since RNAi studies of the PDEB genes in T. brucei demonstrated that both PDEB1 
and PDEB2 had to be disrupted to result in elevated intracellular cAMP 
concentrations and eventual cell death (Oberholzer, M. et al, 2007; Zoraghi, R. 
and Seebeck, T., 2002), a mutation in just one of these enzymes, making it 
insensitive to GJS-128, could give rise to significant resistance. As a means of 
determining whether the resistance displayed by the R0.8 trypanosome cell line 
to GJS-128 was due to mutation of either PDEB, TbrPDEB1 and TbrPDEB2 were 
cloned and sequenced from both the parental Tb427 wildtype and the R0.8 
strains. Two alleles were identified for TbrPDEB2 in both the wildtype and R0.8 
strains and are in excellent agreement with those published by Kunz, S. et al, 
2009, with the GAF-A domain of TbrPDEB1 appearing to have been duplicated in 
allele B of TbrPDEB2. The two alleles of PDEB2 appear to be identical in both the 
resistant cell line and the wildtype except for a single allelic variation at base 
pair 2365, resulting in the substitution of serine to cysteine in allele B of R0.8, Matthew K Gould, 2009     Chapter 5, 208 
making it the same as allele A. While this amino acid residue is located in the 
catalytic domain of the enzyme, it is unlikely to affect the kinetic properties of 
the enzyme for a number of reasons. The first is that the substitution is 
relatively conservative with serine and cysteine being neutral, rather 
hydrophobic, and of similar size. The second is that, although located in the 
catalytic domain of PDEB2, the residue is found towards the start of a 24 amino 
acid sequence divergent in all of the PDEB enzymes yet sequenced in 
kinetoplastids (Johner, A. et al, 2006). In the crystal structure of PDEB1 in 
Leishmania major, the homologous residue is found in helix 12 which is 
orientated towards the surface of the protein and does not appear to interact 
with the active site (Wang, H. et al, 2007). All of the above suggests that this 
region does not need to be absolutely conserved for the correct functioning of 
the protein. The final reason is that the substitution merely reverts the sequence 
from allele B to that of allele A, both of which are found in the GJS-128-sensitive 
wildtype strain. 
The sequence of TbrPDEB1 in the resistant R0.8 strain is identical to that of one 
of the alleles of the wildtype’s gene, having apparently lost the other, and 
becoming homozygous. There are just three base pairs different between the 
two PDEB1 alleles with only one resulting in an amino acid substitution. Again, 
this substitution is relatively conservative, and, being located well outside the 
catalytic domain, is unlikely to affect protein function. 
Loss of heterozygosity is usually the result of either a loss of part of the 
chromosome due to mis-segregation or double-stranded break of the DNA, or 
caused by a recombination event. The loss of heterozygosity for PDEB1, and in 
the catalytic domain of PDEB2, observed in the R0.8 strain may be the result of 
the method used to induce the initial resistance to GJS-128. Methyl methane 
sulphonate (MMS) damages DNA by methylating the bases and one method of 
repairing the damage is by homologous recombination (Wyatt, M. D. and 
Pittman, D. L., 2006). This can result in the transfer of DNA sequence from one 
allele to the other. However, this process is not always a two-way exchange of 
DNA and can result in the loss of part or all of an allele by a short patch gene 
conversion that replaces a missing section (Paques, F. and Haber, J. E., 1999), or 
by break-induced replication that duplicates one strand of the chromosome from 
a double stranded break right to the telomere (Malkova, A. et al, 1996). As the Matthew K Gould, 2009     Chapter 5, 209 
sequences of PDEB1 and PDEB2 in the resistant R0.8 line are also found in the 
wildtype, the loss of heterozygosity is unlikely to have contributed to the 
resistance, although the possibility that one of the alleles in the wildtype is 
defective cannot be formally excluded without cloning each allele and purifying 
the encoded product for the determination of its PDE activity. 
Since there is also no compelling evidence of a mutation having changed the 
activity or inhibitor binding of the PDEs, the tentative conclusion from these 
data is that the adaptation in R0.8 is located downstream of the 
phosphodiesterase enzymes, with the effect of making the trypanosome much 
less sensitive to high levels of cAMP. However, this needs to be formally 
demonstrated with the whole-cell PDE activity determination of both strains 
from cell lysates, as well as showing there has been no change to the expression 
levels of any of the trypanosomal PDEs in the resistant line – this work is 
currently in progress. The hypothesis that the source of resistance in the R0.8 
strain is not found in the phosphodiesterase enzymes is supported by the cross-
resistance of the R0.8 line to the hydrolysis-resistant cAMP analogues (Chapter 
4.2.4). Also, the almost identical profile of cAMP concentration increase in 
response to PDE inhibition by GJS-128 strongly suggests there is no change to the 
adenylyl cyclase capacity (Chapter 4.2.5). This leaves the possibility that the 
adaptation that gives resistance lies in one of the downstream regulatory 
proteins in the cAMP pathway, for example a putative cAMP-binding PKA-
regulatory subunit. Although PKA-like phosphorylating activity has been 
identified in T. brucei, the only isolated and characterised PKA-regulatory 
subunit from the parasite appears to bind cGMP instead of cAMP (Shalaby, T. et 
al, 2001). However, since trypanosomes express a multitude of receptor-like 
adenylyl cyclases, and phosphodiesterases, and since changes in the cAMP 
concentration have such serious effects on the trypanosome, a protein that 
transduces that signal to effector and regulatory proteins is essential in some 
form. As in T. brucei, PKA catalytic activity has been observed in the closely 
related organisms Trypanosoma cruzi and Leishmania species (Ulloa, R. M. et al, 
1988; Ochatt, C. M. et al, 1993; Banerjee, C. and Sarkar, D., 1992; Siman-Tov, 
M. M. et al, 2002). A PKA-regulatory subunit has been characterised from T. 
cruzi and it was demonstrated that cAMP can restore phosphorylating activity to 
the PKA-catalytic domain after inhibition by PKA-R. Although, a cAMP-binding 
regulatory domain has not yet been identified in Leishmania, cAMP has also been Matthew K Gould, 2009     Chapter 5, 210 
shown to modulate PKA activity in Leishmania amazonensis (Genestra, M. et al, 
2004). This suggests that the R0.8 cell line could prove to be a vital tool in 
identifying downstream effectors in the cAMP signalling pathway in Trypanosoma 
brucei for the first time. Matthew K Gould, 2009     Chapter 6, 211 
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There is an urgent need for new chemotherapies for African trypanosomiasis. 
Current treatments can be extremely toxic to the patient, for example: 10% of 
those treated with the melaminophenyl arsenical class of drug, melarsoprol, 
enduring sometimes fatal reactive encephalopathy (Fairlamb, A. H., 2003). The 
treatment regimens can also be costly and difficult to administer and, to make a 
bad situation intolerable, refractory strains have been reported and resistance 
to the few drugs available appears to be growing (Delespaux, V. and De Koning, 
H. P., 2007; Anene, B. M. et al, 2006). 
After the turn of the millennium, phosphodiesterase enzymes were 
demonstrated to be essential to the survival of bloodstream form trypanosomes. 
RNA-interference, resulting in the knockdown of the PDEB family induced a 
massive rise in intracellular cAMP concentration in procyclic forms and was 
lethal to the mammalian life cycle stage (Zoraghi, R. and Seebeck, T., 2002; 
Oberholzer, M. et al, 2007). However, none of the inhibitors active against 
mammalian PDEs could inhibit recombinantly expressed kinetoplastid PDEs with 
high affinity (see review of kinetoplastid PDEs; Chapter 1.4.1), nor inhibit native 
trypanosome or leishmania PDE activity from cell lysates (Goncalves, M. F. et al, 
1980; Al-Chalabi, K. A. K. et al, 1989; Rascon, A. et al, 2000). While this 
suggests there is enough divergence between the mammalian and kinetoplastid 
PDEs to allow the development of specific inhibitors that target the parasite 
only, it also means that there were no suitable positive control compounds that 
can reliably inhibit bloodstream form trypanosome PDEs. The change in cAMP 
concentrations due to RNAi knock down of PDEB had been measured in procyclic 
form T. brucei and before this project started, there were no publications 
showing what effects should be expected on intracellular cAMP concentrations 
by disrupting or inhibiting bloodstream form trypanosomal PDEs, should such a 
compound be identified. Nor were there defined cellular effects of cAMP 
elevation in these cells, or ways to manipulate cAMP production as no receptor 
agonists or antagonists are known for the putative receptor adenylate cyclases 
and the cells do not express classical G-proteins that could be manipulated. 
Well in excess of 200 putative phosphodiesterase inhibitors were provided from 
two sources for assessment of activity against trypanosomes in vitro. In order for 
any potential new chemotherapy against African trypanosomiasis to be effective, 
there must be no cross-resistance to the lead compound by strains refractory to Matthew K Gould, 2009     Chapter 6, 213 
current treatments. To test this, not only were all the compounds assayed 
against wildtype T. brucei, but each was also assayed against the TbAT1 
knockout strain. This strain shows marked resistance to most of the diamidine 
class compounds, as well as minor resistance to pentamidine and 
melaminophenyl arsenical class compounds (Matovu, E. et al, 2003) due to the 
disruption of a purine transporter that actively accumulates the drugs. For the 
majority of compounds no significant resistance was shown, with those that did 
show a statistical increase in EC50 value showing only minor resistance in 
comparison to diminazene being over 20-fold less active against the TbAT1 knock 
out strain (Chapter 2.3.1). A panel of compounds was also tested against the 
wildtype and diminazene resistant veterinary parasite T. equiperdum (Barrett, 
M. et al, 1995) showing a similar lack of cross-resistance – as did a panel tested 
against a TbAT1 knockout strain made further resistant to pentamidine that also 
shows significant resistance to melaminophenyl arsenicals (Bridges, D. J. et al, 
2007). These results demonstrate that the putative PDE inhibitors tested in this 
study do not enter the cell via the same transporters as the current 
chemotherapies, nor kill the trypanosomes by disrupting the same intracellular 
target. 
Analysing the effects of large numbers of test compounds highlighted the need 
for a high-throughput method of determining the speed of action of each 
compound, at various concentrations, on live trypanosomes. Methods utilized 
previously, such as using a haemocytometer to manually count the number of 
cells in a culture, or a light absorbance-based assay had numerous 
disadvantages. Cell counts were extremely time-consuming, limiting the number 
of conditions tested at a time, and was not accurate over relatively short 
intervals. The light absorbance assay relied on high initial cell densities not 
obtained in normal in vitro culturing, possibly affecting results, as well as not 
being able to distinguish between loss of cell motility and cell lysis. During this 
project, a protocol based around the fluorescence of propidium iodide when 
bound to DNA was successfully developed (Chapter 3). Propidium iodide is a 
compound that cannot cross intact cell membranes; however, once the 
membrane has been compromised, and the compound enters the cell, it binds to 
DNA and fluoresces under certain conditions. The breaking up of the cell 
membrane is a definitive indicator of cell death, so when propidium iodide is 
incubated with live cells the fluorescence due to the compound binding DNA is a Matthew K Gould, 2009     Chapter 6, 214 
proxy for cell death that can be easily detected and quantified at relatively low 
cell densities. This allows the monitoring of the lethal effects of a test 
compound on the population of a cell culture. The protocol was optimised to a 
96-well plate format allowing the automating of fluorescence measuring, as well 
as resulting in the monitoring of the effects of many different compounds or test 
conditions in a single assay. This new assay saves time and provides accurate and 
relevant information to allow the efficient design of protocols for future 
biochemical investigations of the effects of test compounds. 
A small number of compounds were identified that rapidly increase the 
intracellular cAMP concentration in bloodstream form trypanosomes, the most 
active of which was GJS-128 (Chapter 4.3.1; 4.3.2). Work conducted by Dr. 
Herrmann Tenor of ALTANA Pharma, The Netherlands, and Prof. Thomas Seebeck 
at the University of Bern, Switzerland, demonstrated that GJS-128 inhibits 
recombinant trypanosomal PDEB enzymes with Ki values consistent with its in 
vitro EC50 value against live trypanosomes. This gives a clear and consistent link 
between the cause of cAMP rise (inhibition of PDEB by GJS-128) and the effect of 
that concentration on bloodstream form trypanosomes (cell death). GJS-128 
chemically validates phosphodiesterase enzymes as good drug targets for 
developing new lead compounds against African trypanosomiasis. 
The downstream effects on the bloodstream form trypanosomes of elevating the 
intracellular cAMP levels were investigated by electron microscopy for gross 
intracellular disruption, as well as by flow cytometry analysis and DAPI staining 
for effects on the cell cycle (Chapter 5.3.1; 5.3.2; 5.3.3). The flow cytometry 
and DAPI staining of DNA-containing organelles showed that raising cAMP 
concentrations result in the cell cycle being blocked in cytokinesis, where the 
DNA has replicated and segregated into new nuclei and kinetoplasts and cell 
division has been initiated  with the cleavage furrow having progressed between 
the mother and daughter flagella almost to separation. At this point, the 
moment of abscission, cell division has been halted with just a small section of 
plasma membrane connecting the two almost separated trypanosomes. While 
physical cell division has been blocked, DNA replication has not, with further 
rounds of DNA synthesis and segregation into nuclei and kinetoplasts observed in 
the mother and daughter cells, as well as secondary cleavage furrows along the 
new flagella which is again halted at the point of abscission. This specific mode Matthew K Gould, 2009     Chapter 6, 215 
of blocking the cell cycle appears to be unique for a chemical action and implies 
a precise role for cAMP signalling in the process of terminating the physical 
separation of the replicating cells. The multiple flagella observed in the 
fluorescent microscopy, and the disruption to the flagellar assembly and swelling 
of the flagella pocket observed by electron microscopy, are all consistent with 
the phenotype of the bloodstream form trypanosomes noted after RNAi against 
TbrPDEB1 and TbrPDEB2 (Oberholzer, M. et al, 2007) – further confirmation that 
the defects in cell cycle seen is due to GJS-128 inhibiting phosphodiesterases 
and not a secondary, off-target effect. 
As a means of examining the mode of action of GJS-128 further, resistance to 
the PDE inhibitor was induced in bloodstream form trypanosomes. A high degree 
of resistance was generated, resulting in the R0.8 strain which displayed cross-
resistance to the other GJS compounds suggesting a common protein target. No 
cross-resistance was observed for current chemotherapies, consistent with the 
lack of cross-resistance to GJS compounds from the TbAT1 knockout and B48 
clonal strains. This is strong additional evidence that the GJS compounds act via 
a different mode from the current drugs and suggests the possibility of a 
combination therapy between PDE inhibitors and diamidines or melaminophenyl 
arsenicals being effective against resistant strains already in the field. As a first 
step we are currently investigating whether the GJS compounds and diamidines 
act in an additive or in a synergistic way. 
The mode of resistance in the R0.8 strain was investigated by examining the 
cAMP generation profile, on incubation with GJS-128, between the resistant and 
parental wildtype strains, as well as by sequencing the PDEB genes in both 
strains to identify mutations. While a loss of heterozygosity was observed in the 
R0.8 strain for PDEB1 and part of PDEB2, no base substitutions were found in the 
R0.8 DNA sequences that could not be found in one or other of the wildtype 
alleles in both genes. This, along with the strikingly similar cAMP profiles of the 
two strains on incubation with GJS-128, suggest that the adaptation giving 
resistance to PDE inhibitors in R0.8 is not located in the PDE genes. The 
comparison of PDE activity in cell lysates from both strains, as well as comparing 
expression levels of the PDE genes, is underway to fully confirm this hypothesis. 
Not only do the cAMP profiles of the R0.8 and wildtype strains suggest that there 
has been no change in the affinity of GJS-128 for the phosphodiesterase Matthew K Gould, 2009     Chapter 6, 216 
enzymes, but it also infers there is no change to the adenylyl cyclase production 
of cAMP.  
This leaves the effector proteins downstream of the PDE enzymes in the cAMP 
signalling pathway as most likely to harbour the adaptation giving PDE inhibitor 
resistance. A compound that inhibits trypanosomal phosphodiesterase enzymes 
both recombinantly and in live trypanosomes, as well as a cell line that has 
adaptations in the effector proteins could prove to be the vital tool required to 
uncover the identity and function of these elusive proteins for the first time in 
kinetoplastids. 217 
Appendix 1:  
Average EC50 values for all Series 1 compounds against Tb427 wild type and TbAT1 
knockout bloodstream form trypanosomes, with standard errors. Values were derived from 
whole-cell in vitro efficacy assays and calculated from sigmoidal dose-response curves, 
with variable slopes, using GraphPad Prism software. Averages are taken from at least 3 
independent experiments. Also shown is the resistance factor of the TbAT1 knockout strain 
compared to Tb427 wild type for each compound. Statistical significance was calculated 
after an F-test was conducted to determine which one-tailed, unpaired Student’s T-test was 
most appropriate: that for equal or unequal variances. Those compounds for which the 
TbAT1 knockout strain is statistically resistant are highlighted with red text. 
University of 
Glasgow 
Compound Code 
EC50 Value (M) Tb427 
WT 
EC50 Value (M) 
TbAT1 KO 
TbAT1 KO 
Resistance 
Factor 
P Value: 
Significantly 
Resistant  Average  S.E.  Average  S.E. 
129  5.8E-09  3.4E-09  7.8E-09  4.2E-09  1.3  0.373 
197  1.2E-08  2.1E-09  5.2E-08  1.8E-08  4.4  0.103 
140  3.3E-08  1.8E-08  3.0E-08  1.6E-08  0.90   
141  3.6E-08  2.1E-08  3.2E-08  1.8E-08  0.89   
48  7.0E-08  2.8E-08  4.2E-08  2.9E-08  0.60   
82  7.0E-08  1.6E-08  4.7E-08  1.4E-08  0.67   
137  8.1E-08  4.3E-08  7.2E-08  4.1E-08  0.89   
Diminazene  8.6E-08  1.2E-08  1.8E-06  1.1E-07  21  0.000 
138  1.2E-07  1.4E-08  9.1E-08  2.5E-08  0.75   
143  1.6E-07  1.9E-08  5.7E-07  5.0E-08  3.6  0.002 
198  1.6E-07  2.1E-08  2.6E-07  4.7E-08  1.6  0.064 
124  1.8E-07  2.4E-08  7.0E-07  4.4E-08  4.0  0.000 
199  1.8E-07  3.0E-08  1.5E-07  4.2E-09  0.84   
128  1.9E-07  9.7E-08  3.1E-07  3.3E-08  1.6  0.169 
114  2.0E-07  2.3E-08  4.7E-07  4.7E-09  2.4  0.004 
142  2.0E-07  9.8E-09  3.3E-07  5.1E-08  1.7  0.078 
139  2.3E-07  4.3E-08  1.9E-07  4.7E-09  0.84   
113  2.6E-07  2.7E-09  6.4E-07  2.5E-08  2.5  0.003 
80  2.7E-07  2.9E-08  3.5E-07  3.6E-08  1.3  0.113 
79  2.9E-07  4.5E-08  3.1E-07  6.2E-08  1.1  0.421 
104  3.4E-07  4.1E-08  5.3E-07  4.8E-08  1.6  0.033 
37  3.5E-07  7.5E-08  3.3E-07  8.0E-08  0.93   
111  3.9E-07  3.8E-08  4.9E-07  1.5E-08  1.3  0.058 
83  4.4E-07  1.9E-08  5.1E-07  3.6E-08  1.2  0.126 
107  4.4E-07  4.7E-09  4.9E-07  2.2E-08  1.1  0.093 
130  4.8E-07  6.8E-08  4.3E-07  2.4E-08  0.89   
158  5.7E-07  4.5E-08  5.3E-07  1.1E-08  0.92   
72  5.8E-07  4.2E-08  8.5E-07  4.8E-08  1.5  0.013 
105  5.9E-07  9.7E-08  8.5E-07  7.2E-08  1.4  0.080 
103  6.6E-07  8.6E-08  1.1E-06  1.6E-07  1.6  0.069 
77  7.6E-07  7.1E-08  5.7E-07  7.5E-08  0.75   
10  8.3E-07  1.7E-07  9.5E-07  2.0E-07  1.2  0.354 
121  9.2E-07  7.3E-08  1.2E-06  2.2E-08  1.3  0.022 
6  1.0E-06  2.3E-07  1.4E-06  4.7E-07  1.3  0.314 
74  1.0E-06  4.7E-08  8.9E-07  1.1E-08  0.86   
152  1.1E-06  7.1E-08  1.6E-06  5.1E-08  1.4  0.006 
151  1.2E-06  6.5E-08  1.7E-06  6.3E-08  1.4  0.005 
131  1.2E-06  1.9E-07  1.3E-06  2.2E-07  1.1  0.376 
145  1.3E-06  1.1E-07  1.4E-06  1.2E-07  1.1  0.284 
112  1.5E-06  7.8E-08  1.2E-06  1.8E-08  0.83   
4  1.6E-06  3.1E-07  1.4E-06  2.4E-07  0.91   
122  1.6E-06  6.3E-08  1.6E-06  3.2E-08  1.0  0.471 
84  1.7E-06  1.9E-08  1.9E-06  9.5E-08  1.1  0.103 218 
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165  1.8E-06  7.5E-08  1.8E-06  3.0E-07  0.99   
186  1.9E-06  4.7E-07  1.6E-06  3.3E-07  0.82   
73  1.9E-06  7.2E-09  2.0E-06  6.4E-08  1.1  0.154 
5  1.9E-06  1.7E-07  1.4E-06  3.9E-07  0.75   
161  1.9E-06  1.3E-07  1.5E-06  1.1E-07  0.77   
164  2.0E-06  7.4E-08  1.9E-06  2.0E-07  0.92   
63  2.1E-06  4.0E-07  2.4E-06  1.7E-07  1.2  0.288 
27  2.1E-06  2.7E-08  4.4E-06  6.0E-07  2.2  0.041 
64  2.1E-06  4.3E-07  2.4E-06  2.2E-07  1.2  0.294 
159  2.1E-06  2.0E-07  1.7E-06  2.2E-07  0.79   
7  2.2E-06  9.9E-07  1.9E-06  5.4E-07  0.87   
136  2.3E-06  1.0E-07  2.7E-06  2.0E-07  1.2  0.118 
192  2.3E-06  5.9E-08  2.4E-06  5.7E-08  1.1  0.089 
157  2.3E-06  1.7E-07  2.1E-06  2.2E-07  0.93   
110  2.3E-06  2.8E-07  3.3E-06  3.2E-07  1.4  0.076 
98  2.5E-06  5.8E-08  4.3E-06  4.2E-07  1.7  0.034 
117  2.5E-06  1.3E-07  2.7E-06  3.8E-07  1.1  0.353 
109  2.5E-06  2.4E-07  3.2E-06  3.4E-07  1.3  0.127 
162  2.7E-06  1.0E-07  2.1E-06  2.5E-07  0.80   
166  2.7E-06  1.1E-07  2.3E-06  2.3E-07  0.83   
62  2.8E-06  2.0E-06  2.1E-06  1.5E-06  0.78   
119  2.8E-06  1.1E-07  3.8E-06  1.8E-08  1.4  0.008 
106  2.9E-06  3.1E-07  3.0E-06  1.7E-07  1.1  0.370 
127  2.9E-06  3.2E-07  2.7E-06  7.8E-08  0.92   
118  2.9E-06  7.1E-08  3.9E-06  4.1E-08  1.3  0.000 
120  2.9E-06  3.3E-08  5.3E-06  5.2E-08  1.8  0.000 
180  3.0E-06  9.6E-08  2.6E-06  3.6E-07  0.84  0.199 
204  3.1E-06  5.0E-08  3.5E-06  2.1E-07  1.1  0.067 
55  3.1E-06  6.5E-07  3.5E-06  7.9E-07  1.1  0.447 
66  3.3E-06  6.7E-07  4.6E-06  7.7E-07  1.4  0.147 
179  3.3E-06  2.8E-07  2.1E-06  2.8E-07  0.63   
168  3.4E-06  6.7E-08  2.7E-06  2.9E-07  0.80   
167  3.4E-06  5.7E-08  2.9E-06  2.3E-07  0.83   
69  3.5E-06  1.5E-07  5.6E-06  5.6E-07  1.6  0.021 
149  3.5E-06  1.4E-07  2.7E-06  1.8E-07  0.77   
60  3.6E-06  1.4E-07  4.4E-06  2.0E-07  1.2  0.027 
163  3.7E-06  1.6E-07  2.9E-06  3.4E-07  0.79   
115  3.9E-06  3.4E-07  4.4E-06  3.5E-07  1.1  0.223 
2  4.0E-06  5.1E-07  1.2E-05  3.8E-06  3.0  0.112 
135  4.0E-06  1.7E-07  4.5E-06  4.1E-07  1.1  0.219 
102  4.0E-06  1.2E-07  6.7E-06  2.5E-07  1.7  0.001 
68  4.2E-06  2.2E-06  5.0E-06  2.4E-06  1.2  0.417 
123  4.2E-06  1.4E-07  4.9E-06  4.2E-07  1.1  0.160 
96  4.4E-06  9.8E-08  4.7E-06  1.6E-07  1.1  0.092 
133  5.1E-06  2.1E-07  5.7E-06  5.5E-07  1.1  0.198 
201  5.1E-06  1.2E-07  5.7E-06  3.2E-07  1.1  0.091 
24  5.4E-06  1.6E-06  5.2E-06  1.4E-06  0.97   
43  5.7E-06  1.9E-06  6.4E-06  2.1E-06  1.1  0.428 
189  5.9E-06  1.5E-07  6.0E-06  1.7E-07  1.0  0.335 
190  6.0E-06  2.4E-07  6.7E-06  3.8E-07  1.1  0.084 
18  6.0E-06  1.0E-06  5.6E-06  1.1E-06  0.95   
132  6.2E-06  3.1E-07  5.3E-06  2.8E-07  0.85   
8  6.3E-06  1.1E-06  7.3E-06  2.5E-06  1.2  0.389 219 
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25  6.3E-06  8.4E-07  6.8E-06  1.6E-07  1.1  0.349 
116  7.0E-06  6.8E-08  9.1E-06  4.5E-07  1.3  0.029 
153  7.0E-06  1.2E-06  7.1E-06  2.0E-07  1.0  0.485 
154  7.3E-06  6.8E-07  7.5E-06  3.4E-07  1.0  0.418 
20  7.7E-06  1.4E-06  1.0E-05  2.2E-06  1.3  0.381 
93  7.7E-06  2.4E-07  7.3E-06  1.5E-07  0.94   
125  7.8E-06  2.5E-07  9.7E-06  3.0E-07  1.2  0.008 
38  8.2E-06  1.8E-07  9.0E-06  7.0E-07  1.1  0.207 
195  9.3E-06  1.8E-07  8.7E-06  7.1E-08  0.93   
173  9.7E-06  4.8E-07  9.7E-06  4.8E-07  1.0  0.492 
34  9.8E-06  5.4E-07  8.3E-06  1.0E-06  0.84   
188  9.9E-06  3.1E-07  9.0E-06  2.8E-07  0.91   
41  1.0E-05  2.9E-07  1.1E-05  1.8E-07  1.1  0.056 
61  1.0E-05  9.2E-07  9.0E-06  1.3E-06  0.87   
187  1.0E-05  4.7E-07  1.2E-05  5.0E-07  1.1  0.110 
150  1.1E-05  2.6E-07  1.2E-05  1.2E-07  1.2  0.003 
16  1.1E-05  2.7E-06  9.1E-06  2.3E-06  0.86   
71  1.1E-05  3.7E-07  1.4E-05  4.9E-07  1.2  0.015 
40  1.1E-05  3.5E-07  1.2E-05  1.5E-07  1.1  0.128 
70  1.1E-05  5.9E-07  1.5E-05  9.5E-07  1.3  0.027 
44  1.2E-05  3.3E-06  1.2E-05  3.1E-06  0.97   
33  1.3E-05  4.2E-07  1.3E-05  5.6E-07  1.0  0.456 
11  1.3E-05  2.9E-06  9.8E-06  1.7E-06  0.75   
53  1.3E-05  2.9E-06  1.2E-05  2.2E-06  0.89   
56  1.4E-05  4.0E-06  1.4E-05  4.7E-06  1.1  0.427 
126  1.4E-05  5.1E-07  1.5E-05  6.7E-07  1.1  0.218 
32  1.4E-05  9.3E-07  1.3E-05  7.3E-07  0.94   
108  1.4E-05  2.7E-07  1.5E-05  3.7E-07  1.1  0.125 
206  1.5E-05  5.1E-07  1.5E-05  4.2E-07  1.0   
51  1.5E-05  3.7E-06  8.1E-06  2.2E-06  0.54   
134  1.6E-05  5.6E-07  1.6E-05  4.6E-07  1.0  0.430 
101  1.6E-05  4.8E-07  2.2E-05  7.6E-07  1.4  0.003 
200  1.6E-05  6.8E-07  1.2E-05  2.6E-07  0.79   
97  1.6E-05  6.4E-08  1.7E-05  3.1E-07  1.0  0.112 
42  1.7E-05  8.1E-06  1.5E-05  7.5E-06  0.91   
21  1.7E-05  4.2E-06  2.2E-05  6.1E-06  1.3  0.310 
160  1.7E-05  1.7E-06  1.5E-05  9.0E-07  0.85   
191  1.8E-05  3.7E-07  1.7E-05  6.0E-07  0.95   
100  1.8E-05  6.6E-07  2.0E-05  1.0E-06  1.1  0.152 
19  1.9E-05  4.7E-06  2.5E-05  3.6E-06  1.3  0.219 
169  1.9E-05  1.0E-06  1.3E-05  9.2E-07  0.68   
176  1.9E-05  5.8E-07  2.0E-05  1.4E-06  1.0  0.413 
95  2.0E-05  1.6E-06  1.6E-05  3.3E-07  0.79   
193  2.0E-05  1.0E-06  1.8E-05  1.3E-06  0.90   
12  2.1E-05  8.0E-06  1.2E-05  2.0E-06  0.58   
54  2.1E-05  2.2E-06  2.3E-05  3.0E-06  1.1  0.127 
76  2.2E-05  4.0E-06  3.1E-05  5.8E-06  1.4  0.173 
202  2.3E-05  2.6E-07  2.1E-05  4.7E-07  0.91   
45  2.3E-05  6.7E-06  2.3E-05  6.6E-06  0.97   
81  2.4E-05  2.8E-06  2.6E-05  4.8E-06  1.1  0.378 
177  2.4E-05  8.0E-06  3.7E-05  2.1E-06  1.6  0.147 
59  2.4E-05  7.5E-06  2.2E-05  6.7E-06  0.91   
9  2.5E-05  2.6E-06  2.6E-05  9.6E-06  1.1  0.446 220 
University of 
Glasgow 
Compound Code 
EC50 Value (M) Tb427 
WT 
EC50 Value (M) 
TbAT1 KO 
TbAT1 KO 
Resistance 
Factor 
P Value: 
Significantly 
Resistant  Average  S.E.  Average  S.E. 
75  2.5E-05  3.6E-06  3.4E-05  4.1E-06  1.3  0.131 
17  2.6E-05  4.1E-06  2.5E-05  3.4E-06  0.95   
205  2.6E-05  2.2E-06  2.1E-05  1.2E-06  0.83   
181  2.6E-05  1.0E-06  1.8E-05  2.5E-06  0.67   
175  2.7E-05  4.5E-07  2.6E-05  1.2E-06  0.97   
15  2.7E-05  6.7E-06  2.7E-05  5.7E-06  1.0   
155  2.7E-05  3.0E-06  1.4E-05  1.4E-06  0.52   
52  2.8E-05  6.0E-06  2.7E-05  6.4E-06  0.94   
46  2.9E-05  9.1E-06  2.5E-05  8.4E-06  0.89   
194  2.9E-05  4.2E-07  2.6E-05  1.0E-06  0.91   
92  3.0E-05  1.2E-06  3.1E-05  7.5E-08  1.0  0.373 
57  3.1E-05  9.7E-06  2.4E-05  8.0E-06  0.78   
196  3.4E-05  1.3E-06  3.0E-05  4.3E-07  0.89   
22  3.4E-05  8.3E-06  3.6E-05  6.4E-06  1.1  0.491 
174  3.4E-05  2.3E-06  2.9E-05  1.4E-06  0.86   
26  3.4E-05  7.5E-06  3.9E-05  7.6E-06  1.1  0.466 
58  3.4E-05  8.2E-06  3.8E-05  8.7E-06  1.1  0.462 
30  3.8E-05  3.0E-06  4.2E-05  4.5E-06  1.1  0.273 
49  3.8E-05  8.7E-06  3.5E-05  8.1E-06  0.91   
156  3.8E-05  8.9E-06  2.5E-05  2.2E-06  0.64   
3  4.0E-05  9.2E-06  2.3E-05  9.1E-06  0.57   
23  4.0E-05  1.1E-05  4.5E-05  8.3E-06  1.1  0.493 
13  4.1E-05  1.9E-05  6.4E-05  1.9E-05  1.6  0.417 
31  4.4E-05  7.8E-06  5.6E-05  1.3E-05  1.3  0.250 
86  4.4E-05  2.1E-06  4.4E-05  1.1E-06  1.0  0.452 
203  4.4E-05  3.0E-06  3.2E-05  1.5E-06  0.73   
184  4.5E-05  2.6E-06  3.8E-05  3.6E-06  0.84   
171  4.6E-05  1.7E-06  5.1E-05  3.9E-06  1.1  0.150 
67  4.8E-05  7.7E-06  7.2E-05  4.4E-06  1.5  0.045 
185  4.8E-05  2.6E-06  3.5E-05  5.3E-06  0.74   
29  5.0E-05  6.2E-06  5.0E-05  2.5E-06  1.0   
172  5.1E-05  7.5E-06  4.6E-05  1.2E-05  0.90   
89  5.6E-05  1.7E-06  6.2E-05  4.1E-06  1.1  0.220 
14  6.1E-05  3.9E-05  6.7E-05  3.6E-05  1.1  0.470 
170  6.1E-05  2.4E-06  5.7E-05  3.5E-06  0.92   
146  7.1E-05  2.3E-06  6.0E-05  5.0E-06  0.84   
178  7.1E-05  6.1E-06  6.2E-05  7.5E-06  0.87   
28  7.2E-05  7.4E-06  8.2E-05  7.2E-06  1.1  0.243 
94  7.5E-05  9.2E-06  4.4E-05  4.0E-06  0.59   
144  7.6E-05  1.1E-06  6.9E-05  2.5E-06  0.91   
39  7.7E-05  1.3E-05  8.9E-05  1.6E-05  1.2  0.313 
99  7.8E-05  9.1E-06  7.5E-05  5.8E-06  0.97   
85  8.4E-05  7.7E-07  7.5E-05  8.8E-06  0.90   
207  8.4E-05  4.0E-06  1.9E-04  1.2E-05  2.2  0.001 
1  8.8E-05  1.1E-05  9.0E-04  6.6E-04  10.2  0.210 
91  8.9E-05  2.2E-06  8.3E-05  1.3E-06  0.94   
183  9.4E-05  1.6E-06  8.7E-05  6.7E-06  0.93   
148  9.5E-05  1.9E-06  6.4E-05  2.8E-06  0.67   
147  9.7E-05  1.5E-06  1.0E-04  2.7E-07  1.1  0.043 
182  9.8E-05  1.3E-06  8.9E-05  7.4E-06  0.91   
90  1.0E-04  4.6E-07  1.0E-04  3.4E-06  0.98   
208  1.0E-04  2.8E-06  6.3E-05  2.9E-06  0.60   
211  1.1E-04  1.1E-06  6.3E-05  1.8E-06  0.56   221 
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210  1.1E-04  1.0E-06  7.0E-05  1.5E-06  0.61   
209  1.2E-04  1.6E-06  6.5E-05  1.8E-06  0.55   
212  1.2E-04  2.1E-06  7.3E-05  1.1E-06  0.62   
35  Not Soluble         
36  Not Soluble         
65  Not Soluble         
47  Not Soluble         
50  Not Soluble         
78  Not Soluble         
87  Not Soluble         
88  Not Soluble         
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Appendix 2:  
Average EC50 values for a panel of Series 1 compounds against Trypanosoma equiperdum 
wild type and the diminazene resistant PBR strain bloodstream form trypanosomes, with 
standard errors. Values were derived from whole-cell in vitro efficacy assays and calculated 
from sigmoidal dose-response curves, with variable slopes, using GraphPad Prism 
software. Averages are taken from at least 3 independent experiments. Also shown is the 
resistance factor of the PBR strain compared to T. equiperdum wild type, as well as the 
efficacy factor between species, comparing the average EC50 values against Tb427 and T. 
equiperdum wild type strains for each compound. Statistical significance for the presence 
of resistance was calculated using the one-tailed, unpaired Student’s T-test after an F-test 
was conducted to determine which was most appropriate: that for equal or unequal 
variances. A two-tailed, unpaired Student’s T-test was carried out to determine the presence 
of significant differences between species, again after the use of the F-test to determine the 
correct T-test to use. Those compounds for which the PBR strain is statistically resistant 
are highlighted in red text, and those showing significant inter-species difference in EC50 
values are highlighted in blue. 
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82  3.5E-09  2.1E-09  3.7E-09  9.8E-10  1.0  0.478  20  0.077 
48  5.4E-09  1.3E-09  5.7E-09  1.6E-09  1.1  0.452  13  0.140 
80  1.9E-08  1.9E-09  2.0E-08  4.7E-09  1.1  0.420  14  0.019 
111  1.9E-08  2.9E-09  2.5E-08  8.2E-10  1.3  0.088  20  0.015 
Diminazene  2.8E-08  4.9E-09  2.0E-06  2.9E-07  71  0.003  3.1  0.002 
107  3.2E-08  1.4E-08  2.9E-08  1.2E-08  0.90    14  0.000 
197  3.5E-08  1.4E-08  2.5E-08  2.2E-09  0.73    0.35  0.326 
79  4.2E-08  6.8E-09  4.3E-08  2.7E-09  1.0  0.445  6.9  0.043 
199  6.2E-08  8.9E-09  6.0E-08  4.6E-09  0.97    2.9  0.037 
139  1.1E-07  4.9E-09  1.0E-07  3.2E-09  0.98    2.1  0.144 
72  1.1E-07  2.0E-08  1.7E-07  1.3E-08  1.5  0.045  5.4  0.000 
112  1.3E-07  1.4E-08  1.4E-07  1.4E-08  1.0  0.442  11  0.004 
83  1.6E-07  2.1E-08  1.4E-07  2.3E-08  0.90    2.8  0.001 
104  2.0E-07  1.5E-08  1.5E-07  4.7E-09  0.76    1.7  0.058 
198  2.0E-07  3.2E-09  1.8E-07  2.0E-08  0.88    0.80  0.151 
84  2.2E-07  2.7E-09  2.3E-07  5.4E-09  1.0  0.125  7.7  0.000 
114  2.3E-07  2.0E-08  2.1E-07  1.8E-08  0.94    0.87  0.466 
37  2.5E-07  1.4E-08  2.9E-07  2.5E-08  1.2  0.160  1.4  0.323 
110  2.5E-07  4.3E-08  2.6E-07  3.3E-08  1.0  0.469  9.3  0.023 
10  3.6E-07  1.4E-08  4.5E-07  2.7E-09  1.3  0.015  2.3  0.151 
74  3.9E-07  9.0E-08  3.7E-07  7.4E-08  0.94    2.7  0.004 
103  4.1E-07  1.2E-07  4.7E-07  1.0E-07  1.1  0.388  1.6  0.247 
105  4.3E-07  1.2E-07  3.7E-07  7.7E-08  0.85    1.4  0.437 
64  4.4E-07  3.6E-08  6.4E-07  4.8E-08  1.4  0.028  4.8  0.086 
4  4.9E-07  4.7E-08  6.7E-07  5.0E-08  1.4  0.052  3.2  0.103 
77  5.2E-07  1.2E-07  4.9E-07  1.3E-07  0.94    1.5  0.234 
113  5.2E-07  3.7E-08  6.6E-07  1.2E-08  1.3  0.022  0.49  0.027 
98  5.3E-07  3.8E-08  8.1E-07  5.9E-08  1.5  0.014  4.7  0.000 
6  8.1E-07  1.9E-07  9.3E-07  1.6E-07  1.1  0.352  1.3  0.547 
158  8.3E-07  3.4E-08  8.8E-07  3.9E-08  1.1  0.254  0.69  0.014 
63  8.5E-07  9.3E-08  1.0E-06  1.1E-07  1.2  0.206  2.4  0.072 
7  1.0E-06  6.0E-08  1.0E-06  3.3E-08  0.99    2.1  0.436 
27  1.3E-06  4.4E-08  1.6E-06  1.4E-07  1.3  0.060  1.6  0.000 
204  1.3E-06  9.1E-08  1.4E-06  4.1E-08  1.1  0.251  2.4  0.000 
73  1.6E-06  3.1E-07  1.7E-06  2.0E-07  1.0  0.473  1.2  0.454 
192  1.8E-06  5.0E-08  1.9E-06  2.0E-08  1.1  0.088  1.3  0.003 
186  2.1E-06  4.3E-08  2.1E-06  1.4E-07  1.0  0.435  0.91  0.732 
165  2.2E-06  1.0E-07  2.3E-06  1.5E-07  1.0  0.406  0.83  0.050 
164  2.2E-06  1.7E-07  2.1E-06  1.1E-07  0.96    0.92  0.408 
159  2.3E-06  1.1E-07  2.5E-06  5.6E-08  1.1  0.121  0.91  0.544 
157  2.5E-06  9.3E-08  2.6E-06  1.5E-07  1.0  0.388  0.91  0.394 
179  2.7E-06  2.0E-07  2.5E-06  2.4E-07  0.94    1.2  0.212 
161  2.7E-06  1.5E-07  2.8E-06  9.8E-08  1.0  0.338  0.72  0.026 
166  2.7E-06  2.4E-07  2.7E-06  6.2E-08  1.0  0.468  1.0  0.975 
201  2.8E-06  1.0E-07  2.8E-06  6.2E-08  0.99    1.8  0.000 
180  2.9E-06  4.5E-08  3.0E-06  6.2E-08  1.0  0.181  1.0  0.425 
162  3.3E-06  4.3E-08  3.4E-06  1.1E-07  1.0  0.183  0.82  0.010 
163  3.7E-06  1.9E-07  4.0E-06  1.0E-07  1.1  0.169  1.0  0.864 
167  4.0E-06  9.8E-08  4.1E-06  1.2E-07  1.0  0.350  0.86  0.006 
168  4.2E-06  1.5E-07  4.3E-06  8.7E-08  1.0  0.383  0.81  0.007 
190  6.0E-06  9.0E-07  4.5E-06  5.5E-07  0.75    1.0  0.981 223 
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189  6.3E-06  1.7E-07  5.7E-06  6.0E-07  0.90    0.93  0.154 
200  7.2E-06  4.4E-07  7.3E-06  3.5E-07  1.0  0.485  2.2  0.000 
154  7.3E-06  8.1E-07  6.5E-06  1.1E-06  0.88    1.0  0.995 
195  8.7E-06  2.7E-07  7.5E-06  1.2E-06  0.86    1.1  0.144 
173  1.3E-05  1.3E-07  9.8E-06  3.8E-07  0.75    0.75  0.004 
153  1.3E-05  8.2E-07  1.1E-05  3.0E-07  0.85    0.54  0.020 
55  1.5E-05  1.7E-07  1.6E-05  1.2E-06  1.1  0.326  0.21  0.000 
208  1.0E-04  2.8E-06  5.4E-05  2.7E-06  0.52    1.0  0.763 
211  1.1E-04  1.6E-06  5.7E-05  2.4E-06  0.54    1.1  0.063 
209  1.1E-04  2.1E-06  6.6E-05  3.1E-06  0.58    1.0  0.429 
210  1.2E-04  3.0E-06  6.4E-05  1.3E-06  0.56    0.99  0.835 
212  1.2E-04  1.5E-06  6.2E-05  1.5E-06  0.53    1.0  0.720  
Appendix 3:  
The nucleotide sequences of TbrPDEB1 from all the cloned sequences taken from the GJS-128 resistant R0.8 strain and parental wildtype. Sequences are 
divided by the published sequence for TbrPDEB1 from GeneDB. 
                             1                                                                                                100 
R0-8 PDE-B1 Clone A1     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A2     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A3     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A4     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A5     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A6     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A7     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone A8     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
R0-8 PDE-B1 Clone B1     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
     GeneDB TbrPDEB1     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone B1     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A1     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A3     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A4     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A8     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A2     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A5     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A6     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
  WT PDE-B1 Clone A7     (1) ATGTTCATGAACAAGCCCTTTGGCAGCAAGCGCTGCGAACCCTTCCACGAGTCGGAGCACCTTTGTGAGGCGTTTGCCATCACTGAAGCAATCCTCGCTC 
                             101                                                                                              200 
R0-8 PDE-B1 Clone A1   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A2   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A3   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A4   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A5   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A6   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A7   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone A8   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
R0-8 PDE-B1 Clone B1   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
     GeneDB TbrPDEB1   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone B1   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A1   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A3   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A4   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A8   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A2   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A5   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A6   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA 
  WT PDE-B1 Clone A7   (101) GCTATCAGCGTGGGAAACGCAGCTTTACGTCCTCCGAAAAAAGTGGACTGGCAGCCCTTATCAAACGTATTCCTTATGATATCCTTGTTGAGGTTCTCGA  
 
                             201                                                                                              300 
R0-8 PDE-B1 Clone A1   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A2   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A3   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A4   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A5   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A6   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A7   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone A8   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
R0-8 PDE-B1 Clone B1   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
     GeneDB TbrPDEB1   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone B1   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A1   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A3   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A4   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A8   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A2   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A5   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A6   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
  WT PDE-B1 Clone A7   (201) TCAAAGCGGATTTACTCCAACAAGCAATGCAACACCCCCCGTTGATTATTTAGCTATGATGGAGCACACAATGACGCACGGTGCGTCTATTACACACGCC 
                             301                                                                                              400 
R0-8 PDE-B1 Clone A1   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A2   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A3   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A4   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A5   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A6   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A7   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone A8   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
R0-8 PDE-B1 Clone B1   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
     GeneDB TbrPDEB1   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone B1   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A1   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A3   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A4   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A8   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A2   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A5   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A6   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC 
  WT PDE-B1 Clone A7   (301) CTGCAGTACCTTAACGATTTGATGACTAAGTGTACCGGGTGCCCGGGGATTCGTACATATTACCATAACCCCAATGATGACGTTCTGGCCGACCCCGTTC  
 
                             401                                                                                              500 
R0-8 PDE-B1 Clone A1   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A2   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A3   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A4   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A5   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A6   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A7   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone A8   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
R0-8 PDE-B1 Clone B1   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
     GeneDB TbrPDEB1   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone B1   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A1   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A3   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A4   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A8   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A2   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A5   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A6   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
  WT PDE-B1 Clone A7   (401) ACGACACGGCAGCATTGATTGATGAAACAACAGCCGTGGGAAAGTCGGTTGTAACTAAACAGTACCTTAATATAGCTGGGGCTCACTACATACCCTTGAT 
                             501                                                                                              600 
R0-8 PDE-B1 Clone A1   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A2   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A3   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A4   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A5   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A6   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A7   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone A8   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
R0-8 PDE-B1 Clone B1   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
     GeneDB TbrPDEB1   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGGAGTTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone B1   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A1   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A3   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A4   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A8   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A2   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A5   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A6   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC 
  WT PDE-B1 Clone A7   (501) CCACGGAGATATTGTGGTTGGTTGTGTTGAGGTACCCCGCTTTTCGGGAAATCTTGAGAAATTGCCATCATTCCCATCTCTCATAAGAGCTGTGACATGC  
 
                             601                                                                                              700 
R0-8 PDE-B1 Clone A1   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A2   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A3   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A4   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A5   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A6   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A7   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone A8   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
R0-8 PDE-B1 Clone B1   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
     GeneDB TbrPDEB1   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone B1   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A1   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A3   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A4   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A8   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A2   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A5   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A6   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
  WT PDE-B1 Clone A7   (601) ACCGCACACAAATTCATTGAGGAAGCGAGAATCAACTGGAACAGGGAGAAGGCGGAAGCTATGTTGCAAATGGCGACCAGGTTGGCCCGTGACAATCTTG 
                             701                                                                                              800 
R0-8 PDE-B1 Clone A1   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A2   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A3   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A4   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A5   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A6   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A7   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone A8   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B1 Clone B1   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
     GeneDB TbrPDEB1   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCACGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone B1   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A1   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A3   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A4   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A8   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A2   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A5   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A6   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B1 Clone A7   (701) ATGAAACAGTACTTGCATCTTCTATCATGAACACTGTGAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC  
 
                             801                                                                                              900 
R0-8 PDE-B1 Clone A1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A2   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A3   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A4   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A5   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A6   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A7   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone A8   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B1 Clone B1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
     GeneDB TbrPDEB1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone B1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A3   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A4   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A8   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A2   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A5   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A6   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B1 Clone A7   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
                             901                                                                                             1000 
R0-8 PDE-B1 Clone A1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A2   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A3   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A4   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A5   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A6   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A7   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone A8   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B1 Clone B1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
     GeneDB TbrPDEB1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone B1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A3   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A4   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A8   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A2   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A5   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A6   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B1 Clone A7   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG  
 
                             1001                                                                                            1100 
R0-8 PDE-B1 Clone A1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A2  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A3  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A4  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A5  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A6  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A7  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone A8  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B1 Clone B1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
     GeneDB TbrPDEB1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone B1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A3  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A4  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A8  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A2  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A5  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A6  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B1 Clone A7  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
                             1101                                                                                            1200 
R0-8 PDE-B1 Clone A1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A2  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A3  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A4  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A5  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A6  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A7  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone A8  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B1 Clone B1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
     GeneDB TbrPDEB1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAATGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone B1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A3  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A4  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A8  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A2  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A5  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A6  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B1 Clone A7  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC  
 
                             1201                                                                                            1300 
R0-8 PDE-B1 Clone A1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A2  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A3  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A4  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A5  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A6  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A7  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone A8  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B1 Clone B1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
     GeneDB TbrPDEB1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone B1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A3  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A4  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A8  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A2  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A5  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A6  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B1 Clone A7  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
                             1301                                                                                            1400 
R0-8 PDE-B1 Clone A1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A2  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A3  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A4  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A5  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A6  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A7  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone A8  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B1 Clone B1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
     GeneDB TbrPDEB1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone B1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGGTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGGTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A3  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGGTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A4  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGGTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A8  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGGTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A2  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A5  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A6  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B1 Clone A7  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC  
 
                             1401                                                                                            1500 
R0-8 PDE-B1 Clone A1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A2  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A3  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A4  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A5  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A6  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A7  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone A8  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B1 Clone B1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
     GeneDB TbrPDEB1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGTTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone B1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A3  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A4  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A8  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A2  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A5  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A6  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B1 Clone A7  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
                             1501                                                                                            1600 
R0-8 PDE-B1 Clone A1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A2  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A3  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A4  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A5  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A6  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A7  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone A8  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B1 Clone B1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
     GeneDB TbrPDEB1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone B1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A3  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A4  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A8  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A2  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A5  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A6  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B1 Clone A7  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG  
 
                             1601                                                                                            1700 
R0-8 PDE-B1 Clone A1  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A2  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A3  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A4  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A5  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A6  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A7  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone A8  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B1 Clone B1  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
     GeneDB TbrPDEB1  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAAGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone B1  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A1  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A3  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A4  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A8  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A2  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A5  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A6  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B1 Clone A7  (1601) AGACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
                             1701                                                                                            1800 
R0-8 PDE-B1 Clone A1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A2  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A3  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A4  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A5  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A6  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A7  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone A8  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
R0-8 PDE-B1 Clone B1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
     GeneDB TbrPDEB1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone B1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A3  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A4  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A8  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A2  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A5  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A6  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT 
  WT PDE-B1 Clone A7  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGCGGTTAAACGAGTCACTGCCATTACGAAGGTTGAAAGGGAAGCGGTCTTGGTCTGT  
 
                             1801                                                                                            1900 
R0-8 PDE-B1 Clone A1  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A2  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A3  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A4  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A5  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A6  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A7  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone A8  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B1 Clone B1  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
     GeneDB TbrPDEB1  (1801) GAACTTCCATCGTTTGACGTTACGGATGTTGAGTTCGACTTGTTCCGAGCGCGTGATACTACGGATAAACCGTTGGATGTTGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone B1  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A1  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A3  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A4  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A8  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A2  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A5  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A6  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B1 Clone A7  (1801) GAACTTCCATCGTTTGATGTTACGGATGTTGAGTTCGACTTGTTCCGAGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
                             1901                                                                                            2000 
R0-8 PDE-B1 Clone A1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A2  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A3  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A4  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A5  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A6  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A7  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone A8  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B1 Clone B1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
     GeneDB TbrPDEB1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone B1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A3  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A4  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A8  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A2  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A5  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A6  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B1 Clone A7  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC  
 
                             2001                                                                                            2100 
R0-8 PDE-B1 Clone A1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A2  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A3  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A4  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A5  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A6  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A7  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone A8  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B1 Clone B1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
     GeneDB TbrPDEB1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone B1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A3  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A4  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A8  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A2  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A5  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A6  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B1 Clone A7  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTCACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
                             2101                                                                                            2200 
R0-8 PDE-B1 Clone A1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A2  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A3  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A4  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A5  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A6  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A7  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone A8  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B1 Clone B1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
     GeneDB TbrPDEB1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone B1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A3  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A4  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A8  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A2  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A5  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A6  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B1 Clone A7  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG  
 
                             2201                                                                                            2300 
R0-8 PDE-B1 Clone A1  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A2  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A3  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A4  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A5  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A6  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A7  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone A8  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B1 Clone B1  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
     GeneDB TbrPDEB1  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone B1  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A1  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A3  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A4  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A8  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A2  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A5  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A6  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B1 Clone A7  (2201) CAAGTGGTAACACCTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
                             2301                                                                                            2400 
R0-8 PDE-B1 Clone A1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A2  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A3  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A4  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A5  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A6  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A7  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone A8  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
R0-8 PDE-B1 Clone B1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
     GeneDB TbrPDEB1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone B1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTATACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A3  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A4  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A8  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A2  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A5  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A6  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG 
  WT PDE-B1 Clone A7  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAAGCATGGAAGTGCATTAGAGGCGTTTCTTGCATCTGCGGCG  
 
                             2401                                                                                            2500 
R0-8 PDE-B1 Clone A1  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A2  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A3  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A4  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A5  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A6  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A7  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone A8  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
R0-8 PDE-B1 Clone B1  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
     GeneDB TbrPDEB1  (2401) GACCAGTCGTCAGACGAGGCGGCGTTTCACCGCATGACGATGGAGATACTCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone B1  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A1  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A3  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A4  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A8  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A2  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A5  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A6  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
  WT PDE-B1 Clone A7  (2401) GACCAGTCGTCAGACGAGGCAGCGTTTCACCGCATGACGATGGAGATAATCTTGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTTCCC 
                             2501                                                                                            2600 
R0-8 PDE-B1 Clone A1  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A2  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A3  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A4  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A5  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A6  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A7  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone A8  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
R0-8 PDE-B1 Clone B1  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
     GeneDB TbrPDEB1  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone B1  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A1  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A3  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A4  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A8  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A2  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A5  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A6  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA 
  WT PDE-B1 Clone A7  (2501) GTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAAGAA  
 
                             2601                                                                                            2700 
R0-8 PDE-B1 Clone A1  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A2  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A3  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A4  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A5  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A6  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A7  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone A8  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
R0-8 PDE-B1 Clone B1  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
     GeneDB TbrPDEB1  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTCGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone B1  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A1  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A3  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A4  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A8  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A2  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A5  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A6  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
  WT PDE-B1 Clone A7  (2601) TATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTT-CCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGGAC 
                             2701                                                                                      2794 
R0-8 PDE-B1 Clone A1  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A2  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A3  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A4  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A5  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A6  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A7  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone A8  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
R0-8 PDE-B1 Clone B1  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
     GeneDB TbrPDEB1  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone B1  (2701) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A1  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A3  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A4  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A8  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A2  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A5  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A6  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  WT PDE-B1 Clone A7  (2700) AGTCGACCGTATCAAATCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAACAAGACTATCAACGAGTTCTGGCAACAACAGCAGTACTCGTTGA 
  
Appendix 4:  
The amino acid sequences of TbrPDEB1 from all the cloned sequences taken from the GJS-128 resistant R0.8 strain and parental wildtype. Sequences are 
divided by the published sequence for TbrPDEB1 from GeneDB. 
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R0-8 PDE-B1 Clone A1    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A2    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A3    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A4    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A5    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A6    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A7    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone A8    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
R0-8 PDE-B1 Clone B1    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
     GeneDB TbrPDEB1    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone B1    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A1    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A3    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A4    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A8    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A2    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A5    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A6    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
  WT PDE-B1 Clone A7    (1) MFMNKPFGSKRCEPFHESEHLCEAFAITEAILARYQRGKRSFTSSEKSGLAALIKRIPYDILVEVLDQSGFTPTSNATPPVDYLAMMEHTMTHGASITHA 
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R0-8 PDE-B1 Clone A1  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A2  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A3  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A4  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A5  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A6  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A7  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone A8  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
R0-8 PDE-B1 Clone B1  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
     GeneDB TbrPDEB1  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEELPSFPSLIRAVTC 
  WT PDE-B1 Clone B1  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A1  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A3  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A4  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A8  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A2  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A5  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A6  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC 
  WT PDE-B1 Clone A7  (101) LQYLNDLMTKCTGCPGIRTYYHNPNDDVLADPVHDTAALIDETTAVGKSVVTKQYLNIAGAHYIPLIHGDIVVGCVEVPRFSGNLEKLPSFPSLIRAVTC  
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R0-8 PDE-B1 Clone A1  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A2  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A3  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A4  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A5  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A6  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A7  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone A8  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B1 Clone B1  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
     GeneDB TbrPDEB1  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone B1  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A1  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A3  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A4  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A8  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A2  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A5  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A6  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B1 Clone A7  (201) TAHKFIEEARINWNREKAEAMLQMATRLARDNLDETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
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R0-8 PDE-B1 Clone A1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A2  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A3  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A4  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A5  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A6  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A7  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone A8  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B1 Clone B1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
     GeneDB TbrPDEB1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone B1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A3  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A4  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A8  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A2  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A5  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A6  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B1 Clone A7  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL  
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R0-8 PDE-B1 Clone A1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A2  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A3  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A4  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A5  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A6  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A7  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone A8  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B1 Clone B1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
     GeneDB TbrPDEB1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone B1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A3  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A4  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A8  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A2  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A5  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A6  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B1 Clone A7  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
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R0-8 PDE-B1 Clone A1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A2  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A3  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A4  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A5  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A6  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A7  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone A8  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
R0-8 PDE-B1 Clone B1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
     GeneDB TbrPDEB1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone B1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A3  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A4  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A8  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A2  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A5  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A6  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC 
  WT PDE-B1 Clone A7  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRETFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRAVKRVTAITKVEREAVLVC  
 
                            601                                                                                              700 
R0-8 PDE-B1 Clone A1  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A2  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A3  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A4  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A5  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A6  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A7  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone A8  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
R0-8 PDE-B1 Clone B1  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
     GeneDB TbrPDEB1  (601) ELPSFDVTDVEFDLFRARDTTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone B1  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A1  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A3  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A4  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A8  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A2  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A5  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A6  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
  WT PDE-B1 Clone A7  (601) ELPSFDVTDVEFDLFRARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIHTFLYRGNVYEKLTELECF 
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R0-8 PDE-B1 Clone A1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A2  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A3  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A4  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A5  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A6  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A7  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone A8  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
R0-8 PDE-B1 Clone B1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
     GeneDB TbrPDEB1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone B1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCILATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A3  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A4  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A8  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A2  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A5  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A6  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA 
  WT PDE-B1 Clone A7  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNTSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMAKHGSALEAFLASAA  
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R0-8 PDE-B1 Clone A1  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A2  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A3  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A4  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A5  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A6  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A7  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone A8  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
R0-8 PDE-B1 Clone B1  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
     GeneDB TbrPDEB1  (801) DQSSDEAAFHRMTMEILLKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone B1  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFPEDS--CLPARDAM 
  WT PDE-B1 Clone A1  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A3  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A4  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A8  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A2  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A5  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A6  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
  WT PDE-B1 Clone A7  (801) DQSSDEAAFHRMTMEIILKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQWT 
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R0-8 PDE-B1 Clone A1  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A2  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A3  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A4  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A5  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A6  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A7  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone A8  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
R0-8 PDE-B1 Clone B1  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
     GeneDB TbrPDEB1  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone B1  (899) DSRPYQIEPRTVGASSGNKTINEFWQQQQYSL 
  WT PDE-B1 Clone A1  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A3  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A4  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A8  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A2  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A5  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A6  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
  WT PDE-B1 Clone A7  (901) VDRIKSNRAQWERVLETRLSTSSGNNSSTR-- 
 
  
Appendix 5:  
The nucleotide sequences of TbrPDEB2 from all the cloned sequences taken from the GJS-128 resistant R0.8 strain and parental wildtype. Sequences are 
divided by the published sequence for TbrPDEB2 from GeneDB. 
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R0-8 PDE-B2 Clone B1     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A1     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A2     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A3     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A4     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A5     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A6     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A7     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
R0-8 PDE-B2 Clone A8     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
     GeneDB TbrPDEB2     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACCCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A1     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A2     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A3     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A4     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A5     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A6     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone A7     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
  WT PDE-B2 Clone B1     (1) ATGACACACAACGGTGGTCGTCATCTGCTTGAGGCGGTTACGCTATGCGGGTCCATTCTTACTCGCTATAAGCGGAGCAACATGAAGCTCGACGAAGCTG 
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R0-8 PDE-B2 Clone B1   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A1   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A2   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A3   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A4   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A5   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A6   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A7   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
R0-8 PDE-B2 Clone A8   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
     GeneDB TbrPDEB2   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A1   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A2   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A3   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A4   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A5   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A6   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone A7   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC 
  WT PDE-B2 Clone B1   (101) AGGTAAGGGCATTAAAGGAGTTATTCGAGAAGTATCAAGATATCCTCGTGGATGGATCCCCTGGTTTGCCCACCCACGCTAGCGGGCCCATGATCCAGCC  
 
                             201                                                                                              300 
R0-8 PDE-B2 Clone B1   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A1   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A2   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A3   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A4   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A5   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A6   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A7   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
R0-8 PDE-B2 Clone A8   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
     GeneDB TbrPDEB2   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A1   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A2   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A3   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A4   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A5   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A6   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone A7   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
  WT PDE-B2 Clone B1   (201) TCCCGTTACAAACATGGTCGCCCCTTATGATTCCCCCACGGATACTATAGTGAAGTTCGTTGAAGGAACGATAAACCTGCAGAGACCAATTGTTGAGGTC 
                             301                                                                                              400 
R0-8 PDE-B2 Clone B1   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A1   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A2   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A3   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A4   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A5   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A6   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A7   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
R0-8 PDE-B2 Clone A8   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
     GeneDB TbrPDEB2   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATTC 
  WT PDE-B2 Clone A1   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone A2   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone A3   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone A4   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone A5   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone A6   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone A7   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC 
  WT PDE-B2 Clone B1   (301) CTTCACGTTATGAACGAGCATTTGTCCCTTGTCCTTCGCGCAAAGAACACTCATGTCTTTTATGTCGACCCCGTTAATAACCTGTTATACGACCCTATAC  
 
                             401                                                                                              500 
R0-8 PDE-B2 Clone B1   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A1   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A2   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A3   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A4   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A5   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A6   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A7   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
R0-8 PDE-B2 Clone A8   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
     GeneDB TbrPDEB2   (401) ACGGGGTGGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A1   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A2   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A3   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A4   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A5   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A6   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone A7   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
  WT PDE-B2 Clone B1   (401) ACGGGGTTGCCGCTGCACTCGATGAATCGTCACCAATAGGAAAGGCCATAGTTTCGGGTGAGCGGCTTAACGTAGCGGGGACACTATATATACCCATCAT 
                             501                                                                                              600 
R0-8 PDE-B2 Clone B1   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A1   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A2   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A3   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A4   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A5   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A6   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A7   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
R0-8 PDE-B2 Clone A8   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
     GeneDB TbrPDEB2   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A1   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A2   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A3   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A4   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A5   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A6   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone A7   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA 
  WT PDE-B2 Clone B1   (501) CTCCGAGGGGATGCCGTTGGGTTGCGTACTGAGTCCTTGTGGAAGGGCAGATTACCACGCCTCTACGATGCTTGAGTCATCACTCCGTGTTATTTCCACA  
 
                             601                                                                                              700 
R0-8 PDE-B2 Clone B1   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A1   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A2   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A3   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A4   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A5   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A6   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A7   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
R0-8 PDE-B2 Clone A8   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
     GeneDB TbrPDEB2   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTAAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A1   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A2   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A3   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A4   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A5   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A6   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone A7   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
  WT PDE-B2 Clone B1   (601) TCCCTCAAAAACATCATTCAGGCAGAGAAACTGAACTGGAACAAAGAAAAGGCGGAGGCTATGCTCCGGATGGCAACGCAGCTGGCCCGTGACAATCTTG 
                             701                                                                                              800 
R0-8 PDE-B2 Clone B1   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B2 Clone A1   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B2 Clone A2   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B2 Clone A3   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B2 Clone A4   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
R0-8 PDE-B2 Clone A5   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
R0-8 PDE-B2 Clone A6   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
R0-8 PDE-B2 Clone A7   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
R0-8 PDE-B2 Clone A8   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
     GeneDB TbrPDEB2   (701) AAGAAACAGTACTCGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTTCTTGAAGC 
  WT PDE-B2 Clone A1   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B2 Clone A2   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B2 Clone A3   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B2 Clone A4   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTGAAAGACGACAAGCTTGAAGC 
  WT PDE-B2 Clone A5   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
  WT PDE-B2 Clone A6   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
  WT PDE-B2 Clone A7   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC 
  WT PDE-B2 Clone B1   (701) AAGAAACAGTACTTGCATCTTCTATCATGAACACTGTCAAGAGTCTCACGGAAAGTGCGCGTTGCAGTCTCTTCCTTGTCAGGGGTGACGTACTTGAAGC  
 
                             801                                                                                              900 
R0-8 PDE-B2 Clone B1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A2   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A3   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A4   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A5   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A6   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A7   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
R0-8 PDE-B2 Clone A8   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
     GeneDB TbrPDEB2   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A1   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A2   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A3   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A4   (801) GCATTTTGAGGATGGTAACGTCGTTTCCATACCCAAGGGAACAGGCATTGTAGGGTATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A5   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A6   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone A7   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
  WT PDE-B2 Clone B1   (801) GCATTTTGAGGATGGTAACGTTGTTACAATCCCTAGGGGTGCAGGTATTGCCGGATATGTGGCGCAAACTGGTGAGACTGTTAATATTGTTGATGCCTAC 
                             901                                                                                             1000 
R0-8 PDE-B2 Clone B1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A2   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A3   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A4   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A5   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A6   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A7   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
R0-8 PDE-B2 Clone A8   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
     GeneDB TbrPDEB2   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A2   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A3   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A4   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A5   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A6   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone A7   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG 
  WT PDE-B2 Clone B1   (901) GCCGATGACCGCTTTAACCGTGAGGTTGACAAGGCTACTGGGTACCGTACAAAGACGATACTCTGCATGCCTGTGATGTACGAAGGAACGATTGTGGCTG  
 
                             1001                                                                                            1100 
R0-8 PDE-B2 Clone B1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A2  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A3  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A4  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A5  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A6  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A7  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
R0-8 PDE-B2 Clone A8  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
     GeneDB TbrPDEB2  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A1  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A2  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A3  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A4  (1001) TAACCCAGCTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAAACGTGACGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A5  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A6  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone A7  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
  WT PDE-B2 Clone B1  (1001) TTGCCCAACTGATTAATAAATTGGATCTGACAACTGAGAGTGGATTGCGCCTACCTCGTGTGTTCGGAAGGCGTGATGAGGAGCTGTTCCAAACCTTCTC 
                             1101                                                                                            1200 
R0-8 PDE-B2 Clone B1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A2  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A3  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A4  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A5  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A6  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A7  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
R0-8 PDE-B2 Clone A8  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
     GeneDB TbrPDEB2  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A2  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A3  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A4  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A5  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A6  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone A7  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC 
  WT PDE-B2 Clone B1  (1101) TATGTTTGCTGGCGCCTCACTACGTAACTGTCGTATCAACGACCGACTCTTAAAGGAGAAGAAAAAGAGTGACGTGATTCTCGATGTTGTTACTGTTCTC  
 
                             1201                                                                                            1300 
R0-8 PDE-B2 Clone B1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A2  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A3  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A4  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A5  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A6  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A7  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
R0-8 PDE-B2 Clone A8  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
     GeneDB TbrPDEB2  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A2  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A3  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A4  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A5  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A6  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone A7  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
  WT PDE-B2 Clone B1  (1201) TCGAACACGGATATCCGCGATGTGGATGGTATTGTTCGCCACGCACTGCACGGAGCAAAGAAACTACTGAACGCGGATCGCTCTACTTTGTTTTTGGTGG 
                             1301                                                                                            1400 
R0-8 PDE-B2 Clone B1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A2  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A3  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A4  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A5  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A6  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A7  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
R0-8 PDE-B2 Clone A8  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
     GeneDB TbrPDEB2  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A2  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A3  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A4  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A5  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A6  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone A7  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC 
  WT PDE-B2 Clone B1  (1301) ACAAGGAACGGAACGAACTTTGCAGTCGTATGGCAGATAGCGTTGCTGGTAAGGAGATTCGTTTTCCGTGTGGCCAAGGTATTGCGGGCACTGTGGCGGC  
 
                             1401                                                                                            1500 
R0-8 PDE-B2 Clone B1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A2  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A3  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A4  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A5  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A6  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A7  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
R0-8 PDE-B2 Clone A8  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
     GeneDB TbrPDEB2  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGTTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGGCCATATTGTGC 
  WT PDE-B2 Clone A1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone A2  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone A3  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone A4  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone A5  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone A6  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone A7  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
  WT PDE-B2 Clone B1  (1401) ATCTGGAGTTGGTGAGAATATTCAGGACGCGTACCAGGATCCGCGCTTCAACCGTGAGGTTGACAAACAACTTGGATACCGCACGCAGACCATATTGTGC 
                             1501                                                                                            1600 
R0-8 PDE-B2 Clone B1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A2  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A3  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A4  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A5  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A6  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A7  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
R0-8 PDE-B2 Clone A8  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
     GeneDB TbrPDEB2  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATTCATCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A2  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A3  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A4  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A5  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A6  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone A7  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG 
  WT PDE-B2 Clone B1  (1501) GAGCCCATCATACTAAATGGTGAGATCCTTGCTGTCGTGCAGCTCGTGAACAAGCTTGATACGTCTGGAGAAGTGACTGTGTTTACCGAGGATGATCGTG  
 
                             1601                                                                                            1700 
R0-8 PDE-B2 Clone B1  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A1  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A2  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A3  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A4  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A5  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A6  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A7  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
R0-8 PDE-B2 Clone A8  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
     GeneDB TbrPDEB2  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCGGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A1  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTACTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A2  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A3  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A4  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A5  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A6  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone A7  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
  WT PDE-B2 Clone B1  (1601) ACACCTTCCGTGTGTTTTCCTTATTTGCAGGTATATCCATCAACAACTCTCACCTGCTTGAGTTCGCTGTGAAGGCAGGTCGTGAGGTGATGGAATTAAA 
                             1701                                                                                            1800 
R0-8 PDE-B2 Clone B1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A2  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A3  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A4  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A5  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A6  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A7  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
R0-8 PDE-B2 Clone A8  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
     GeneDB TbrPDEB2  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A2  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A3  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A4  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A5  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A6  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone A7  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT 
  WT PDE-B2 Clone B1  (1701) TGAACACCGAGCAACATTGTTTAATAAGAACGTTCCCTCACGTGGAGTTAAACGAGTCACTGCCATCACAAATAGAGAAAGGGAGGCTGTGCTACGTATT  
 
                             1801                                                                                            1900 
R0-8 PDE-B2 Clone B1  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A1  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A2  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A3  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A4  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A5  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A6  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A7  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
R0-8 PDE-B2 Clone A8  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
     GeneDB TbrPDEB2  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGTACAGATAAACCGTTGGATGTTGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A1  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A2  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A3  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A4  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A5  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A6  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone A7  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
  WT PDE-B2 Clone B1  (1801) GAGTTCCCCAACGTGGACGTTACGGATATTGACTTCGACTTGTTCCAGGCACGTGAAAGCACAGATAAACCGTTGGATGTCGCTGCTGCTATTGCATACA 
                             1901                                                                                            2000 
R0-8 PDE-B2 Clone B1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A2  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A3  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A4  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A5  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A6  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A7  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
R0-8 PDE-B2 Clone A8  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
     GeneDB TbrPDEB2  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A2  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A3  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A4  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A5  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A6  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone A7  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC 
  WT PDE-B2 Clone B1  (1901) GACTACTGCTTGGAAGCGGCCTTCCACAAAAGTTTGGTTGCTCTGACGAGGTGCTTCTTAACTTCATTCTGCAATGCCGTAAGAAATACCGTAATGTCCC  
 
                             2001                                                                                            2100 
R0-8 PDE-B2 Clone B1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A2  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A3  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A4  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A5  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A6  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A7  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
R0-8 PDE-B2 Clone A8  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
     GeneDB TbrPDEB2  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A2  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A3  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A4  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A5  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A6  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone A7  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
  WT PDE-B2 Clone B1  (2001) TTATCACAACTTTTACCATGTTGTGGATGTATGCCAAACCATTTACACATTCTTGTACAGGGGAAATGTGTATGAGAAGTTAACCGAGCTTGAGTGCTTT 
                             2101                                                                                            2200 
R0-8 PDE-B2 Clone B1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A2  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTTTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A3  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A4  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A5  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A6  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTCCCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A7  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
R0-8 PDE-B2 Clone A8  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
     GeneDB TbrPDEB2  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A2  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A3  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A4  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A5  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGTATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A6  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone A7  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG 
  WT PDE-B2 Clone B1  (2101) GTGCTGCTTATCACCGCACTGGTGCATGATCTTGATCATATGGGGCTGAACAACAGTTTCTACCTGAAAACAGAATCTCCACTTGGTATTCTTTCCAGCG  
 
                             2201                                                                                            2300 
R0-8 PDE-B2 Clone B1  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A1  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A2  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A3  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A4  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A5  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A6  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A7  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
R0-8 PDE-B2 Clone A8  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
     GeneDB TbrPDEB2  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A1  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A2  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A3  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A4  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A5  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A6  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone A7  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
  WT PDE-B2 Clone B1  (2201) CAAGTGGTAACAAGTCTGTTCTTGAGGTGCATCACTGCAACCTTGCTGTTGAGATCCTCTCTGATCCGGAATCTGATGTGTTTGGTGGTCTGGAGGGTGC 
                             2301                                                                                            2400 
R0-8 PDE-B2 Clone B1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A2  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A3  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A4  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A5  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A6  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A7  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
R0-8 PDE-B2 Clone A8  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
     GeneDB TbrPDEB2  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAGCTTATGAAA 
  WT PDE-B2 Clone A1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATTGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone A2  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATTGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone A3  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATTGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone A4  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATTGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone A5  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone A6  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone A7  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA 
  WT PDE-B2 Clone B1  (2301) AGAGCGTACTCTTGCGTTCCGATCGATGATTGATTGTGTACTTGCGACAGATATGGCGAGACATAGTGAATTTCTTGAGAAGTACCTAGAACTTATGAAA  
 
                             2401                                                                                            2500 
R0-8 PDE-B2 Clone B1  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A1  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A2  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A3  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A4  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A5  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A6  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A7  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
R0-8 PDE-B2 Clone A8  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
     GeneDB TbrPDEB2  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A1  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A2  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A3  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A4  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A5  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A6  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone A7  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
  WT PDE-B2 Clone B1  (2401) ACATCTTACAACGTTGATGATTCCGATCATCGGCAAATGACAATGGATGTGCTTATGAAAGCTGGAGATATCTCTAACGTAACGAAACCGTTCGACATTT 
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R0-8 PDE-B2 Clone B1  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A1  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A2  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A3  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A4  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A5  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A6  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A7  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
R0-8 PDE-B2 Clone A8  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
     GeneDB TbrPDEB2  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAAAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A1  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A2  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A3  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A4  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A5  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A6  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone A7  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA 
  WT PDE-B2 Clone B1  (2501) CCCGTCAGTGGGCAATGGCTGTGACGGAGGAGTTCTACCGTCAAGGAGACATGGAGAAGGAGAGGGGTGTGGAAGTATTGCCCATGTTTGACCGATCTAA  
 
                             2601                                                                                            2700 
R0-8 PDE-B2 Clone B1  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A1  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A2  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A3  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A4  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A5  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A6  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A7  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
R0-8 PDE-B2 Clone A8  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
     GeneDB TbrPDEB2  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTCGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A1  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A2  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A3  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A4  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A5  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A6  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone A7  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
  WT PDE-B2 Clone B1  (2601) GAATATGGAGCTTGCAAAAGGTCAAATTGGATTCATTGACTTTGTTGCAGCCCCATTTTTCCAGAAGATAGTTGATGCCTGCCTGCAAGGGATGCAATGG 
                             2701                                                                      2778 
R0-8 PDE-B2 Clone B1  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A1  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A2  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A3  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A4  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A5  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A6  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A7  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
R0-8 PDE-B2 Clone A8  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
     GeneDB TbrPDEB2  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACAGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A1  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A2  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A3  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A4  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A5  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A6  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone A7  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
  WT PDE-B2 Clone B1  (2701) ACAGTCGACCGTACAAAGTCGAACCGCGCACAGTGGGAGCGAGTTCTGGAAGCAAGGAGTACTGGGGCTTCGTCTTAG 
 
  
Appendix 6:  
The amino acid sequences of TbrPDEB2 from all the cloned sequences taken from the GJS-128 resistant R0.8 strain and parental wildtype. Sequences are 
divided by the published sequence for TbrPDEB2 from GeneDB. 
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R0-8 PDE-B2 Clone B1    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A1    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A2    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A3    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A4    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A5    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A6    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A7    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
R0-8 PDE-B2 Clone A8    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
     GeneDB TbrPDEB2    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A1    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A2    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A3    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A4    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A5    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A6    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone A7    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
  WT PDE-B2 Clone B1    (1) MTHNGGRHLLEAVTLCGSILTRYKRSNMKLDEAEVRALKELFEKYQDILVDGSPGLPTHASGPMIQPPVTNMVAPYDSPTDTIVKFVEGTINLQRPIVEV 
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R0-8 PDE-B2 Clone B1  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A1  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A2  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A3  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A4  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A5  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A6  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A7  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
R0-8 PDE-B2 Clone A8  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
     GeneDB TbrPDEB2  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A1  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A2  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A3  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A4  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A5  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A6  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone A7  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST 
  WT PDE-B2 Clone B1  (101) LHVMNEHLSLVLRAKNTHVFYVDPVNNLLYDPIHGVAAALDESSPIGKAIVSGERLNVAGTLYIPIISEGMPLGCVLSPCGRADYHASTMLESSLRVIST  
 
                            201                                                                                              300 
R0-8 PDE-B2 Clone B1  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A1  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A2  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A3  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A4  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A5  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A6  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A7  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
R0-8 PDE-B2 Clone A8  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
     GeneDB TbrPDEB2  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A1  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A2  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A3  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A4  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVKDDKLEAHFEDGNVVSIPKGTGIVGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A5  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A6  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone A7  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
  WT PDE-B2 Clone B1  (201) SLKNIIQAEKLNWNKEKAEAMLRMATQLARDNLEETVLASSIMNTVKSLTESARCSLFLVRGDVLEAHFEDGNVVTIPRGAGIAGYVAQTGETVNIVDAY 
                            301                                                                                              400 
R0-8 PDE-B2 Clone B1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A2  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A3  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A4  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A5  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A6  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A7  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
R0-8 PDE-B2 Clone A8  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
     GeneDB TbrPDEB2  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A2  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A3  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A4  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVTQLINKLDLTTESGLRLPRVFGKRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A5  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A6  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone A7  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL 
  WT PDE-B2 Clone B1  (301) ADDRFNREVDKATGYRTKTILCMPVMYEGTIVAVAQLINKLDLTTESGLRLPRVFGRRDEELFQTFSMFAGASLRNCRINDRLLKEKKKSDVILDVVTVL  
 
                            401                                                                                              500 
R0-8 PDE-B2 Clone B1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A2  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A3  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A4  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A5  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A6  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A7  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
R0-8 PDE-B2 Clone A8  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
     GeneDB TbrPDEB2  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQAILC 
  WT PDE-B2 Clone A1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone A2  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone A3  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone A4  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone A5  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone A6  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone A7  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
  WT PDE-B2 Clone B1  (401) SNTDIRDVDGIVRHALHGAKKLLNADRSTLFLVDKERNELCSRMADSVAGKEIRFPCGQGIAGTVAASGVGENIQDAYQDPRFNREVDKQLGYRTQTILC 
                            501                                                                                              600 
R0-8 PDE-B2 Clone B1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A2  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A3  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A4  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A5  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A6  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A7  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
R0-8 PDE-B2 Clone A8  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
     GeneDB TbrPDEB2  (501) EPIILNGEILAVVQLVNKLDSSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A2  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A3  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A4  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A5  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A6  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone A7  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI 
  WT PDE-B2 Clone B1  (501) EPIILNGEILAVVQLVNKLDTSGEVTVFTEDDRDTFRVFSLFAGISINNSHLLEFAVKAGREVMELNEHRATLFNKNVPSRGVKRVTAITNREREAVLRI  
 
                            601                                                                                              700 
R0-8 PDE-B2 Clone B1  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A1  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A2  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A3  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A4  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A5  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A6  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A7  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
R0-8 PDE-B2 Clone A8  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
     GeneDB TbrPDEB2  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A1  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A2  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A3  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A4  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A5  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A6  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone A7  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
  WT PDE-B2 Clone B1  (601) EFPNVDVTDIDFDLFQARESTDKPLDVAAAIAYRLLLGSGLPQKFGCSDEVLLNFILQCRKKYRNVPYHNFYHVVDVCQTIYTFLYRGNVYEKLTELECF 
                            701                                                                                              800 
R0-8 PDE-B2 Clone B1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A2  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A3  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A4  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A5  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A6  (701) VLLITALVHDLDHMGLNNSFSLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A7  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
R0-8 PDE-B2 Clone A8  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
     GeneDB TbrPDEB2  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
  WT PDE-B2 Clone A1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHCEFLEKYLELMK 
  WT PDE-B2 Clone A2  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHCEFLEKYLELMK 
  WT PDE-B2 Clone A3  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHCEFLEKYLELMK 
  WT PDE-B2 Clone A4  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHCEFLEKYLELMK 
  WT PDE-B2 Clone A5  (701) VLLITALVHDLDHMGLNNSFYLKTVSPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
  WT PDE-B2 Clone A6  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
  WT PDE-B2 Clone A7  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK 
  WT PDE-B2 Clone B1  (701) VLLITALVHDLDHMGLNNSFYLKTESPLGILSSASGNKSVLEVHHCNLAVEILSDPESDVFGGLEGAERTLAFRSMIDCVLATDMARHSEFLEKYLELMK  
 
                            801                                                                                              900 
R0-8 PDE-B2 Clone B1  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A1  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A2  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A3  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A4  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A5  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A6  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A7  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
R0-8 PDE-B2 Clone A8  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
     GeneDB TbrPDEB2  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A1  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A2  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A3  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A4  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A5  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A6  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone A7  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
  WT PDE-B2 Clone B1  (801) TSYNVDDSDHRQMTMDVLMKAGDISNVTKPFDISRQWAMAVTEEFYRQGDMEKERGVEVLPMFDRSKNMELAKGQIGFIDFVAAPFFQKIVDACLQGMQW 
                            901                    926 
R0-8 PDE-B2 Clone B1  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A1  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A2  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A3  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A4  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A5  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A6  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A7  (901) TVDRTKSNRAQWERVLEARSTGASS- 
R0-8 PDE-B2 Clone A8  (901) TVDRTKSNRAQWERVLEARSTGASS- 
     GeneDB TbrPDEB2  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A1  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A2  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A3  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A4  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A5  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A6  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone A7  (901) TVDRTKSNRAQWERVLEARSTGASS- 
  WT PDE-B2 Clone B1  (901) TVDRTKSNRAQWERVLEARSTGASS- 
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